{
  "935682c8cf258e8878904337fd63fa45": {
    "return": "(\"entity\"<|>\"Male\"<|>\"person\"<|>\"Male refers to the male sex group included in the statistical analysis of rates for various causes, including all causes, unintentional falls, motor vehicle crashes, and opioid overdoses. Males are used as a reference group in the data.\")##\n(\"entity\"<|>\"Female\"<|>\"person\"<|>\"Female refers to the female sex group included in the statistical analysis of rates for various causes, including all causes, unintentional falls, motor vehicle crashes, and opioid overdoses. Females are compared to males in the data.\")##\n(\"entity\"<|>\"Age group 65-74\"<|>\"person\"<|>\"Age group 65-74 refers to individuals aged between 65 and 74 years, used as a reference group in the analysis of rates for various causes.\")##\n(\"entity\"<|>\"Age group 75-84\"<|>\"person\"<|>\"Age group 75-84 refers to individuals aged between 75 and 84 years, included in the analysis of rates for various causes.\")##\n(\"entity\"<|>\"Age group 85+\"<|>\"person\"<|>\"Age group 85+ refers to individuals aged 85 years and older, included in the analysis of rates for various causes.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional Falls refers to accidental falls that result in injury or death, analyzed as a cause in the statistical data.\")##\n(\"entity\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional Motor Vehicle Crashes refers to accidental motor vehicle accidents, analyzed as a cause in the statistical data.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdoses\"<|>\"event\"<|>\"Unintentional Opioid Overdoses refers to accidental overdoses involving opioids, analyzed as a cause in the statistical data.\")##\n(\"entity\"<|>\"All Causes\"<|>\"event\"<|>\"All Causes refers to the total of all causes of injury or death included in the statistical analysis.\")##\n\n(\"relationship\"<|>\"Male\"<|>\"Unintentional Falls\"<|>\"Males are analyzed as a demographic group in the rates of unintentional falls.\"<|>8)##\n(\"relationship\"<|>\"Female\"<|>\"Unintentional Falls\"<|>\"Females are analyzed as a demographic group in the rates of unintentional falls.\"<|>8)##\n(\"relationship\"<|>\"Male\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Males are analyzed as a demographic group in the rates of unintentional motor vehicle crashes.\"<|>8)##\n(\"relationship\"<|>\"Female\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Females are analyzed as a demographic group in the rates of unintentional motor vehicle crashes.\"<|>8)##\n(\"relationship\"<|>\"Male\"<|>\"Unintentional Opioid Overdoses\"<|>\"Males are analyzed as a demographic group in the rates of unintentional opioid overdoses.\"<|>8)##\n(\"relationship\"<|>\"Female\"<|>\"Unintentional Opioid Overdoses\"<|>\"Females are analyzed as a demographic group in the rates of unintentional opioid overdoses.\"<|>8)##\n(\"relationship\"<|>\"Age group 65-74\"<|>\"Unintentional Falls\"<|>\"Individuals aged 65-74 are analyzed as a reference group in the rates of unintentional falls.\"<|>7)##\n(\"relationship\"<|>\"Age group 75-84\"<|>\"Unintentional Falls\"<|>\"Individuals aged 75-84 are analyzed in the rates of unintentional falls.\"<|>7)##\n(\"relationship\"<|>\"Age group 85+\"<|>\"Unintentional Falls\"<|>\"Individuals aged 85+ are analyzed in the rates of unintentional falls.\"<|>7)##\n(\"relationship\"<|>\"Age group 65-74\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Individuals aged 65-74 are analyzed as a reference group in the rates of unintentional motor vehicle crashes.\"<|>7)##\n(\"relationship\"<|>\"Age group 75-84\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Individuals aged 75-84 are analyzed in the rates of unintentional motor vehicle crashes.\"<|>7)##\n(\"relationship\"<|>\"Age group 85+\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Individuals aged 85+ are analyzed in the rates of unintentional motor vehicle crashes.\"<|>7)##\n(\"relationship\"<|>\"Age group 65-74\"<|>\"Unintentional Opioid Overdoses\"<|>\"Individuals aged 65-74 are analyzed as a reference group in the rates of unintentional opioid overdoses.\"<|>7)##\n(\"relationship\"<|>\"Age group 75-84\"<|>\"Unintentional Opioid Overdoses\"<|>\"Individuals aged 75-84 are analyzed in the rates of unintentional opioid overdoses.\"<|>7)##\n(\"relationship\"<|>\"Age group 85+\"<|>\"Unintentional Opioid Overdoses\"<|>\"Individuals aged 85+ are analyzed in the rates of unintentional opioid overdoses.\"<|>7)##\n(\"relationship\"<|>\"Male\"<|>\"All Causes\"<|>\"Males are analyzed as a demographic group in the rates of all causes.\"<|>8)##\n(\"relationship\"<|>\"Female\"<|>\"All Causes\"<|>\"Females are analyzed as a demographic group in the rates of all causes.\"<|>8)##\n(\"relationship\"<|>\"Age group 65-74\"<|>\"All Causes\"<|>\"Individuals aged 65-74 are analyzed as a reference group in the rates of all causes.\"<|>7)##\n(\"relationship\"<|>\"Age group 75-84\"<|>\"All Causes\"<|>\"Individuals aged 75-84 are analyzed in the rates of all causes.\"<|>7)##\n(\"relationship\"<|>\"Age group 85+\"<|>\"All Causes\"<|>\"Individuals aged 85+ are analyzed in the rates of all causes.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "a429338a83fff673c1e6650509598c99": {
    "return": "(\"entity\"<|>\"Weighted Number\"<|>\"event\"<|>\"Weighted Number refers to the statistically adjusted count of cases or events in each category, used to estimate rates in the population.\")##\n(\"entity\"<|>\"Rate (95% CI)\"<|>\"event\"<|>\"Rate (95% CI) refers to the calculated rate of occurrence for each event, with a 95% confidence interval indicating the statistical reliability of the estimate.\")##\n(\"entity\"<|>\"Reference Group\"<|>\"person\"<|>\"Reference Group refers to the baseline demographic group (such as males or age group 65-74) against which other groups are compared in the statistical analysis.\")##\n(\"entity\"<|>\"CI (Confidence Interval)\"<|>\"event\"<|>\"CI (Confidence Interval) refers to the statistical range within which the true rate is expected to fall, with 95% certainty.\")##\n(\"entity\"<|>\"Total\"<|>\"event\"<|>\"Total refers to the sum of cases or rates for each category, such as all causes, unintentional falls, motor vehicle crashes, and opioid overdoses.\")##\n(\"entity\"<|>\"Unintentional Injuries\"<|>\"event\"<|>\"Unintentional Injuries refers to all injuries that occur without intent, including falls, motor vehicle crashes, and opioid overdoses, as analyzed in the data.\")##\n\n(\"relationship\"<|>\"Weighted Number\"<|>\"Rate (95% CI)\"<|>\"Weighted Number is used to calculate the Rate (95% CI) for each event category.\"<|>9)##\n(\"relationship\"<|>\"Rate (95% CI)\"<|>\"CI (Confidence Interval)\"<|>\"Rate (95% CI) includes the Confidence Interval to indicate statistical reliability.\"<|>9)##\n(\"relationship\"<|>\"Reference Group\"<|>\"Male\"<|>\"Male is used as a reference group for comparison in the statistical analysis.\"<|>8)##\n(\"relationship\"<|>\"Reference Group\"<|>\"Age group 65-74\"<|>\"Age group 65-74 is used as a reference group for comparison in the statistical analysis.\"<|>8)##\n(\"relationship\"<|>\"Total\"<|>\"All Causes\"<|>\"Total is the sum of all causes analyzed in the data.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Injuries\"<|>\"Unintentional Falls\"<|>\"Unintentional Falls is a subset of Unintentional Injuries analyzed in the data.\"<|>8)##\n(\"relationship\"<|>\"Unintentional Injuries\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Unintentional Motor Vehicle Crashes is a subset of Unintentional Injuries analyzed in the data.\"<|>8)##\n(\"relationship\"<|>\"Unintentional Injuries\"<|>\"Unintentional Opioid Overdoses\"<|>\"Unintentional Opioid Overdoses is a subset of Unintentional Injuries analyzed in the data.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "8ec251bf823387e32a1d3737c4884958": {
    "return": "(\"entity\"<|>\"Central African Republic\"<|>\"geo\"<|>\"Central African Republic is a country in Africa, listed with various statistics in the text, indicating its inclusion in a regional dataset.\")##\n(\"entity\"<|>\"Chad\"<|>\"geo\"<|>\"Chad is a country in Africa, included in the dataset with multiple numerical indicators.\")##\n(\"entity\"<|>\"Congo\"<|>\"geo\"<|>\"Congo is a country in Africa, represented in the dataset with several statistics.\")##\n(\"entity\"<|>\"Cte dIvoire\"<|>\"geo\"<|>\"Cte dIvoire (Ivory Coast) is a country in West Africa, included in the dataset with various metrics.\")##\n(\"entity\"<|>\"Democratic Republic of the Congo\"<|>\"geo\"<|>\"Democratic Republic of the Congo is a large country in Central Africa, listed with several statistics.\")##\n(\"entity\"<|>\"Eritrea\"<|>\"geo\"<|>\"Eritrea is a country in East Africa, included in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Ethiopia\"<|>\"geo\"<|>\"Ethiopia is a country in East Africa, represented in the dataset with several metrics.\")##\n(\"entity\"<|>\"Ghana\"<|>\"geo\"<|>\"Ghana is a country in West Africa, included in the dataset with various statistics.\")##\n(\"entity\"<|>\"Guinea\"<|>\"geo\"<|>\"Guinea is a country in West Africa, listed in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Guinea-Bissau\"<|>\"geo\"<|>\"Guinea-Bissau is a small country in West Africa, included in the dataset with several metrics.\")##\n(\"entity\"<|>\"Kenya\"<|>\"geo\"<|>\"Kenya is a country in East Africa, represented in the dataset with various statistics.\")##\n(\"entity\"<|>\"Liberia\"<|>\"geo\"<|>\"Liberia is a country in West Africa, included in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Madagascar\"<|>\"geo\"<|>\"Madagascar is an island country off the southeast coast of Africa, listed in the dataset with several metrics.\")##\n(\"entity\"<|>\"Mali\"<|>\"geo\"<|>\"Mali is a country in West Africa, included in the dataset with various statistics.\")##\n(\"entity\"<|>\"Mauritania\"<|>\"geo\"<|>\"Mauritania is a country in Northwest Africa, represented in the dataset with several indicators.\")##\n(\"entity\"<|>\"Mozambique\"<|>\"geo\"<|>\"Mozambique is a country in Southeast Africa, included in the dataset with multiple metrics.\")##\n(\"entity\"<|>\"Niger\"<|>\"geo\"<|>\"Niger is a country in West Africa, listed in the dataset with several statistics.\")##\n(\"entity\"<|>\"Nigeria\"<|>\"geo\"<|>\"Nigeria is the most populous country in Africa, included in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in West Africa, represented in the dataset with various statistics.\")##\n(\"entity\"<|>\"Sierra Leone\"<|>\"geo\"<|>\"Sierra Leone is a country in West Africa, included in the dataset with several metrics.\")##\n(\"entity\"<|>\"South Sudan\"<|>\"geo\"<|>\"South Sudan is a country in East-Central Africa, listed in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Togo\"<|>\"geo\"<|>\"Togo is a country in West Africa, included in the dataset with several statistics.\")##\n(\"entity\"<|>\"Zambia\"<|>\"geo\"<|>\"Zambia is a country in Southern Africa, represented in the dataset with various metrics.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"Eastern Mediterranean Region is a WHO regional grouping, including several countries in the dataset.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country in South Asia, included in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Egypt\"<|>\"geo\"<|>\"Egypt is a country in North Africa, represented in the dataset with various statistics.\")##\n(\"entity\"<|>\"Iran\"<|>\"geo\"<|>\"Iran is a country in the Middle East, included in the dataset with several metrics.\")##\n(\"entity\"<|>\"Iraq\"<|>\"geo\"<|>\"Iraq is a country in the Middle East, listed in the dataset with multiple indicators.\")##\n(\"entity\"<|>\"Libya\"<|>\"geo\"<|>\"Libya is a country in North Africa, included in the dataset with several statistics.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in South Asia, represented in the dataset with multiple metrics.\")##\n(\"entity\"<|>\"Somalia\"<|>\"geo\"<|>\"Somalia is a country in East Africa, included in the dataset with several indicators.\")##\n(\"entity\"<|>\"Sudan\"<|>\"geo\"<|>\"Sudan is a country in North-East Africa, listed in the dataset with multiple statistics.\")##\n(\"entity\"<|>\"Syria\"<|>\"geo\"<|>\"Syria is a country in the Middle East, included in the dataset with several metrics.\")##\n(\"entity\"<|>\"Yemen\"<|>\"geo\"<|>\"Yemen is a country in the Middle East, represented in the dataset with various statistics.\")##\n(\"entity\"<|>\"European Region\"<|>\"geo\"<|>\"European Region is a WHO regional grouping, including countries in Europe, represented in the dataset.\")##\n(\"entity\"<|>\"Tajikistan\"<|>\"geo\"<|>\"Tajikistan is a country in Central Asia, included in the dataset with several indicators.\")##\n(\"entity\"<|>\"Uzbekistan\"<|>\"geo\"<|>\"Uzbekistan is a country in Central Asia, represented in the dataset with multiple metrics.\")##\n(\"entity\"<|>\"South-East Asia Region\"<|>\"geo\"<|>\"South-East Asia Region is a WHO regional grouping, including countries in South-East Asia, listed in the dataset.\")##\n(\"entity\"<|>\"Burma (Myanmar)\"<|>\"geo\"<|>\"Burma (Myanmar) is a country in South-East Asia, included in the dataset with several statistics.\")##\n(\"relationship\"<|>\"Central African Republic\"<|>\"Eastern Mediterranean Region\"<|>\"Central African Republic is part of a dataset that includes the Eastern Mediterranean Region, indicating regional grouping for statistical purposes.\"<|>5)##\n(\"relationship\"<|>\"Chad\"<|>\"Eastern Mediterranean Region\"<|>\"Chad is included in the dataset alongside other countries in the Eastern Mediterranean Region, suggesting regional analysis.\"<|>5)##\n(\"relationship\"<|>\"Nigeria\"<|>\"African countries\"<|>\"Nigeria is listed among other African countries in the dataset, indicating a shared regional context and comparative analysis.\"<|>7)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"Eastern Mediterranean Region\"<|>\"Afghanistan is part of the Eastern Mediterranean Region grouping in the dataset, indicating regional classification.\"<|>8)##\n(\"relationship\"<|>\"Egypt\"<|>\"Eastern Mediterranean Region\"<|>\"Egypt is included in the Eastern Mediterranean Region grouping, showing regional association in the dataset.\"<|>8)##\n(\"relationship\"<|>\"Iran\"<|>\"Eastern Mediterranean Region\"<|>\"Iran is part of the Eastern Mediterranean Region grouping in the dataset, indicating regional classification.\"<|>8)##\n(\"relationship\"<|>\"Iraq\"<|>\"Eastern Mediterranean Region\"<|>\"Iraq is included in the Eastern Mediterranean Region grouping, showing regional association in the dataset.\"<|>8)##\n(\"relationship\"<|>\"Libya\"<|>\"Eastern Mediterranean Region\"<|>\"Libya is part of the Eastern Mediterranean Region grouping in the dataset, indicating regional classification.\"<|>8)##\n(\"relationship\"<|>\"Pakistan\"<|>\"Eastern Mediterranean Region\"<|>\"Pakistan is included in the Eastern Mediterranean Region grouping, showing regional association in the dataset.\"<|>8)##\n(\"relationship\"<|>\"Somalia\"<|>\"Eastern Mediterranean Region\"<|>\"Somalia is part of the Eastern Mediterranean Region grouping in the dataset, indicating regional classification.\"<|>8)##\n(\"relationship\"<|>\"Sudan\"<|>\"Eastern Mediterranean Region\"<|>\"Sudan is included in the Eastern Mediterranean Region grouping, showing regional association in the dataset.\"<|>8)##\n(\"relationship\"<|>\"Syria\"<|>\"Eastern Mediterranean Region\"<|>\"Syria is part of the Eastern Mediterranean Region grouping in the dataset, indicating regional classification.\"<|>8)##\n(\"relationship\"<|>\"Yemen\"<|>\"Eastern Mediterranean Region\"<|>\"Yemen is included in the Eastern Mediterranean Region grouping, showing regional association in the dataset.\"<|>8)##\n(\"relationship\"<|>\"Tajikistan\"<|>\"European Region\"<|>\"Tajikistan is included in the European Region grouping in the dataset, indicating regional classification.\"<|>7)##\n(\"relationship\"<|>\"Uzbekistan\"<|>\"European Region\"<|>\"Uzbekistan is included in the European Region grouping in the dataset, indicating regional classification.\"<|>7)##\n(\"relationship\"<|>\"Burma (Myanmar)\"<|>\"South-East Asia Region\"<|>\"Burma (Myanmar) is included in the South-East Asia Region grouping in the dataset, indicating regional classification.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "4892f3d7a4c779db1f52fa0a5d7f8ec6": {
    "return": "(\"entity\"<|>\"Tajikistan\"<|>\"geo\"<|>\"Tajikistan is a country in Central Asia, listed with acute flaccid paralysis surveillance performance indicators and polio case data.\")##\n(\"entity\"<|>\"Uzbekistan\"<|>\"geo\"<|>\"Uzbekistan is a country in Central Asia, included in the surveillance report with relevant health data.\")##\n(\"entity\"<|>\"South-East Asia Region\"<|>\"geo\"<|>\"South-East Asia Region is a WHO regional grouping, encompassing several countries for health surveillance purposes.\")##\n(\"entity\"<|>\"Burma (Myanmar)\"<|>\"geo\"<|>\"Burma (Myanmar) is a country in Southeast Asia, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Western Pacific Region\"<|>\"geo\"<|>\"Western Pacific Region is a WHO regional grouping, covering countries in the western Pacific for health surveillance.\")##\n(\"entity\"<|>\"Malaysia\"<|>\"geo\"<|>\"Malaysia is a country in Southeast Asia, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Philippines\"<|>\"geo\"<|>\"Philippines is a country in Southeast Asia, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"African Region\"<|>\"geo\"<|>\"African Region is a WHO regional grouping, covering countries in Africa for health surveillance.\")##\n(\"entity\"<|>\"Angola\"<|>\"geo\"<|>\"Angola is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Benin\"<|>\"geo\"<|>\"Benin is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Burkina Faso\"<|>\"geo\"<|>\"Burkina Faso is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Cameroon\"<|>\"geo\"<|>\"Cameroon is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Central African Republic\"<|>\"geo\"<|>\"Central African Republic is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Chad\"<|>\"geo\"<|>\"Chad is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Congo\"<|>\"geo\"<|>\"Congo is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"C么te d'Ivoire\"<|>\"geo\"<|>\"C么te d'Ivoire is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Democratic Republic of the Congo\"<|>\"geo\"<|>\"Democratic Republic of the Congo is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Eritrea\"<|>\"geo\"<|>\"Eritrea is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Ethiopia\"<|>\"geo\"<|>\"Ethiopia is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Ghana\"<|>\"geo\"<|>\"Ghana is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Guinea\"<|>\"geo\"<|>\"Guinea is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Guinea-Bissau\"<|>\"geo\"<|>\"Guinea-Bissau is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Kenya\"<|>\"geo\"<|>\"Kenya is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Liberia\"<|>\"geo\"<|>\"Liberia is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Madagascar\"<|>\"geo\"<|>\"Madagascar is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Mali\"<|>\"geo\"<|>\"Mali is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Mauritania\"<|>\"geo\"<|>\"Mauritania is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Mozambique\"<|>\"geo\"<|>\"Mozambique is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Niger\"<|>\"geo\"<|>\"Niger is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Nigeria\"<|>\"geo\"<|>\"Nigeria is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"Sierra Leone\"<|>\"geo\"<|>\"Sierra Leone is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"South Sudan\"<|>\"geo\"<|>\"South Sudan is a country in Africa, included in the WHO surveillance report.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"World Health Organization (WHO) is an international public health agency responsible for coordinating health surveillance and reporting globally.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a US government agency involved in public health and disease prevention.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a US federal agency focused on public health, disease surveillance, and prevention.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication reporting on public health surveillance, including acute flaccid paralysis and polio data.\")##\n(\"relationship\"<|>\"World Health Organization\"<|>\"African Region\"<|>\"WHO oversees health surveillance and reporting for the African Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"South-East Asia Region\"<|>\"WHO oversees health surveillance and reporting for the South-East Asia Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Western Pacific Region\"<|>\"WHO oversees health surveillance and reporting for the Western Pacific Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Tajikistan\"<|>\"WHO collects and reports health surveillance data for Tajikistan.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Uzbekistan\"<|>\"WHO collects and reports health surveillance data for Uzbekistan.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Burma (Myanmar)\"<|>\"WHO collects and reports health surveillance data for Burma (Myanmar).\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Malaysia\"<|>\"WHO collects and reports health surveillance data for Malaysia.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Philippines\"<|>\"WHO collects and reports health surveillance data for Philippines.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Angola\"<|>\"WHO collects and reports health surveillance data for Angola.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Benin\"<|>\"WHO collects and reports health surveillance data for Benin.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Burkina Faso\"<|>\"WHO collects and reports health surveillance data for Burkina Faso.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Cameroon\"<|>\"WHO collects and reports health surveillance data for Cameroon.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Central African Republic\"<|>\"WHO collects and reports health surveillance data for Central African Republic.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Chad\"<|>\"WHO collects and reports health surveillance data for Chad.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Congo\"<|>\"WHO collects and reports health surveillance data for Congo.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"C么te d'Ivoire\"<|>\"WHO collects and reports health surveillance data for C么te d'Ivoire.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Democratic Republic of the Congo\"<|>\"WHO collects and reports health surveillance data for Democratic Republic of the Congo.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Eritrea\"<|>\"WHO collects and reports health surveillance data for Eritrea.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Ethiopia\"<|>\"WHO collects and reports health surveillance data for Ethiopia.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Ghana\"<|>\"WHO collects and reports health surveillance data for Ghana.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Guinea\"<|>\"WHO collects and reports health surveillance data for Guinea.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Guinea-Bissau\"<|>\"WHO collects and reports health surveillance data for Guinea-Bissau.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Kenya\"<|>\"WHO collects and reports health surveillance data for Kenya.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Liberia\"<|>\"WHO collects and reports health surveillance data for Liberia.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Madagascar\"<|>\"WHO collects and reports health surveillance data for Madagascar.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Mali\"<|>\"WHO collects and reports health surveillance data for Mali.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Mauritania\"<|>\"WHO collects and reports health surveillance data for Mauritania.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Mozambique\"<|>\"WHO collects and reports health surveillance data for Mozambique.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Niger\"<|>\"WHO collects and reports health surveillance data for Niger.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Nigeria\"<|>\"WHO collects and reports health surveillance data for Nigeria.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Senegal\"<|>\"WHO collects and reports health surveillance data for Senegal.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Sierra Leone\"<|>\"WHO collects and reports health surveillance data for Sierra Leone.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"South Sudan\"<|>\"WHO collects and reports health surveillance data for South Sudan.\"<|>8)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC operates under the US Department of Health and Human Services, focusing on disease surveillance and prevention.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which includes public health surveillance data.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "cc5647d9a0b9089d718435a098ee8bc8": {
    "return": "(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a federal public health agency in the United States that reviewed and oversaw the activity described in the text, ensuring it was conducted in accordance with federal law and CDC policy.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal government department responsible for protecting the health of all Americans and providing essential human services. It is referenced as a publisher and overseer of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"SAS Institute\"<|>\"organization\"<|>\"SAS Institute is a software company that produces SAS statistical software, which was used for survey procedures and data weighting in the study.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the study was conducted, and the population data was weighted to represent the US population.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"event\"<|>\"The Morbidity and Mortality Weekly Report is a publication that disseminates public health information and statistics, including the results of this injury surveillance study.\")##\n(\"entity\"<|>\"Healthcare Cost and Utilization Project\"<|>\"organization\"<|>\"The Healthcare Cost and Utilization Project is a nationwide database that provides samples for emergency department and inpatient data, used in this study to analyze injury-related visits and hospitalizations.\")##\n(\"entity\"<|>\"Nationwide Emergency Department Sample\"<|>\"event\"<|>\"The Nationwide Emergency Department Sample is a dataset within the Healthcare Cost and Utilization Project, used to analyze emergency department visits for injuries among older adults in the United States.\")##\n(\"entity\"<|>\"National Inpatient Sample\"<|>\"event\"<|>\"The National Inpatient Sample is a dataset within the Healthcare Cost and Utilization Project, used to analyze hospitalizations for injuries among older adults in the United States.\")##\n(\"entity\"<|>\"Adults aged 65 years and older\"<|>\"person\"<|>\"Adults aged 65 years and older are the population group studied for injury-related emergency department visits and hospitalizations, including subgroups by age and sex.\")##\n(\"entity\"<|>\"Women\"<|>\"person\"<|>\"Women are a subgroup of adults aged 65 years and older, analyzed for rates of injury-related ED visits and hospitalizations.\")##\n(\"entity\"<|>\"Men\"<|>\"person\"<|>\"Men are a subgroup of adults aged 65 years and older, analyzed for rates of injury-related ED visits and hospitalizations.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional Falls are a type of injury event that accounted for the majority of ED visits and hospitalizations among older adults in the study.\")##\n(\"entity\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional Motor Vehicle Crashes are a type of injury event analyzed for their impact on ED visits and hospitalizations among older adults.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdose\"<|>\"event\"<|>\"Unintentional Opioid Overdose is an injury event included in the study, with rates analyzed by age and sex among older adults.\")##\n(\"entity\"<|>\"Self-Harm\"<|>\"event\"<|>\"Self-Harm is an injury event included in the study, with rates analyzed by age among older adults.\")##\n(\"entity\"<|>\"ICD-10-CM/ICD-10-PCS codes\"<|>\"event\"<|>\"ICD-10-CM/ICD-10-PCS codes are medical classification codes used to identify unintentional opioid overdose cases in the study.\")##\n\n(\"relationship\"<|>\"CDC\"<|>\"US Department of Health and Human Services\"<|>\"CDC operates under the US Department of Health and Human Services and is responsible for public health activities and reporting, including the reviewed activity.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which disseminates the findings of the injury surveillance study.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"Healthcare Cost and Utilization Project\"<|>\"CDC utilized data from the Healthcare Cost and Utilization Project for the analysis of injury-related ED visits and hospitalizations.\"<|>8)##\n(\"relationship\"<|>\"Healthcare Cost and Utilization Project\"<|>\"Nationwide Emergency Department Sample\"<|>\"The Nationwide Emergency Department Sample is a dataset within the Healthcare Cost and Utilization Project, used for ED visit analysis.\"<|>10)##\n(\"relationship\"<|>\"Healthcare Cost and Utilization Project\"<|>\"National Inpatient Sample\"<|>\"The National Inpatient Sample is a dataset within the Healthcare Cost and Utilization Project, used for hospitalization analysis.\"<|>10)##\n(\"relationship\"<|>\"SAS Institute\"<|>\"CDC\"<|>\"CDC used SAS Institute's statistical software for survey procedures and data weighting in the study.\"<|>7)##\n(\"relationship\"<|>\"United States\"<|>\"Adults aged 65 years and older\"<|>\"Adults aged 65 years and older are the population group in the United States studied for injury-related ED visits and hospitalizations.\"<|>10)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Women\"<|>\"Women are a subgroup of adults aged 65 years and older, analyzed separately for injury rates.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Men\"<|>\"Men are a subgroup of adults aged 65 years and older, analyzed separately for injury rates.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Falls\"<|>\"Unintentional Falls are a major cause of injury-related ED visits and hospitalizations among adults aged 65 years and older.\"<|>10)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Unintentional Motor Vehicle Crashes are a significant cause of injury-related ED visits and hospitalizations among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Opioid Overdose\"<|>\"Unintentional Opioid Overdose is a cause of injury-related ED visits and hospitalizations among adults aged 65 years and older, with rates analyzed by age and sex.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Self-Harm\"<|>\"Self-Harm is a cause of injury-related ED visits and hospitalizations among adults aged 65 years and older, with rates analyzed by age.\"<|>7)##\n(\"relationship\"<|>\"Unintentional Opioid Overdose\"<|>\"ICD-10-CM/ICD-10-PCS codes\"<|>\"ICD-10-CM/ICD-10-PCS codes are used to identify cases of unintentional opioid overdose in the study data.\"<|>9)##\n(\"relationship\"<|>\"Nationwide Emergency Department Sample\"<|>\"Unintentional Falls\"<|>\"The Nationwide Emergency Department Sample provides data on ED visits for unintentional falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"National Inpatient Sample\"<|>\"Unintentional Falls\"<|>\"The National Inpatient Sample provides data on hospitalizations for unintentional falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Women\"<|>\"Unintentional Falls\"<|>\"Women aged 65 years and older have higher rates of ED visits and hospitalizations for unintentional falls compared to men.\"<|>8)##\n(\"relationship\"<|>\"Men\"<|>\"Unintentional Opioid Overdose\"<|>\"Men aged 65 years and older have higher rates of ED visits for unintentional opioid overdose compared to women.\"<|>7)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Nationwide Emergency Department Sample\"<|>\"The Nationwide Emergency Department Sample is used to analyze ED visits among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"National Inpatient Sample\"<|>\"The National Inpatient Sample is used to analyze hospitalizations among adults aged 65 years and older.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "638bb0aa1baac50a9aceb9842b23d2b0": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. It oversees agencies such as the CDC and is involved in public health initiatives, including injury prevention among older adults.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a national public health institute in the United States, operating under the US Department of Health and Human Services. The CDC conducts research, provides guidance, and implements campaigns to prevent injuries and promote health, particularly among older adults.\")##\n(\"entity\"<|>\"National Center for Injury Prevention and Control\"<|>\"organization\"<|>\"The National Center for Injury Prevention and Control is a division within the CDC focused on preventing injuries and violence, and reducing their consequences. It conducts research, develops resources, and supports public health campaigns related to injury prevention.\")##\n(\"entity\"<|>\"Alana Vivolo-Kantor\"<|>\"person\"<|>\"Alana Vivolo-Kantor is acknowledged as a contributor to the report, affiliated with the National Center for Injury Prevention and Control, CDC.\")##\n(\"entity\"<|>\"Deborah Stone\"<|>\"person\"<|>\"Deborah Stone is acknowledged as a contributor to the report, affiliated with the National Center for Injury Prevention and Control, CDC.\")##\n(\"entity\"<|>\"Gwen Bergen\"<|>\"person\"<|>\"Gwen Bergen is acknowledged as a contributor to the report, affiliated with the National Center for Injury Prevention and Control, CDC.\")##\n(\"entity\"<|>\"Briana Moreland\"<|>\"person\"<|>\"Briana Moreland is the corresponding author for the report, with an email address at CDC, indicating her involvement in the research and publication process.\")##\n(\"entity\"<|>\"Synergy America, Inc.\"<|>\"organization\"<|>\"Synergy America, Inc. is a company based in Duluth, Georgia, mentioned as an affiliation for one of the authors.\")##\n(\"entity\"<|>\"Duluth, Georgia\"<|>\"geo\"<|>\"Duluth is a city in the state of Georgia, United States, and is the location of Synergy America, Inc.\")##\n(\"entity\"<|>\"Atlanta, GA\"<|>\"geo\"<|>\"Atlanta is the capital city of Georgia, United States, and is referenced as the location for CDC and related activities.\")##\n(\"entity\"<|>\"Still Going Strong awareness campaign\"<|>\"event\"<|>\"The Still Going Strong awareness campaign is a CDC initiative aimed at guiding older adults to prevent injuries as they age, through education and promotion of healthy behaviors.\")##\n(\"entity\"<|>\"Web-based Injury Statistics Query and Reporting System (WISQARS)\"<|>\"event\"<|>\"WISQARS is a web-based system developed by CDC for querying and reporting injury statistics, used for surveillance and research purposes.\")##\n(\"entity\"<|>\"2019 annual surveillance report of drug-related risks and outcomes\"<|>\"event\"<|>\"This is a CDC report providing surveillance data on drug-related risks and outcomes in the United States, referenced as a source of information in the text.\")##\n(\"entity\"<|>\"Older adults in the United States\"<|>\"person\"<|>\"Older adults in the United States refers to the population aged 65 years and older, who are the focus of the injury prevention efforts described in the report.\")##\n(\"entity\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"event\"<|>\"This refers to the estimated 2.4 million emergency department visits and over 700,000 hospitalizations among older adults in 2018 due to injuries such as falls, motor vehicle crashes, opioid overdoses, and self-harm.\")##\n(\"entity\"<|>\"Unintentional falls\"<|>\"event\"<|>\"Unintentional falls are a leading cause of injury among older adults, accounting for over 90% of emergency department visits related to injuries in this population.\")##\n(\"entity\"<|>\"Motor vehicle crashes\"<|>\"event\"<|>\"Motor vehicle crashes are a significant cause of injury and hospitalization among older adults, as discussed in the report.\")##\n(\"entity\"<|>\"Opioid overdoses\"<|>\"event\"<|>\"Opioid overdoses, particularly unintentional ones, are a major cause of injury and death among older adults, accounting for approximately 53% of unintentional overdose deaths in this group.\")##\n(\"entity\"<|>\"Self-harm\"<|>\"event\"<|>\"Self-harm, including poisoning, is a mechanism of injury among older adults, often involving medications such as opioids, benzodiazepines, and tricyclic antidepressants.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services, implementing public health initiatives and research.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"National Center for Injury Prevention and Control\"<|>\"The National Center for Injury Prevention and Control is a division within the CDC focused on injury prevention.\"<|>10)##\n(\"relationship\"<|>\"Alana Vivolo-Kantor\"<|>\"National Center for Injury Prevention and Control\"<|>\"Alana Vivolo-Kantor is affiliated with the National Center for Injury Prevention and Control and contributed to the report.\"<|>9)##\n(\"relationship\"<|>\"Deborah Stone\"<|>\"National Center for Injury Prevention and Control\"<|>\"Deborah Stone is affiliated with the National Center for Injury Prevention and Control and contributed to the report.\"<|>9)##\n(\"relationship\"<|>\"Gwen Bergen\"<|>\"National Center for Injury Prevention and Control\"<|>\"Gwen Bergen is affiliated with the National Center for Injury Prevention and Control and contributed to the report.\"<|>9)##\n(\"relationship\"<|>\"Briana Moreland\"<|>\"Centers for Disease Control and Prevention\"<|>\"Briana Moreland is the corresponding author for the report and is affiliated with the CDC.\"<|>8)##\n(\"relationship\"<|>\"Synergy America, Inc.\"<|>\"Duluth, Georgia\"<|>\"Synergy America, Inc. is located in Duluth, Georgia, as indicated by the author affiliation.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Still Going Strong awareness campaign\"<|>\"The CDC runs the Still Going Strong awareness campaign to educate older adults about injury prevention.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Web-based Injury Statistics Query and Reporting System (WISQARS)\"<|>\"CDC developed and maintains WISQARS for injury statistics and surveillance.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"2019 annual surveillance report of drug-related risks and outcomes\"<|>\"CDC published the 2019 annual surveillance report to provide data on drug-related risks and outcomes.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Older adults in the United States\"<|>\"CDC targets older adults in the United States for injury prevention campaigns and research.\"<|>9)##\n(\"relationship\"<|>\"Older adults in the United States\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"Older adults are the population experiencing high rates of emergency department visits and hospitalizations due to injuries.\"<|>10)##\n(\"relationship\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"Unintentional falls\"<|>\"Unintentional falls account for over 90% of emergency department visits and hospitalizations from injuries among older adults.\"<|>10)##\n(\"relationship\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"Motor vehicle crashes\"<|>\"Motor vehicle crashes are a significant cause of injury-related emergency department visits and hospitalizations among older adults.\"<|>9)##\n(\"relationship\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"Opioid overdoses\"<|>\"Opioid overdoses contribute to emergency department visits and hospitalizations among older adults.\"<|>9)##\n(\"relationship\"<|>\"Emergency department visits and hospitalizations from injuries\"<|>\"Self-harm\"<|>\"Self-harm is a mechanism of injury leading to emergency department visits and hospitalizations among older adults.\"<|>8)##\n(\"relationship\"<|>\"Unintentional falls\"<|>\"Older adults in the United States\"<|>\"Unintentional falls are the most common cause of injury among older adults in the United States.\"<|>10)##\n(\"relationship\"<|>\"Motor vehicle crashes\"<|>\"Older adults in the United States\"<|>\"Motor vehicle crashes are a significant risk for injury among older adults.\"<|>9)##\n(\"relationship\"<|>\"Opioid overdoses\"<|>\"Older adults in the United States\"<|>\"Opioid overdoses, especially unintentional ones, are a major cause of injury and death among older adults.\"<|>9)##\n(\"relationship\"<|>\"Self-harm\"<|>\"Older adults in the United States\"<|>\"Self-harm, including poisoning, is a mechanism of injury among older adults, often involving medications.\"<|>8)##\n(\"relationship\"<|>\"Atlanta, GA\"<|>\"Centers for Disease Control and Prevention\"<|>\"Atlanta, GA is the location of the CDC headquarters and related activities.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "5d8fa3c3713dd3e3a603d289872fdca8": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services. It oversees various public health initiatives and agencies, including the Centers for Disease Control and Prevention.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a national public health institute under the US Department of Health and Human Services. It conducts research, provides health information, and works to prevent and control diseases, injuries, and disabilities.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication produced by the CDC that provides data and analysis on public health topics, including injury rates and trends.\")##\n(\"entity\"<|>\"Men\"<|>\"person\"<|>\"Men are a demographic group referenced in the report, with higher rates of motor vehicle crash-related hospitalizations and fall-related mortality among adults aged 65 years and older.\")##\n(\"entity\"<|>\"Women\"<|>\"person\"<|>\"Women are a demographic group referenced in the report, with higher rates of fall-related injury ED visits and hospitalizations, and higher rates of unintentional opioid overdose-related hospitalizations among adults aged 65 years and older.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country in which the study and data collection took place, focusing on adults aged 65 years and older.\")##\n(\"entity\"<|>\"Emergency Department Visits\"<|>\"event\"<|>\"Emergency Department Visits refer to instances where adults aged 65 years and older sought emergency medical care for injuries such as falls, motor vehicle crashes, opioid overdoses, and self-harm in 2018.\")##\n(\"entity\"<|>\"Hospitalizations\"<|>\"event\"<|>\"Hospitalizations refer to instances where adults aged 65 years and older were admitted to hospitals due to injuries from falls, motor vehicle crashes, opioid overdoses, and self-harm in 2018.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional Falls are a leading cause of injury among adults aged 65 years and older, accounting for over 90% of emergency department visits and hospitalizations for injuries in 2018.\")##\n(\"entity\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional Motor Vehicle Crashes refer to accidents involving vehicles that resulted in injuries among adults aged 65 years and older, with higher hospitalization rates among men.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdoses\"<|>\"event\"<|>\"Unintentional Opioid Overdoses refer to accidental overdoses from opioid medications among adults aged 65 years and older, with higher hospitalization rates among women.\")##\n(\"entity\"<|>\"Self-Harm\"<|>\"event\"<|>\"Self-Harm refers to intentional injury inflicted by oneself, which resulted in emergency department visits and hospitalizations among adults aged 65 years and older in 2018.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services, conducting public health research and reporting.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"The CDC publishes the Morbidity and Mortality Weekly Report to disseminate public health data and findings.\"<|>9)##\n(\"relationship\"<|>\"United States\"<|>\"Emergency Department Visits\"<|>\"Emergency Department Visits for injuries among adults aged 65 years and older occurred throughout the United States in 2018.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Hospitalizations\"<|>\"Hospitalizations for injuries among adults aged 65 years and older occurred throughout the United States in 2018.\"<|>8)##\n(\"relationship\"<|>\"Emergency Department Visits\"<|>\"Unintentional Falls\"<|>\"Unintentional Falls accounted for over 90% of emergency department visits for injuries among adults aged 65 years and older.\"<|>10)##\n(\"relationship\"<|>\"Hospitalizations\"<|>\"Unintentional Falls\"<|>\"Unintentional Falls accounted for the majority of hospitalizations for injuries among adults aged 65 years and older.\"<|>10)##\n(\"relationship\"<|>\"Men\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Men had higher rates of hospitalization due to unintentional motor vehicle crashes among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Women\"<|>\"Unintentional Falls\"<|>\"Women had higher rates of emergency department visits and hospitalizations for fall-related injuries among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Men\"<|>\"Unintentional Falls\"<|>\"Men had higher fall-related mortality rates among adults aged 65 years and older, despite lower rates of ED visits and hospitalizations compared to women.\"<|>7)##\n(\"relationship\"<|>\"Women\"<|>\"Unintentional Opioid Overdoses\"<|>\"Women had higher rates of unintentional opioid overdose-related hospitalizations among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Men\"<|>\"Unintentional Opioid Overdoses\"<|>\"Men had lower rates of unintentional opioid overdose-related hospitalizations among adults aged 65 years and older compared to women.\"<|>6)##\n(\"relationship\"<|>\"Emergency Department Visits\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Emergency department visits for crash-related injuries decreased with age among adults aged 65 years and older.\"<|>7)##\n(\"relationship\"<|>\"Emergency Department Visits\"<|>\"Unintentional Opioid Overdoses\"<|>\"Emergency department visits for unintentional opioid overdoses among adults aged 65 years and older were less common than for falls or motor vehicle crashes.\"<|>6)##\n(\"relationship\"<|>\"Emergency Department Visits\"<|>\"Self-Harm\"<|>\"Emergency department visits for self-harm among adults aged 65 years and older were less common than for falls or motor vehicle crashes.\"<|>6)##\n(\"relationship\"<|>\"Hospitalizations\"<|>\"Unintentional Opioid Overdoses\"<|>\"Hospitalizations for unintentional opioid overdoses among adults aged 65 years and older were higher than ED visits for the same cause.\"<|>7)##\n(\"relationship\"<|>\"Hospitalizations\"<|>\"Self-Harm\"<|>\"Hospitalizations for self-harm among adults aged 65 years and older were higher than ED visits for the same cause.\"<|>7)##\n(\"relationship\"<|>\"Unintentional Opioid Overdoses\"<|>\"Self-Harm\"<|>\"Unintentional opioid overdoses and self-harm share common risk factors among older adults, such as depression and medication use.\"<|>7)##\n(\"relationship\"<|>\"Unintentional Falls\"<|>\"Self-Harm\"<|>\"Unintentional falls and self-harm share common risk factors among older adults, such as depression and medication use.\"<|>6)##\n(\"relationship\"<|>\"Unintentional Falls\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Unintentional falls and motor vehicle crashes are both major causes of injury among adults aged 65 years and older, with overlapping risk factors such as visual impairment and medication use.\"<|>7)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"United States\"<|>\"The CDC collects and analyzes public health data from the United States, including injury rates among older adults.\"<|>9)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Emergency Department Visits\"<|>\"The MMWR reports on emergency department visits for injuries among adults aged 65 years and older in the United States.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Hospitalizations\"<|>\"The MMWR reports on hospitalizations for injuries among adults aged 65 years and older in the United States.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Unintentional Falls\"<|>\"The MMWR provides data and analysis on unintentional falls among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"The MMWR provides data and analysis on unintentional motor vehicle crashes among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Unintentional Opioid Overdoses\"<|>\"The MMWR provides data and analysis on unintentional opioid overdoses among adults aged 65 years and older.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Self-Harm\"<|>\"The MMWR provides data and analysis on self-harm among adults aged 65 years and older.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "35a7f231fe80674d54c8f7dcc9d98a42": {
    "return": "(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in Africa included in the surveillance data for acute flaccid paralysis (AFP) and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Sierra Leone\"<|>\"geo\"<|>\"Sierra Leone is a country in Africa included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"South Sudan\"<|>\"geo\"<|>\"South Sudan is a country in Africa included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Togo\"<|>\"geo\"<|>\"Togo is a country in Africa included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Zambia\"<|>\"geo\"<|>\"Zambia is a country in Africa included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"Eastern Mediterranean Region is a WHO-defined region including multiple countries, reported in the context of AFP and polio surveillance.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Egypt\"<|>\"geo\"<|>\"Egypt is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Iran\"<|>\"geo\"<|>\"Iran is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Iraq\"<|>\"geo\"<|>\"Iraq is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Libya\"<|>\"geo\"<|>\"Libya is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Somalia\"<|>\"geo\"<|>\"Somalia is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Sudan\"<|>\"geo\"<|>\"Sudan is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Syria\"<|>\"geo\"<|>\"Syria is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Yemen\"<|>\"geo\"<|>\"Yemen is a country in the Eastern Mediterranean Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"European Region\"<|>\"geo\"<|>\"European Region is a WHO-defined region included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Tajikistan\"<|>\"geo\"<|>\"Tajikistan is a country in the European Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Uzbekistan\"<|>\"geo\"<|>\"Uzbekistan is a country in the European Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"South-East Asia Region\"<|>\"geo\"<|>\"South-East Asia Region is a WHO-defined region included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Burma (Myanmar)\"<|>\"geo\"<|>\"Burma (Myanmar) is a country in the South-East Asia Region, included in the surveillance data for AFP and polio, with performance indicators reported. The country is referred to as Burma by MMWR and Myanmar by WHO.\")##\n(\"entity\"<|>\"Western Pacific Region\"<|>\"geo\"<|>\"Western Pacific Region is a WHO-defined region included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Malaysia\"<|>\"geo\"<|>\"Malaysia is a country in the Western Pacific Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"Philippines\"<|>\"geo\"<|>\"Philippines is a country in the Western Pacific Region, included in the surveillance data for AFP and polio, with performance indicators reported.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"World Health Organization (WHO) is an international public health agency responsible for setting surveillance targets, accrediting laboratories, and defining regions for AFP and polio surveillance.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a U.S. public health agency involved in reporting and analysis of AFP and polio surveillance data.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal agency overseeing public health, including CDC, and involved in the publication of surveillance reports.\")##\n(\"entity\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"event\"<|>\"Acute Flaccid Paralysis Surveillance is a public health activity involving monitoring and reporting of AFP cases, specimen collection, and laboratory analysis to detect polio and related viruses.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication reporting surveillance data, including AFP and polio indicators, produced by CDC.\")##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Eastern Mediterranean Region\"<|>\"WHO defines and oversees the Eastern Mediterranean Region for surveillance and reporting purposes.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"European Region\"<|>\"WHO defines and oversees the European Region for surveillance and reporting purposes.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"South-East Asia Region\"<|>\"WHO defines and oversees the South-East Asia Region for surveillance and reporting purposes.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Western Pacific Region\"<|>\"WHO defines and oversees the Western Pacific Region for surveillance and reporting purposes.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"WHO sets standards and targets for AFP surveillance, specimen collection, and laboratory accreditation.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC produces and publishes the Morbidity and Mortality Weekly Report, which includes AFP surveillance data.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC operates under the US Department of Health and Human Services, which oversees public health activities.\"<|>10)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Senegal\"<|>\"Senegal is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Sierra Leone\"<|>\"Sierra Leone is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"South Sudan\"<|>\"South Sudan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Togo\"<|>\"Togo is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Zambia\"<|>\"Zambia is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Afghanistan\"<|>\"Afghanistan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Egypt\"<|>\"Egypt is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Iran\"<|>\"Iran is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Iraq\"<|>\"Iraq is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Libya\"<|>\"Libya is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Pakistan\"<|>\"Pakistan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Somalia\"<|>\"Somalia is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Sudan\"<|>\"Sudan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Syria\"<|>\"Syria is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Yemen\"<|>\"Yemen is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Tajikistan\"<|>\"Tajikistan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Uzbekistan\"<|>\"Uzbekistan is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Burma (Myanmar)\"<|>\"Burma (Myanmar) is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Malaysia\"<|>\"Malaysia is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Philippines\"<|>\"Philippines is included in the AFP surveillance activity, with performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"US Department of Health and Human Services\"<|>\"MMWR is published under the auspices of the US Department of Health and Human Services.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Burma (Myanmar)\"<|>\"WHO refers to the country as Myanmar, indicating its role in international nomenclature and surveillance reporting.\"<|>7)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"MMWR reports and analyzes data from AFP surveillance activities.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "2732b008f823b8470241912c287bb408": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of all Americans and providing essential human services. It oversees public health, welfare programs, and health-related research and policy.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a national public health institute in the United States, operating under the Department of Health and Human Services. It conducts research, provides health information, and works to prevent and control disease, injury, and disability.\")##\n(\"entity\"<|>\"Healthcare Cost and Utilization Project\"<|>\"organization\"<|>\"The Healthcare Cost and Utilization Project (HCUP) is a family of healthcare databases and related software tools developed through a federal-state-industry partnership and sponsored by the Agency for Healthcare Research and Quality. It provides data on hospital care, including emergency department visits and inpatient stays.\")##\n(\"entity\"<|>\"Nationwide Emergency Department Sample\"<|>\"organization\"<|>\"The Nationwide Emergency Department Sample (NEDS) is a database within HCUP that provides national estimates of emergency department visits, including injury-related cases.\")##\n(\"entity\"<|>\"National Inpatient Sample\"<|>\"organization\"<|>\"The National Inpatient Sample (NIS) is a database within HCUP that provides national estimates of hospital inpatient stays, including those related to injuries.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is a country in North America, referenced here as the location for the data collection and analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years and older.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that provides timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.\")##\n(\"entity\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"event\"<|>\"This event refers to the collection and analysis of data on emergency department visits and hospitalizations due to injuries among adults aged 65 years and older in the United States, as reported in 2018.\")##\n(\"entity\"<|>\"Self-harm\"<|>\"event\"<|>\"Self-harm refers to intentional injury inflicted by individuals upon themselves, tracked as a specific cause of emergency department visits and hospitalizations among adults aged 65 years and older.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional falls are accidental events resulting in injury, and are a major cause of emergency department visits and hospitalizations among older adults in the United States.\")##\n(\"entity\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional motor vehicle crashes refer to accidental traffic incidents resulting in injury, tracked as a cause of emergency department visits and hospitalizations among older adults.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdoses\"<|>\"event\"<|>\"Unintentional opioid overdoses refer to accidental consumption of opioid drugs leading to overdose and injury, tracked as a cause of emergency department visits and hospitalizations among older adults.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services, which oversees its activities and public health initiatives.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"The CDC publishes the Morbidity and Mortality Weekly Report to disseminate public health data and recommendations.\"<|>9)##\n(\"relationship\"<|>\"Healthcare Cost and Utilization Project\"<|>\"Nationwide Emergency Department Sample\"<|>\"The Nationwide Emergency Department Sample is a database within the Healthcare Cost and Utilization Project, providing data on emergency department visits.\"<|>8)##\n(\"relationship\"<|>\"Healthcare Cost and Utilization Project\"<|>\"National Inpatient Sample\"<|>\"The National Inpatient Sample is a database within the Healthcare Cost and Utilization Project, providing data on hospital inpatient stays.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Healthcare Cost and Utilization Project\"<|>\"The CDC uses data from the Healthcare Cost and Utilization Project to analyze injury-related emergency department visits and hospitalizations.\"<|>7)##\n(\"relationship\"<|>\"United States\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"The event of injury-related emergency department visits and hospitalizations among adults aged 65 years is analyzed within the United States.\"<|>10)##\n(\"relationship\"<|>\"Nationwide Emergency Department Sample\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"The Nationwide Emergency Department Sample provides data for analyzing injury-related emergency department visits among adults aged 65 years.\"<|>9)##\n(\"relationship\"<|>\"National Inpatient Sample\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"The National Inpatient Sample provides data for analyzing injury-related hospitalizations among adults aged 65 years.\"<|>9)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Self-harm\"<|>\"Self-harm is one of the causes tracked in the analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Unintentional Falls\"<|>\"Unintentional falls are a major cause included in the analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Unintentional motor vehicle crashes are a tracked cause in the analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Unintentional Opioid Overdoses\"<|>\"Unintentional opioid overdoses are a tracked cause in the analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "e75143206f737d281e1046a721d10fbe": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services. It oversees public health, medical research, and disease prevention activities, including the Centers for Disease Control and Prevention.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency under the Department of Health and Human Services, focused on public health, disease surveillance, and prevention, including monitoring acute flaccid paralysis and poliovirus outbreaks.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health, including setting surveillance targets and accrediting laboratories for poliovirus detection and monitoring.\")##\n(\"entity\"<|>\"Global Polio Laboratory Network\"<|>\"organization\"<|>\"The WHO Global Polio Laboratory Network (GPLN) is a network of 145 quality-assured laboratories across six WHO regions, responsible for poliovirus surveillance, isolation, differentiation, and genomic sequencing, with standardized protocols and annual accreditation.\")##\n(\"entity\"<|>\"Burma (Myanmar)\"<|>\"geo\"<|>\"Burma (Myanmar) is a country in Southeast Asia, referred to as Burma by the US State Department and Myanmar by WHO. It is a priority country for acute flaccid paralysis surveillance in the WHO South-East Asia Region.\")##\n(\"entity\"<|>\"Uzbekistan\"<|>\"geo\"<|>\"Uzbekistan is a country in Central Asia, monitored for acute flaccid paralysis surveillance. In 2019 and 2020, it met only the stool adequacy indicator target at the national level, with poor subnational performance.\")##\n(\"entity\"<|>\"Tajikistan\"<|>\"geo\"<|>\"Tajikistan is a country in Central Asia that met both surveillance indicator targets at the national level in 2019 and 2020. It experienced a cVDPV2 outbreak starting in 2020, which continued into 2021.\")##\n(\"entity\"<|>\"Malaysia\"<|>\"geo\"<|>\"Malaysia is a country in Southeast Asia, assessed for acute flaccid paralysis surveillance. It met the NPAFP indicator target in 2019 and 2020, and the stool adequacy indicator in 2020. It reported cVDPV1 and cVDPV2 cases.\")##\n(\"entity\"<|>\"Philippines\"<|>\"geo\"<|>\"Philippines is a country in Southeast Asia, assessed for acute flaccid paralysis surveillance. It met the NPAFP indicator target in 2019 and 2020, but not the stool adequacy indicator. It reported cVDPV1 and cVDPV2 cases.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country in South Asia, where environmental surveillance detected poliovirus, including cVDPV2 and WPV1 genetic clusters. The number of cVDPV2 detections increased significantly in 2020.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in South Asia, where environmental surveillance detected poliovirus, including cVDPV2 and WPV1 genetic clusters. The number of cVDPV2 detections increased significantly in 2020.\")##\n(\"entity\"<|>\"Cameroon\"<|>\"geo\"<|>\"Cameroon is a country in Central Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Chad\"<|>\"geo\"<|>\"Chad is a country in Central Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"C么te d'Ivoire\"<|>\"geo\"<|>\"C么te d'Ivoire is a country in West Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Egypt\"<|>\"geo\"<|>\"Egypt is a country in North Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Ghana\"<|>\"geo\"<|>\"Ghana is a country in West Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Iran\"<|>\"geo\"<|>\"Iran is a country in the Middle East, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Kenya\"<|>\"geo\"<|>\"Kenya is a country in East Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Liberia\"<|>\"geo\"<|>\"Liberia is a country in West Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in West Africa, where environmental surveillance detected cVDPV2 in sewage samples before confirmed AFP cases.\")##\n(\"entity\"<|>\"Nigeria\"<|>\"geo\"<|>\"Nigeria is a country in West Africa, where environmental surveillance detected cVDPV2 in sewage samples, with a decline in isolations from 2019 to 2020.\")##\n(\"entity\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"event\"<|>\"Acute Flaccid Paralysis (AFP) Surveillance is a public health activity to monitor and detect cases of paralysis, particularly for poliovirus detection, using performance indicators such as NPAFP and stool adequacy.\")##\n(\"entity\"<|>\"cVDPV2 Outbreak in Tajikistan\"<|>\"event\"<|>\"The cVDPV2 outbreak in Tajikistan began in 2020 following detection of a case and continued into 2021, representing ongoing poliovirus transmission.\")##\n(\"entity\"<|>\"cVDPV1 Cases in Malaysia and Philippines\"<|>\"event\"<|>\"cVDPV1 cases occurred in Malaysia and Philippines in 2019, with one case in Malaysia in 2020, indicating poliovirus transmission in these countries.\")##\n(\"entity\"<|>\"cVDPV2 Cases in Philippines\"<|>\"event\"<|>\"Philippines reported cVDPV2 cases in both 2019 and 2020, indicating ongoing poliovirus transmission.\")##\n(\"entity\"<|>\"Environmental Surveillance\"<|>\"event\"<|>\"Environmental Surveillance is the systematic testing of sewage samples to identify populations shedding polioviruses, often more sensitive than AFP surveillance for detecting poliovirus transmission.\")##\n(\"entity\"<|>\"Genomic Sequence Analysis of cVDPV\"<|>\"event\"<|>\"Genomic sequence analysis is used to identify and track cVDPV emergences from AFP cases, with 41 emergences in 18 countries in 2019 and 34 in 25 countries in 2020.\")##\n(\"entity\"<|>\"WPV1 Genetic Clusters in Afghanistan and Pakistan\"<|>\"event\"<|>\"In 2019, 10 WPV1 genetic clusters were detected in environmental sites from four provinces in Afghanistan and four provinces in Pakistan, indicating poliovirus transmission pathways.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services, conducting public health surveillance and disease prevention activities.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"The CDC monitors and reports on acute flaccid paralysis surveillance as part of its public health mandate.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Global Polio Laboratory Network\"<|>\"The WHO oversees the Global Polio Laboratory Network, which is essential for poliovirus surveillance and laboratory accreditation.\"<|>10)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Genomic Sequence Analysis of cVDPV\"<|>\"GPLN laboratories conduct genomic sequence analysis to identify and track cVDPV emergences from AFP cases.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"WHO sets surveillance targets and accredits laboratories for AFP surveillance globally.\"<|>9)##\n(\"relationship\"<|>\"Burma (Myanmar)\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Burma (Myanmar) is a priority country for AFP surveillance in the WHO South-East Asia Region, with national and subnational performance indicators tracked.\"<|>8)##\n(\"relationship\"<|>\"Uzbekistan\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Uzbekistan is monitored for AFP surveillance, with national and subnational performance indicators reported.\"<|>8)##\n(\"relationship\"<|>\"Tajikistan\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Tajikistan met both AFP surveillance indicator targets at the national level in 2019 and 2020.\"<|>8)##\n(\"relationship\"<|>\"Tajikistan\"<|>\"cVDPV2 Outbreak in Tajikistan\"<|>\"Tajikistan experienced a cVDPV2 outbreak beginning in 2020, following detection of a case during AFP surveillance.\"<|>10)##\n(\"relationship\"<|>\"Malaysia\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Malaysia's performance in AFP surveillance is tracked, with indicator targets met in 2019 and 2020.\"<|>8)##\n(\"relationship\"<|>\"Malaysia\"<|>\"cVDPV1 Cases in Malaysia and Philippines\"<|>\"Malaysia reported cVDPV1 cases in 2019 and 2020, indicating poliovirus transmission detected through surveillance.\"<|>9)##\n(\"relationship\"<|>\"Philippines\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Philippines' performance in AFP surveillance is tracked, with indicator targets met in 2019 and 2020.\"<|>8)##\n(\"relationship\"<|>\"Philippines\"<|>\"cVDPV1 Cases in Malaysia and Philippines\"<|>\"Philippines reported cVDPV1 cases in 2019, indicating poliovirus transmission detected through surveillance.\"<|>9)##\n(\"relationship\"<|>\"Philippines\"<|>\"cVDPV2 Cases in Philippines\"<|>\"Philippines reported cVDPV2 cases in both 2019 and 2020, indicating ongoing transmission.\"<|>10)##\n(\"relationship\"<|>\"Malaysia\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Malaysia detected cVDPV1 and cVDPV2 in sewage samples before confirmed AFP cases.\"<|>9)##\n(\"relationship\"<|>\"Philippines\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Philippines detected cVDPV1 in sewage samples before confirmed AFP cases.\"<|>9)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Afghanistan detected cVDPV2 and WPV1 genetic clusters in sewage samples before confirmed AFP cases.\"<|>9)##\n(\"relationship\"<|>\"Pakistan\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Pakistan detected cVDPV2 and WPV1 genetic clusters in sewage samples before confirmed AFP cases.\"<|>9)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"WPV1 Genetic Clusters in Afghanistan and Pakistan\"<|>\"WPV1 genetic clusters were detected in environmental sites in Afghanistan, indicating transmission pathways.\"<|>8)##\n(\"relationship\"<|>\"Pakistan\"<|>\"WPV1 Genetic Clusters in Afghanistan and Pakistan\"<|>\"WPV1 genetic clusters were detected in environmental sites in Pakistan, indicating transmission pathways.\"<|>8)##\n(\"relationship\"<|>\"Nigeria\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Nigeria detected cVDPV2 in sewage samples, with a decline in isolations from 2019 to 2020.\"<|>8)##\n(\"relationship\"<|>\"Cameroon\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Cameroon detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Chad\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Chad detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"C么te d'Ivoire\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in C么te d'Ivoire detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Egypt\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Egypt detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Ghana\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Ghana detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Iran\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Iran detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Kenya\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Kenya detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Liberia\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Liberia detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Senegal\"<|>\"Environmental Surveillance\"<|>\"Environmental surveillance in Senegal detected cVDPV2 in sewage samples before confirmed AFP cases.\"<|>8)##\n(\"relationship\"<|>\"Genomic Sequence Analysis of cVDPV\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Genomic sequence analysis is used to identify and track cVDPV emergences from AFP cases, enhancing surveillance effectiveness.\"<|>8)##\n(\"relationship\"<|>\"Environmental Surveillance\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Environmental surveillance complements AFP surveillance by detecting poliovirus transmission in populations, sometimes before paralysis cases are confirmed.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "b2da6c98730ef4de8b6a7a236beeb7a7": {
    "return": "(\"entity\"<|>\"African countries\"<|>\"geo\"<|>\"African countries refers collectively to the nations on the African continent listed in the dataset, including Central African Republic, Chad, Congo, Cte dIvoire, Democratic Republic of the Congo, Eritrea, Ethiopia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Mali, Mauritania, Mozambique, Niger, Nigeria, Senegal, Sierra Leone, South Sudan, Togo, Zambia, Sudan, and Somalia.\")##\n(\"entity\"<|>\"West Africa\"<|>\"geo\"<|>\"West Africa is a region of Africa that includes countries such as Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, and Cte dIvoire, as represented in the dataset.\")##\n(\"entity\"<|>\"East Africa\"<|>\"geo\"<|>\"East Africa is a region of Africa that includes countries such as Eritrea, Ethiopia, Kenya, Madagascar, South Sudan, and Somalia, as represented in the dataset.\")##\n(\"entity\"<|>\"Central Africa\"<|>\"geo\"<|>\"Central Africa is a region of Africa that includes countries such as Central African Republic, Chad, Congo, Democratic Republic of the Congo, as represented in the dataset.\")##\n(\"entity\"<|>\"Southern Africa\"<|>\"geo\"<|>\"Southern Africa is a region of Africa that includes countries such as Zambia and Mozambique, as represented in the dataset.\")##\n(\"entity\"<|>\"North Africa\"<|>\"geo\"<|>\"North Africa is a region of Africa that includes countries such as Egypt, Libya, and Sudan, as represented in the dataset.\")##\n(\"entity\"<|>\"Middle East\"<|>\"geo\"<|>\"Middle East is a region that includes countries such as Iran, Iraq, Syria, Yemen, and Afghanistan, as represented in the dataset.\")##\n(\"entity\"<|>\"Central Asia\"<|>\"geo\"<|>\"Central Asia is a region that includes countries such as Tajikistan and Uzbekistan, as represented in the dataset.\")##\n(\"entity\"<|>\"South Asia\"<|>\"geo\"<|>\"South Asia is a region that includes countries such as Afghanistan and Pakistan, as represented in the dataset.\")##\n(\"entity\"<|>\"WHO\"<|>\"organization\"<|>\"WHO (World Health Organization) is an international public health agency that organizes countries into regions such as Eastern Mediterranean Region, European Region, and South-East Asia Region for statistical and health reporting purposes.\")##\n(\"relationship\"<|>\"African countries\"<|>\"WHO\"<|>\"African countries are grouped and reported by WHO for health and statistical purposes, as indicated by the dataset.\"<|>9)##\n(\"relationship\"<|>\"West Africa\"<|>\"African countries\"<|>\"West Africa is a subregion within African countries, grouping several listed nations for regional analysis.\"<|>8)##\n(\"relationship\"<|>\"East Africa\"<|>\"African countries\"<|>\"East Africa is a subregion within African countries, grouping several listed nations for regional analysis.\"<|>8)##\n(\"relationship\"<|>\"Central Africa\"<|>\"African countries\"<|>\"Central Africa is a subregion within African countries, grouping several listed nations for regional analysis.\"<|>8)##\n(\"relationship\"<|>\"Southern Africa\"<|>\"African countries\"<|>\"Southern Africa is a subregion within African countries, grouping several listed nations for regional analysis.\"<|>8)##\n(\"relationship\"<|>\"North Africa\"<|>\"African countries\"<|>\"North Africa is a subregion within African countries, grouping several listed nations for regional analysis.\"<|>8)##\n(\"relationship\"<|>\"Middle East\"<|>\"Eastern Mediterranean Region\"<|>\"Middle East countries are included in the Eastern Mediterranean Region grouping by WHO for statistical purposes.\"<|>8)##\n(\"relationship\"<|>\"Central Asia\"<|>\"European Region\"<|>\"Central Asia countries are included in the European Region grouping by WHO for statistical purposes.\"<|>7)##\n(\"relationship\"<|>\"South Asia\"<|>\"Eastern Mediterranean Region\"<|>\"South Asia countries are included in the Eastern Mediterranean Region grouping by WHO for statistical purposes.\"<|>7)##\n(\"relationship\"<|>\"WHO\"<|>\"Eastern Mediterranean Region\"<|>\"WHO organizes the Eastern Mediterranean Region for health and statistical reporting, grouping relevant countries.\"<|>10)##\n(\"relationship\"<|>\"WHO\"<|>\"European Region\"<|>\"WHO organizes the European Region for health and statistical reporting, grouping relevant countries.\"<|>10)##\n(\"relationship\"<|>\"WHO\"<|>\"South-East Asia Region\"<|>\"WHO organizes the South-East Asia Region for health and statistical reporting, grouping relevant countries.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "353a82bacdc7c0b0b2aba1381a68d7a1": {
    "return": "(\"entity\"<|>\"GPLN\"<|>\"organization\"<|>\"The Global Polio Laboratory Network (GPLN) is a network of laboratories responsible for poliovirus testing, including intratypic differentiation, identification of WPV, Sabin polioviruses, and VDPV, as well as conducting genomic sequencing. GPLN monitors the accuracy and quality of testing through annual accreditation and proficiency testing, and supports environmental surveillance with specialized checklists.\")##\n(\"entity\"<|>\"GPEI\"<|>\"organization\"<|>\"The Global Polio Eradication Initiative (GPEI) is an international partnership that coordinates polio eradication activities, provides recommendations for surveillance and response, and manages logistical assets for polio and COVID-19 surveillance.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"The World Health Organization (WHO) is a global health agency that oversees regional polio surveillance, accredits national polio laboratories, and sets standards for timeliness and quality of laboratory results.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency involved in public health, including oversight and publication of surveillance data related to polio and other diseases.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency that contributes to disease surveillance, laboratory testing, and public health reporting, including polio and COVID-19.\")##\n(\"entity\"<|>\"COVID-19 pandemic\"<|>\"event\"<|>\"The COVID-19 pandemic is a global health crisis that began in 2019, substantially affecting polio eradication activities, laboratory workloads, and movement restrictions in 2020.\")##\n(\"entity\"<|>\"Polio eradication activities\"<|>\"event\"<|>\"Polio eradication activities refer to coordinated efforts to eliminate polio globally, including surveillance, laboratory testing, and response measures, which were impacted by the COVID-19 pandemic.\")##\n(\"entity\"<|>\"African Region\"<|>\"geo\"<|>\"The African Region (AFR) is a WHO-designated geographic area comprising countries in Africa, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"The Eastern Mediterranean Region (EMR) is a WHO-designated geographic area comprising countries in the Middle East and North Africa, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"European Region\"<|>\"geo\"<|>\"The European Region (EUR) is a WHO-designated geographic area comprising countries in Europe, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"South-East Asia Region\"<|>\"geo\"<|>\"The South-East Asia Region (SEA) is a WHO-designated geographic area comprising countries in South-East Asia, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"Western Pacific Region\"<|>\"geo\"<|>\"The Western Pacific Region (WPR) is a WHO-designated geographic area comprising countries in the Western Pacific, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"American Region\"<|>\"geo\"<|>\"The American Region is a WHO-designated geographic area comprising countries in the Americas, monitored for polio surveillance and laboratory testing.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country in South Asia where the South Asia genotype of WPV1 was detected in 2019 and 2020, and where orphan WPV1 isolates were found, indicating surveillance gaps.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in South Asia where the South Asia genotype of WPV1 was detected in 2019 and 2020, and where orphan WPV1 isolates were found, indicating surveillance gaps.\")##\n(\"entity\"<|>\"South Asia genotype\"<|>\"event\"<|>\"The South Asia genotype refers to the only WPV1 genotype detected globally since 2016, found in Afghanistan and Pakistan in 2019 and 2020.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication of the CDC and US Department of Health and Human Services, reporting on public health surveillance data.\")##\n(\"relationship\"<|>\"GPLN\"<|>\"World Health Organization\"<|>\"GPLN operates under the standards and accreditation set by the World Health Organization for polio laboratory testing and surveillance.\"<|>9)##\n(\"relationship\"<|>\"GPLN\"<|>\"GPEI\"<|>\"GPLN laboratories and staff support GPEI's polio eradication activities and recommendations, including surveillance and response efforts.\"<|>8)##\n(\"relationship\"<|>\"GPLN\"<|>\"COVID-19 pandemic\"<|>\"The COVID-19 pandemic increased the workload of GPLN staff, who were required to analyze COVID-19 specimens in addition to polio specimens.\"<|>7)##\n(\"relationship\"<|>\"GPEI\"<|>\"COVID-19 pandemic\"<|>\"GPEI recommended the reemployment of polio surveillance staff and logistical assets to support COVID-19 response efforts in AFR countries.\"<|>8)##\n(\"relationship\"<|>\"GPLN\"<|>\"Polio eradication activities\"<|>\"GPLN is central to polio eradication activities through laboratory testing, surveillance, and quality assurance.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Polio eradication activities\"<|>\"WHO oversees and coordinates polio eradication activities globally, including laboratory accreditation and surveillance standards.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services and contributes to public health surveillance and reporting.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which includes surveillance data on polio and other diseases.\"<|>10)##\n(\"relationship\"<|>\"Polio eradication activities\"<|>\"COVID-19 pandemic\"<|>\"Polio eradication activities were substantially affected by the COVID-19 pandemic, leading to changes in staff deployment and laboratory operations.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the African Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the Eastern Mediterranean Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"European Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the European Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"South-East Asia Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the South-East Asia Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"Western Pacific Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the Western Pacific Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"American Region\"<|>\"GPLN\"<|>\"GPLN laboratories in the American Region conduct polio surveillance and laboratory testing, with data reported in the text.\"<|>8)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"South Asia genotype\"<|>\"Afghanistan is one of the countries where the South Asia genotype of WPV1 was detected in 2019 and 2020.\"<|>9)##\n(\"relationship\"<|>\"Pakistan\"<|>\"South Asia genotype\"<|>\"Pakistan is one of the countries where the South Asia genotype of WPV1 was detected in 2019 and 2020.\"<|>9)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"GPLN\"<|>\"GPLN laboratories test specimens from Afghanistan for polio surveillance and genotype detection.\"<|>8)##\n(\"relationship\"<|>\"Pakistan\"<|>\"GPLN\"<|>\"GPLN laboratories test specimens from Pakistan for polio surveillance and genotype detection.\"<|>8)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"Polio eradication activities\"<|>\"Afghanistan is a priority country for polio eradication activities, with surveillance and laboratory testing reported in the text.\"<|>8)##\n(\"relationship\"<|>\"Pakistan\"<|>\"Polio eradication activities\"<|>\"Pakistan is a priority country for polio eradication activities, with surveillance and laboratory testing reported in the text.\"<|>8)##\n(\"relationship\"<|>\"Afghanistan\"<|>\"Orphan WPV1 isolates\"<|>\"Orphan WPV1 isolates were found in Afghanistan, indicating possible gaps in AFP surveillance in 2019 and 2020.\"<|>7)##\n(\"relationship\"<|>\"Pakistan\"<|>\"Orphan WPV1 isolates\"<|>\"Orphan WPV1 isolates were found in Pakistan, indicating possible gaps in AFP surveillance in 2019 and 2020.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "4295096e8492e00f12e34b5870d51464": {
    "return": "(\"entity\"<|>\"Brian A. King\"<|>\"person\"<|>\"Brian A. King, PhD, MPH, is the Editor and Guest Science Editor, indicating a leadership and scientific oversight role in the editorial process.\")##\n(\"entity\"<|>\"Paul Z. Siegel\"<|>\"person\"<|>\"Paul Z. Siegel, MD, MPH, serves as Associate Editor, contributing medical and public health expertise to the editorial team.\")##\n(\"entity\"<|>\"Mary Dott\"<|>\"person\"<|>\"Mary Dott, MD, MPH, is the Online Editor, responsible for digital content management and editorial decisions.\")##\n(\"entity\"<|>\"Terisa F. Rutledge\"<|>\"person\"<|>\"Terisa F. Rutledge is the Managing Editor, overseeing editorial operations and workflow.\")##\n(\"entity\"<|>\"Teresa M. Hood\"<|>\"person\"<|>\"Teresa M. Hood, MS, is the Acting Lead Technical Writer-Editor, managing technical writing and editing tasks.\")##\n(\"entity\"<|>\"Glenn Damon\"<|>\"person\"<|>\"Glenn Damon is listed among the editorial staff, likely contributing to technical writing or editing.\")##\n(\"entity\"<|>\"Soumya Dunworth\"<|>\"person\"<|>\"Soumya Dunworth, PhD, is part of the editorial team, likely providing scientific expertise.\")##\n(\"entity\"<|>\"Catherine B. Lansdowne\"<|>\"person\"<|>\"Catherine B. Lansdowne, MS, is a member of the editorial staff, contributing to technical writing or editing.\")##\n(\"entity\"<|>\"Srila Sen\"<|>\"person\"<|>\"Srila Sen, MA, is part of the editorial team, likely involved in writing or editing.\")##\n(\"entity\"<|>\"Stacy Simon\"<|>\"person\"<|>\"Stacy Simon, MA, is a member of the editorial staff, contributing to writing or editing.\")##\n(\"entity\"<|>\"Jeffrey D. Sokolow\"<|>\"person\"<|>\"Jeffrey D. Sokolow, MA, is part of the editorial team, likely involved in technical writing or editing.\")##\n(\"entity\"<|>\"Martha F. Boyd\"<|>\"person\"<|>\"Martha F. Boyd is the Lead Visual Information Specialist, overseeing visual content and information design.\")##\n(\"entity\"<|>\"Alexander J. Gottardy\"<|>\"person\"<|>\"Alexander J. Gottardy is a Visual Information Specialist, contributing to visual content and design.\")##\n(\"entity\"<|>\"Maureen A. Leahy\"<|>\"person\"<|>\"Maureen A. Leahy is a Visual Information Specialist, involved in visual content creation.\")##\n(\"entity\"<|>\"Julia C. Martinroe\"<|>\"person\"<|>\"Julia C. Martinroe is a Visual Information Specialist, contributing to visual information design.\")##\n(\"entity\"<|>\"Stephen R. Spriggs\"<|>\"person\"<|>\"Stephen R. Spriggs is a Visual Information Specialist, involved in visual content creation.\")##\n(\"entity\"<|>\"Tong Yang\"<|>\"person\"<|>\"Tong Yang is a Visual Information Specialist, contributing to visual information design.\")##\n(\"entity\"<|>\"Quang M. Doan\"<|>\"person\"<|>\"Quang M. Doan, MBA, is an Information Technology Specialist, supporting IT needs for the editorial process.\")##\n(\"entity\"<|>\"Phyllis H. King\"<|>\"person\"<|>\"Phyllis H. King is an Information Technology Specialist, providing IT support for editorial operations.\")##\n(\"entity\"<|>\"Terraye M. Starr\"<|>\"person\"<|>\"Terraye M. Starr is an Information Technology Specialist, supporting editorial IT infrastructure.\")##\n(\"entity\"<|>\"Moua Yang\"<|>\"person\"<|>\"Moua Yang is an Information Technology Specialist, contributing to IT support for the editorial team.\")##\n(\"entity\"<|>\"MMWR Editorial Board\"<|>\"organization\"<|>\"The MMWR Editorial Board is the governing body overseeing editorial standards, content, and scientific integrity for the publication.\")##\n(\"entity\"<|>\"Timothy F. Jones\"<|>\"person\"<|>\"Timothy F. Jones, MD, is the Chairman of the MMWR Editorial Board, providing leadership and oversight.\")##\n(\"entity\"<|>\"Matthew L. Boulton\"<|>\"person\"<|>\"Matthew L. Boulton, MD, MPH, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"Carolyn Brooks\"<|>\"person\"<|>\"Carolyn Brooks, ScD, MA, is a member of the MMWR Editorial Board, providing scientific expertise.\")##\n(\"entity\"<|>\"Jay C. Butler\"<|>\"person\"<|>\"Jay C. Butler, MD, is a member of the MMWR Editorial Board, contributing medical expertise.\")##\n(\"entity\"<|>\"Virginia A. Caine\"<|>\"person\"<|>\"Virginia A. Caine, MD, is a member of the MMWR Editorial Board, providing medical expertise.\")##\n(\"entity\"<|>\"Jonathan E. Fielding\"<|>\"person\"<|>\"Jonathan E. Fielding, MD, MPH, MBA, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"David W. Fleming\"<|>\"person\"<|>\"David W. Fleming, MD, is a member of the MMWR Editorial Board, providing medical expertise.\")##\n(\"entity\"<|>\"William E. Halperin\"<|>\"person\"<|>\"William E. Halperin, MD, DrPH, MPH, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"Christopher M. Jones\"<|>\"person\"<|>\"Christopher M. Jones, PharmD, DrPH, MPH, is a member of the MMWR Editorial Board, providing expertise in pharmacy, public health, and medicine.\")##\n(\"entity\"<|>\"Jewel Mullen\"<|>\"person\"<|>\"Jewel Mullen, MD, MPH, MPA, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"Jeff Niederdeppe\"<|>\"person\"<|>\"Jeff Niederdeppe, PhD, is a member of the MMWR Editorial Board, providing scientific expertise.\")##\n(\"entity\"<|>\"Celeste Philip\"<|>\"person\"<|>\"Celeste Philip, MD, MPH, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"Patricia Quinlisk\"<|>\"person\"<|>\"Patricia Quinlisk, MD, MPH, is a member of the MMWR Editorial Board, providing medical and public health expertise.\")##\n(\"entity\"<|>\"Patrick L. Remington\"<|>\"person\"<|>\"Patrick L. Remington, MD, MPH, is a member of the MMWR Editorial Board, contributing medical and public health expertise.\")##\n(\"entity\"<|>\"Carlos Roig\"<|>\"person\"<|>\"Carlos Roig, MS, MA, is a member of the MMWR Editorial Board, providing scientific expertise.\")##\n(\"entity\"<|>\"William Schaffner\"<|>\"person\"<|>\"William Schaffner, MD, is a member of the MMWR Editorial Board, contributing medical expertise.\")##\n(\"entity\"<|>\"Nathaniel Smith\"<|>\"person\"<|>\"Nathaniel Smith, MD, MPH, is a member of the MMWR Editorial Board, providing medical and public health expertise.\")##\n(\"entity\"<|>\"Morgan Bobb Swanson\"<|>\"person\"<|>\"Morgan Bobb Swanson, BS, is a member of the editorial staff, likely contributing to health communication.\")##\n(\"entity\"<|>\"Ian Branam\"<|>\"person\"<|>\"Ian Branam, MA, is the Acting Lead Health Communication Specialist, overseeing health communication activities.\")##\n(\"entity\"<|>\"Shelton Bartley\"<|>\"person\"<|>\"Shelton Bartley, MPH, is a Health Communication Specialist, contributing to health communication efforts.\")##\n(\"entity\"<|>\"Lowery Johnson\"<|>\"person\"<|>\"Lowery Johnson is a Health Communication Specialist, contributing to health communication activities.\")##\n(\"entity\"<|>\"Amanda Ray\"<|>\"person\"<|>\"Amanda Ray is a Health Communication Specialist, involved in health communication efforts.\")##\n(\"entity\"<|>\"Jacqueline N. Sanchez\"<|>\"person\"<|>\"Jacqueline N. Sanchez, MS, is a Health Communication Specialist, contributing to health communication activities.\")##\n(\"entity\"<|>\"Will Yang\"<|>\"person\"<|>\"Will Yang, MA, is a Visual Information Specialist, contributing to visual content and design.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional Falls are a type of injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes are a type of injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Self-Harm\"<|>\"event\"<|>\"Self-Harm is an injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdose\"<|>\"event\"<|>\"Unintentional Opioid Overdose is an injury mechanism tracked using ICD-10-CM and ICD-10-PCS codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"HCUP-NEDS\"<|>\"organization\"<|>\"HCUP-NEDS (Healthcare Cost and Utilization Project - Nationwide Emergency Department Sample) is a database containing diagnosis codes for emergency department visits.\")##\n(\"entity\"<|>\"HCUP-NIS\"<|>\"organization\"<|>\"HCUP-NIS (Healthcare Cost and Utilization Project - Nationwide Inpatient Sample) is a database containing diagnosis codes for hospital inpatient visits.\")##\n(\"entity\"<|>\"CSTE\"<|>\"organization\"<|>\"CSTE (Council of State and Territorial Epidemiologists) is an organization providing resources and toolkits for injury surveillance methods.\")##\n(\"relationship\"<|>\"Brian A. King\"<|>\"MMWR Editorial Board\"<|>\"Brian A. King serves as Editor and Guest Science Editor, working under the oversight of the MMWR Editorial Board.\"<|>9)##\n(\"relationship\"<|>\"Paul Z. Siegel\"<|>\"MMWR Editorial Board\"<|>\"Paul Z. Siegel is Associate Editor, contributing to the editorial process overseen by the MMWR Editorial Board.\"<|>8)##\n(\"relationship\"<|>\"Mary Dott\"<|>\"MMWR Editorial Board\"<|>\"Mary Dott is Online Editor, working within the editorial structure governed by the MMWR Editorial Board.\"<|>8)##\n(\"relationship\"<|>\"Terisa F. Rutledge\"<|>\"MMWR Editorial Board\"<|>\"Terisa F. Rutledge is Managing Editor, operating under the MMWR Editorial Board's oversight.\"<|>8)##\n(\"relationship\"<|>\"Teresa M. Hood\"<|>\"MMWR Editorial Board\"<|>\"Teresa M. Hood is Acting Lead Technical Writer-Editor, contributing to editorial work under the MMWR Editorial Board.\"<|>7)##\n(\"relationship\"<|>\"Martha F. Boyd\"<|>\"MMWR Editorial Board\"<|>\"Martha F. Boyd is Lead Visual Information Specialist, supporting editorial content for the MMWR Editorial Board.\"<|>7)##\n(\"relationship\"<|>\"Alexander J. Gottardy\"<|>\"Martha F. Boyd\"<|>\"Alexander J. Gottardy works as a Visual Information Specialist under the leadership of Martha F. Boyd, Lead Visual Information Specialist.\"<|>6)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"HCUP-NIS\"<|>\"Both HCUP-NEDS and HCUP-NIS are databases under the Healthcare Cost and Utilization Project, containing diagnosis codes for injury surveillance.\"<|>8)##\n(\"relationship\"<|>\"Unintentional Falls\"<|>\"HCUP-NEDS\"<|>\"Unintentional Falls are tracked as injury mechanisms in the HCUP-NEDS database using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Falls\"<|>\"HCUP-NIS\"<|>\"Unintentional Falls are tracked as injury mechanisms in the HCUP-NIS database using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"HCUP-NEDS\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes are tracked in HCUP-NEDS using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"HCUP-NIS\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes are tracked in HCUP-NIS using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Self-Harm\"<|>\"HCUP-NEDS\"<|>\"Self-Harm is tracked as an injury mechanism in HCUP-NEDS using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Self-Harm\"<|>\"HCUP-NIS\"<|>\"Self-Harm is tracked as an injury mechanism in HCUP-NIS using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Opioid Overdose\"<|>\"HCUP-NEDS\"<|>\"Unintentional Opioid Overdose is tracked in HCUP-NEDS using ICD-10-CM and ICD-10-PCS codes.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Opioid Overdose\"<|>\"HCUP-NIS\"<|>\"Unintentional Opioid Overdose is tracked in HCUP-NIS using ICD-10-CM and ICD-10-PCS codes.\"<|>9)##\n(\"relationship\"<|>\"CSTE\"<|>\"Unintentional Falls\"<|>\"CSTE provides resources and toolkits for injury surveillance, including tracking of Unintentional Falls.\"<|>7)##\n(\"relationship\"<|>\"CSTE\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"CSTE provides resources for surveillance of Unintentional Traffic-Related Motor Vehicle Crashes.\"<|>7)##\n(\"relationship\"<|>\"CSTE\"<|>\"Self-Harm\"<|>\"CSTE provides resources for surveillance of Self-Harm injuries.\"<|>7)##\n(\"relationship\"<|>\"CSTE\"<|>\"Unintentional Opioid Overdose\"<|>\"CSTE provides resources for surveillance of Unintentional Opioid Overdose.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "c97ff083f66a206f0899729ce0c81138": {
    "return": "(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"A weekly publication series focused on public health surveillance, epidemiology, and laboratory services, published by the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"A major U.S. federal public health agency responsible for disease control, prevention, and public health research, headquartered in Atlanta, GA. The CDC publishes the Morbidity and Mortality Weekly Report and leads various public health campaigns and surveillance activities.\")##\n(\"entity\"<|>\"U.S. Department of Health and Human Services\"<|>\"organization\"<|>\"The principal U.S. government agency for protecting the health of all Americans and providing essential human services. It oversees the CDC and is involved in national health policy and administration.\")##\n(\"entity\"<|>\"Briana Moreland\"<|>\"person\"<|>\"An author of the report, holding an MPH degree and affiliated with the CDC and possibly other public health organizations.\")##\n(\"entity\"<|>\"Robin Lee\"<|>\"person\"<|>\"An author of the report, holding a PhD and affiliated with the CDC, contributing to research on injury epidemiology among older adults.\")##\n(\"entity\"<|>\"Rochelle P. Walensky\"<|>\"person\"<|>\"Director of the Centers for Disease Control and Prevention, MD, MPH, responsible for overseeing CDC operations and public health initiatives.\")##\n(\"entity\"<|>\"Anne Schuchat\"<|>\"person\"<|>\"Principal Deputy Director of the CDC, MD, involved in high-level public health leadership and administration.\")##\n(\"entity\"<|>\"Daniel B. Jernigan\"<|>\"person\"<|>\"Acting Deputy Director for Public Health Science and Surveillance at CDC, MD, MPH, overseeing scientific and surveillance activities.\")##\n(\"entity\"<|>\"Rebecca Bunnell\"<|>\"person\"<|>\"Director of the Office of Science at CDC, PhD, MEd, responsible for scientific leadership and research oversight.\")##\n(\"entity\"<|>\"Jennifer Layden\"<|>\"person\"<|>\"Deputy Director of the Office of Science at CDC, MD, PhD, involved in scientific administration and policy.\")##\n(\"entity\"<|>\"Michael F. Iademarco\"<|>\"person\"<|>\"Director of the Center for Surveillance, Epidemiology, and Laboratory Services at CDC, MD, MPH, overseeing surveillance and laboratory activities.\")##\n(\"entity\"<|>\"Charlotte K. Kent\"<|>\"person\"<|>\"Editor in Chief of the Morbidity and Mortality Weekly Report, PhD, MPH, responsible for editorial leadership.\")##\n(\"entity\"<|>\"Jacqueline Gindler\"<|>\"person\"<|>\"Editor of the Morbidity and Mortality Weekly Report, MD, involved in editorial processes.\")##\n(\"entity\"<|>\"Brian A. King\"<|>\"person\"<|>\"Guest Science Editor of the Morbidity and Mortality Weekly Report, PhD, MPH, contributing scientific expertise.\")##\n(\"entity\"<|>\"Paul Z. Siegel\"<|>\"person\"<|>\"Associate Editor of the Morbidity and Mortality Weekly Report, MD, MPH, involved in editorial review.\")##\n(\"entity\"<|>\"Mary Dott\"<|>\"person\"<|>\"Online Editor of the Morbidity and Mortality Weekly Report, MD, MPH, responsible for online publication.\")##\n(\"entity\"<|>\"Terisa F. Rutledge\"<|>\"person\"<|>\"Managing Editor of the Morbidity and Mortality Weekly Report, overseeing editorial management.\")##\n(\"entity\"<|>\"Teresa M. Hood\"<|>\"person\"<|>\"Acting Lead Technical Writer-Editor of the Morbidity and Mortality Weekly Report, MS, responsible for technical writing and editing.\")##\n(\"entity\"<|>\"Glenn Damon\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Soumya Dunworth\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report, PhD.\")##\n(\"entity\"<|>\"Catherine B. Lansdowne\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report, MS.\")##\n(\"entity\"<|>\"Srila Sen\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report, MA.\")##\n(\"entity\"<|>\"Stacy Simon\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report, MA.\")##\n(\"entity\"<|>\"Jeffrey D.\"<|>\"person\"<|>\"Editorial staff member of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"A country in North America, the primary geographic focus of the report, including data from multiple states and the District of Columbia.\")##\n(\"entity\"<|>\"District of Columbia\"<|>\"geo\"<|>\"A federal district in the United States, included in the data analysis for emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Atlanta, GA\"<|>\"geo\"<|>\"The city and state where the CDC headquarters is located.\")##\n(\"entity\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"event\"<|>\"A public health study and report analyzing emergency department visits and hospitalizations for nonfatal injuries among adults aged 65 years in the United States in 2018.\")##\n(\"entity\"<|>\"CDC's Still Going Strong awareness campaign\"<|>\"event\"<|>\"An educational campaign by the CDC aimed at encouraging older adults to take steps to prevent injuries, using positive messaging.\")##\n(\"entity\"<|>\"HCUP Nationwide Emergency Department Sample (NEDS)\"<|>\"event\"<|>\"A dataset from the Agency for Healthcare Research and Quality, including data from 990 hospital EDs across 36 U.S. states and the District of Columbia, used to analyze nonfatal injuries.\")##\n(\"entity\"<|>\"National Inpatient Sample (NIS)\"<|>\"event\"<|>\"A dataset from the Agency for Healthcare Research and Quality, including data from 47 states and the District of Columbia, covering over 97% of the U.S. population, used to analyze hospitalizations for nonfatal injuries.\")##\n(\"entity\"<|>\"Agency for Healthcare Research and Quality\"<|>\"organization\"<|>\"A U.S. federal agency responsible for improving the quality, safety, efficiency, and effectiveness of health care, providing datasets such as HCUP, NEDS, and NIS.\")##\n\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Centers for Disease Control and Prevention\"<|>\"The Morbidity and Mortality Weekly Report is published by the CDC as part of its public health surveillance and communication activities.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"U.S. Department of Health and Human Services\"<|>\"The CDC operates under the U.S. Department of Health and Human Services, which oversees its activities and administration.\"<|>9)##\n(\"relationship\"<|>\"Briana Moreland\"<|>\"Centers for Disease Control and Prevention\"<|>\"Briana Moreland is an author affiliated with the CDC, contributing to public health research and reporting.\"<|>8)##\n(\"relationship\"<|>\"Robin Lee\"<|>\"Centers for Disease Control and Prevention\"<|>\"Robin Lee is an author affiliated with the CDC, contributing to research on injury epidemiology among older adults.\"<|>8)##\n(\"relationship\"<|>\"Rochelle P. Walensky\"<|>\"Centers for Disease Control and Prevention\"<|>\"Rochelle P. Walensky is the Director of the CDC, overseeing its operations and public health initiatives.\"<|>10)##\n(\"relationship\"<|>\"Anne Schuchat\"<|>\"Centers for Disease Control and Prevention\"<|>\"Anne Schuchat is the Principal Deputy Director of the CDC, involved in high-level leadership and administration.\"<|>9)##\n(\"relationship\"<|>\"Daniel B. Jernigan\"<|>\"Centers for Disease Control and Prevention\"<|>\"Daniel B. Jernigan is the Acting Deputy Director for Public Health Science and Surveillance at CDC.\"<|>9)##\n(\"relationship\"<|>\"Rebecca Bunnell\"<|>\"Centers for Disease Control and Prevention\"<|>\"Rebecca Bunnell is the Director of the Office of Science at CDC.\"<|>8)##\n(\"relationship\"<|>\"Jennifer Layden\"<|>\"Centers for Disease Control and Prevention\"<|>\"Jennifer Layden is the Deputy Director of the Office of Science at CDC.\"<|>8)##\n(\"relationship\"<|>\"Michael F. Iademarco\"<|>\"Centers for Disease Control and Prevention\"<|>\"Michael F. Iademarco is the Director of the Center for Surveillance, Epidemiology, and Laboratory Services at CDC.\"<|>8)##\n(\"relationship\"<|>\"Charlotte K. Kent\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Charlotte K. Kent is the Editor in Chief of the Morbidity and Mortality Weekly Report.\"<|>9)##\n(\"relationship\"<|>\"Jacqueline Gindler\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Jacqueline Gindler is an Editor of the Morbidity and Mortality Weekly Report.\"<|>8)##\n(\"relationship\"<|>\"Brian A. King\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Brian A. King is a Guest Science Editor of the Morbidity and Mortality Weekly Report.\"<|>7)##\n(\"relationship\"<|>\"Paul Z. Siegel\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Paul Z. Siegel is an Associate Editor of the Morbidity and Mortality Weekly Report.\"<|>7)##\n(\"relationship\"<|>\"Mary Dott\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Mary Dott is the Online Editor of the Morbidity and Mortality Weekly Report.\"<|>7)##\n(\"relationship\"<|>\"Terisa F. Rutledge\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Terisa F. Rutledge is the Managing Editor of the Morbidity and Mortality Weekly Report.\"<|>7)##\n(\"relationship\"<|>\"Teresa M. Hood\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Teresa M. Hood is the Acting Lead Technical Writer-Editor of the Morbidity and Mortality Weekly Report.\"<|>7)##\n(\"relationship\"<|>\"Glenn Damon\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Glenn Damon is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Soumya Dunworth\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Soumya Dunworth is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Catherine B. Lansdowne\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Catherine B. Lansdowne is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Srila Sen\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Srila Sen is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Stacy Simon\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Stacy Simon is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Jeffrey D.\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Jeffrey D. is an editorial staff member of the Morbidity and Mortality Weekly Report.\"<|>6)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Atlanta, GA\"<|>\"The CDC is headquartered in Atlanta, GA.\"<|>8)##\n(\"relationship\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"United States\"<|>\"The event is a study and report focused on emergency department visits and hospitalizations for nonfatal injuries among adults aged 65 years in the United States.\"<|>10)##\n(\"relationship\"<|>\"CDC's Still Going Strong awareness campaign\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC's Still Going Strong awareness campaign is an educational initiative by the CDC to prevent injuries among older adults.\"<|>9)##\n(\"relationship\"<|>\"HCUP Nationwide Emergency Department Sample (NEDS)\"<|>\"Agency for Healthcare Research and Quality\"<|>\"NEDS is a dataset provided by the Agency for Healthcare Research and Quality for analyzing emergency department visits.\"<|>9)##\n(\"relationship\"<|>\"National Inpatient Sample (NIS)\"<|>\"Agency for Healthcare Research and Quality\"<|>\"NIS is a dataset provided by the Agency for Healthcare Research and Quality for analyzing hospitalizations.\"<|>9)##\n(\"relationship\"<|>\"HCUP Nationwide Emergency Department Sample (NEDS)\"<|>\"United States\"<|>\"NEDS includes data from 990 hospital EDs across 36 U.S. states and the District of Columbia.\"<|>8)##\n(\"relationship\"<|>\"National Inpatient Sample (NIS)\"<|>\"United States\"<|>\"NIS includes data from 47 states and the District of Columbia, covering over 97% of the U.S. population.\"<|>8)##\n(\"relationship\"<|>\"HCUP Nationwide Emergency Department Sample (NEDS)\"<|>\"District of Columbia\"<|>\"NEDS includes data from the District of Columbia as part of its sample.\"<|>7)##\n(\"relationship\"<|>\"National Inpatient Sample (NIS)\"<|>\"District of Columbia\"<|>\"NIS includes data from the District of Columbia as part of its sample.\"<|>7)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"The CDC publishes the Morbidity and Mortality Weekly Report as part of its public health communication efforts.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Agency for Healthcare Research and Quality\"<|>\"The CDC uses datasets provided by the Agency for Healthcare Research and Quality for public health research and reporting.\"<|>8)##\n(\"relationship\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"HCUP Nationwide Emergency Department Sample (NEDS)\"<|>\"The event uses data from NEDS to analyze emergency department visits for nonfatal injuries among older adults.\"<|>9)##\n(\"relationship\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"National Inpatient Sample (NIS)\"<|>\"The event uses data from NIS to analyze hospitalizations for nonfatal injuries among older adults.\"<|>9)##\n(\"relationship\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"CDC's Still Going Strong awareness campaign\"<|>\"The event references the CDC's Still Going Strong awareness campaign as an intervention to prevent injuries among older adults.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"The CDC conducted and published the study and report on emergency department visits and hospitalizations for nonfatal injuries among older adults.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "3e20227e6669802925c934d1a01eb7de": {
    "return": "(\"entity\"<|>\"Buckeridge D\"<|>\"person\"<|>\"Buckeridge D is an author cited in the references, contributing research on the risk of injury associated with opioid use in older adults.\")##\n(\"entity\"<|>\"Huang A\"<|>\"person\"<|>\"Huang A is an author cited in the references, contributing to research on injury risk and opioid use in older adults.\")##\n(\"entity\"<|>\"Hanley J\"<|>\"person\"<|>\"Hanley J is an author cited in the references, contributing to research on injury risk and opioid use in older adults.\")##\n(\"entity\"<|>\"Steinman MA\"<|>\"person\"<|>\"Steinman MA is an author cited in the references, contributing research on opioid and analgesic use by older adults in the United States.\")##\n(\"entity\"<|>\"Komaiko KDR\"<|>\"person\"<|>\"Komaiko KDR is an author cited in the references, contributing research on opioid and analgesic use by older adults in the United States.\")##\n(\"entity\"<|>\"Fung KZ\"<|>\"person\"<|>\"Fung KZ is an author cited in the references, contributing research on opioid and analgesic use by older adults in the United States.\")##\n(\"entity\"<|>\"Ritchie CS\"<|>\"person\"<|>\"Ritchie CS is an author cited in the references, contributing research on opioid and analgesic use by older adults in the United States.\")##\n(\"entity\"<|>\"Ambrose AF\"<|>\"person\"<|>\"Ambrose AF is an author cited in the references, contributing research on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"Paul G\"<|>\"person\"<|>\"Paul G is an author cited in the references, contributing research on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"Hausdorff JM\"<|>\"person\"<|>\"Hausdorff JM is an author cited in the references, contributing research on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"Pomidor A\"<|>\"person\"<|>\"Pomidor A is an editor cited in the references, responsible for the 'Clinicians guide to assessing and counseling older drivers.'\")##\n(\"entity\"<|>\"Division of Injury Prevention\"<|>\"organization\"<|>\"The Division of Injury Prevention is a division within the National Center for Injury Prevention and Control, CDC, focused on preventing injuries through research, policy, and outreach.\")##\n(\"entity\"<|>\"International Committee of Medical Journal Editors\"<|>\"organization\"<|>\"The International Committee of Medical Journal Editors is an organization that sets standards for the disclosure of potential conflicts of interest in medical journal publications.\")##\n(\"entity\"<|>\"Older drivers\"<|>\"person\"<|>\"Older drivers refers to adults aged 65 and older who drive motor vehicles and are the focus of research and guidance on injury prevention.\")##\n(\"entity\"<|>\"Benzodiazepines\"<|>\"event\"<|>\"Benzodiazepines are medications commonly linked to increased risk of falls and injuries among older adults, mentioned as a risk factor in the report.\")##\n(\"entity\"<|>\"Tricyclic antidepressants\"<|>\"event\"<|>\"Tricyclic antidepressants are medications associated with increased risk of falls and injuries among older adults, mentioned as a risk factor in the report.\")##\n(\"entity\"<|>\"Pain Med\"<|>\"organization\"<|>\"Pain Med is a medical journal cited in the references, publishing research on opioid and analgesic use by older adults.\")##\n(\"entity\"<|>\"J Am Geriatr Soc\"<|>\"organization\"<|>\"J Am Geriatr Soc (Journal of the American Geriatrics Society) is a medical journal cited in the references, publishing research on injury risk and opioid use in older adults.\")##\n(\"entity\"<|>\"Maturitas\"<|>\"organization\"<|>\"Maturitas is a medical journal cited in the references, publishing research on risk factors for falls among older adults.\")##\n\n(\"relationship\"<|>\"Buckeridge D\"<|>\"Huang A\"<|>\"Buckeridge D and Huang A are co-authors of research on injury risk and opioid use in older adults.\"<|>8)##\n(\"relationship\"<|>\"Buckeridge D\"<|>\"Hanley J\"<|>\"Buckeridge D and Hanley J are co-authors of research on injury risk and opioid use in older adults.\"<|>8)##\n(\"relationship\"<|>\"Steinman MA\"<|>\"Komaiko KDR\"<|>\"Steinman MA and Komaiko KDR are co-authors of research on opioid and analgesic use by older adults.\"<|>8)##\n(\"relationship\"<|>\"Steinman MA\"<|>\"Fung KZ\"<|>\"Steinman MA and Fung KZ are co-authors of research on opioid and analgesic use by older adults.\"<|>8)##\n(\"relationship\"<|>\"Steinman MA\"<|>\"Ritchie CS\"<|>\"Steinman MA and Ritchie CS are co-authors of research on opioid and analgesic use by older adults.\"<|>8)##\n(\"relationship\"<|>\"Ambrose AF\"<|>\"Paul G\"<|>\"Ambrose AF and Paul G are co-authors of research on risk factors for falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Ambrose AF\"<|>\"Hausdorff JM\"<|>\"Ambrose AF and Hausdorff JM are co-authors of research on risk factors for falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Pomidor A\"<|>\"Older drivers\"<|>\"Pomidor A is the editor of a guide focused on assessing and counseling older drivers.\"<|>9)##\n(\"relationship\"<|>\"Division of Injury Prevention\"<|>\"National Center for Injury Prevention and Control\"<|>\"The Division of Injury Prevention is a division within the National Center for Injury Prevention and Control, CDC.\"<|>10)##\n(\"relationship\"<|>\"International Committee of Medical Journal Editors\"<|>\"Briana Moreland\"<|>\"Briana Moreland and other authors submitted conflict of interest disclosures to the International Committee of Medical Journal Editors.\"<|>7)##\n(\"relationship\"<|>\"Pain Med\"<|>\"Steinman MA\"<|>\"Pain Med published research by Steinman MA on opioid and analgesic use by older adults.\"<|>8)##\n(\"relationship\"<|>\"J Am Geriatr Soc\"<|>\"Buckeridge D\"<|>\"J Am Geriatr Soc published research by Buckeridge D on injury risk and opioid use in older adults.\"<|>8)##\n(\"relationship\"<|>\"Maturitas\"<|>\"Ambrose AF\"<|>\"Maturitas published research by Ambrose AF on risk factors for falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Benzodiazepines\"<|>\"Older adults in the United States\"<|>\"Benzodiazepines are medications linked to increased risk of falls and injuries among older adults in the United States.\"<|>9)##\n(\"relationship\"<|>\"Tricyclic antidepressants\"<|>\"Older adults in the United States\"<|>\"Tricyclic antidepressants are medications linked to increased risk of falls and injuries among older adults in the United States.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "10a21ea76e9cf45d577721f71ec7cc1c": {
    "return": "(\"entity\"<|>\"African Region\"<|>\"geo\"<|>\"African Region is a WHO-defined region comprising multiple African countries, included in the surveillance data for acute flaccid paralysis (AFP) and polio.\")##\n(\"entity\"<|>\"cVDPV\"<|>\"event\"<|>\"cVDPV stands for circulating vaccine-derived poliovirus, an event associated with at least one case of AFP with evidence of community transmission and genetic linkage.\")##\n(\"entity\"<|>\"WPV\"<|>\"event\"<|>\"WPV stands for wild poliovirus, a naturally occurring poliovirus tracked in AFP surveillance.\")##\n(\"entity\"<|>\"NPAFP\"<|>\"event\"<|>\"NPAFP stands for nonpolio acute flaccid paralysis, a surveillance indicator used to monitor cases not caused by poliovirus.\")##\n(\"entity\"<|>\"AFP\"<|>\"event\"<|>\"AFP stands for acute flaccid paralysis, a clinical syndrome and surveillance target for polio eradication efforts.\")##\n(\"entity\"<|>\"Stool Specimen Collection\"<|>\"event\"<|>\"Stool specimen collection is a surveillance activity involving the collection of stool samples from AFP cases to assess for poliovirus, with standards set by WHO.\")##\n(\"entity\"<|>\"WHO-accredited Laboratory\"<|>\"organization\"<|>\"WHO-accredited Laboratory is a laboratory certified by the World Health Organization to process and analyze specimens for AFP surveillance, maintaining reverse cold chain and specimen integrity.\")##\n(\"entity\"<|>\"Reverse Cold Chain\"<|>\"event\"<|>\"Reverse cold chain is a process ensuring specimens are kept at appropriate temperatures during transport to maintain integrity for laboratory analysis.\")##\n(\"entity\"<|>\"U.S. State Department\"<|>\"organization\"<|>\"U.S. State Department is a U.S. government agency referenced for country naming conventions in surveillance reports.\")##\n(\"entity\"<|>\"Reporting and Classification of VDPVs Guidelines\"<|>\"event\"<|>\"Reporting and Classification of VDPVs Guidelines is a document outlining criteria for classifying vaccine-derived polioviruses, referenced in the surveillance report.\")##\n(\"entity\"<|>\"April 16, 2021\"<|>\"event\"<|>\"April 16, 2021 is the date as of which the surveillance data in the report is current.\")##\n(\"entity\"<|>\"May 7, 2021\"<|>\"event\"<|>\"May 7, 2021 is the publication date of the Morbidity and Mortality Weekly Report referenced in the document.\")##\n(\"entity\"<|>\"Vol. 70 / No. 18\"<|>\"event\"<|>\"Vol. 70 / No. 18 is the volume and issue number of the Morbidity and Mortality Weekly Report in which the surveillance data was published.\")##\n(\"entity\"<|>\"FIGURE. Combined performance indicators for the quality of acute flaccid paralysis surveillance* in subnational areas of 42 priority countries\"<|>\"event\"<|>\"This figure presents combined performance indicators for AFP surveillance quality in subnational areas of 42 priority countries, as reported in the document.\")##\n(\"entity\"<|>\"Subnational Areas\"<|>\"geo\"<|>\"Subnational areas refer to regions within countries, regardless of population size, assessed for AFP surveillance performance indicators.\")##\n(\"entity\"<|>\"Surveillance Indicators\"<|>\"event\"<|>\"Surveillance indicators are metrics used to assess the quality and effectiveness of AFP surveillance, including NPAFP rates and adequate specimen collection.\")##\n(\"entity\"<|>\"Population Aged <15 Years\"<|>\"geo\"<|>\"Population aged under 15 years is the demographic group targeted for AFP surveillance and reporting rates per 100,000 persons.\")##\n(\"entity\"<|>\"Community Transmission\"<|>\"event\"<|>\"Community transmission refers to the spread of cVDPV within a population, evidenced by genetically linked AFP cases.\")##\n(\"entity\"<|>\"Good Condition Specimens\"<|>\"event\"<|>\"Good condition specimens are stool samples arriving at WHO-accredited laboratories with reverse cold chain maintained and without leakage or desiccation, meeting surveillance standards.\")##\n(\"entity\"<|>\"Timeliness\"<|>\"event\"<|>\"Timeliness is a surveillance indicator defined as two specimens collected 24 hours apart, both within 14 days of paralysis onset.\")##\n(\"entity\"<|>\"Genetic Linkage\"<|>\"event\"<|>\"Genetic linkage refers to the genetic connection between cases of cVDPV, used to confirm community transmission.\")##\n(\"entity\"<|>\"Polio Eradication\"<|>\"event\"<|>\"Polio eradication is the global public health campaign to eliminate poliovirus transmission, referenced in the context of surveillance and reporting.\")##\n(\"entity\"<|>\"https://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf\"<|>\"event\"<|>\"This is the URL for the Reporting and Classification of VDPVs Guidelines document referenced in the surveillance report.\")##\n(\"entity\"<|>\"Dashes\"<|>\"event\"<|>\"Dashes are used in the report to indicate that no confirmed cases were found for a given country or region.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "e827595b8bfc9746907207486f35b042": {
    "return": "(\"entity\"<|>\"World Health Organization (WHO)\"<|>\"organization\"<|>\"The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. In this context, WHO oversees surveillance systems for poliovirus transmission and sets performance indicators for acute flaccid paralysis (AFP) surveillance across multiple regions and countries.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services. It is mentioned as the publisher of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a national public health institute in the United States, part of the US Department of Health and Human Services, and is involved in disease surveillance and reporting.\")##\n(\"entity\"<|>\"African Region\"<|>\"geo\"<|>\"The African Region refers to the group of countries in Africa under the WHO's regional classification, including Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, C么te d'Ivoire, Democratic Republic of the Congo, Eritrea, Ethiopia, Ghana, Guinea, Kenya, Liberia, Madagascar, Mali, Mauritania, Mozambique, Niger, Nigeria, Senegal, Sierra Leone, South Sudan, Togo, and Zambia. This region is a focus for poliovirus surveillance and reporting.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"The Eastern Mediterranean Region is a WHO regional classification including Afghanistan, Egypt, Iran, Iraq, Libya, Pakistan, Somalia, Sudan, Syria, and Yemen. It is a priority region for poliovirus surveillance.\")##\n(\"entity\"<|>\"European Region\"<|>\"geo\"<|>\"The European Region is a WHO regional classification including Tajikistan and Uzbekistan, which are priority countries for poliovirus surveillance.\")##\n(\"entity\"<|>\"South-East Asia Region\"<|>\"geo\"<|>\"The South-East Asia Region is a WHO regional classification including Burma (Myanmar), a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Western Pacific Region\"<|>\"geo\"<|>\"The Western Pacific Region is a WHO regional classification including Malaysia and Philippines, which are priority countries for poliovirus surveillance.\")##\n(\"entity\"<|>\"Angola\"<|>\"geo\"<|>\"Angola is a country in the African Region, identified as a priority country for poliovirus surveillance due to endemic transmission or high risk.\")##\n(\"entity\"<|>\"Benin\"<|>\"geo\"<|>\"Benin is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Burkina Faso\"<|>\"geo\"<|>\"Burkina Faso is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Cameroon\"<|>\"geo\"<|>\"Cameroon is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Central African Republic\"<|>\"geo\"<|>\"Central African Republic is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Chad\"<|>\"geo\"<|>\"Chad is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Congo\"<|>\"geo\"<|>\"Congo is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"C么te d'Ivoire\"<|>\"geo\"<|>\"C么te d'Ivoire is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Democratic Republic of the Congo\"<|>\"geo\"<|>\"Democratic Republic of the Congo is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Eritrea\"<|>\"geo\"<|>\"Eritrea is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Ethiopia\"<|>\"geo\"<|>\"Ethiopia is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Ghana\"<|>\"geo\"<|>\"Ghana is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Guinea\"<|>\"geo\"<|>\"Guinea is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Kenya\"<|>\"geo\"<|>\"Kenya is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Liberia\"<|>\"geo\"<|>\"Liberia is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Madagascar\"<|>\"geo\"<|>\"Madagascar is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Mali\"<|>\"geo\"<|>\"Mali is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Mauritania\"<|>\"geo\"<|>\"Mauritania is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Mozambique\"<|>\"geo\"<|>\"Mozambique is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Niger\"<|>\"geo\"<|>\"Niger is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Nigeria\"<|>\"geo\"<|>\"Nigeria is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Sierra Leone\"<|>\"geo\"<|>\"Sierra Leone is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"South Sudan\"<|>\"geo\"<|>\"South Sudan is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Togo\"<|>\"geo\"<|>\"Togo is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Zambia\"<|>\"geo\"<|>\"Zambia is a country in the African Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Egypt\"<|>\"geo\"<|>\"Egypt is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Iran\"<|>\"geo\"<|>\"Iran is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Iraq\"<|>\"geo\"<|>\"Iraq is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Libya\"<|>\"geo\"<|>\"Libya is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Somalia\"<|>\"geo\"<|>\"Somalia is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Sudan\"<|>\"geo\"<|>\"Sudan is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Syria\"<|>\"geo\"<|>\"Syria is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Yemen\"<|>\"geo\"<|>\"Yemen is a country in the Eastern Mediterranean Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Tajikistan\"<|>\"geo\"<|>\"Tajikistan is a country in the European Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Uzbekistan\"<|>\"geo\"<|>\"Uzbekistan is a country in the European Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Burma (Myanmar)\"<|>\"geo\"<|>\"Burma (Myanmar) is a country in the South-East Asia Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Malaysia\"<|>\"geo\"<|>\"Malaysia is a country in the Western Pacific Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Philippines\"<|>\"geo\"<|>\"Philippines is a country in the Western Pacific Region, identified as a priority country for poliovirus surveillance.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC and US Department of Health and Human Services, reporting on public health surveillance and statistics, including poliovirus transmission and surveillance performance.\")##\n(\"entity\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"event\"<|>\"Acute Flaccid Paralysis Surveillance is a public health activity focused on monitoring and detecting cases of acute flaccid paralysis, a key indicator for poliovirus transmission. It involves performance indicators such as the nonpolio AFP rate and stool specimen collection adequacy.\")##\n(\"entity\"<|>\"Wild Poliovirus (WPV)\"<|>\"event\"<|>\"Wild Poliovirus (WPV) refers to naturally occurring poliovirus strains that cause polio outbreaks. Surveillance tracks WPV cases to monitor transmission and interruption.\")##\n(\"entity\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"event\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV) refers to poliovirus strains that have mutated from the oral polio vaccine and regained the ability to cause outbreaks. Surveillance tracks cVDPV cases to monitor transmission and risks.\")##\n\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"African Region\"<|>\"WHO oversees and coordinates poliovirus surveillance activities in the African Region, setting performance indicators and reviewing country data.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"Eastern Mediterranean Region\"<|>\"WHO oversees and coordinates poliovirus surveillance activities in the Eastern Mediterranean Region, setting performance indicators and reviewing country data.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"European Region\"<|>\"WHO oversees and coordinates poliovirus surveillance activities in the European Region, setting performance indicators and reviewing country data.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"South-East Asia Region\"<|>\"WHO oversees and coordinates poliovirus surveillance activities in the South-East Asia Region, setting performance indicators and reviewing country data.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"Western Pacific Region\"<|>\"WHO oversees and coordinates poliovirus surveillance activities in the Western Pacific Region, setting performance indicators and reviewing country data.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"WHO sets the standards and monitors the implementation of Acute Flaccid Paralysis Surveillance as a key activity for poliovirus detection and control.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"Wild Poliovirus (WPV)\"<|>\"WHO tracks and reports cases of Wild Poliovirus as part of its global eradication efforts.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization (WHO)\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"WHO tracks and reports cases of cVDPV as part of its global eradication efforts and risk management.\"<|>9)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC is an agency within the US Department of Health and Human Services, responsible for public health surveillance and reporting, including the MMWR publication.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which includes data on poliovirus surveillance and transmission.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Angola\"<|>\"Angola is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Benin\"<|>\"Benin is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Burkina Faso\"<|>\"Burkina Faso is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Cameroon\"<|>\"Cameroon is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Central African Republic\"<|>\"Central African Republic is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Chad\"<|>\"Chad is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Congo\"<|>\"Congo is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"C么te d'Ivoire\"<|>\"C么te d'Ivoire is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Democratic Republic of the Congo\"<|>\"Democratic Republic of the Congo is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Eritrea\"<|>\"Eritrea is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Ethiopia\"<|>\"Ethiopia is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Ghana\"<|>\"Ghana is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Guinea\"<|>\"Guinea is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Kenya\"<|>\"Kenya is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Liberia\"<|>\"Liberia is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Madagascar\"<|>\"Madagascar is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Mali\"<|>\"Mali is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Mauritania\"<|>\"Mauritania is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Mozambique\"<|>\"Mozambique is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Niger\"<|>\"Niger is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Nigeria\"<|>\"Nigeria is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Senegal\"<|>\"Senegal is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Sierra Leone\"<|>\"Sierra Leone is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"South Sudan\"<|>\"South Sudan is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Togo\"<|>\"Togo is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"African Region\"<|>\"Zambia\"<|>\"Zambia is a country within the African Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Afghanistan\"<|>\"Afghanistan is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Egypt\"<|>\"Egypt is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Iran\"<|>\"Iran is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Iraq\"<|>\"Iraq is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Libya\"<|>\"Libya is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Pakistan\"<|>\"Pakistan is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Somalia\"<|>\"Somalia is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Sudan\"<|>\"Sudan is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Syria\"<|>\"Syria is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Eastern Mediterranean Region\"<|>\"Yemen\"<|>\"Yemen is a country within the Eastern Mediterranean Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"European Region\"<|>\"Tajikistan\"<|>\"Tajikistan is a country within the European Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"European Region\"<|>\"Uzbekistan\"<|>\"Uzbekistan is a country within the European Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"South-East Asia Region\"<|>\"Burma (Myanmar)\"<|>\"Burma (Myanmar) is a country within the South-East Asia Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Western Pacific Region\"<|>\"Malaysia\"<|>\"Malaysia is a country within the Western Pacific Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Western Pacific Region\"<|>\"Philippines\"<|>\"Philippines is a country within the Western Pacific Region and is a priority for poliovirus surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Wild Poliovirus (WPV)\"<|>\"AFP Surveillance is used to detect and monitor cases of Wild Poliovirus as part of public health efforts.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"AFP Surveillance is used to detect and monitor cases of cVDPV as part of public health efforts.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "2de54fc6bbecdc6d70ccc031c819406e": {
    "return": "(\"entity\"<|>\"Adults aged 65 years and older\"<|>\"person\"<|>\"Adults aged 65 years and older are the primary population studied in the report, experiencing high rates of injuries from falls, motor vehicle crashes, opioid overdoses, and self-harm.\")##\n(\"entity\"<|>\"Adults aged 65-74 years\"<|>\"person\"<|>\"Adults aged 65-74 years are a subgroup within the older adult population, with a hospitalization rate for unintentional opioid overdose of 31 per 100,000.\")##\n(\"entity\"<|>\"Adults aged 75-84 years\"<|>\"person\"<|>\"Adults aged 75-84 years are a subgroup within the older adult population, with a hospitalization rate for unintentional opioid overdose of 24 per 100,000.\")##\n(\"entity\"<|>\"Adults aged 85 years and older\"<|>\"person\"<|>\"Adults aged 85 years and older are a subgroup within the older adult population, with a hospitalization rate for unintentional opioid overdose of 18 per 100,000.\")##\n(\"entity\"<|>\"Emergency Departments (EDs)\"<|>\"organization\"<|>\"Emergency Departments (EDs) are healthcare facilities where patients are treated for injuries and either released or admitted for further care.\")##\n(\"entity\"<|>\"Hospital\"<|>\"organization\"<|>\"Hospitals are healthcare institutions where patients are admitted for treatment of injuries, including those resulting from falls, motor vehicle crashes, opioid overdoses, and self-harm.\")##\n(\"entity\"<|>\"Brain Injuries\"<|>\"event\"<|>\"Brain injuries are a long-term health consequence of nonfatal injuries among older adults, often resulting from falls or other trauma.\")##\n(\"entity\"<|>\"Loss of Independence\"<|>\"event\"<|>\"Loss of independence is a significant outcome of nonfatal injuries among older adults, impacting their ability to live autonomously.\")##\n(\"entity\"<|>\"Depression\"<|>\"event\"<|>\"Depression is a mental health condition associated with increased risk of opioid use, self-harm, and falls among older adults.\")##\n(\"entity\"<|>\"Poor Balance\"<|>\"event\"<|>\"Poor balance is a risk factor for injuries, particularly falls, among older adults.\")##\n(\"entity\"<|>\"Visual Impairment\"<|>\"event\"<|>\"Visual impairment is a risk factor for injuries, including falls and motor vehicle crashes, among older adults.\")##\n(\"entity\"<|>\"Medication Use\"<|>\"event\"<|>\"Medication use, especially increased use with age, is a risk factor for injuries such as falls, motor vehicle crashes, opioid overdoses, and self-harm among older adults.\")##\n(\"entity\"<|>\"Frailty\"<|>\"event\"<|>\"Frailty is a condition associated with aging that increases the risk of injury, particularly from motor vehicle crashes and falls.\")##\n\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Falls\"<|>\"Adults aged 65 years and older are the primary group affected by unintentional falls, which account for the majority of injury-related ED visits and hospitalizations.\"<|>10)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Adults aged 65 years and older experience injuries from unintentional motor vehicle crashes, with rates varying by sex and age.\"<|>9)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Unintentional Opioid Overdoses\"<|>\"Adults aged 65 years and older are hospitalized for unintentional opioid overdoses, with rates decreasing as age increases.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65 years and older\"<|>\"Self-Harm\"<|>\"Adults aged 65 years and older experience self-harm injuries resulting in ED visits and hospitalizations.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65-74 years\"<|>\"Unintentional Opioid Overdoses\"<|>\"Adults aged 65-74 years have the highest hospitalization rate for unintentional opioid overdose among older age groups.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 75-84 years\"<|>\"Unintentional Opioid Overdoses\"<|>\"Adults aged 75-84 years have a lower hospitalization rate for unintentional opioid overdose compared to the 65-74 age group.\"<|>7)##\n(\"relationship\"<|>\"Adults aged 85 years and older\"<|>\"Unintentional Opioid Overdoses\"<|>\"Adults aged 85 years and older have the lowest hospitalization rate for unintentional opioid overdose among the older age groups.\"<|>7)##\n(\"relationship\"<|>\"Emergency Departments (EDs)\"<|>\"Emergency Department Visits\"<|>\"Emergency Departments are the sites where injury-related visits occur for older adults.\"<|>10)##\n(\"relationship\"<|>\"Hospital\"<|>\"Hospitalizations\"<|>\"Hospitals are the sites where older adults are admitted for injury-related hospitalizations.\"<|>10)##\n(\"relationship\"<|>\"Brain Injuries\"<|>\"Unintentional Falls\"<|>\"Unintentional falls among older adults can result in brain injuries, a serious long-term health consequence.\"<|>8)##\n(\"relationship\"<|>\"Loss of Independence\"<|>\"Unintentional Falls\"<|>\"Unintentional falls among older adults can lead to loss of independence, affecting their ability to live autonomously.\"<|>8)##\n(\"relationship\"<|>\"Depression\"<|>\"Unintentional Opioid Overdoses\"<|>\"Depression is associated with increased risk of opioid use and unintentional opioid overdoses among older adults.\"<|>7)##\n(\"relationship\"<|>\"Depression\"<|>\"Self-Harm\"<|>\"Depression is a risk factor for self-harm among older adults.\"<|>8)##\n(\"relationship\"<|>\"Depression\"<|>\"Unintentional Falls\"<|>\"Depression is associated with increased risk of falls among older adults.\"<|>7)##\n(\"relationship\"<|>\"Poor Balance\"<|>\"Unintentional Falls\"<|>\"Poor balance increases the risk of unintentional falls among older adults.\"<|>9)##\n(\"relationship\"<|>\"Visual Impairment\"<|>\"Unintentional Falls\"<|>\"Visual impairment increases the risk of unintentional falls among older adults.\"<|>9)##\n(\"relationship\"<|>\"Visual Impairment\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Visual impairment increases the risk of motor vehicle crashes among older adults.\"<|>8)##\n(\"relationship\"<|>\"Medication Use\"<|>\"Unintentional Falls\"<|>\"Increased medication use with age is a risk factor for unintentional falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Medication Use\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Use of certain medications increases the risk of motor vehicle crashes among older adults.\"<|>8)##\n(\"relationship\"<|>\"Medication Use\"<|>\"Unintentional Opioid Overdoses\"<|>\"Medication use, especially opioids, is directly related to the risk of unintentional opioid overdoses among older adults.\"<|>9)##\n(\"relationship\"<|>\"Medication Use\"<|>\"Self-Harm\"<|>\"Medication use is a risk factor for self-harm among older adults.\"<|>7)##\n(\"relationship\"<|>\"Frailty\"<|>\"Unintentional Motor Vehicle Crashes\"<|>\"Frailty increases the risk of injury from motor vehicle crashes among older adults.\"<|>8)##\n(\"relationship\"<|>\"Frailty\"<|>\"Unintentional Falls\"<|>\"Frailty increases the risk of injury from falls among older adults.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "618b702da575edd7bc82468c79e5e2b3": {
    "return": "(\"entity\"<|>\"AFP cases\"<|>\"event\"<|>\"AFP cases refer to instances of acute flaccid paralysis, a key indicator in polio surveillance, reported by country and region.\")##\n(\"entity\"<|>\"NPAFP rate\"<|>\"event\"<|>\"NPAFP rate is the non-polio acute flaccid paralysis rate, used as a surveillance performance indicator for polio eradication efforts.\")##\n(\"entity\"<|>\"WPV cases\"<|>\"event\"<|>\"WPV cases are confirmed cases of wild poliovirus, tracked as part of global polio surveillance.\")##\n(\"entity\"<|>\"cVDPV cases\"<|>\"event\"<|>\"cVDPV cases are confirmed cases of circulating vaccine-derived poliovirus, monitored in polio surveillance.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"Eastern Mediterranean Region is a WHO regional grouping, covering countries in the eastern Mediterranean for health surveillance.\")##\n(\"entity\"<|>\"European Region\"<|>\"geo\"<|>\"European Region is a WHO regional grouping, covering countries in Europe for health surveillance.\")##\n(\"entity\"<|>\"Table 1\"<|>\"event\"<|>\"Table 1 is a data table presenting national and subnational acute flaccid paralysis surveillance performance indicators and polio case numbers by country and region.\")##\n(\"entity\"<|>\"Table footnotes\"<|>\"event\"<|>\"Table footnotes provide additional context and explanations for the data presented in Table 1.\")##\n(\"entity\"<|>\"2020\"<|>\"event\"<|>\"2020 is the year referenced for the surveillance data and polio case reporting.\")##\n(\"entity\"<|>\"2019\"<|>\"event\"<|>\"2019 is the year referenced for the surveillance data and polio case reporting.\")##\n(\"entity\"<|>\"Vol. 70 / No. 18\"<|>\"event\"<|>\"Vol. 70 / No. 18 refers to the volume and issue number of the Morbidity and Mortality Weekly Report in which the data is published.\")##\n(\"entity\"<|>\"Confirmed wild poliovirus cases\"<|>\"event\"<|>\"Confirmed wild poliovirus cases are instances where wild poliovirus has been detected and verified in surveillance.\")##\n(\"entity\"<|>\"Confirmed circulating vaccine-derived poliovirus cases\"<|>\"event\"<|>\"Confirmed circulating vaccine-derived poliovirus cases are instances where vaccine-derived poliovirus has been detected and verified in surveillance.\")##\n(\"entity\"<|>\"42 priority countries\"<|>\"geo\"<|>\"42 priority countries are those identified by WHO as high-priority for polio surveillance and eradication efforts.\")##\n(\"entity\"<|>\"Subnational areas\"<|>\"geo\"<|>\"Subnational areas refer to regions within countries that are monitored for surveillance performance indicators.\")##\n(\"entity\"<|>\"Population living in areas meeting both indicators\"<|>\"event\"<|>\"Population living in areas meeting both indicators refers to the percentage of people residing in regions that meet both NPAFP rate and adequate specimen collection standards.\")##\n(\"entity\"<|>\"Adequate specimens\"<|>\"event\"<|>\"Adequate specimens are biological samples collected for polio surveillance that meet quality standards for laboratory testing.\")##\n(\"entity\"<|>\"National AFP cases\"<|>\"event\"<|>\"National AFP cases are acute flaccid paralysis cases reported at the national level for surveillance purposes.\")##\n(\"entity\"<|>\"Regional AFP cases\"<|>\"event\"<|>\"Regional AFP cases are acute flaccid paralysis cases reported at the regional level for surveillance purposes.\")##\n(\"entity\"<|>\"Surveillance performance indicators\"<|>\"event\"<|>\"Surveillance performance indicators are metrics used to assess the effectiveness of polio surveillance systems, including NPAFP rate and specimen adequacy.\")##\n(\"relationship\"<|>\"Table 1\"<|>\"AFP cases\"<|>\"Table 1 presents data on AFP cases by country and region.\"<|>10)##\n(\"relationship\"<|>\"Table 1\"<|>\"NPAFP rate\"<|>\"Table 1 includes NPAFP rate as a key surveillance performance indicator.\"<|>10)##\n(\"relationship\"<|>\"Table 1\"<|>\"WPV cases\"<|>\"Table 1 reports the number of confirmed wild poliovirus cases.\"<|>10)##\n(\"relationship\"<|>\"Table 1\"<|>\"cVDPV cases\"<|>\"Table 1 reports the number of confirmed circulating vaccine-derived poliovirus cases.\"<|>10)##\n(\"relationship\"<|>\"Table 1\"<|>\"Adequate specimens\"<|>\"Table 1 includes data on the percentage of AFP cases with adequate specimens.\"<|>9)##\n(\"relationship\"<|>\"Table 1\"<|>\"Population living in areas meeting both indicators\"<|>\"Table 1 presents the percentage of population living in areas meeting both surveillance indicators.\"<|>9)##\n(\"relationship\"<|>\"Table 1\"<|>\"Surveillance performance indicators\"<|>\"Table 1 is structured around surveillance performance indicators for polio eradication.\"<|>10)##\n(\"relationship\"<|>\"Table 1\"<|>\"Table footnotes\"<|>\"Table footnotes provide additional context and explanation for the data in Table 1.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"42 priority countries\"<|>\"WHO identifies and monitors 42 priority countries for polio surveillance and eradication.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Surveillance performance indicators\"<|>\"WHO sets and monitors surveillance performance indicators for polio eradication.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Confirmed wild poliovirus cases\"<|>\"WHO tracks and reports confirmed wild poliovirus cases globally.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Confirmed circulating vaccine-derived poliovirus cases\"<|>\"WHO tracks and reports confirmed circulating vaccine-derived poliovirus cases globally.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Subnational areas\"<|>\"WHO monitors surveillance performance in subnational areas within countries.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"National AFP cases\"<|>\"WHO collects and reports national AFP case data for surveillance.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Regional AFP cases\"<|>\"WHO collects and reports regional AFP case data for surveillance.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Adequate specimens\"<|>\"WHO sets standards for adequate specimen collection in polio surveillance.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"WHO data is published in the Morbidity and Mortality Weekly Report for global dissemination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which includes WHO surveillance data.\"<|>10)##\n(\"relationship\"<|>\"AFP cases\"<|>\"NPAFP rate\"<|>\"NPAFP rate is calculated based on AFP cases to assess surveillance quality.\"<|>9)##\n(\"relationship\"<|>\"AFP cases\"<|>\"Adequate specimens\"<|>\"Adequate specimens are collected from AFP cases for laboratory confirmation.\"<|>9)##\n(\"relationship\"<|>\"AFP cases\"<|>\"WPV cases\"<|>\"Some AFP cases are confirmed as wild poliovirus cases through laboratory testing.\"<|>8)##\n(\"relationship\"<|>\"AFP cases\"<|>\"cVDPV cases\"<|>\"Some AFP cases are confirmed as circulating vaccine-derived poliovirus cases through laboratory testing.\"<|>8)##\n(\"relationship\"<|>\"Population living in areas meeting both indicators\"<|>\"Surveillance performance indicators\"<|>\"Population living in areas meeting both indicators is a metric derived from surveillance performance indicators.\"<|>8)##\n(\"relationship\"<|>\"2019\"<|>\"Table 1\"<|>\"Table 1 includes surveillance data from the year 2019.\"<|>7)##\n(\"relationship\"<|>\"2020\"<|>\"Table 1\"<|>\"Table 1 includes surveillance data from the year 2020.\"<|>7)##\n(\"relationship\"<|>\"Vol. 70 / No. 18\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Vol. 70 / No. 18 is the specific issue of the Morbidity and Mortality Weekly Report containing this data.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "a58039d89203fc9ebd4dc3170cfe2ad6": {
    "return": "(\"entity\"<|>\"Ambrose AF\"<|>\"person\"<|>\"Ambrose AF is an author of a review article on risk factors for falls among older adults, contributing to geriatric research.\")##\n(\"entity\"<|>\"Paul G\"<|>\"person\"<|>\"Paul G is a co-author of a literature review on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"Hausdorff JM\"<|>\"person\"<|>\"Hausdorff JM is a co-author of a review article on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"Pomidor A\"<|>\"person\"<|>\"Pomidor A is the editor of the 'Clinicians guide to assessing and counseling older drivers', contributing to geriatric clinical guidance.\")##\n(\"entity\"<|>\"The American Geriatrics Society\"<|>\"organization\"<|>\"The American Geriatrics Society is a professional organization focused on improving the health, independence, and quality of life of older people; publisher of clinical guides.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency responsible for public health, disease prevention, and safety initiatives.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal department overseeing health-related agencies, including the CDC.\")##\n(\"entity\"<|>\"Shen S\"<|>\"person\"<|>\"Shen S is an author of a cross-sectional study on travel patterns of older adults in the USA, focusing on mobility and traffic safety.\")##\n(\"entity\"<|>\"Koech W\"<|>\"person\"<|>\"Koech W is a co-author of a study on travel patterns of older adults in the USA.\")##\n(\"entity\"<|>\"Feng J\"<|>\"person\"<|>\"Feng J is a co-author of a study on travel patterns of older adults in the USA.\")##\n(\"entity\"<|>\"Rice TM\"<|>\"person\"<|>\"Rice TM is a co-author of a study on travel patterns of older adults in the USA.\")##\n(\"entity\"<|>\"Zhu M\"<|>\"person\"<|>\"Zhu M is a co-author of a study on travel patterns of older adults in the USA.\")##\n(\"entity\"<|>\"Troya MI\"<|>\"person\"<|>\"Troya MI is an author of a systematic review on self-harm in older adults.\")##\n(\"entity\"<|>\"Babatunde O\"<|>\"person\"<|>\"Babatunde O is a co-author of a systematic review on self-harm in older adults.\")##\n(\"entity\"<|>\"Polidano K\"<|>\"person\"<|>\"Polidano K is a co-author of a systematic review on self-harm in older adults.\")##\n(\"entity\"<|>\"Doak MW\"<|>\"person\"<|>\"Doak MW is an author of a study on self-poisoning in older adults, focusing on drug ingestion patterns and clinical outcomes.\")##\n(\"entity\"<|>\"Nixon AC\"<|>\"person\"<|>\"Nixon AC is a co-author of a study on self-poisoning in older adults.\")##\n(\"entity\"<|>\"Lupton DJ\"<|>\"person\"<|>\"Lupton DJ is a co-author of a study on self-poisoning in older adults.\")##\n(\"entity\"<|>\"Waring WS\"<|>\"person\"<|>\"Waring WS is a co-author of a study on self-poisoning in older adults.\")##\n(\"entity\"<|>\"Gillespie LD\"<|>\"person\"<|>\"Gillespie LD is an author of a systematic review on interventions for preventing falls in older people living in the community.\")##\n(\"entity\"<|>\"Robertson MC\"<|>\"person\"<|>\"Robertson MC is a co-author of a systematic review on interventions for preventing falls in older people.\")##\n(\"entity\"<|>\"Gillespie WJ\"<|>\"person\"<|>\"Gillespie WJ is a co-author of a systematic review on interventions for preventing falls in older people.\")##\n(\"entity\"<|>\"Global Polio Eradication Initiative\"<|>\"organization\"<|>\"The Global Polio Eradication Initiative (GPEI) is an international partnership established in 1988 to eradicate polio worldwide.\")##\n(\"entity\"<|>\"Jude N. Tuma\"<|>\"person\"<|>\"Jude N. Tuma, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Amanda L. Wilkinson\"<|>\"person\"<|>\"Amanda L. Wilkinson, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Ousmane M. Diop\"<|>\"person\"<|>\"Ousmane M. Diop, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Jaume Jorba\"<|>\"person\"<|>\"Jaume Jorba, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Tracie Gardner\"<|>\"person\"<|>\"Tracie Gardner, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Cynthia J. Snider\"<|>\"person\"<|>\"Cynthia J. Snider, PhD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Abhijeet Anand\"<|>\"person\"<|>\"Abhijeet Anand, MBBS, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"Jamal Ahmed\"<|>\"person\"<|>\"Jamal Ahmed, MD, is an author of a report on polio surveillance and eradication efforts worldwide.\")##\n(\"entity\"<|>\"COVID-19 pandemic\"<|>\"event\"<|>\"The COVID-19 pandemic is a global health crisis declared in 2020, impacting public health activities including polio surveillance and immunization.\")##\n(\"entity\"<|>\"Polio Eradication Efforts 2019-2020\"<|>\"event\"<|>\"Polio Eradication Efforts 2019-2020 refers to global surveillance and immunization activities aimed at eradicating polio, with performance indicators tracked in 42 priority countries.\")##\n(\"entity\"<|>\"African Region\"<|>\"geo\"<|>\"The African Region refers to a group of countries in Africa prioritized for polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region\"<|>\"geo\"<|>\"The Eastern Mediterranean Region refers to a group of countries prioritized for polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country where wild poliovirus type 1 transmission remains endemic as of 2020.\")##\n(\"entity\"<|>\"Afghanistan\"<|>\"geo\"<|>\"Afghanistan is a country where wild poliovirus type 1 transmission remains endemic as of 2020.\")##\n(\"entity\"<|>\"Angola\"<|>\"geo\"<|>\"Angola is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Benin\"<|>\"geo\"<|>\"Benin is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Burkina Faso\"<|>\"geo\"<|>\"Burkina Faso is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Cameroon\"<|>\"geo\"<|>\"Cameroon is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Central African Republic\"<|>\"geo\"<|>\"Central African Republic is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Chad\"<|>\"geo\"<|>\"Chad is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Congo\"<|>\"geo\"<|>\"Congo is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"C么te d'Ivoire\"<|>\"geo\"<|>\"C么te d'Ivoire is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Democratic Republic of the Congo\"<|>\"geo\"<|>\"Democratic Republic of the Congo is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Eritrea\"<|>\"geo\"<|>\"Eritrea is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Ethiopia\"<|>\"geo\"<|>\"Ethiopia is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Ghana\"<|>\"geo\"<|>\"Ghana is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Guinea\"<|>\"geo\"<|>\"Guinea is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Kenya\"<|>\"geo\"<|>\"Kenya is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Liberia\"<|>\"geo\"<|>\"Liberia is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Madagascar\"<|>\"geo\"<|>\"Madagascar is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Mali\"<|>\"geo\"<|>\"Mali is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Mauritania\"<|>\"geo\"<|>\"Mauritania is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Mozambique\"<|>\"geo\"<|>\"Mozambique is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Niger\"<|>\"geo\"<|>\"Niger is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Nigeria\"<|>\"geo\"<|>\"Nigeria is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Senegal\"<|>\"geo\"<|>\"Senegal is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"entity\"<|>\"Sierra Leone\"<|>\"geo\"<|>\"Sierra Leone is a country in the African Region identified as a priority for polio surveillance and eradication.\")##\n(\"relationship\"<|>\"Ambrose AF\"<|>\"Paul G\"<|>\"Ambrose AF and Paul G are co-authors of a review article on risk factors for falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Ambrose AF\"<|>\"Hausdorff JM\"<|>\"Ambrose AF and Hausdorff JM are co-authors of a review article on risk factors for falls among older adults.\"<|>8)##\n(\"relationship\"<|>\"Pomidor A\"<|>\"The American Geriatrics Society\"<|>\"Pomidor A is the editor of a clinical guide published by The American Geriatrics Society.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"US Department of Health and Human Services\"<|>\"The CDC is an agency under the US Department of Health and Human Services.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Global Polio Eradication Initiative\"<|>\"The CDC is a partner in the Global Polio Eradication Initiative, contributing to polio surveillance and eradication efforts.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Polio Eradication Efforts 2019-2020\"<|>\"GPEI coordinates and oversees polio eradication efforts globally, including surveillance and immunization activities in 2019-2020.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"Polio Eradication Efforts 2019-2020\"<|>\"The COVID-19 pandemic impacted polio eradication efforts, leading to the pausing of supplementary immunization activities and changes in surveillance.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Amanda L. Wilkinson\"<|>\"Jude N. Tuma and Amanda L. Wilkinson are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Ousmane M. Diop\"<|>\"Jude N. Tuma and Ousmane M. Diop are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Jaume Jorba\"<|>\"Jude N. Tuma and Jaume Jorba are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Tracie Gardner\"<|>\"Jude N. Tuma and Tracie Gardner are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Cynthia J. Snider\"<|>\"Jude N. Tuma and Cynthia J. Snider are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Abhijeet Anand\"<|>\"Jude N. Tuma and Abhijeet Anand are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Jude N. Tuma\"<|>\"Jamal Ahmed\"<|>\"Jude N. Tuma and Jamal Ahmed are co-authors of a report on polio surveillance and eradication.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Pakistan\"<|>\"Pakistan is one of the two countries where wild poliovirus type 1 transmission remains endemic, making it a focus of GPEI activities.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Afghanistan\"<|>\"Afghanistan is one of the two countries where wild poliovirus type 1 transmission remains endemic, making it a focus of GPEI activities.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"African Region\"<|>\"The African Region contains multiple priority countries for polio surveillance and eradication under GPEI.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Eastern Mediterranean Region\"<|>\"The Eastern Mediterranean Region contains priority countries for polio surveillance and eradication under GPEI.\"<|>8)##\n(\"relationship\"<|>\"African Region\"<|>\"Angola\"<|>\"Angola is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Benin\"<|>\"Benin is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Burkina Faso\"<|>\"Burkina Faso is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Cameroon\"<|>\"Cameroon is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Central African Republic\"<|>\"Central African Republic is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Chad\"<|>\"Chad is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Congo\"<|>\"Congo is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"C么te d'Ivoire\"<|>\"C么te d'Ivoire is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Democratic Republic of the Congo\"<|>\"Democratic Republic of the Congo is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Eritrea\"<|>\"Eritrea is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Ethiopia\"<|>\"Ethiopia is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Ghana\"<|>\"Ghana is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Guinea\"<|>\"Guinea is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Kenya\"<|>\"Kenya is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Liberia\"<|>\"Liberia is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Madagascar\"<|>\"Madagascar is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Mali\"<|>\"Mali is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Mauritania\"<|>\"Mauritania is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Mozambique\"<|>\"Mozambique is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Niger\"<|>\"Niger is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Nigeria\"<|>\"Nigeria is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Senegal\"<|>\"Senegal is a country within the African Region prioritized for polio eradication activities.\"<|>10)##\n(\"relationship\"<|>\"African Region\"<|>\"Sierra Leone\"<|>\"Sierra Leone is a country within the African Region prioritized for polio eradication activities.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "ef8716027cf5ca405ef9a9422a6a949c": {
    "return": "(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"World Health Organization (WHO) is an international public health agency headquartered in Geneva, Switzerland. It leads global efforts in disease surveillance, immunization, and eradication programs, including polio eradication. WHO coordinates with various partners and provides technical guidance, data analysis, and policy recommendations.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a United States federal agency under the Department of Health and Human Services. It is involved in global health initiatives, including immunization and disease surveillance, and collaborates with WHO and other organizations on polio eradication and COVID-19 response.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal department overseeing public health, including the CDC. It supports disease surveillance, immunization, and public health reporting.\")##\n(\"entity\"<|>\"Global Polio Eradication Initiative\"<|>\"organization\"<|>\"Global Polio Eradication Initiative (GPEI) is a partnership of organizations dedicated to eradicating polio worldwide. It coordinates surveillance, immunization, and laboratory networks, and organizes oversight board meetings to guide strategy.\")##\n(\"entity\"<|>\"Global Polio Laboratory Network\"<|>\"organization\"<|>\"Global Polio Laboratory Network is a network of laboratories supporting the detection and analysis of poliovirus, providing technical expertise and laboratory testing for surveillance activities.\")##\n(\"entity\"<|>\"Data and Information Management Network\"<|>\"organization\"<|>\"Data and Information Management Network is a group involved in managing and analyzing surveillance data related to polio and other diseases.\")##\n(\"entity\"<|>\"Surveillance Task Team\"<|>\"organization\"<|>\"Surveillance Task Team is a group of experts responsible for overseeing and improving disease surveillance activities, particularly for polio.\")##\n(\"entity\"<|>\"Ana Chevez\"<|>\"person\"<|>\"Ana Chevez is acknowledged as a contributor to polio surveillance and eradication efforts, likely as a member of one of the mentioned organizations or networks.\")##\n(\"entity\"<|>\"Eugene Saxentoff\"<|>\"person\"<|>\"Eugene Saxentoff is acknowledged for contributions to polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Gloria Rey\"<|>\"person\"<|>\"Gloria Rey is recognized for her work in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Hieronyma Nelisiwe Gumede-Moeletsi\"<|>\"person\"<|>\"Hieronyma Nelisiwe Gumede-Moeletsi is acknowledged for her involvement in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Humayun Asghar\"<|>\"person\"<|>\"Humayun Asghar is listed as a contributor to polio surveillance and eradication efforts.\")##\n(\"entity\"<|>\"Johnson Muluh Ticha\"<|>\"person\"<|>\"Johnson Muluh Ticha is recognized for his work in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Lucky Sangal\"<|>\"person\"<|>\"Lucky Sangal is acknowledged for contributions to polio surveillance and eradication.\")##\n(\"entity\"<|>\"Muhammad Obaid-ul Butt\"<|>\"person\"<|>\"Muhammad Obaid-ul Butt is listed as a contributor to polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Patrick Michael OConnor\"<|>\"person\"<|>\"Patrick Michael OConnor is recognized for his involvement in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Shahin Huseynov\"<|>\"person\"<|>\"Shahin Huseynov is acknowledged for contributions to polio surveillance and eradication.\")##\n(\"entity\"<|>\"Sudhir Joshi\"<|>\"person\"<|>\"Sudhir Joshi is listed as a contributor to polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Tigran Avagyan\"<|>\"person\"<|>\"Tigran Avagyan is recognized for his work in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Varja Grabovac\"<|>\"person\"<|>\"Varja Grabovac is acknowledged for contributions to polio surveillance and eradication.\")##\n(\"entity\"<|>\"Jane Iber\"<|>\"person\"<|>\"Jane Iber is listed as a contributor to polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"Elizabeth Henderson\"<|>\"person\"<|>\"Elizabeth Henderson is recognized for her involvement in polio surveillance and eradication.\")##\n(\"entity\"<|>\"Jude Tuma\"<|>\"person\"<|>\"Jude Tuma is the corresponding author for the report, affiliated with the Polio Eradication Department at WHO in Geneva, Switzerland.\")##\n(\"entity\"<|>\"Geneva, Switzerland\"<|>\"geo\"<|>\"Geneva, Switzerland is the location of the World Health Organization headquarters and the Polio Eradication Department.\")##\n(\"entity\"<|>\"COVID-19 pandemic\"<|>\"event\"<|>\"COVID-19 pandemic is a global health crisis that has impacted disease surveillance activities, including polio surveillance, and led to repurposing of resources.\")##\n(\"entity\"<|>\"Polio eradication\"<|>\"event\"<|>\"Polio eradication is the global effort to eliminate poliovirus transmission, relying on surveillance, immunization, and laboratory testing.\")##\n(\"entity\"<|>\"Expanded Programmes on Immunization\"<|>\"organization\"<|>\"Expanded Programmes on Immunization are national programs aimed at integrating surveillance for vaccine-preventable and other diseases.\")##\n(\"entity\"<|>\"Acute flaccid paralysis surveillance\"<|>\"event\"<|>\"Acute flaccid paralysis (AFP) surveillance is a critical activity for detecting poliovirus transmission, involving case detection, notification, investigation, specimen transport, and laboratory testing.\")##\n(\"entity\"<|>\"Environmental surveillance\"<|>\"event\"<|>\"Environmental surveillance involves monitoring sewage samples to supplement AFP surveillance for poliovirus detection.\")##\n(\"entity\"<|>\"Polio oversight board meeting\"<|>\"event\"<|>\"Polio oversight board meeting is an event organized by the Global Polio Eradication Initiative to review progress and guide strategy for polio eradication.\")##\n(\"entity\"<|>\"IHR Emergency Committee on Novel Coronavirus (2019-nCoV)\"<|>\"event\"<|>\"IHR Emergency Committee on Novel Coronavirus (2019-nCoV) is a committee convened by WHO to address the COVID-19 pandemic.\")##\n(\"entity\"<|>\"42 countries at high risk for poliovirus transmission\"<|>\"geo\"<|>\"42 countries at high risk for poliovirus transmission refers to a group of nations identified as priorities for polio surveillance and eradication activities.\")##\n(\"entity\"<|>\"National Center for Immunization and Respiratory Diseases\"<|>\"organization\"<|>\"National Center for Immunization and Respiratory Diseases is a division of CDC involved in immunization and disease surveillance, including polio.\")##\n(\"entity\"<|>\"Global Immunization Division, Center for Global Health, CDC\"<|>\"organization\"<|>\"Global Immunization Division, Center for Global Health, CDC is a division of CDC focused on global immunization efforts, including polio eradication.\")##\n(\"entity\"<|>\"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC\"<|>\"organization\"<|>\"Division of Viral Diseases is a division within CDC's National Center for Immunization and Respiratory Diseases, involved in viral disease surveillance and response.\")##\n(\"entity\"<|>\"International Committee of Medical Journal Editors\"<|>\"organization\"<|>\"International Committee of Medical Journal Editors is a group that sets standards for disclosure of potential conflicts of interest in medical publications.\")##\n(\"entity\"<|>\"Chard AN\"<|>\"person\"<|>\"Chard AN is an author referenced for work on progress toward polio eradication worldwide.\")##\n(\"entity\"<|>\"Datta SD\"<|>\"person\"<|>\"Datta SD is an author referenced for work on polio eradication.\")##\n(\"entity\"<|>\"Tallis G\"<|>\"person\"<|>\"Tallis G is an author referenced for work on polio eradication.\")##\n(\"entity\"<|>\"Alleman MM\"<|>\"person\"<|>\"Alleman MM is an author referenced for work on vaccine-derived poliovirus outbreaks.\")##\n(\"entity\"<|>\"Jorba J\"<|>\"person\"<|>\"Jorba J is an author referenced for work on vaccine-derived poliovirus outbreaks.\")##\n(\"entity\"<|>\"Greene SA\"<|>\"person\"<|>\"Greene SA is an author referenced for work on vaccine-derived poliovirus outbreaks.\")##\n(\"entity\"<|>\"Lickness JS\"<|>\"person\"<|>\"Lickness JS is an author referenced for work on surveillance to track progress toward polio eradication.\")##\n(\"entity\"<|>\"Gardner T\"<|>\"person\"<|>\"Gardner T is an author referenced for work on polio surveillance.\")##\n(\"entity\"<|>\"Diop OM\"<|>\"person\"<|>\"Diop OM is an author referenced for work on polio surveillance.\")##\n\n(\"relationship\"<|>\"World Health Organization\"<|>\"Geneva, Switzerland\"<|>\"WHO is headquartered in Geneva, Switzerland, and its Polio Eradication Department is located there.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Polio eradication\"<|>\"WHO leads and coordinates global efforts for polio eradication, providing technical guidance and policy recommendations.\"<|>10)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Centers for Disease Control and Prevention\"<|>\"WHO collaborates with CDC on global health initiatives, including polio eradication and surveillance activities.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"US Department of Health and Human Services\"<|>\"CDC is a federal agency under the US Department of Health and Human Services, responsible for public health and disease surveillance.\"<|>10)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"World Health Organization\"<|>\"GPEI is a partnership that includes WHO as a leading member in coordinating polio eradication activities.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Global Polio Laboratory Network\"<|>\"GPEI coordinates with the Global Polio Laboratory Network for laboratory testing and surveillance of poliovirus.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Polio oversight board meeting\"<|>\"GPEI organizes Polio oversight board meetings to review progress and guide strategy for polio eradication.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Acute flaccid paralysis surveillance\"<|>\"The Global Polio Laboratory Network supports AFP surveillance by providing laboratory testing and analysis for poliovirus detection.\"<|>8)##\n(\"relationship\"<|>\"Data and Information Management Network\"<|>\"Global Polio Eradication Initiative\"<|>\"The Data and Information Management Network manages and analyzes surveillance data for GPEI.\"<|>7)##\n(\"relationship\"<|>\"Surveillance Task Team\"<|>\"Global Polio Eradication Initiative\"<|>\"Surveillance Task Team members are acknowledged for their role in improving surveillance activities for GPEI.\"<|>7)##\n(\"relationship\"<|>\"Expanded Programmes on Immunization\"<|>\"World Health Organization\"<|>\"WHO supports country Expanded Programmes on Immunization to integrate surveillance for vaccine-preventable diseases.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"Polio eradication\"<|>\"The COVID-19 pandemic has impacted polio eradication efforts by diverting resources and affecting surveillance activities.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC has repurposed polio resources to support COVID-19 pandemic challenges.\"<|>7)##\n(\"relationship\"<|>\"42 countries at high risk for poliovirus transmission\"<|>\"Polio eradication\"<|>\"These countries are priority areas for polio eradication efforts due to high risk of poliovirus transmission.\"<|>8)##\n(\"relationship\"<|>\"Acute flaccid paralysis surveillance\"<|>\"Polio eradication\"<|>\"AFP surveillance is a critical component of polio eradication, enabling detection of poliovirus transmission.\"<|>10)##\n(\"relationship\"<|>\"Environmental surveillance\"<|>\"Polio eradication\"<|>\"Environmental surveillance supplements AFP surveillance to detect poliovirus in sewage samples, aiding eradication efforts.\"<|>8)##\n(\"relationship\"<|>\"IHR Emergency Committee on Novel Coronavirus (2019-nCoV)\"<|>\"World Health Organization\"<|>\"WHO convened the IHR Emergency Committee to address the COVID-19 pandemic.\"<|>8)##\n(\"relationship\"<|>\"National Center for Immunization and Respiratory Diseases\"<|>\"Centers for Disease Control and Prevention\"<|>\"The National Center for Immunization and Respiratory Diseases is a division within CDC focused on immunization and disease surveillance.\"<|>10)##\n(\"relationship\"<|>\"Global Immunization Division, Center for Global Health, CDC\"<|>\"Centers for Disease Control and Prevention\"<|>\"Global Immunization Division is part of CDC's Center for Global Health, working on global immunization efforts.\"<|>9)##\n(\"relationship\"<|>\"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC\"<|>\"Centers for Disease Control and Prevention\"<|>\"Division of Viral Diseases is a division within CDC's National Center for Immunization and Respiratory Diseases, involved in viral disease surveillance and response.\"<|>9)##\n(\"relationship\"<|>\"International Committee of Medical Journal Editors\"<|>\"World Health Organization\"<|>\"WHO authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest for this report.\"<|>6)##\n(\"relationship\"<|>\"Jude Tuma\"<|>\"World Health Organization\"<|>\"Jude Tuma is the corresponding author for the report and is affiliated with the Polio Eradication Department at WHO in Geneva, Switzerland.\"<|>9)##\n(\"relationship\"<|>\"Ana Chevez\"<|>\"World Health Organization\"<|>\"Ana Chevez is acknowledged for her contributions to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Eugene Saxentoff\"<|>\"World Health Organization\"<|>\"Eugene Saxentoff is acknowledged for contributions to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Gloria Rey\"<|>\"World Health Organization\"<|>\"Gloria Rey is recognized for her work in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Hieronyma Nelisiwe Gumede-Moeletsi\"<|>\"World Health Organization\"<|>\"Hieronyma Nelisiwe Gumede-Moeletsi is acknowledged for her involvement in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Humayun Asghar\"<|>\"World Health Organization\"<|>\"Humayun Asghar is listed as a contributor to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Johnson Muluh Ticha\"<|>\"World Health Organization\"<|>\"Johnson Muluh Ticha is recognized for his work in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Lucky Sangal\"<|>\"World Health Organization\"<|>\"Lucky Sangal is acknowledged for contributions to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Muhammad Obaid-ul Butt\"<|>\"World Health Organization\"<|>\"Muhammad Obaid-ul Butt is listed as a contributor to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Patrick Michael OConnor\"<|>\"World Health Organization\"<|>\"Patrick Michael OConnor is recognized for his involvement in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Shahin Huseynov\"<|>\"World Health Organization\"<|>\"Shahin Huseynov is acknowledged for contributions to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Sudhir Joshi\"<|>\"World Health Organization\"<|>\"Sudhir Joshi is listed as a contributor to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Tigran Avagyan\"<|>\"World Health Organization\"<|>\"Tigran Avagyan is recognized for his work in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Varja Grabovac\"<|>\"World Health Organization\"<|>\"Varja Grabovac is acknowledged for contributions to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Jane Iber\"<|>\"World Health Organization\"<|>\"Jane Iber is listed as a contributor to polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Elizabeth Henderson\"<|>\"World Health Organization\"<|>\"Elizabeth Henderson is recognized for her involvement in polio surveillance and eradication, likely as a member or collaborator with WHO.\"<|>7)##\n(\"relationship\"<|>\"Chard AN\"<|>\"World Health Organization\"<|>\"Chard AN is referenced as an author for work on polio eradication, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Datta SD\"<|>\"World Health Organization\"<|>\"Datta SD is referenced as an author for work on polio eradication, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Tallis G\"<|>\"World Health Organization\"<|>\"Tallis G is referenced as an author for work on polio eradication, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Alleman MM\"<|>\"World Health Organization\"<|>\"Alleman MM is referenced as an author for work on vaccine-derived poliovirus outbreaks, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Jorba J\"<|>\"World Health Organization\"<|>\"Jorba J is referenced as an author for work on vaccine-derived poliovirus outbreaks, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Greene SA\"<|>\"World Health Organization\"<|>\"Greene SA is referenced as an author for work on vaccine-derived poliovirus outbreaks, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Lickness JS\"<|>\"World Health Organization\"<|>\"Lickness JS is referenced as an author for work on polio surveillance, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Gardner T\"<|>\"World Health Organization\"<|>\"Gardner T is referenced as an author for work on polio surveillance, likely collaborating with WHO.\"<|>6)##\n(\"relationship\"<|>\"Diop OM\"<|>\"World Health Organization\"<|>\"Diop OM is referenced as an author for work on polio surveillance, likely collaborating with WHO.\"<|>6)<|COMPLETE|>",
    "model": "gpt41"
  },
  "c34d4312b041c7598918c90651aff837": {
    "return": "(\"entity\"<|>\"Global Polio Eradication Initiative\"<|>\"organization\"<|>\"The Global Polio Eradication Initiative is an international public health program focused on eradicating polio worldwide through surveillance, vaccination, and coordination among countries and organizations.\")##\n(\"entity\"<|>\"Global Polio Laboratory Network\"<|>\"organization\"<|>\"The Global Polio Laboratory Network is a platform for laboratory networks focused on viral vaccine-preventable and emerging diseases, supporting polio eradication efforts through laboratory surveillance and diagnostics.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services, including oversight of public health initiatives.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency under the Department of Health and Human Services, leading efforts in disease control, prevention, and public health research.\")##\n(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"Pfizer-BioNTech is a collaboration between Pfizer Inc. and BioNTech SE, responsible for developing one of the first COVID-19 vaccines authorized for emergency use.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"Moderna is a biotechnology company that developed one of the first COVID-19 vaccines authorized for emergency use in the United States.\")##\n(\"entity\"<|>\"Pakistan\"<|>\"geo\"<|>\"Pakistan is a country in South Asia, referenced in the context of progress toward poliomyelitis eradication between January 2019 and September 2020.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is a country in North America, referenced as the location for COVID-19 vaccine effectiveness studies and as the jurisdiction for the CDC and HHS.\")##\n(\"entity\"<|>\"COVID-19 pandemic\"<|>\"event\"<|>\"The COVID-19 pandemic is a global health crisis caused by the spread of the SARS-CoV-2 virus, impacting public health surveillance and vaccination efforts worldwide.\")##\n(\"entity\"<|>\"Polio eradication\"<|>\"event\"<|>\"Polio eradication refers to the global effort to eliminate poliomyelitis through vaccination, surveillance, and international cooperation.\")##\n(\"entity\"<|>\"COVID-19 vaccination\"<|>\"event\"<|>\"COVID-19 vaccination is the process of immunizing populations against COVID-19 using vaccines such as Pfizer-BioNTech and Moderna, with a focus on high-risk groups like adults aged 65 years.\")##\n(\"entity\"<|>\"Mark W. Tenforde\"<|>\"person\"<|>\"Mark W. Tenforde, MD, PhD, is an author and medical researcher involved in studies assessing the effectiveness of COVID-19 vaccines among hospitalized adults in the United States.\")##\n(\"entity\"<|>\"Samantha M. Olson\"<|>\"person\"<|>\"Samantha M. Olson, MPH, is a public health researcher and author contributing to studies on COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"Wesley H. Self\"<|>\"person\"<|>\"Wesley H. Self, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"H. Keipp Talbot\"<|>\"person\"<|>\"H. Keipp Talbot, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Christopher J. Lindsell\"<|>\"person\"<|>\"Christopher J. Lindsell, PhD, is a researcher involved in public health studies, including COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"Jay S. Steingrub\"<|>\"person\"<|>\"Jay S. Steingrub, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Nathan I. Shapiro\"<|>\"person\"<|>\"Nathan I. Shapiro, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Adit A. Ginde\"<|>\"person\"<|>\"Adit A. Ginde, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"David J. Douin\"<|>\"person\"<|>\"David J. Douin, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Matthew E. Prekker\"<|>\"person\"<|>\"Matthew E. Prekker, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Samuel M. Brown\"<|>\"person\"<|>\"Samuel M. Brown, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Ithan D. Peltan\"<|>\"person\"<|>\"Ithan D. Peltan, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Michelle N. Gong\"<|>\"person\"<|>\"Michelle N. Gong, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Amira Mohamed\"<|>\"person\"<|>\"Amira Mohamed, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Akram Khan\"<|>\"person\"<|>\"Akram Khan, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Matthew C. Exline\"<|>\"person\"<|>\"Matthew C. Exline, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"D. Clark Files\"<|>\"person\"<|>\"D. Clark Files, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Kevin W. Gibbs\"<|>\"person\"<|>\"Kevin W. Gibbs, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"William B. Stubblefield\"<|>\"person\"<|>\"William B. Stubblefield, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Jonathan D. Casey\"<|>\"person\"<|>\"Jonathan D. Casey, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Todd W. Rice\"<|>\"person\"<|>\"Todd W. Rice, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Carlos G. Grijalva\"<|>\"person\"<|>\"Carlos G. Grijalva, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"David N. Hager\"<|>\"person\"<|>\"David N. Hager, MD, PhD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Arber Shehu\"<|>\"person\"<|>\"Arber Shehu, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Nida Qadir\"<|>\"person\"<|>\"Nida Qadir, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Steven Y. Chang\"<|>\"person\"<|>\"Steven Y. Chang, MD, PhD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Jennifer G. Wilson\"<|>\"person\"<|>\"Jennifer G. Wilson, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Manjusha Gaglani\"<|>\"person\"<|>\"Manjusha Gaglani, MBBS, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Kempapura Murthy\"<|>\"person\"<|>\"Kempapura Murthy, MPH, is a public health researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Nicole Calhoun\"<|>\"person\"<|>\"Nicole Calhoun, LMSW, MPA, is a public health researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Arnold S. Monto\"<|>\"person\"<|>\"Arnold S. Monto, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Emily T. Martin\"<|>\"person\"<|>\"Emily T. Martin, PhD, is a researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Anurag Malani\"<|>\"person\"<|>\"Anurag Malani, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Richard K. Zimmerman\"<|>\"person\"<|>\"Richard K. Zimmerman, MD, is a medical doctor and researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Fernanda P. Silveira\"<|>\"person\"<|>\"Fernanda P. Silveira, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Donald B. Middleton\"<|>\"person\"<|>\"Donald B. Middleton, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Yuwei Zhu\"<|>\"person\"<|>\"Yuwei Zhu, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Dayna Wyatt\"<|>\"person\"<|>\"Dayna Wyatt is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Meagan Stephenson\"<|>\"person\"<|>\"Meagan Stephenson, MPH, is a public health researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Adrienne Baughman\"<|>\"person\"<|>\"Adrienne Baughman is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Kelsey N. Womack\"<|>\"person\"<|>\"Kelsey N. Womack, PhD, is a researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Kimberly W. Hart\"<|>\"person\"<|>\"Kimberly W. Hart is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Miwako Kobayashi\"<|>\"person\"<|>\"Miwako Kobayashi, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"Jennifer R. Verani\"<|>\"person\"<|>\"Jennifer R. Verani, MD, is a medical doctor and researcher contributing to COVID-19 vaccine effectiveness research.\")##\n(\"entity\"<|>\"Manish M. Patel\"<|>\"person\"<|>\"Manish M. Patel, MD, is a medical doctor and researcher involved in COVID-19 vaccine effectiveness studies.\")##\n(\"entity\"<|>\"IVY Network\"<|>\"organization\"<|>\"The IVY Network is a collaborative research network involved in studies assessing the effectiveness of COVID-19 vaccines among hospitalized adults.\")##\n(\"entity\"<|>\"HAIVEN Investigators\"<|>\"organization\"<|>\"HAIVEN Investigators are a group of researchers involved in COVID-19 vaccine effectiveness studies.\")##\n(\"relationship\"<|>\"Global Polio Eradication Initiative\"<|>\"Global Polio Laboratory Network\"<|>\"The Global Polio Laboratory Network operates as a platform within the Global Polio Eradication Initiative, supporting laboratory surveillance and diagnostics for polio eradication.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"US Department of Health and Human Services\"<|>\"The CDC is a federal agency under the US Department of Health and Human Services, responsible for disease control and public health.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-19 pandemic\"<|>\"The CDC is actively involved in monitoring, reporting, and responding to the COVID-19 pandemic in the United States.\"<|>9)##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19 vaccination\"<|>\"Pfizer-BioNTech developed one of the first COVID-19 vaccines used in mass vaccination campaigns.\"<|>10)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19 vaccination\"<|>\"Moderna developed one of the first COVID-19 vaccines used in mass vaccination campaigns.\"<|>10)##\n(\"relationship\"<|>\"United States\"<|>\"COVID-19 vaccination\"<|>\"COVID-19 vaccination efforts, including studies on vaccine effectiveness, are conducted in the United States, especially among adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Pakistan\"<|>\"Polio eradication\"<|>\"Pakistan is a country where progress toward polio eradication is monitored and reported, highlighting its role in global eradication efforts.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"COVID-19 vaccination\"<|>\"The COVID-19 pandemic prompted the development and deployment of COVID-19 vaccines to control the spread of the virus.\"<|>10)##\n(\"relationship\"<|>\"Mark W. Tenforde\"<|>\"COVID-19 vaccination\"<|>\"Mark W. Tenforde is a lead author and researcher in studies assessing the effectiveness of COVID-19 vaccines among hospitalized adults.\"<|>9)##\n(\"relationship\"<|>\"Samantha M. Olson\"<|>\"COVID-19 vaccination\"<|>\"Samantha M. Olson is a researcher contributing to studies on COVID-19 vaccine effectiveness.\"<|>8)##\n(\"relationship\"<|>\"Wesley H. Self\"<|>\"COVID-19 vaccination\"<|>\"Wesley H. Self is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"H. Keipp Talbot\"<|>\"COVID-19 vaccination\"<|>\"H. Keipp Talbot is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"COVID-19 vaccination\"<|>\"Christopher J. Lindsell is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Jay S. Steingrub\"<|>\"COVID-19 vaccination\"<|>\"Jay S. Steingrub is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Nathan I. Shapiro\"<|>\"COVID-19 vaccination\"<|>\"Nathan I. Shapiro is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Adit A. Ginde\"<|>\"COVID-19 vaccination\"<|>\"Adit A. Ginde is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"David J. Douin\"<|>\"COVID-19 vaccination\"<|>\"David J. Douin is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Matthew E. Prekker\"<|>\"COVID-19 vaccination\"<|>\"Matthew E. Prekker is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"COVID-19 vaccination\"<|>\"Samuel M. Brown is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Ithan D. Peltan\"<|>\"COVID-19 vaccination\"<|>\"Ithan D. Peltan is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Michelle N. Gong\"<|>\"COVID-19 vaccination\"<|>\"Michelle N. Gong is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Amira Mohamed\"<|>\"COVID-19 vaccination\"<|>\"Amira Mohamed is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Akram Khan\"<|>\"COVID-19 vaccination\"<|>\"Akram Khan is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Matthew C. Exline\"<|>\"COVID-19 vaccination\"<|>\"Matthew C. Exline is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"D. Clark Files\"<|>\"COVID-19 vaccination\"<|>\"D. Clark Files is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Kevin W. Gibbs\"<|>\"COVID-19 vaccination\"<|>\"Kevin W. Gibbs is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"William B. Stubblefield\"<|>\"COVID-19 vaccination\"<|>\"William B. Stubblefield is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Jonathan D. Casey\"<|>\"COVID-19 vaccination\"<|>\"Jonathan D. Casey is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Todd W. Rice\"<|>\"COVID-19 vaccination\"<|>\"Todd W. Rice is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"COVID-19 vaccination\"<|>\"Carlos G. Grijalva is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"David N. Hager\"<|>\"COVID-19 vaccination\"<|>\"David N. Hager is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Arber Shehu\"<|>\"COVID-19 vaccination\"<|>\"Arber Shehu is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Nida Qadir\"<|>\"COVID-19 vaccination\"<|>\"Nida Qadir is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Steven Y. Chang\"<|>\"COVID-19 vaccination\"<|>\"Steven Y. Chang is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Jennifer G. Wilson\"<|>\"COVID-19 vaccination\"<|>\"Jennifer G. Wilson is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Manjusha Gaglani\"<|>\"COVID-19 vaccination\"<|>\"Manjusha Gaglani is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Kempapura Murthy\"<|>\"COVID-19 vaccination\"<|>\"Kempapura Murthy is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Nicole Calhoun\"<|>\"COVID-19 vaccination\"<|>\"Nicole Calhoun is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Arnold S. Monto\"<|>\"COVID-19 vaccination\"<|>\"Arnold S. Monto is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Emily T. Martin\"<|>\"COVID-19 vaccination\"<|>\"Emily T. Martin is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Anurag Malani\"<|>\"COVID-19 vaccination\"<|>\"Anurag Malani is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Richard K. Zimmerman\"<|>\"COVID-19 vaccination\"<|>\"Richard K. Zimmerman is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Fernanda P. Silveira\"<|>\"COVID-19 vaccination\"<|>\"Fernanda P. Silveira is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Donald B. Middleton\"<|>\"COVID-19 vaccination\"<|>\"Donald B. Middleton is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Yuwei Zhu\"<|>\"COVID-19 vaccination\"<|>\"Yuwei Zhu is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Dayna Wyatt\"<|>\"COVID-19 vaccination\"<|>\"Dayna Wyatt is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Meagan Stephenson\"<|>\"COVID-19 vaccination\"<|>\"Meagan Stephenson is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Adrienne Baughman\"<|>\"COVID-19 vaccination\"<|>\"Adrienne Baughman is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Kelsey N. Womack\"<|>\"COVID-19 vaccination\"<|>\"Kelsey N. Womack is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Kimberly W. Hart\"<|>\"COVID-19 vaccination\"<|>\"Kimberly W. Hart is a researcher listed as an author in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Miwako Kobayashi\"<|>\"COVID-19 vaccination\"<|>\"Miwako Kobayashi is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"Jennifer R. Verani\"<|>\"COVID-19 vaccination\"<|>\"Jennifer R. Verani is a researcher contributing to COVID-19 vaccine effectiveness research.\"<|>8)##\n(\"relationship\"<|>\"Manish M. Patel\"<|>\"COVID-19 vaccination\"<|>\"Manish M. Patel is a researcher involved in COVID-19 vaccine effectiveness studies.\"<|>8)##\n(\"relationship\"<|>\"IVY Network\"<|>\"COVID-19 vaccination\"<|>\"The IVY Network is a collaborative research network involved in studies assessing the effectiveness of COVID-19 vaccines among hospitalized adults.\"<|>9)##\n(\"relationship\"<|>\"HAIVEN Investigators\"<|>\"COVID-19 vaccination\"<|>\"HAIVEN Investigators are a group of researchers involved in COVID-19 vaccine effectiveness studies.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "2ab07bc182a420089e533aaafa84e7b8": {
    "return": "(\"entity\"<|>\"Adults Aged 65 Years and Older\"<|>\"person\"<|>\"Adults aged 65 years and older are the population group studied in the report, with data collected on their injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Male\"<|>\"person\"<|>\"Male refers to the male sex subgroup within the population of adults aged 65 years and older, analyzed for injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Female\"<|>\"person\"<|>\"Female refers to the female sex subgroup within the population of adults aged 65 years and older, analyzed for injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Age Group 65-74\"<|>\"person\"<|>\"Age Group 65-74 refers to adults aged between 65 and 74 years, analyzed as a reference group for injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Age Group 75-84\"<|>\"person\"<|>\"Age Group 75-84 refers to adults aged between 75 and 84 years, analyzed for injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Age Group 85+\"<|>\"person\"<|>\"Age Group 85+ refers to adults aged 85 years and older, analyzed for injury-related emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Emergency Department\"<|>\"organization\"<|>\"Emergency Department (ED) is a hospital-based facility providing immediate medical care for acute illnesses and injuries, and is the setting for many injury-related visits analyzed in the report.\")##\n(\"entity\"<|>\"Hospital\"<|>\"organization\"<|>\"Hospital refers to the healthcare institution where patients are admitted for inpatient care, including those hospitalized for injuries as analyzed in the report.\")##\n(\"entity\"<|>\"ICD-10-CM Codes\"<|>\"organization\"<|>\"ICD-10-CM Codes are the International Classification of Diseases, 10th Revision, Clinical Modification codes used for classifying injury diagnoses and mechanisms in the report.\")##\n(\"entity\"<|>\"Confidence Interval\"<|>\"event\"<|>\"Confidence Interval (CI) is a statistical measure used in the report to indicate the reliability of the estimated rates for emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Weighted Number Estimates\"<|>\"event\"<|>\"Weighted Number Estimates are statistical calculations used to ensure the data is representative of the U.S. population, adjusting for sampling and exclusions.\")##\n(\"entity\"<|>\"P-value\"<|>\"event\"<|>\"P-value is a statistical metric used in the report to determine the significance of differences between groups, such as sex and age categories.\")##\n(\"entity\"<|>\"Reference Group\"<|>\"event\"<|>\"Reference Group is a baseline category (such as Age Group 65-74 or Male) used for statistical comparison in the analysis of injury rates.\")##\n(\"entity\"<|>\"Initial Encounter\"<|>\"event\"<|>\"Initial Encounter refers to the first medical visit for an injury, included in the analysis of emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Subsequent Encounter\"<|>\"event\"<|>\"Subsequent Encounter refers to follow-up medical visits for an injury, included in the analysis of emergency department visits and hospitalizations.\")##\n(\"entity\"<|>\"Sequelae\"<|>\"event\"<|>\"Sequelae refers to the aftereffects or complications resulting from an injury, included in the analysis of emergency department visits and hospitalizations.\")##\n\n(\"relationship\"<|>\"Adults Aged 65 Years and Older\"<|>\"Age Group 65-74\"<|>\"Age Group 65-74 is a subgroup of adults aged 65 years and older, used as a reference group in the analysis.\"<|>9)##\n(\"relationship\"<|>\"Adults Aged 65 Years and Older\"<|>\"Age Group 75-84\"<|>\"Age Group 75-84 is a subgroup of adults aged 65 years and older, analyzed for injury-related visits and hospitalizations.\"<|>9)##\n(\"relationship\"<|>\"Adults Aged 65 Years and Older\"<|>\"Age Group 85+\"<|>\"Age Group 85+ is a subgroup of adults aged 65 years and older, analyzed for injury-related visits and hospitalizations.\"<|>9)##\n(\"relationship\"<|>\"Adults Aged 65 Years and Older\"<|>\"Male\"<|>\"Male is a sex subgroup within adults aged 65 years and older, analyzed for injury-related visits and hospitalizations.\"<|>8)##\n(\"relationship\"<|>\"Adults Aged 65 Years and Older\"<|>\"Female\"<|>\"Female is a sex subgroup within adults aged 65 years and older, analyzed for injury-related visits and hospitalizations.\"<|>8)##\n(\"relationship\"<|>\"Emergency Department\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Emergency Department is the setting for many injury-related visits analyzed in the report.\"<|>10)##\n(\"relationship\"<|>\"Hospital\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Hospital is the setting for inpatient care and hospitalizations analyzed in the report.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-CM Codes\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"ICD-10-CM Codes are used to classify and analyze injury diagnoses and mechanisms in the report.\"<|>9)##\n(\"relationship\"<|>\"Confidence Interval\"<|>\"Weighted Number Estimates\"<|>\"Confidence Interval is used to express the reliability of Weighted Number Estimates in the report's statistical analysis.\"<|>7)##\n(\"relationship\"<|>\"Reference Group\"<|>\"P-value\"<|>\"P-value is used to compare the Reference Group to other groups for statistical significance in injury rates.\"<|>7)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Initial Encounter\"<|>\"Initial Encounter is one type of medical visit included in the analysis of injury-related visits and hospitalizations.\"<|>7)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Subsequent Encounter\"<|>\"Subsequent Encounter is another type of medical visit included in the analysis of injury-related visits and hospitalizations.\"<|>7)##\n(\"relationship\"<|>\"Injury-related Emergency Department Visits and Hospitalizations among Adults Aged 65 Years\"<|>\"Sequelae\"<|>\"Sequelae refers to complications from injuries, included in the analysis of injury-related visits and hospitalizations.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "2cc9c9d3f728741419d86d0b60fcd273": {
    "return": "(\"entity\"<|>\"ICD-10-CM\"<|>\"organization\"<|>\"ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification) is a medical coding system used in the United States to classify diagnoses and reasons for visits in all health care settings. It was used in this study to identify injury and overdose cases.\")##\n(\"entity\"<|>\"ICD-10-PCS\"<|>\"organization\"<|>\"ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) is a medical coding system used in the United States for coding inpatient hospital procedures. It was used in this study to identify opioid overdose cases.\")##\n(\"entity\"<|>\"ED Visits\"<|>\"event\"<|>\"Emergency Department (ED) Visits refer to instances when patients seek care in hospital emergency departments for injuries such as falls, crashes, opioid overdoses, and self-harm. These visits were analyzed by age, sex, and cause.\")##\n(\"entity\"<|>\"Hospitalizations\"<|>\"event\"<|>\"Hospitalizations refer to instances when patients are admitted to hospitals for injuries such as falls, crashes, opioid overdoses, and self-harm. These were analyzed by age, sex, and cause.\")##\n(\"entity\"<|>\"Prescription Opioids\"<|>\"event\"<|>\"Prescription Opioids are medications prescribed to manage pain, which can lead to unintentional overdose, especially among older adults. These were included in the opioid overdose analysis.\")##\n(\"entity\"<|>\"Heroin\"<|>\"event\"<|>\"Heroin is an illicit opioid drug included in the analysis of unintentional opioid overdoses among older adults.\")##\n(\"entity\"<|>\"Adults aged 65-74 years\"<|>\"person\"<|>\"Adults aged 65-74 years are a subgroup of older adults analyzed for rates of injury-related ED visits and hospitalizations, with specific mention of higher rates of opioid overdose and self-harm.\")##\n(\"entity\"<|>\"Adults aged 75-84 years\"<|>\"person\"<|>\"Adults aged 75-84 years are a subgroup of older adults analyzed for rates of injury-related ED visits and hospitalizations, with increasing rates of fall injuries compared to younger groups.\")##\n(\"entity\"<|>\"Adults aged 85 years and older\"<|>\"person\"<|>\"Adults aged 85 years and older are a subgroup of older adults analyzed for rates of injury-related ED visits and hospitalizations, with the highest rates of fall injuries.\")##\n(\"entity\"<|>\"T-tests\"<|>\"event\"<|>\"T-tests are statistical tests used in the study for selected pairwise comparisons to determine statistical significance between groups.\")##\n(\"entity\"<|>\"Survey Procedures\"<|>\"event\"<|>\"Survey Procedures refer to the statistical methods used to weight ED visits and hospitalizations to represent the US population in the analysis.\")##\n(\"entity\"<|>\"Age-Adjustment to 2000 US Standard Population\"<|>\"event\"<|>\"Age-Adjustment to the 2000 US Standard Population is a statistical method used to standardize rates of ED visits and hospitalizations for comparison across age groups.\")##\n(\"entity\"<|>\"Federal Law and CDC Policy\"<|>\"event\"<|>\"Federal Law and CDC Policy refer to the legal and regulatory framework under which the study was reviewed and conducted.\")##\n(\"entity\"<|>\"45 C.F.R. part 46.102 (l) (2)\"<|>\"event\"<|>\"45 C.F.R. part 46.102 (l) (2) is a section of the Code of Federal Regulations related to the protection of human subjects in research, referenced as part of the regulatory compliance for the study.\")##\n(\"entity\"<|>\"21 C.F.R. part 56\"<|>\"event\"<|>\"21 C.F.R. part 56 is a section of the Code of Federal Regulations related to Institutional Review Boards, referenced as part of the regulatory compliance for the study.\")##\n(\"entity\"<|>\"42 U.S.C. Sect. 241 (d)\"<|>\"event\"<|>\"42 U.S.C. Sect. 241 (d) is a section of the United States Code related to research and investigations, referenced as part of the regulatory compliance for the study.\")##\n(\"entity\"<|>\"5 U.S.C. Sect. 552a\"<|>\"event\"<|>\"5 U.S.C. Sect. 552a is a section of the United States Code related to the Privacy Act, referenced as part of the regulatory compliance for the study.\")##\n(\"entity\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"event\"<|>\"44 U.S.C. Sect. 3501 et seq. is a section of the United States Code related to federal information policy, referenced as part of the regulatory compliance for the study.\")##\n(\"entity\"<|>\"General Injury Indicators\"<|>\"event\"<|>\"General Injury Indicators are metrics or codes used to identify and classify injuries in surveillance systems, referenced in the context of the Injury Surveillance Methods Toolkit.\")##\n(\"entity\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"organization\"<|>\"The Injury Surveillance Methods Toolkit is a resource provided by CSTE for identifying and analyzing injury indicators, referenced in the study.\")##\n(\"entity\"<|>\"CSTE\"<|>\"organization\"<|>\"CSTE (Council of State and Territorial Epidemiologists) is an organization that provides resources and guidance for injury surveillance, referenced in the study.\")##\n\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"ICD-10-PCS\"<|>\"Both ICD-10-CM and ICD-10-PCS are medical coding systems used to identify injury and overdose cases in the study.\"<|>9)##\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"Unintentional Opioid Overdose\"<|>\"ICD-10-CM codes are used to identify cases of unintentional opioid overdose in the study data.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-PCS\"<|>\"Unintentional Opioid Overdose\"<|>\"ICD-10-PCS codes are used to identify cases of unintentional opioid overdose in the study data.\"<|>10)##\n(\"relationship\"<|>\"ED Visits\"<|>\"Hospitalizations\"<|>\"ED visits and hospitalizations are both outcomes analyzed for injury events among older adults in the study.\"<|>8)##\n(\"relationship\"<|>\"Prescription Opioids\"<|>\"Unintentional Opioid Overdose\"<|>\"Prescription opioids are a major contributor to unintentional opioid overdose events among older adults.\"<|>9)##\n(\"relationship\"<|>\"Heroin\"<|>\"Unintentional Opioid Overdose\"<|>\"Heroin is included as a cause of unintentional opioid overdose events among older adults.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 65-74 years\"<|>\"Unintentional Opioid Overdose\"<|>\"Adults aged 65-74 years had the highest rates of ED visits for unintentional opioid overdose among older adults.\"<|>9)##\n(\"relationship\"<|>\"Adults aged 65-74 years\"<|>\"Self-Harm\"<|>\"Adults aged 65-74 years had the highest rates of ED visits for self-harm among older adults.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 75-84 years\"<|>\"Unintentional Falls\"<|>\"Adults aged 75-84 years had increased rates of ED visits and hospitalizations for unintentional falls compared to younger groups.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 85 years and older\"<|>\"Unintentional Falls\"<|>\"Adults aged 85 years and older had the highest rates of ED visits and hospitalizations for unintentional falls.\"<|>9)##\n(\"relationship\"<|>\"T-tests\"<|>\"ED Visits\"<|>\"T-tests were used to compare rates of ED visits between groups for statistical significance.\"<|>7)##\n(\"relationship\"<|>\"T-tests\"<|>\"Hospitalizations\"<|>\"T-tests were used to compare rates of hospitalizations between groups for statistical significance.\"<|>7)##\n(\"relationship\"<|>\"Survey Procedures\"<|>\"SAS Institute\"<|>\"Survey procedures were conducted using SAS Institute's statistical software to weight data to the US population.\"<|>8)##\n(\"relationship\"<|>\"Age-Adjustment to 2000 US Standard Population\"<|>\"ED Visits\"<|>\"Rates of ED visits were age-adjusted to the 2000 US standard population for comparison across age groups.\"<|>8)##\n(\"relationship\"<|>\"Age-Adjustment to 2000 US Standard Population\"<|>\"Hospitalizations\"<|>\"Rates of hospitalizations were age-adjusted to the 2000 US standard population for comparison across age groups.\"<|>8)##\n(\"relationship\"<|>\"Federal Law and CDC Policy\"<|>\"CDC\"<|>\"CDC reviewed and conducted the activity consistent with applicable federal law and CDC policy.\"<|>10)##\n(\"relationship\"<|>\"45 C.F.R. part 46.102 (l) (2)\"<|>\"CDC\"<|>\"CDC referenced 45 C.F.R. part 46.102 (l) (2) for regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"21 C.F.R. part 56\"<|>\"CDC\"<|>\"CDC referenced 21 C.F.R. part 56 for regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"42 U.S.C. Sect. 241 (d)\"<|>\"CDC\"<|>\"CDC referenced 42 U.S.C. Sect. 241 (d) for regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"5 U.S.C. Sect. 552a\"<|>\"CDC\"<|>\"CDC referenced 5 U.S.C. Sect. 552a for regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"CDC\"<|>\"CDC referenced 44 U.S.C. Sect. 3501 et seq. for regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"General Injury Indicators\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"General Injury Indicators are part of the Injury Surveillance Methods Toolkit provided by CSTE for injury analysis.\"<|>8)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"CSTE\"<|>\"The Injury Surveillance Methods Toolkit is a resource provided by CSTE for injury surveillance and analysis.\"<|>9)##\n(\"relationship\"<|>\"CSTE\"<|>\"CDC\"<|>\"CSTE provides resources and guidance for injury surveillance, which are used by CDC in public health studies.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "5a7b51e2928df7c710222e53f79c1772": {
    "return": "(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication produced by the Centers for Disease Control and Prevention, providing timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.\")##\n(\"entity\"<|>\"U.S. State Department\"<|>\"organization\"<|>\"The U.S. State Department is the federal executive department responsible for international relations of the United States, including the official naming conventions for countries such as Burma (Myanmar).\")##\n(\"entity\"<|>\"WHO African Region\"<|>\"geo\"<|>\"The WHO African Region is one of the six regions of the World Health Organization, encompassing countries in Africa and serving as a focus for public health surveillance and interventions.\")##\n(\"entity\"<|>\"WHO Eastern Mediterranean Region\"<|>\"geo\"<|>\"The WHO Eastern Mediterranean Region is one of the six regions of the World Health Organization, covering countries in the Middle East and North Africa, and is a focus for disease surveillance.\")##\n(\"entity\"<|>\"WHO South-East Asia Region\"<|>\"geo\"<|>\"The WHO South-East Asia Region (SEAR) is one of the six regions of the World Health Organization, including countries such as Burma (Myanmar), Malaysia, and the Philippines, and is a focus for acute flaccid paralysis surveillance.\")##\n(\"entity\"<|>\"WHO Western Pacific Region\"<|>\"geo\"<|>\"The WHO Western Pacific Region (WPR) is one of the six regions of the World Health Organization, including countries such as Malaysia and the Philippines, and is a focus for acute flaccid paralysis surveillance.\")##\n(\"entity\"<|>\"NPAFP Indicator Target\"<|>\"event\"<|>\"The NPAFP indicator target refers to the surveillance goal of detecting two or more nonpolio acute flaccid paralysis cases per 100,000 children under 15 years of age per year, used to monitor the sensitivity of polio surveillance systems.\")##\n(\"entity\"<|>\"Stool Adequacy Indicator Target\"<|>\"event\"<|>\"The stool adequacy indicator target is a surveillance goal requiring that 80% of persons with AFP have two stool specimens collected 24 hours apart within 14 days of paralysis onset and arrival at a WHO-accredited laboratory in good condition.\")##\n(\"entity\"<|>\"Reverse Cold Chain\"<|>\"event\"<|>\"Reverse cold chain is the process of transporting biological specimens, such as stool samples, from the field to laboratories under controlled, cold conditions to preserve sample integrity for accurate testing.\")##\n(\"entity\"<|>\"Poliovirus Transmission\"<|>\"event\"<|>\"Poliovirus transmission refers to the spread of poliovirus among populations, detected through both acute flaccid paralysis surveillance and environmental surveillance, and tracked by genomic sequencing.\")##\n(\"entity\"<|>\"cVDPV Emergence\"<|>\"event\"<|>\"cVDPV emergence refers to the appearance of circulating vaccine-derived poliovirus (cVDPV) cases, identified through genomic sequence analysis and surveillance activities in multiple countries.\")##\n(\"entity\"<|>\"WPV1\"<|>\"event\"<|>\"WPV1 refers to wild poliovirus type 1, detected through genetic clustering and environmental surveillance in countries such as Afghanistan and Pakistan.\")##\n(\"entity\"<|>\"Sabin Poliovirus\"<|>\"event\"<|>\"Sabin poliovirus refers to the attenuated virus strains used in oral polio vaccines, differentiated from wild and vaccine-derived polioviruses in laboratory testing.\")##\n(\"entity\"<|>\"VDPV\"<|>\"event\"<|>\"VDPV stands for vaccine-derived poliovirus, which can circulate and cause outbreaks, detected through laboratory differentiation and genomic sequencing.\")##\n(\"entity\"<|>\"Capsid Protein (VP1) Coding Region\"<|>\"event\"<|>\"The capsid protein (VP1) coding region is a part of the poliovirus genome analyzed in sequence studies to monitor transmission pathways and genetic relatedness of isolates.\")##\n(\"entity\"<|>\"Accreditation Program\"<|>\"event\"<|>\"The accreditation program is an annual process of on-site reviews and proficiency testing to ensure the accuracy and quality of testing at GPLN laboratories.\")##\n(\"entity\"<|>\"Proficiency Testing\"<|>\"event\"<|>\"Proficiency testing is part of the laboratory accreditation process, ensuring that laboratories maintain high standards in poliovirus detection and analysis.\")##\n(\"entity\"<|>\"Environmental Sites\"<|>\"geo\"<|>\"Environmental sites are locations where sewage samples are collected for environmental surveillance to detect poliovirus circulation in the population.\")##\n(\"entity\"<|>\"Subnational Areas\"<|>\"geo\"<|>\"Subnational areas refer to administrative regions within countries, assessed for performance indicators in acute flaccid paralysis surveillance.\")##\n(\"entity\"<|>\"Children Aged <15 Years\"<|>\"person\"<|>\"Children aged under 15 years are the target population for acute flaccid paralysis surveillance, as polio primarily affects this age group.\")##\n\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report to disseminate public health surveillance findings and recommendations.\"<|>10)##\n(\"relationship\"<|>\"U.S. State Department\"<|>\"Burma (Myanmar)\"<|>\"The U.S. State Department uses the short-form name Burma for Myanmar in official communications and reporting.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"WHO African Region\"<|>\"WHO oversees public health activities and surveillance in the African Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"WHO Eastern Mediterranean Region\"<|>\"WHO oversees public health activities and surveillance in the Eastern Mediterranean Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"WHO South-East Asia Region\"<|>\"WHO oversees public health activities and surveillance in the South-East Asia Region.\"<|>9)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"WHO Western Pacific Region\"<|>\"WHO oversees public health activities and surveillance in the Western Pacific Region.\"<|>9)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"NPAFP Indicator Target\"<|>\"NPAFP indicator target is a key metric for evaluating the sensitivity of AFP surveillance systems.\"<|>10)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Stool Adequacy Indicator Target\"<|>\"Stool adequacy indicator target is a key metric for evaluating the quality of AFP surveillance systems.\"<|>10)##\n(\"relationship\"<|>\"Stool Adequacy Indicator Target\"<|>\"Reverse Cold Chain\"<|>\"Reverse cold chain is required to ensure stool specimens meet the adequacy indicator for AFP surveillance.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Accreditation Program\"<|>\"GPLN laboratories undergo annual accreditation programs to ensure quality and accuracy in poliovirus testing.\"<|>10)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Proficiency Testing\"<|>\"GPLN laboratories participate in proficiency testing as part of the accreditation process.\"<|>9)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Sabin Poliovirus\"<|>\"GPLN laboratories differentiate Sabin poliovirus from wild and vaccine-derived strains during testing.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"VDPV\"<|>\"GPLN laboratories identify and differentiate vaccine-derived poliovirus (VDPV) during surveillance and testing.\"<|>8)##\n(\"relationship\"<|>\"Global Polio Laboratory Network\"<|>\"Capsid Protein (VP1) Coding Region\"<|>\"GPLN laboratories analyze the capsid protein (VP1) coding region to monitor poliovirus transmission pathways.\"<|>8)##\n(\"relationship\"<|>\"Environmental Surveillance\"<|>\"Environmental Sites\"<|>\"Environmental surveillance is conducted at environmental sites where sewage samples are collected for poliovirus detection.\"<|>9)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Subnational Areas\"<|>\"AFP surveillance performance is assessed in subnational areas to monitor regional effectiveness.\"<|>8)##\n(\"relationship\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"Children Aged <15 Years\"<|>\"AFP surveillance targets children under 15 years, the primary population at risk for polio.\"<|>10)##\n(\"relationship\"<|>\"Poliovirus Transmission\"<|>\"cVDPV Emergence\"<|>\"cVDPV emergence is a form of poliovirus transmission detected through surveillance and genomic analysis.\"<|>9)##\n(\"relationship\"<|>\"Poliovirus Transmission\"<|>\"WPV1\"<|>\"WPV1 is a type of poliovirus involved in transmission events detected through surveillance and genetic clustering.\"<|>8)##\n(\"relationship\"<|>\"Genomic Sequence Analysis of cVDPV\"<|>\"cVDPV Emergence\"<|>\"Genomic sequence analysis is used to identify and track cVDPV emergences in multiple countries.\"<|>10)##\n(\"relationship\"<|>\"Environmental Surveillance\"<|>\"Poliovirus Transmission\"<|>\"Environmental surveillance detects poliovirus transmission in populations by identifying virus in sewage samples.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "d62b88fd662a4627d0b58ac41e680b72": {
    "return": "(\"entity\"<|>\"Soumya Dunworth\"<|>\"person\"<|>\"Soumya Dunworth, PhD, is listed among the editorial staff, likely contributing scientific expertise to the editorial process.\")##\n(\"entity\"<|>\"Catherine B. Lansdowne\"<|>\"person\"<|>\"Catherine B. Lansdowne, MS, is a member of the editorial staff, likely involved in technical writing or editing.\")##\n(\"entity\"<|>\"Srila Sen\"<|>\"person\"<|>\"Srila Sen, MA, is part of the editorial team, likely involved in writing or editing.\")##\n(\"entity\"<|>\"Stacy Simon\"<|>\"person\"<|>\"Stacy Simon, MA, is a member of the editorial staff, contributing to writing or editing.\")##\n(\"entity\"<|>\"Jeffrey D. Sokolow\"<|>\"person\"<|>\"Jeffrey D. Sokolow, MA, is part of the editorial team, likely involved in technical writing or editing.\")##\n(\"entity\"<|>\"Stephen R. Spriggs\"<|>\"person\"<|>\"Stephen R. Spriggs is a Visual Information Specialist, involved in visual content creation.\")##\n(\"entity\"<|>\"Tong Yang\"<|>\"person\"<|>\"Tong Yang is a Visual Information Specialist, contributing to visual information design.\")##\n(\"entity\"<|>\"Quang M. Doan\"<|>\"person\"<|>\"Quang M. Doan, MBA, is an Information Technology Specialist, supporting IT needs for the editorial process.\")##\n(\"entity\"<|>\"Phyllis H. King\"<|>\"person\"<|>\"Phyllis H. King is an Information Technology Specialist, providing IT support for editorial operations.\")##\n(\"entity\"<|>\"Terraye M. Starr\"<|>\"person\"<|>\"Terraye M. Starr is an Information Technology Specialist, supporting editorial IT infrastructure.\")##\n(\"entity\"<|>\"Moua Yang\"<|>\"person\"<|>\"Moua Yang is an Information Technology Specialist, contributing to IT support for the editorial team.\")##\n(\"entity\"<|>\"Morgan Bobb Swanson\"<|>\"person\"<|>\"Morgan Bobb Swanson, BS, is a member of the editorial staff, likely contributing to health communication.\")##\n(\"entity\"<|>\"Ian Branam\"<|>\"person\"<|>\"Ian Branam, MA, is the Acting Lead Health Communication Specialist, overseeing health communication activities.\")##\n(\"entity\"<|>\"Shelton Bartley\"<|>\"person\"<|>\"Shelton Bartley, MPH, is a Health Communication Specialist, contributing to health communication efforts.\")##\n(\"entity\"<|>\"Lowery Johnson\"<|>\"person\"<|>\"Lowery Johnson is a Health Communication Specialist, contributing to health communication activities.\")##\n(\"entity\"<|>\"Amanda Ray\"<|>\"person\"<|>\"Amanda Ray is a Health Communication Specialist, involved in health communication efforts.\")##\n(\"entity\"<|>\"Jacqueline N. Sanchez\"<|>\"person\"<|>\"Jacqueline N. Sanchez, MS, is a Health Communication Specialist, contributing to health communication activities.\")##\n(\"entity\"<|>\"Will Yang\"<|>\"person\"<|>\"Will Yang, MA, is a Visual Information Specialist, contributing to visual content and design.\")##\n(\"entity\"<|>\"Terisa F. Rutledge\"<|>\"person\"<|>\"Terisa F. Rutledge is the Online Editor, responsible for digital content management and editorial decisions.\")##\n(\"entity\"<|>\"Teresa M. Hood\"<|>\"person\"<|>\"Teresa M. Hood, MS, is the Managing Editor, overseeing editorial operations and workflow.\")##\n(\"entity\"<|>\"Glenn Damon\"<|>\"person\"<|>\"Glenn Damon is listed among the editorial staff, likely contributing to technical writing or editing.\")##\n(\"entity\"<|>\"Martha F. Boyd\"<|>\"person\"<|>\"Martha F. Boyd is the Lead Visual Information Specialist, overseeing visual content and information design.\")##\n(\"entity\"<|>\"Alexander J. Gottardy\"<|>\"person\"<|>\"Alexander J. Gottardy is a Visual Information Specialist, contributing to visual content and design.\")##\n(\"entity\"<|>\"Maureen A. Leahy\"<|>\"person\"<|>\"Maureen A. Leahy is a Visual Information Specialist, involved in visual content creation.\")##\n(\"entity\"<|>\"Julia C. Martinroe\"<|>\"person\"<|>\"Julia C. Martinroe is a Visual Information Specialist, contributing to visual information design.\")##\n(\"entity\"<|>\"HCUP-NEDS\"<|>\"organization\"<|>\"HCUP-NEDS (Healthcare Cost and Utilization Project - Nationwide Emergency Department Sample) is a database containing diagnosis codes for emergency department visits.\")##\n(\"entity\"<|>\"HCUP-NIS\"<|>\"organization\"<|>\"HCUP-NIS (Healthcare Cost and Utilization Project - Nationwide Inpatient Sample) is a database containing diagnosis codes for hospital inpatient visits.\")##\n(\"entity\"<|>\"CSTE\"<|>\"organization\"<|>\"CSTE (Council of State and Territorial Epidemiologists) is an organization providing resources and toolkits for injury surveillance methods.\")##\n(\"entity\"<|>\"ICD-10-CM\"<|>\"organization\"<|>\"ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification) is a coding system used to classify diagnoses and injury mechanisms in healthcare data.\")##\n(\"entity\"<|>\"ICD-10-PCS\"<|>\"organization\"<|>\"ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) is a coding system used to classify inpatient procedures in healthcare data.\")##\n(\"entity\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"organization\"<|>\"The Injury Surveillance Methods Toolkit is a resource provided by CSTE for standardized injury surveillance practices.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"Unintentional Falls are a type of injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"event\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes are a type of injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Self-Harm\"<|>\"event\"<|>\"Self-Harm is an injury mechanism tracked using ICD-10-CM codes, relevant for hospitalizations and emergency department visits.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdose\"<|>\"event\"<|>\"Unintentional Opioid Overdose is an injury mechanism tracked using ICD-10-CM and ICD-10-PCS codes, relevant for hospitalizations and emergency department visits.\")##\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"Unintentional Falls\"<|>\"ICD-10-CM codes are used to classify and track Unintentional Falls in healthcare data.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"ICD-10-CM codes are used to classify and track Unintentional Traffic-Related Motor Vehicle Crashes in healthcare data.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"Self-Harm\"<|>\"ICD-10-CM codes are used to classify and track Self-Harm injuries in healthcare data.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-CM\"<|>\"Unintentional Opioid Overdose\"<|>\"ICD-10-CM codes are used to classify and track Unintentional Opioid Overdose in healthcare data.\"<|>10)##\n(\"relationship\"<|>\"ICD-10-PCS\"<|>\"Unintentional Opioid Overdose\"<|>\"ICD-10-PCS codes are used to classify and track procedures related to Unintentional Opioid Overdose in inpatient healthcare data.\"<|>10)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"CSTE\"<|>\"The Injury Surveillance Methods Toolkit is provided by CSTE to support standardized injury surveillance.\"<|>9)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"Unintentional Falls\"<|>\"The Injury Surveillance Methods Toolkit includes guidance for tracking Unintentional Falls.\"<|>8)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"The Injury Surveillance Methods Toolkit includes guidance for tracking Unintentional Traffic-Related Motor Vehicle Crashes.\"<|>8)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"Self-Harm\"<|>\"The Injury Surveillance Methods Toolkit includes guidance for tracking Self-Harm injuries.\"<|>8)##\n(\"relationship\"<|>\"Injury Surveillance Methods Toolkit\"<|>\"Unintentional Opioid Overdose\"<|>\"The Injury Surveillance Methods Toolkit includes guidance for tracking Unintentional Opioid Overdose.\"<|>8)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"ICD-10-CM\"<|>\"HCUP-NEDS uses ICD-10-CM codes to record diagnoses for emergency department visits.\"<|>10)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"ICD-10-CM\"<|>\"HCUP-NIS uses ICD-10-CM codes to record diagnoses for inpatient hospital visits.\"<|>10)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"ICD-10-PCS\"<|>\"HCUP-NIS uses ICD-10-PCS codes to record inpatient procedures.\"<|>10)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"Unintentional Falls\"<|>\"HCUP-NEDS tracks Unintentional Falls using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"Unintentional Falls\"<|>\"HCUP-NIS tracks Unintentional Falls using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"HCUP-NEDS tracks Unintentional Traffic-Related Motor Vehicle Crashes using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"HCUP-NIS tracks Unintentional Traffic-Related Motor Vehicle Crashes using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"Self-Harm\"<|>\"HCUP-NEDS tracks Self-Harm injuries using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"Self-Harm\"<|>\"HCUP-NIS tracks Self-Harm injuries using ICD-10-CM codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NEDS\"<|>\"Unintentional Opioid Overdose\"<|>\"HCUP-NEDS tracks Unintentional Opioid Overdose using ICD-10-CM and ICD-10-PCS codes.\"<|>9)##\n(\"relationship\"<|>\"HCUP-NIS\"<|>\"Unintentional Opioid Overdose\"<|>\"HCUP-NIS tracks Unintentional Opioid Overdose using ICD-10-CM and ICD-10-PCS codes.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "f24d367c8735d42a50cc2f615998989a": {
    "return": "(\"entity\"<|>\"Healthcare Cost and Utilization Project\"<|>\"organization\"<|>\"A project of the Agency for Healthcare Research and Quality that provides large-scale databases (such as NEDS and NIS) for analyzing healthcare utilization, costs, and outcomes in the United States.\")##\n(\"entity\"<|>\"Center for Surveillance, Epidemiology, and Laboratory Services\"<|>\"organization\"<|>\"A division within the CDC responsible for public health surveillance, epidemiology, and laboratory services, and for publishing the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Office of Science\"<|>\"organization\"<|>\"A division within the CDC focused on scientific leadership, research, and policy, led by Rebecca Bunnell and Jennifer Layden.\")##\n(\"entity\"<|>\"International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)\"<|>\"event\"<|>\"A standardized coding system for diagnoses used in the United States, referenced in the report for selecting ED visit diagnosis codes for injury analysis.\")##\n(\"entity\"<|>\"Pfizer-BioNTech COVID-19 Vaccine\"<|>\"event\"<|>\"A COVID-19 vaccine referenced in the report for its effectiveness among hospitalized adults aged 65 years in the United States, JanuaryMarch 2021.\")##\n(\"entity\"<|>\"Moderna COVID-19 Vaccine\"<|>\"event\"<|>\"A COVID-19 vaccine referenced in the report for its effectiveness among hospitalized adults aged 65 years in the United States, JanuaryMarch 2021.\")##\n(\"entity\"<|>\"Janssen (Johnson & Johnson) COVID-19 Vaccine\"<|>\"event\"<|>\"A COVID-19 vaccine referenced in the report for safety monitoring and anxiety-related adverse event clusters in the United States, MarchApril 2021.\")##\n(\"entity\"<|>\"Polio Eradication\"<|>\"event\"<|>\"A global public health initiative referenced in the report, with surveillance to track progress worldwide during 20192020.\")##\n(\"entity\"<|>\"Outbreak of Escherichia coli O157:H7 Infections Linked to Romaine Lettuce Exposure\"<|>\"event\"<|>\"A public health outbreak in the United States in 2019, referenced in the report as an example of disease surveillance and investigation.\")##\n(\"entity\"<|>\"STEADI Initiative\"<|>\"event\"<|>\"A CDC initiative referenced in the report, focused on preventing falls among older adults through clinical tools and education.\")##\n(\"entity\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"person\"<|>\"A population group in the United States, the primary focus of the report, analyzed for nonfatal and fatal injuries, including falls, motor vehicle crashes, drug poisoning, and suicide.\")##\n(\"entity\"<|>\"Physical Therapy\"<|>\"event\"<|>\"An intervention recommended by healthcare providers to older adults to help prevent injuries and improve mobility and independence.\")##\n(\"entity\"<|>\"Deprescribing Certain Medications\"<|>\"event\"<|>\"A clinical intervention recommended to reduce injury risk among older adults by discontinuing medications that may contribute to falls or other adverse events.\")##\n(\"entity\"<|>\"Unintentional Falls\"<|>\"event\"<|>\"A leading cause of injury and death among older adults, accounting for over 90% of selected ED visits and hospitalizations in the report.\")##\n(\"entity\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"event\"<|>\"A significant cause of injury and death among older adults, analyzed in the report.\")##\n(\"entity\"<|>\"Unintentional Opioid Overdoses\"<|>\"event\"<|>\"A cause of injury and death among older adults, included in the report's analysis of injury mechanisms.\")##\n(\"entity\"<|>\"Self-Harm (Suicidal and Nonsuicidal)\"<|>\"event\"<|>\"A mechanism of injury among older adults, including suicide and other self-harm behaviors, analyzed in the report.\")##\n(\"entity\"<|>\"Suicide Deaths Among Older Adults\"<|>\"event\"<|>\"A public health concern referenced in the report, with over 9,000 deaths annually among adults aged 65 years.\")##\n(\"entity\"<|>\"Fall Deaths\"<|>\"event\"<|>\"A specific category of unintentional injury deaths among older adults, with 34,000 deaths in 2019.\")##\n(\"entity\"<|>\"Traffic-Related Motor Vehicle Crash Deaths\"<|>\"event\"<|>\"A specific category of unintentional injury deaths among older adults, with 8,000 deaths in 2019.\")##\n(\"entity\"<|>\"Drug Poisoning Deaths\"<|>\"event\"<|>\"A specific category of unintentional injury deaths among older adults, with 3,000 deaths in 2019.\")##\n(\"entity\"<|>\"Brain Injury\"<|>\"event\"<|>\"A long-term health consequence of nonfatal injuries among older adults, referenced in the report.\")##\n(\"entity\"<|>\"Loss of Independence\"<|>\"event\"<|>\"A long-term health consequence of nonfatal injuries among older adults, referenced in the report.\")##\n\n(\"relationship\"<|>\"Healthcare Cost and Utilization Project\"<|>\"Agency for Healthcare Research and Quality\"<|>\"The Healthcare Cost and Utilization Project is managed by the Agency for Healthcare Research and Quality and provides key healthcare datasets.\"<|>10)##\n(\"relationship\"<|>\"Center for Surveillance, Epidemiology, and Laboratory Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The Center for Surveillance, Epidemiology, and Laboratory Services is a division within the CDC responsible for surveillance and laboratory services.\"<|>9)##\n(\"relationship\"<|>\"Office of Science\"<|>\"Centers for Disease Control and Prevention\"<|>\"The Office of Science is a division within the CDC focused on scientific leadership and research.\"<|>8)##\n(\"relationship\"<|>\"International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"ICD-10-CM codes were used to select and analyze ED visit diagnoses for the report's injury analysis.\"<|>9)##\n(\"relationship\"<|>\"Pfizer-BioNTech COVID-19 Vaccine\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC monitored and reported on the effectiveness of the Pfizer-BioNTech COVID-19 vaccine among hospitalized adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Moderna COVID-19 Vaccine\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC monitored and reported on the effectiveness of the Moderna COVID-19 vaccine among hospitalized adults aged 65 years.\"<|>8)##\n(\"relationship\"<|>\"Janssen (Johnson & Johnson) COVID-19 Vaccine\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC monitored and reported on the safety and adverse events related to the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Polio Eradication\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC tracks global progress toward polio eradication through surveillance activities.\"<|>7)##\n(\"relationship\"<|>\"Outbreak of Escherichia coli O157:H7 Infections Linked to Romaine Lettuce Exposure\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC investigated and reported on the outbreak of E. coli infections linked to romaine lettuce in the United States in 2019.\"<|>8)##\n(\"relationship\"<|>\"STEADI Initiative\"<|>\"Centers for Disease Control and Prevention\"<|>\"The STEADI Initiative is a CDC program aimed at preventing falls among older adults through clinical tools and education.\"<|>9)##\n(\"relationship\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Emergency Department Visits and Hospitalizations for Selected Nonfatal Injuries Among Adults Aged 65 Years\"<|>\"Older adults are the primary population group analyzed in the report for nonfatal and fatal injuries.\"<|>10)##\n(\"relationship\"<|>\"Physical Therapy\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Physical therapy is recommended as an intervention to help older adults prevent injuries and maintain independence.\"<|>8)##\n(\"relationship\"<|>\"Deprescribing Certain Medications\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Deprescribing certain medications is recommended to reduce injury risk among older adults.\"<|>8)##\n(\"relationship\"<|>\"Unintentional Falls\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Unintentional falls are the leading cause of injury and death among older adults, accounting for most ED visits and hospitalizations.\"<|>10)##\n(\"relationship\"<|>\"Unintentional Traffic-Related Motor Vehicle Crashes\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Traffic-related motor vehicle crashes are a significant cause of injury and death among older adults.\"<|>9)##\n(\"relationship\"<|>\"Unintentional Opioid Overdoses\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Unintentional opioid overdoses are a cause of injury and death among older adults, analyzed in the report.\"<|>8)##\n(\"relationship\"<|>\"Self-Harm (Suicidal and Nonsuicidal)\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Self-harm, including suicide, is a mechanism of injury among older adults, with significant public health impact.\"<|>8)##\n(\"relationship\"<|>\"Suicide Deaths Among Older Adults\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Suicide deaths are a major public health concern among older adults, with over 9,000 deaths annually.\"<|>9)##\n(\"relationship\"<|>\"Fall Deaths\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Fall deaths are a specific category of unintentional injury deaths among older adults, with 34,000 deaths in 2019.\"<|>9)##\n(\"relationship\"<|>\"Traffic-Related Motor Vehicle Crash Deaths\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Motor vehicle crash deaths are a specific category of unintentional injury deaths among older adults, with 8,000 deaths in 2019.\"<|>9)##\n(\"relationship\"<|>\"Drug Poisoning Deaths\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Drug poisoning deaths are a specific category of unintentional injury deaths among older adults, with 3,000 deaths in 2019.\"<|>8)##\n(\"relationship\"<|>\"Brain Injury\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Brain injury is a long-term health consequence of nonfatal injuries among older adults.\"<|>7)##\n(\"relationship\"<|>\"Loss of Independence\"<|>\"Older Adults (Aged 65 Years and Older)\"<|>\"Loss of independence is a long-term health consequence of nonfatal injuries among older adults.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "6532874ad5598a04c4d2aa90bb052f41": {
    "return": "(\"entity\"<|>\"AFP Surveillance System\"<|>\"event\"<|>\"The AFP Surveillance System is a sensitive surveillance system designed to track poliovirus transmission and provide evidence of interruption of transmission. It uses key performance indicators such as the nonpolio AFP rate and stool specimen adequacy.\")##\n(\"entity\"<|>\"Nonpolio AFP (NPAFP) Rate\"<|>\"event\"<|>\"The Nonpolio AFP (NPAFP) Rate is a key performance indicator for AFP surveillance quality, measuring the rate of acute flaccid paralysis cases not caused by poliovirus per 100,000 children under 15 years. A rate of 2 or more indicates sufficient sensitivity to detect circulating poliovirus.\")##\n(\"entity\"<|>\"Stool Specimen Adequacy\"<|>\"event\"<|>\"Stool Specimen Adequacy is a key performance indicator for AFP surveillance, defined as the collection of adequate stool specimens from 80% of persons with AFP. Adequacy is determined by timing, condition, and proper transport to a WHO-accredited laboratory.\")##\n(\"entity\"<|>\"Subnational Administrative Areas\"<|>\"geo\"<|>\"Subnational Administrative Areas refer to divisions within countries, such as states or provinces, used for assessing surveillance performance at a more granular level.\")##\n(\"entity\"<|>\"Reverse Cold Chain\"<|>\"event\"<|>\"Reverse Cold Chain is the process of storing and transporting biological samples at recommended temperatures from the point of collection to the laboratory to ensure sample integrity for poliovirus testing.\")##\n(\"entity\"<|>\"Children Aged <15 Years\"<|>\"person\"<|>\"Children aged less than 15 years are the primary population group monitored for acute flaccid paralysis and poliovirus surveillance.\")##\n(\"entity\"<|>\"AFP Patients\"<|>\"person\"<|>\"AFP Patients are individuals presenting with acute flaccid paralysis, whose cases are monitored and tested for evidence of poliovirus infection.\")##\n(\"entity\"<|>\"Environmental Surveillance\"<|>\"event\"<|>\"Environmental Surveillance refers to the monitoring of environmental samples (such as sewage) for poliovirus, supplementing AFP surveillance to detect virus circulation.\")##\n(\"entity\"<|>\"cVDPV2\"<|>\"event\"<|>\"cVDPV2 is a specific type of circulating vaccine-derived poliovirus, type 2, tracked in surveillance data and reported as cases in several countries.\")##\n(\"entity\"<|>\"WPV1\"<|>\"event\"<|>\"WPV1 is a specific strain of wild poliovirus, type 1, tracked in surveillance data and reported as cases in several countries.\")##\n(\"entity\"<|>\"cVDPV1\"<|>\"event\"<|>\"cVDPV1 is a specific type of circulating vaccine-derived poliovirus, type 1, tracked in surveillance data and reported as cases in several countries.\")##\n(\"entity\"<|>\"Table 1\"<|>\"event\"<|>\"Table 1 is a referenced data table summarizing national and subnational acute flaccid paralysis surveillance performance indicators and the number of confirmed wild poliovirus and circulating vaccine-derived poliovirus cases by country for 2019-2020.\")##\n(\"entity\"<|>\"Figure\"<|>\"event\"<|>\"Figure is a referenced visual representation showing subnational surveillance performance and population coverage for meeting both surveillance indicator targets.\")##\n\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Nonpolio AFP (NPAFP) Rate\"<|>\"The AFP Surveillance System uses the Nonpolio AFP Rate as a key indicator to assess sensitivity for detecting poliovirus transmission.\"<|>10)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Stool Specimen Adequacy\"<|>\"The AFP Surveillance System uses stool specimen adequacy as a key indicator to assess surveillance quality and reliability.\"<|>10)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Environmental Surveillance\"<|>\"Environmental Surveillance is a supplementary method used alongside AFP Surveillance to detect poliovirus circulation in the environment.\"<|>8)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Children Aged <15 Years\"<|>\"The AFP Surveillance System primarily monitors children under 15 years for acute flaccid paralysis and poliovirus infection.\"<|>9)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"AFP Patients\"<|>\"AFP Patients are the subjects of the AFP Surveillance System, whose cases are tracked and tested for poliovirus.\"<|>9)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Reverse Cold Chain\"<|>\"Reverse Cold Chain is a critical process in the AFP Surveillance System for ensuring the integrity of stool specimens collected from AFP patients.\"<|>8)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Subnational Administrative Areas\"<|>\"Surveillance performance is assessed at the subnational administrative area level to identify gaps and strengths in poliovirus detection.\"<|>8)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Table 1\"<|>\"Table 1 presents the results and performance indicators of the AFP Surveillance System across countries and regions.\"<|>7)##\n(\"relationship\"<|>\"AFP Surveillance System\"<|>\"Figure\"<|>\"Figure visually represents the subnational performance and population coverage of the AFP Surveillance System.\"<|>7)##\n(\"relationship\"<|>\"Nonpolio AFP (NPAFP) Rate\"<|>\"Children Aged <15 Years\"<|>\"The Nonpolio AFP Rate is calculated based on the number of AFP cases per 100,000 children under 15 years.\"<|>10)##\n(\"relationship\"<|>\"Stool Specimen Adequacy\"<|>\"AFP Patients\"<|>\"Stool specimen adequacy is measured by the percentage of AFP patients from whom adequate specimens are collected and tested.\"<|>10)##\n(\"relationship\"<|>\"Reverse Cold Chain\"<|>\"Stool Specimen Adequacy\"<|>\"Reverse Cold Chain ensures that stool specimens remain in good condition, which is necessary for meeting adequacy standards.\"<|>9)##\n(\"relationship\"<|>\"Environmental Surveillance\"<|>\"cVDPV2\"<|>\"Environmental Surveillance detects cVDPV2 isolates in environmental samples, supplementing case detection.\"<|>8)##\n(\"relationship\"<|>\"Environmental Surveillance\"<|>\"cVDPV1\"<|>\"Environmental Surveillance detects cVDPV1 isolates in environmental samples, supplementing case detection.\"<|>8)##\n(\"relationship\"<|>\"Table 1\"<|>\"Wild Poliovirus (WPV)\"<|>\"Table 1 reports the number of confirmed WPV cases by country and region.\"<|>8)##\n(\"relationship\"<|>\"Table 1\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"Table 1 reports the number of confirmed cVDPV cases by country and region.\"<|>8)##\n(\"relationship\"<|>\"Table 1\"<|>\"Nonpolio AFP (NPAFP) Rate\"<|>\"Table 1 includes data on the Nonpolio AFP Rate for each country and region.\"<|>8)##\n(\"relationship\"<|>\"Table 1\"<|>\"Stool Specimen Adequacy\"<|>\"Table 1 includes data on stool specimen adequacy for each country and region.\"<|>8)##\n(\"relationship\"<|>\"Figure\"<|>\"Subnational Administrative Areas\"<|>\"Figure shows the percentage of population living in subnational administrative areas meeting both surveillance indicator targets.\"<|>8)##\n(\"relationship\"<|>\"WPV1\"<|>\"Wild Poliovirus (WPV)\"<|>\"WPV1 is a specific strain of Wild Poliovirus tracked in surveillance and reporting.\"<|>9)##\n(\"relationship\"<|>\"cVDPV2\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"cVDPV2 is a specific type of cVDPV tracked in surveillance and reporting.\"<|>9)##\n(\"relationship\"<|>\"cVDPV1\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV)\"<|>\"cVDPV1 is a specific type of cVDPV tracked in surveillance and reporting.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "fc3c408ffaa087a4df94f84f371334f8": {
    "return": "(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"organization\"<|>\"The Janssen COVID-19 Vaccine is a single-dose vaccine authorized for emergency use in the United States for persons aged 18 years and older. It is notable for its simple storage requirements and is used in settings such as college campuses and drive-through vaccination sites. The vaccine has been associated with rare but serious adverse events, including thrombosis with thrombocytopenia syndrome (TTS), primarily in women aged 18-49 years.\")##\n(\"entity\"<|>\"ACIP\"<|>\"organization\"<|>\"The Advisory Committee on Immunization Practices (ACIP) is a group that reviews and makes recommendations regarding the use of vaccines in the United States. ACIP considered the benefits and risks of the Janssen COVID-19 vaccine and reaffirmed its interim recommendation for its use under the FDA's Emergency Use Authorization (EUA).\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"The Food and Drug Administration (FDA) is the U.S. regulatory authority that grants Emergency Use Authorization (EUA) for vaccines, including the Janssen COVID-19 vaccine. The FDA's EUA includes warnings for rare clotting events associated with the vaccine.\")##\n(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"The Vaccine Adverse Events Reporting System (VAERS) is a passive surveillance system in the United States for monitoring adverse events after vaccination. VAERS collects reports from healthcare providers as required under the EUA for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"V-safe\"<|>\"organization\"<|>\"V-safe is a U.S. COVID-19 vaccine safety monitoring system that uses text messages for opt-in enrollment and survey reporting. Participation is contingent on promotion by vaccine administrators. V-safe collects data on local and systemic reactions and health impacts after vaccination.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency overseeing public health, including vaccine safety and monitoring systems such as VAERS and V-safe.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a federal agency involved in public health surveillance, vaccine safety, and reporting, including publication of the Morbidity and Mortality Weekly Report (MMWR).\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that reports on public health issues, including vaccine safety data and adverse event monitoring.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the vaccine safety monitoring systems (VAERS, V-safe) and the use of the Janssen COVID-19 vaccine are being implemented.\")##\n(\"entity\"<|>\"Patient A\"<|>\"person\"<|>\"Patient A is a 30-39 year old individual who developed thrombosis with thrombocytopenia syndrome (TTS) 10 days after receiving the Janssen COVID-19 vaccine, with symptoms including headache and left-sided paresis, and evidence of thrombus in multiple arteries and veins.\")##\n(\"entity\"<|>\"Patient B\"<|>\"person\"<|>\"Patient B is a 50-59 year old individual who developed TTS 11 days after receiving the Janssen COVID-19 vaccine, with symptoms including left leg swelling and bruising, and evidence of thrombus in lower extremity veins and arteries.\")##\n(\"entity\"<|>\"Patient C\"<|>\"person\"<|>\"Patient C is a 30-39 year old individual who developed TTS 6 days after receiving the Janssen COVID-19 vaccine, with symptoms including nausea, vomiting, shortness of breath, and altered mental status, with evidence of thrombus in portal vein, mesenteric and splenic arteries, and pulmonary artery.\")##\n(\"entity\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"event\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare but serious adverse event characterized by acute venous or arterial thrombosis and new onset thrombocytopenia, occurring after receipt of certain COVID-19 vaccines, including Janssen and AstraZeneca. TTS has been detected primarily in women and is monitored by U.S. vaccine safety systems.\")##\n(\"entity\"<|>\"AstraZeneca COVID-19 Vaccine\"<|>\"organization\"<|>\"The AstraZeneca COVID-19 Vaccine is another vaccine associated with rare cases of TTS, similar to the Janssen COVID-19 vaccine. Anti-PF4 antibodies have been detected in patients with TTS after receiving this vaccine.\")##\n(\"entity\"<|>\"Brighton Collaboration\"<|>\"organization\"<|>\"Brighton Collaboration is an organization that provides case definitions for vaccine adverse events, including a draft interim case finding definition for TTS.\")##\n(\"entity\"<|>\"Heparin-induced Thrombocytopenia\"<|>\"event\"<|>\"Heparin-induced Thrombocytopenia is an autoimmune reaction to administration of heparin, an anticoagulant, involving the heparin:PF4 complex as the antigen. Anti-PF4 antibodies are also found in TTS cases without heparin exposure.\")##\n(\"entity\"<|>\"Anti-PF4 Antibodies\"<|>\"event\"<|>\"Anti-PF4 antibodies are pathological antibodies detected in patients with thrombosis and thrombocytopenia after receipt of the Janssen and AstraZeneca COVID-19 vaccines, as well as in heparin-induced thrombocytopenia.\")##\n\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"ACIP\"<|>\"ACIP reviews and recommends the use of the Janssen COVID-19 vaccine, considering its benefits and risks.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"FDA\"<|>\"The FDA grants Emergency Use Authorization for the Janssen COVID-19 vaccine and includes warnings for rare adverse events.\"<|>8)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"VAERS\"<|>\"VAERS collects reports of adverse events following administration of the Janssen COVID-19 vaccine as required by the EUA.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"V-safe\"<|>\"V-safe monitors local and systemic reactions and health impacts after receipt of the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"TTS is a rare but serious adverse event that has occurred after administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"United States\"<|>\"The Janssen COVID-19 vaccine is administered and monitored for safety in the United States.\"<|>7)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Patient A\"<|>\"Patient A developed TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Patient B\"<|>\"Patient B developed TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Patient C\"<|>\"Patient C developed TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Anti-PF4 Antibodies\"<|>\"Anti-PF4 antibodies have been detected in patients with TTS after receiving the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"AstraZeneca COVID-19 Vaccine\"<|>\"Anti-PF4 Antibodies\"<|>\"Anti-PF4 antibodies have been detected in patients with TTS after receiving the AstraZeneca COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Heparin-induced Thrombocytopenia\"<|>\"Anti-PF4 Antibodies\"<|>\"Anti-PF4 antibodies are the antigen in heparin-induced thrombocytopenia and are also found in TTS cases without heparin exposure.\"<|>8)##\n(\"relationship\"<|>\"Brighton Collaboration\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"Brighton Collaboration provides the case definition for TTS used in vaccine safety monitoring.\"<|>7)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services and is responsible for vaccine safety monitoring and reporting.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"The CDC publishes the Morbidity and Mortality Weekly Report (MMWR), which includes vaccine safety data and adverse event monitoring.\"<|>9)##\n(\"relationship\"<|>\"VAERS\"<|>\"US Department of Health and Human Services\"<|>\"VAERS is a vaccine safety monitoring system overseen by the US Department of Health and Human Services.\"<|>8)##\n(\"relationship\"<|>\"V-safe\"<|>\"US Department of Health and Human Services\"<|>\"V-safe is a vaccine safety monitoring system overseen by the US Department of Health and Human Services.\"<|>8)##\n(\"relationship\"<|>\"VAERS\"<|>\"Centers for Disease Control and Prevention\"<|>\"VAERS is operated by the CDC for monitoring vaccine adverse events.\"<|>9)##\n(\"relationship\"<|>\"V-safe\"<|>\"Centers for Disease Control and Prevention\"<|>\"V-safe is operated by the CDC for monitoring vaccine safety and reactions.\"<|>9)##\n(\"relationship\"<|>\"Patient A\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"Patient A is a case of TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Patient B\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"Patient B is a case of TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Patient C\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS)\"<|>\"Patient C is a case of TTS after receiving the Janssen COVID-19 vaccine.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "1fcfd6b2579bf4a87fc00f34610623b6": {
    "return": "(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC (Centers for Disease Control and Prevention) is a U.S. federal agency involved in medical reviews of adverse events related to COVID-19 vaccines, including reviewing medical records, death certificates, and autopsy reports to determine causes of death.\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"FDA (Food and Drug Administration) is a U.S. federal agency whose staff physicians participated in medical reviews of adverse events and deaths following COVID-19 vaccination.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is the parent federal department overseeing agencies such as CDC and FDA, involved in public health and vaccine safety monitoring.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"The Janssen COVID-19 Vaccine is a single-dose adenoviral vector vaccine authorized for use in the United States, notable for its simple storage requirements and use in settings where ensuring a second dose is difficult.\")##\n(\"entity\"<|>\"ACIP\"<|>\"organization\"<|>\"ACIP (Advisory Committee on Immunization Practices) is a group that provides recommendations on vaccine use, including reviewing the benefits and risks of the Janssen COVID-19 vaccine and updating guidance based on safety concerns.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the vaccine adverse event reporting and reviews described in the text took place.\")##\n(\"entity\"<|>\"Medical Reviews\"<|>\"event\"<|>\"Medical reviews refer to the process conducted by CDC and FDA staff physicians, involving analysis of medical records, death certificates, and autopsy reports to determine causes of death after vaccination.\")##\n(\"entity\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"organization\"<|>\"The Vaccine Adverse Event Reporting System (VAERS) is a national system in the United States for collecting and analyzing reports of adverse events following vaccination.\")##\n(\"entity\"<|>\"College Campuses\"<|>\"geo\"<|>\"College campuses are mentioned as settings where the Janssen COVID-19 vaccine has been used due to its simple storage requirements and single-dose regimen.\")##\n(\"entity\"<|>\"Drive-through Vaccination Sites\"<|>\"geo\"<|>\"Drive-through vaccination sites are locations where the Janssen COVID-19 vaccine has been administered, benefiting from its simple storage and single-dose protocol.\")##\n(\"entity\"<|>\"CVST\"<|>\"event\"<|>\"CVST (Cerebral Venous Sinus Thrombosis) is a rare but serious adverse event reported in three deaths following Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"mRNA COVID-19 Vaccines\"<|>\"event\"<|>\"mRNA COVID-19 vaccines are a class of vaccines authorized for use in the United States as a two-dose series prior to the Janssen vaccine, using a different technology platform.\")##\n\n(\"relationship\"<|>\"CDC\"<|>\"FDA\"<|>\"CDC and FDA staff physicians jointly conducted medical reviews of adverse events and deaths following COVID-19 vaccination.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"US Department of Health and Human Services\"<|>\"CDC operates under the US Department of Health and Human Services, which oversees public health activities including vaccine safety.\"<|>8)##\n(\"relationship\"<|>\"FDA\"<|>\"US Department of Health and Human Services\"<|>\"FDA is an agency within the US Department of Health and Human Services, involved in vaccine safety and regulation.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"Medical Reviews\"<|>\"CDC staff physicians conducted medical reviews to determine causes of death after vaccination.\"<|>10)##\n(\"relationship\"<|>\"FDA\"<|>\"Medical Reviews\"<|>\"FDA staff physicians participated in medical reviews of adverse events and deaths after vaccination.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Medical Reviews\"<|>\"Medical reviews were conducted specifically to assess adverse events and deaths following receipt of the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"Adverse events following the Janssen COVID-19 vaccine were reported and analyzed through the Vaccine Adverse Event Reporting System (VAERS).\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"United States\"<|>\"The Janssen COVID-19 vaccine was administered and monitored for adverse events in the United States.\"<|>8)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"College Campuses\"<|>\"The Janssen COVID-19 vaccine was used on college campuses due to its single-dose regimen and simple storage requirements.\"<|>7)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Drive-through Vaccination Sites\"<|>\"Drive-through vaccination sites utilized the Janssen COVID-19 vaccine for its ease of storage and single-dose protocol.\"<|>7)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"CVST\"<|>\"CVST was a rare but serious adverse event reported in three deaths following the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"ACIP\"<|>\"ACIP reviewed the benefits and risks of the Janssen COVID-19 vaccine and updated recommendations based on safety concerns.\"<|>9)##\n(\"relationship\"<|>\"ACIP\"<|>\"CDC\"<|>\"ACIP works closely with CDC to provide recommendations on vaccine use and safety.\"<|>8)##\n(\"relationship\"<|>\"mRNA COVID-19 Vaccines\"<|>\"Janssen COVID-19 Vaccine\"<|>\"mRNA COVID-19 vaccines were authorized for use as a two-dose series before the Janssen vaccine, which uses a different technology and dosing regimen.\"<|>7)##\n(\"relationship\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"CDC\"<|>\"CDC utilizes the Vaccine Adverse Event Reporting System to monitor and analyze adverse events following vaccination.\"<|>8)##\n(\"relationship\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"FDA\"<|>\"FDA uses the Vaccine Adverse Event Reporting System to track and review vaccine safety data.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"The Vaccine Adverse Event Reporting System operates nationally in the United States to collect adverse event data.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"CDC\"<|>\"CDC is a federal agency based in the United States responsible for public health and vaccine safety.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"FDA\"<|>\"FDA is a federal agency in the United States responsible for regulating vaccines and conducting safety reviews.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "c2d2c962cb59edcf05e08a9153a0de29": {
    "return": "(\"entity\"<|>\"Acute Flaccid Paralysis\"<|>\"event\"<|>\"Acute Flaccid Paralysis (AFP) is a clinical syndrome characterized by rapid onset of weakness and reduced muscle tone, often used as a key indicator for poliovirus surveillance and detection.\")##\n(\"entity\"<|>\"Circulating Vaccine-Derived Poliovirus\"<|>\"event\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV) refers to strains of poliovirus that have genetically mutated from the oral polio vaccine and regained the ability to cause paralysis and circulate in populations.\")##\n(\"entity\"<|>\"Intratypic Differentiation\"<|>\"event\"<|>\"Intratypic Differentiation (ITD) is a laboratory technique used to distinguish between wild-type and vaccine-derived polioviruses in surveillance specimens.\")##\n(\"entity\"<|>\"Sabin Vaccine Virus\"<|>\"event\"<|>\"Sabin Vaccine Virus is the attenuated poliovirus strain used in oral polio vaccines, serving as a reference for genetic comparison in surveillance and laboratory testing.\")##\n(\"entity\"<|>\"VP1 Nucleotide Sequence Difference\"<|>\"event\"<|>\"VP1 Nucleotide Sequence Difference refers to the genetic variation in the VP1 region of the poliovirus genome, used to distinguish between wild-type, vaccine-derived, and Sabin-like viruses.\")##\n(\"entity\"<|>\"Stool Specimen Collection\"<|>\"event\"<|>\"Stool Specimen Collection is a critical step in AFP surveillance, involving the timely collection of stool samples from suspected cases for laboratory testing to detect poliovirus.\")##\n(\"entity\"<|>\"Field Investigator\"<|>\"person\"<|>\"Field Investigator is a role responsible for identifying AFP cases, collecting specimens, and ensuring accurate reporting of paralysis onset dates in surveillance activities.\")##\n(\"entity\"<|>\"Polio Resources Repurposing\"<|>\"event\"<|>\"Polio Resources Repurposing refers to the process of redirecting polio program assets, personnel, and infrastructure to support other public health challenges, such as the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Disease Surveillance\"<|>\"event\"<|>\"Disease Surveillance is the systematic collection, analysis, and interpretation of health data to monitor and respond to disease outbreaks, including polio and COVID-19.\")##\n(\"entity\"<|>\"National Data\"<|>\"event\"<|>\"National Data refers to country-level surveillance statistics and indicators used to assess the adequacy and sensitivity of AFP and polio surveillance systems.\")##\n(\"entity\"<|>\"Subnational AFP Rates\"<|>\"event\"<|>\"Subnational AFP Rates are surveillance indicators measuring the incidence of acute flaccid paralysis at regional or local levels within countries, used to identify gaps in detection and reporting.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that disseminates public health information, including surveillance data and analysis on polio and other diseases.\")##\n(\"entity\"<|>\"PMID: 32584798\"<|>\"event\"<|>\"PMID: 32584798 is a PubMed identifier for a referenced publication on progress toward polio eradication worldwide, January 2018March 2020.\")##\n(\"entity\"<|>\"PMID: 32324719\"<|>\"event\"<|>\"PMID: 32324719 is a PubMed identifier for a referenced publication on vaccine-derived poliovirus outbreaks worldwide, July 2019February 2020.\")##\n(\"entity\"<|>\"PMID: 32437342\"<|>\"event\"<|>\"PMID: 32437342 is a PubMed identifier for a referenced publication on surveillance to track progress toward polio eradication worldwide, 20182019.\")##\n(\"entity\"<|>\"Polio Oversight Board\"<|>\"organization\"<|>\"Polio Oversight Board is a governance body within the Global Polio Eradication Initiative responsible for strategic oversight and decision-making regarding polio eradication activities.\")##\n(\"entity\"<|>\"Sewage Samples\"<|>\"event\"<|>\"Sewage Samples are environmental specimens collected for surveillance to detect poliovirus circulation in communities, supplementing AFP surveillance.\")##\n(\"entity\"<|>\"Weighted Mean Percentage of Regional Performance\"<|>\"event\"<|>\"Weighted Mean Percentage of Regional Performance is a statistical measure used to summarize surveillance indicators across regions, reflecting overall program effectiveness.\")##\n(\"entity\"<|>\"Paralysis Onset Date\"<|>\"event\"<|>\"Paralysis Onset Date is the date when paralysis symptoms begin in AFP cases, critical for determining specimen collection timeliness and surveillance accuracy.\")##\n(\"entity\"<|>\"Case Detection\"<|>\"event\"<|>\"Case Detection is the process of identifying suspected AFP or polio cases in the field, forming the basis for notification, investigation, and laboratory testing.\")##\n(\"entity\"<|>\"Notification\"<|>\"event\"<|>\"Notification is the reporting of suspected AFP or polio cases to surveillance authorities for further investigation and response.\")##\n(\"entity\"<|>\"Investigation\"<|>\"event\"<|>\"Investigation is the follow-up process after case notification, involving data collection, specimen sampling, and assessment of case details.\")##\n(\"entity\"<|>\"Specimen Transport\"<|>\"event\"<|>\"Specimen Transport is the logistical process of moving collected specimens from the field to laboratories for testing and analysis.\")##\n(\"entity\"<|>\"Laboratory Testing\"<|>\"event\"<|>\"Laboratory Testing is the analysis of specimens to detect and differentiate poliovirus strains, essential for confirming cases and guiding public health response.\")##\n(\"entity\"<|>\"Proper Infection Control Precautions\"<|>\"event\"<|>\"Proper Infection Control Precautions are measures taken to prevent the spread of infectious diseases during surveillance and specimen collection activities.\")##\n(\"entity\"<|>\"Country Expanded Programmes on Immunization\"<|>\"organization\"<|>\"Country Expanded Programmes on Immunization are national-level initiatives aimed at increasing immunization coverage and integrating surveillance for vaccine-preventable diseases.\")##\n(\"entity\"<|>\"High Risk for Poliovirus Transmission\"<|>\"event\"<|>\"High Risk for Poliovirus Transmission refers to countries or regions identified as having increased vulnerability to poliovirus outbreaks, requiring intensified surveillance and immunization efforts.\")##\n(\"entity\"<|>\"Adequate National Data\"<|>\"event\"<|>\"Adequate National Data refers to surveillance statistics that meet established standards at the national level, though they may mask subnational disparities.\")##\n(\"entity\"<|>\"Wide Heterogeneity in Subnational AFP Rates\"<|>\"event\"<|>\"Wide Heterogeneity in Subnational AFP Rates describes significant variation in AFP surveillance indicators within different regions of a country, indicating uneven detection and reporting.\")##\n(\"entity\"<|>\"Timely Case Detection\"<|>\"event\"<|>\"Timely Case Detection is the prompt identification of AFP or polio cases, crucial for effective surveillance and outbreak response.\")##\n(\"entity\"<|>\"Sensitive AFP Surveillance\"<|>\"event\"<|>\"Sensitive AFP Surveillance is a surveillance system capable of detecting most or all AFP cases, ensuring early identification of poliovirus transmission.\")##\n(\"entity\"<|>\"Restoration of Sensitive Surveillance\"<|>\"event\"<|>\"Restoration of Sensitive Surveillance refers to efforts to re-establish high-quality AFP and polio surveillance systems after disruptions, such as those caused by the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Further Investments in Disease Surveillance\"<|>\"event\"<|>\"Further Investments in Disease Surveillance are recommended actions to strengthen surveillance systems, enabling rapid response to emerging public health threats.\")##\n(\"entity\"<|>\"Integration of Surveillance for Vaccine-Preventable and Other Diseases\"<|>\"event\"<|>\"Integration of Surveillance for Vaccine-Preventable and Other Diseases is the process of combining surveillance activities for polio and other diseases within national immunization programs.\")##\n(\"entity\"<|>\"Analysis of 20192020 AFP Surveillance Data\"<|>\"event\"<|>\"Analysis of 20192020 AFP Surveillance Data refers to the review of surveillance indicators from 42 high-risk countries, highlighting declines in nonpolio AFP rates and specimen adequacy.\")##\n(\"entity\"<|>\"Decline in Nonpolio AFP Rates and Stool Specimen Adequacy\"<|>\"event\"<|>\"Decline in Nonpolio AFP Rates and Stool Specimen Adequacy describes the observed reduction in surveillance performance in many priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Improvement Efforts to Restore Surveillance Activities\"<|>\"event\"<|>\"Improvement Efforts to Restore Surveillance Activities are recommended actions to address declines in surveillance performance and restore timely, sensitive field activities.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "80c40807edb4cf515e6417144f0e3d71": {
    "return": "(\"entity\"<|>\"Lickness JS\"<|>\"person\"<|>\"Lickness JS is an author and researcher involved in studies tracking progress toward polio eradication worldwide.\")##\n(\"entity\"<|>\"Gardner T\"<|>\"person\"<|>\"Gardner T is an author and researcher contributing to polio eradication surveillance studies.\")##\n(\"entity\"<|>\"Diop OM\"<|>\"person\"<|>\"Diop OM is a researcher and author involved in polio eradication, environmental surveillance for polioviruses, and laboratory network studies.\")##\n(\"entity\"<|>\"Asghar H\"<|>\"person\"<|>\"Asghar H is an author and researcher involved in environmental surveillance for polioviruses within the Global Polio Eradication Initiative.\")##\n(\"entity\"<|>\"Weldegebriel G\"<|>\"person\"<|>\"Weldegebriel G is a researcher and author contributing to environmental surveillance for polioviruses.\")##\n(\"entity\"<|>\"Hsu CH\"<|>\"person\"<|>\"Hsu CH is an author and researcher involved in studies on progress toward poliomyelitis eradication in Pakistan.\")##\n(\"entity\"<|>\"Rehman MS\"<|>\"person\"<|>\"Rehman MS is a researcher and author contributing to studies on poliomyelitis eradication in Pakistan.\")##\n(\"entity\"<|>\"Bullard K\"<|>\"person\"<|>\"Bullard K is a researcher and author involved in studies on poliomyelitis eradication in Pakistan.\")##\n(\"entity\"<|>\"Kew OM\"<|>\"person\"<|>\"Kew OM is a researcher and author involved in studies on the Global Polio Laboratory Network and polio eradication.\")##\n(\"entity\"<|>\"de Gourville EM\"<|>\"person\"<|>\"de Gourville EM is a researcher and author contributing to studies on the Global Polio Laboratory Network.\")##\n(\"entity\"<|>\"Pallansch MA\"<|>\"person\"<|>\"Pallansch MA is a researcher and author involved in studies on the Global Polio Laboratory Network and polio eradication.\")##\n(\"entity\"<|>\"Zomahoun DJ\"<|>\"person\"<|>\"Zomahoun DJ is a researcher and author involved in studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\")##\n(\"entity\"<|>\"Burman AL\"<|>\"person\"<|>\"Burman AL is a researcher and author contributing to studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\")##\n(\"entity\"<|>\"Snider CJ\"<|>\"person\"<|>\"Snider CJ is a researcher and author involved in studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\")##\n(\"entity\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"MMWR Morbidity and Mortality Weekly Report is a publication by the CDC that disseminates public health information, including surveillance and research findings on diseases such as polio and COVID-19.\")##\n(\"entity\"<|>\"Hospitalized adults aged 65 years\"<|>\"person\"<|>\"Hospitalized adults aged 65 years refers to the population group studied for COVID-19 vaccine effectiveness in the United States, identified as being at increased risk for severe outcomes.\")##\n(\"entity\"<|>\"Long-term care facility\"<|>\"organization\"<|>\"Long-term care facility refers to institutions providing residential care for elderly or disabled individuals, mentioned as a living situation for some study participants.\")##\n(\"entity\"<|>\"Non-Hispanic White\"<|>\"person\"<|>\"Non-Hispanic White refers to a demographic group included in the COVID-19 vaccine effectiveness study among hospitalized adults aged 65 years.\")##\n(\"entity\"<|>\"Non-Hispanic Black\"<|>\"person\"<|>\"Non-Hispanic Black refers to a demographic group included in the COVID-19 vaccine effectiveness study among hospitalized adults aged 65 years.\")##\n(\"entity\"<|>\"Hispanic\"<|>\"person\"<|>\"Hispanic refers to a demographic group included in the COVID-19 vaccine effectiveness study among hospitalized adults aged 65 years.\")##\n(\"entity\"<|>\"Emergency Use Authorization (EUA)\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is a regulatory mechanism by which the FDA allows the use of medical products, such as COVID-19 vaccines, during public health emergencies.\")##\n(\"entity\"<|>\"J Infect Dis\"<|>\"organization\"<|>\"J Infect Dis (Journal of Infectious Diseases) is a scientific journal publishing research on infectious diseases, including studies on polio and COVID-19.\")##\n(\"entity\"<|>\"MMWR Early Release\"<|>\"event\"<|>\"MMWR Early Release refers to the expedited publication of important public health findings on the CDC's MMWR website.\")##\n(\"entity\"<|>\"Case-patients\"<|>\"person\"<|>\"Case-patients refers to the group of hospitalized adults aged 65 years who were diagnosed with COVID-19 in the vaccine effectiveness study.\")##\n(\"entity\"<|>\"Controls\"<|>\"person\"<|>\"Controls refers to the group of hospitalized adults aged 65 years who were not diagnosed with COVID-19 in the vaccine effectiveness study.\")##\n(\"entity\"<|>\"24 hospitals in 14 states\"<|>\"organization\"<|>\"24 hospitals in 14 states refers to the network of medical institutions where the COVID-19 vaccine effectiveness study was conducted.\")##\n(\"relationship\"<|>\"Lickness JS\"<|>\"Polio eradication\"<|>\"Lickness JS is an author of studies tracking progress toward polio eradication worldwide.\"<|>8)##\n(\"relationship\"<|>\"Gardner T\"<|>\"Polio eradication\"<|>\"Gardner T is a researcher contributing to polio eradication surveillance studies.\"<|>7)##\n(\"relationship\"<|>\"Diop OM\"<|>\"Global Polio Eradication Initiative\"<|>\"Diop OM is an author and researcher involved in environmental surveillance for polioviruses within the Global Polio Eradication Initiative.\"<|>9)##\n(\"relationship\"<|>\"Diop OM\"<|>\"Global Polio Laboratory Network\"<|>\"Diop OM is an author of studies on the Global Polio Laboratory Network.\"<|>8)##\n(\"relationship\"<|>\"Asghar H\"<|>\"Global Polio Eradication Initiative\"<|>\"Asghar H is an author involved in environmental surveillance for polioviruses in the Global Polio Eradication Initiative.\"<|>8)##\n(\"relationship\"<|>\"Weldegebriel G\"<|>\"Global Polio Eradication Initiative\"<|>\"Weldegebriel G is a researcher contributing to environmental surveillance for polioviruses in the Global Polio Eradication Initiative.\"<|>7)##\n(\"relationship\"<|>\"Hsu CH\"<|>\"Pakistan\"<|>\"Hsu CH is an author of studies on progress toward poliomyelitis eradication in Pakistan.\"<|>8)##\n(\"relationship\"<|>\"Rehman MS\"<|>\"Pakistan\"<|>\"Rehman MS is a researcher contributing to studies on poliomyelitis eradication in Pakistan.\"<|>7)##\n(\"relationship\"<|>\"Bullard K\"<|>\"Pakistan\"<|>\"Bullard K is a researcher involved in studies on poliomyelitis eradication in Pakistan.\"<|>7)##\n(\"relationship\"<|>\"Kew OM\"<|>\"Global Polio Laboratory Network\"<|>\"Kew OM is an author of studies on the Global Polio Laboratory Network.\"<|>8)##\n(\"relationship\"<|>\"de Gourville EM\"<|>\"Global Polio Laboratory Network\"<|>\"de Gourville EM is a researcher contributing to studies on the Global Polio Laboratory Network.\"<|>7)##\n(\"relationship\"<|>\"Pallansch MA\"<|>\"Global Polio Laboratory Network\"<|>\"Pallansch MA is an author of studies on the Global Polio Laboratory Network.\"<|>8)##\n(\"relationship\"<|>\"Zomahoun DJ\"<|>\"COVID-19 pandemic\"<|>\"Zomahoun DJ is an author of studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\"<|>8)##\n(\"relationship\"<|>\"Burman AL\"<|>\"COVID-19 pandemic\"<|>\"Burman AL is a researcher contributing to studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\"<|>7)##\n(\"relationship\"<|>\"Snider CJ\"<|>\"COVID-19 pandemic\"<|>\"Snider CJ is an author involved in studies on the impact of the COVID-19 pandemic on global poliovirus surveillance.\"<|>7)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR Morbidity and Mortality Weekly Report is a CDC publication disseminating public health information and research findings.\"<|>10)##\n(\"relationship\"<|>\"Hospitalized adults aged 65 years\"<|>\"COVID-19 vaccination\"<|>\"Hospitalized adults aged 65 years are the population group studied for COVID-19 vaccine effectiveness in the United States.\"<|>9)##\n(\"relationship\"<|>\"Long-term care facility\"<|>\"Hospitalized adults aged 65 years\"<|>\"Some hospitalized adults aged 65 years lived in long-term care facilities, as noted in the vaccine effectiveness study.\"<|>7)##\n(\"relationship\"<|>\"Non-Hispanic White\"<|>\"Hospitalized adults aged 65 years\"<|>\"Non-Hispanic White is a demographic group included in the study of hospitalized adults aged 65 years.\"<|>7)##\n(\"relationship\"<|>\"Non-Hispanic Black\"<|>\"Hospitalized adults aged 65 years\"<|>\"Non-Hispanic Black is a demographic group included in the study of hospitalized adults aged 65 years.\"<|>7)##\n(\"relationship\"<|>\"Hispanic\"<|>\"Hospitalized adults aged 65 years\"<|>\"Hispanic is a demographic group included in the study of hospitalized adults aged 65 years.\"<|>7)##\n(\"relationship\"<|>\"Emergency Use Authorization (EUA)\"<|>\"COVID-19 vaccination\"<|>\"COVID-19 vaccines were approved for use under Emergency Use Authorization (EUA) during the pandemic.\"<|>9)##\n(\"relationship\"<|>\"J Infect Dis\"<|>\"Global Polio Eradication Initiative\"<|>\"J Infect Dis published research on environmental surveillance for polioviruses in the Global Polio Eradication Initiative.\"<|>8)##\n(\"relationship\"<|>\"J Infect Dis\"<|>\"Global Polio Laboratory Network\"<|>\"J Infect Dis published research on the Global Polio Laboratory Network.\"<|>8)##\n(\"relationship\"<|>\"MMWR Early Release\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"MMWR Early Release is an expedited publication format for urgent public health findings in the MMWR Morbidity and Mortality Weekly Report.\"<|>8)##\n(\"relationship\"<|>\"Case-patients\"<|>\"Hospitalized adults aged 65 years\"<|>\"Case-patients are a subset of hospitalized adults aged 65 years diagnosed with COVID-19 in the vaccine effectiveness study.\"<|>8)##\n(\"relationship\"<|>\"Controls\"<|>\"Hospitalized adults aged 65 years\"<|>\"Controls are a subset of hospitalized adults aged 65 years not diagnosed with COVID-19 in the vaccine effectiveness study.\"<|>8)##\n(\"relationship\"<|>\"24 hospitals in 14 states\"<|>\"COVID-19 vaccination\"<|>\"COVID-19 vaccine effectiveness was assessed at 24 hospitals in 14 states in the United States.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "a7a0303dec56840723be43c025bbd410": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services (HHS) is a federal agency responsible for protecting the health of all Americans and providing essential human services. It oversees agencies such as the CDC and is involved in public health surveillance, disease prevention, and health statistics reporting.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a federal agency under HHS focused on public health, disease control, and prevention. It conducts surveillance, research, and publishes reports such as the Morbidity and Mortality Weekly Report (MMWR).\")##\n(\"entity\"<|>\"Colin Schwensohn\"<|>\"person\"<|>\"Colin Schwensohn is listed as the corresponding author for the report, affiliated with CDC, and provides contact information for correspondence regarding the publication.\")##\n(\"entity\"<|>\"Division of Foodborne, Waterborne, and Environmental Diseases\"<|>\"organization\"<|>\"A division within the National Center for Emerging and Zoonotic Infectious Diseases at CDC, responsible for monitoring and investigating diseases transmitted through food, water, and the environment.\")##\n(\"entity\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases\"<|>\"organization\"<|>\"A center within CDC focused on emerging infectious diseases and those transmitted from animals to humans (zoonoses).\")##\n(\"entity\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"organization\"<|>\"A research and education institute located in Oak Ridge, Tennessee, collaborating with CDC and other agencies on scientific and public health projects.\")##\n(\"entity\"<|>\"Oak Ridge, Tennessee\"<|>\"geo\"<|>\"A city in Tennessee, home to the Oak Ridge Institute for Science and Education.\")##\n(\"entity\"<|>\"California Department of Public Health\"<|>\"organization\"<|>\"The state agency responsible for public health in California, involved in disease surveillance and outbreak response.\")##\n(\"entity\"<|>\"Food and Drug Administration\"<|>\"organization\"<|>\"The FDA is a federal agency responsible for regulating food, drugs, and medical devices, and is involved in public health surveillance and outbreak investigations.\")##\n(\"entity\"<|>\"College Park, Maryland\"<|>\"geo\"<|>\"A city in Maryland, location of an FDA office mentioned in the report.\")##\n(\"entity\"<|>\"Placer County Health and Human Services\"<|>\"organization\"<|>\"The local health and human services agency for Placer County, California, involved in public health activities and outbreak response.\")##\n(\"entity\"<|>\"Auburn, California\"<|>\"geo\"<|>\"A city in California, location of Placer County Health and Human Services.\")##\n(\"entity\"<|>\"Eagle Medical Services, LLC\"<|>\"organization\"<|>\"A medical services company based in San Antonio, Texas, collaborating with public health agencies.\")##\n(\"entity\"<|>\"San Antonio, Texas\"<|>\"geo\"<|>\"A city in Texas, location of Eagle Medical Services, LLC.\")##\n(\"entity\"<|>\"International Committee of Medical Journal Editors\"<|>\"organization\"<|>\"An organization that sets standards for disclosure of potential conflicts of interest in medical journal publications.\")##\n(\"entity\"<|>\"PulseNet\"<|>\"organization\"<|>\"A national laboratory network coordinated by CDC that uses whole genome sequencing (WGS) to track foodborne pathogens and outbreaks.\")##\n(\"entity\"<|>\"Foodborne Active Surveillance Network (FoodNet)\"<|>\"organization\"<|>\"A CDC-coordinated network that conducts active surveillance of foodborne diseases and collects population survey data on exposures.\")##\n(\"entity\"<|>\"National Center for Health Statistics\"<|>\"organization\"<|>\"A division of CDC responsible for collecting and analyzing health statistics, including the National Health Interview Survey.\")##\n(\"entity\"<|>\"National Health Interview Survey\"<|>\"event\"<|>\"An annual survey conducted by the National Center for Health Statistics to collect health-related data from a representative sample of the US population.\")##\n(\"entity\"<|>\"Ellen A. Kramarow\"<|>\"person\"<|>\"Ellen A. Kramarow, PhD, is listed as a reporter and contact for the National Health Interview Survey data, affiliated with CDC.\")##\n(\"entity\"<|>\"Nazik Elgaddal\"<|>\"person\"<|>\"Nazik Elgaddal, MS, is listed as a reporter for the National Health Interview Survey data, affiliated with CDC.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"A publication series prepared by CDC that provides public health information, surveillance data, and outbreak reports.\")##\n(\"entity\"<|>\"Atlanta, Georgia\"<|>\"geo\"<|>\"A city in Georgia, location of CDC headquarters and referenced in multiple CDC publications.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The country in which the public health surveillance and reporting activities described in the document take place.\")##\n(\"entity\"<|>\"E. coli Outbreaks Linked to Romaine Lettuce\"<|>\"event\"<|>\"Multiple outbreaks of E. coli O157:H7 infections linked to romaine lettuce, investigated and reported by CDC in 2018 and 2019.\")##\n(\"entity\"<|>\"Urbanization Level (Metropolitan and Nonmetropolitan Areas)\"<|>\"geo\"<|>\"Categories used in health statistics to differentiate between metropolitan statistical areas (MSAs) and nonmetropolitan areas based on population size and urbanization.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC is an agency under the US Department of Health and Human Services, responsible for public health surveillance and reporting.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Division of Foodborne, Waterborne, and Environmental Diseases\"<|>\"The Division is part of CDC and focuses on foodborne, waterborne, and environmental disease surveillance.\"<|>9)##\n(\"relationship\"<|>\"Division of Foodborne, Waterborne, and Environmental Diseases\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases\"<|>\"The Division operates within the National Center for Emerging and Zoonotic Infectious Diseases at CDC.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"PulseNet\"<|>\"PulseNet is coordinated by CDC and uses whole genome sequencing for tracking foodborne outbreaks.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Foodborne Active Surveillance Network (FoodNet)\"<|>\"FoodNet is a CDC-coordinated network for active surveillance of foodborne diseases.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"National Center for Health Statistics\"<|>\"The National Center for Health Statistics is a division of CDC responsible for health statistics and surveys.\"<|>9)##\n(\"relationship\"<|>\"National Center for Health Statistics\"<|>\"National Health Interview Survey\"<|>\"The National Health Interview Survey is conducted by the National Center for Health Statistics.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"MMWR is a publication series prepared and published by CDC.\"<|>10)##\n(\"relationship\"<|>\"Colin Schwensohn\"<|>\"Centers for Disease Control and Prevention\"<|>\"Colin Schwensohn is the corresponding author for the report and is affiliated with CDC.\"<|>8)##\n(\"relationship\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"Oak Ridge, Tennessee\"<|>\"The Oak Ridge Institute for Science and Education is located in Oak Ridge, Tennessee.\"<|>10)##\n(\"relationship\"<|>\"California Department of Public Health\"<|>\"Centers for Disease Control and Prevention\"<|>\"California Department of Public Health collaborates with CDC on public health surveillance and outbreak investigations.\"<|>7)##\n(\"relationship\"<|>\"Food and Drug Administration\"<|>\"College Park, Maryland\"<|>\"The FDA office referenced in the report is located in College Park, Maryland.\"<|>8)##\n(\"relationship\"<|>\"Placer County Health and Human Services\"<|>\"Auburn, California\"<|>\"Placer County Health and Human Services is located in Auburn, California.\"<|>10)##\n(\"relationship\"<|>\"Eagle Medical Services, LLC\"<|>\"San Antonio, Texas\"<|>\"Eagle Medical Services, LLC is based in San Antonio, Texas.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Ellen A. Kramarow\"<|>\"Ellen A. Kramarow is a reporter and contact for CDC's National Health Interview Survey data.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Nazik Elgaddal\"<|>\"Nazik Elgaddal is a reporter for CDC's National Health Interview Survey data.\"<|>7)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"E. coli Outbreaks Linked to Romaine Lettuce\"<|>\"CDC investigated and reported on E. coli outbreaks linked to romaine lettuce in 2018 and 2019.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Atlanta, Georgia\"<|>\"CDC headquarters are located in Atlanta, Georgia.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"United States\"<|>\"CDC conducts public health surveillance and reporting throughout the United States.\"<|>10)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Urbanization Level (Metropolitan and Nonmetropolitan Areas)\"<|>\"The National Health Interview Survey reports health statistics by urbanization level, differentiating between metropolitan and nonmetropolitan areas.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR is prepared and published by CDC, providing public health information and surveillance data.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"MMWR is a service mark of the US Department of Health and Human Services and is published under its authority.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "3aa853f3f2268bd9304cfb0d8b80cddf": {
    "return": "(\"entity\"<|>\"Telehealth\"<|>\"organization\"<|>\"Telehealth refers to the provision of healthcare services remotely via telecommunications technology, allowing patients to consult with healthcare providers without visiting a physical clinic.\")##\n(\"entity\"<|>\"Clinic\"<|>\"organization\"<|>\"Clinic is a healthcare facility where patients receive medical care, including routine checkups and treatment for various conditions.\")##\n(\"entity\"<|>\"Emergency Visit\"<|>\"event\"<|>\"Emergency Visit refers to an unscheduled medical event where a patient seeks urgent care due to acute symptoms or health impacts.\")##\n(\"entity\"<|>\"Hospitalization\"<|>\"event\"<|>\"Hospitalization is the event of admitting a patient to a hospital for treatment and monitoring, typically for serious health conditions.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that provides public health information and updates on disease trends and health impacts.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a national public health institute in the United States, responsible for disease control, prevention, and health promotion.\")##\n(\"entity\"<|>\"Food and Drug Administration (FDA)\"<|>\"organization\"<|>\"Food and Drug Administration (FDA) is a federal agency responsible for regulating food, drugs, medical devices, and vaccines in the United States.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"Janssen COVID-19 Vaccine refers to the vaccine developed by Janssen (Johnson & Johnson) for the prevention of COVID-19, which received Emergency Use Authorization in the US.\")##\n(\"entity\"<|>\"Emergency Use Authorization (EUA)\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is a regulatory mechanism by which the FDA allows the use of medical products during public health emergencies.\")##\n(\"entity\"<|>\"Cerebral Venous Sinus Thrombosis (CVST)\"<|>\"event\"<|>\"Cerebral Venous Sinus Thrombosis (CVST) is a rare type of blood clot in the brain's venous sinuses, reported as an adverse event following vaccination.\")##\n(\"entity\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"organization\"<|>\"Advisory Committee on Immunization Practices (ACIP) is a group within the CDC that provides recommendations on vaccine use in the United States.\")##\n(\"entity\"<|>\"Johnson & Johnson\"<|>\"organization\"<|>\"Johnson & Johnson is a multinational corporation that owns Janssen, the developer of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Silver Spring, MD\"<|>\"geo\"<|>\"Silver Spring, MD is a geographic location in Maryland, United States, where the FDA is headquartered.\")##\n(\"entity\"<|>\"Atlanta, GA\"<|>\"geo\"<|>\"Atlanta, GA is a geographic location in Georgia, United States, where the CDC is headquartered.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"United States is the country where the described vaccine administration, monitoring, and regulatory activities are taking place.\")##\n(\"entity\"<|>\"Rita F. Helfand\"<|>\"person\"<|>\"Rita F. Helfand is acknowledged in the report, likely as a contributor or expert affiliated with the CDC.\")##\n(\"entity\"<|>\"David K. Shay\"<|>\"person\"<|>\"David K. Shay is listed as the corresponding author for the report, affiliated with the CDC.\")##\n(\"entity\"<|>\"CDC COVID-19 Response Team\"<|>\"organization\"<|>\"CDC COVID-19 Response Team is a group within the CDC responsible for coordinating the response to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"ENSEMBLE Study Group\"<|>\"organization\"<|>\"ENSEMBLE Study Group is a research group involved in the clinical trials and safety/efficacy studies of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Sadoff J\"<|>\"person\"<|>\"Sadoff J is an author of a referenced study on the safety and efficacy of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Gray G\"<|>\"person\"<|>\"Gray G is an author of a referenced study on the safety and efficacy of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Vandebosch A\"<|>\"person\"<|>\"Vandebosch A is an author of a referenced study on the safety and efficacy of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Oliver SE\"<|>\"person\"<|>\"Oliver SE is an author of a referenced report on the Advisory Committee on Immunization Practices interim recommendation for use of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Gargano JW\"<|>\"person\"<|>\"Gargano JW is an author of a referenced report on the Advisory Committee on Immunization Practices interim recommendation for use of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Scobie H\"<|>\"person\"<|>\"Scobie H is an author of a referenced report on the Advisory Committee on Immunization Practices interim recommendation for use of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Greinacher A\"<|>\"person\"<|>\"Greinacher A is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Thiele T\"<|>\"person\"<|>\"Thiele T is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Warkentin TE\"<|>\"person\"<|>\"Warkentin TE is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Weisser K\"<|>\"person\"<|>\"Weisser K is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Kyrle PA\"<|>\"person\"<|>\"Kyrle PA is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Eichinger S\"<|>\"person\"<|>\"Eichinger S is an author of a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\")##\n(\"entity\"<|>\"Schultz NH\"<|>\"person\"<|>\"Schultz NH is an author of a referenced study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Sr voll IH\"<|>\"person\"<|>\"Sr voll IH is an author of a referenced study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Michelsen AE\"<|>\"person\"<|>\"Michelsen AE is an author of a referenced study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Scully M\"<|>\"person\"<|>\"Scully M is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Singh D\"<|>\"person\"<|>\"Singh D is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Lown R\"<|>\"person\"<|>\"Lown R is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"See I\"<|>\"person\"<|>\"See I is an author of a referenced study on US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\")##\n(\"entity\"<|>\"Su JR\"<|>\"person\"<|>\"Su JR is an author of a referenced study on US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\")##\n(\"entity\"<|>\"Lale A\"<|>\"person\"<|>\"Lale A is an author of a referenced study on US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\")##\n\n(\"relationship\"<|>\"Telehealth\"<|>\"Clinic\"<|>\"Telehealth and Clinic are both healthcare service providers, offering different modalities for patient care (remote vs. in-person).\"<|>6)##\n(\"relationship\"<|>\"Emergency Visit\"<|>\"Hospitalization\"<|>\"Emergency Visits can lead to Hospitalization if the patient's condition is severe enough to require inpatient care.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"MMWR is a publication produced by the CDC to disseminate public health information.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"CDC operates under the US Department of Health and Human Services as a national public health institute.\"<|>9)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Food and Drug Administration (FDA)\"<|>\"FDA is an agency within the US Department of Health and Human Services responsible for regulating medical products.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Emergency Use Authorization (EUA)\"<|>\"The Janssen COVID-19 Vaccine was granted Emergency Use Authorization by the FDA for use in the United States.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"CDC monitors the safety and efficacy of the Janssen COVID-19 Vaccine and provides public health recommendations.\"<|>8)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Food and Drug Administration (FDA)\"<|>\"FDA authorized the Janssen COVID-19 Vaccine for emergency use and oversees its regulation.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Johnson & Johnson\"<|>\"Johnson & Johnson is the parent company of Janssen, which developed the Janssen COVID-19 Vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Cerebral Venous Sinus Thrombosis (CVST)\"<|>\"CVST was reported as a rare adverse event following administration of the Janssen COVID-19 Vaccine.\"<|>8)##\n(\"relationship\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"ACIP is a committee within the CDC that provides recommendations on vaccine use.\"<|>9)##\n(\"relationship\"<|>\"Food and Drug Administration (FDA)\"<|>\"Silver Spring, MD\"<|>\"FDA is headquartered in Silver Spring, MD.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Atlanta, GA\"<|>\"CDC is headquartered in Atlanta, GA.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"United States\"<|>\"The Janssen COVID-19 Vaccine was administered in the United States as part of the national vaccination campaign.\"<|>10)##\n(\"relationship\"<|>\"Rita F. Helfand\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Rita F. Helfand is acknowledged as a contributor or expert affiliated with the CDC.\"<|>8)##\n(\"relationship\"<|>\"David K. Shay\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"David K. Shay is the corresponding author for the report and is affiliated with the CDC.\"<|>8)##\n(\"relationship\"<|>\"CDC COVID-19 Response Team\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"CDC COVID-19 Response Team is a specialized group within the CDC focused on the COVID-19 pandemic response.\"<|>9)##\n(\"relationship\"<|>\"ENSEMBLE Study Group\"<|>\"Janssen COVID-19 Vaccine\"<|>\"ENSEMBLE Study Group conducted clinical trials and safety/efficacy studies for the Janssen COVID-19 Vaccine.\"<|>9)##\n(\"relationship\"<|>\"Sadoff J\"<|>\"ENSEMBLE Study Group\"<|>\"Sadoff J is an author and member of the ENSEMBLE Study Group.\"<|>8)##\n(\"relationship\"<|>\"Gray G\"<|>\"ENSEMBLE Study Group\"<|>\"Gray G is an author and member of the ENSEMBLE Study Group.\"<|>8)##\n(\"relationship\"<|>\"Vandebosch A\"<|>\"ENSEMBLE Study Group\"<|>\"Vandebosch A is an author and member of the ENSEMBLE Study Group.\"<|>8)##\n(\"relationship\"<|>\"Oliver SE\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"Oliver SE is an author of a report on ACIP's interim recommendation for the Janssen COVID-19 Vaccine.\"<|>8)##\n(\"relationship\"<|>\"Gargano JW\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"Gargano JW is an author of a report on ACIP's interim recommendation for the Janssen COVID-19 Vaccine.\"<|>8)##\n(\"relationship\"<|>\"Scobie H\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"Scobie H is an author of a report on ACIP's interim recommendation for the Janssen COVID-19 Vaccine.\"<|>8)##\n(\"relationship\"<|>\"Greinacher A\"<|>\"Thiele T\"<|>\"Greinacher A and Thiele T are co-authors of a study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Greinacher A\"<|>\"Warkentin TE\"<|>\"Greinacher A and Warkentin TE are co-authors of a study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Greinacher A\"<|>\"Weisser K\"<|>\"Greinacher A and Weisser K are co-authors of a study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Greinacher A\"<|>\"Kyrle PA\"<|>\"Greinacher A and Kyrle PA are co-authors of a study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Greinacher A\"<|>\"Eichinger S\"<|>\"Greinacher A and Eichinger S are co-authors of a study on thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Schultz NH\"<|>\"Sr voll IH\"<|>\"Schultz NH and Sr voll IH are co-authors of a study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Schultz NH\"<|>\"Michelsen AE\"<|>\"Schultz NH and Michelsen AE are co-authors of a study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Scully M\"<|>\"Singh D\"<|>\"Scully M and Singh D are co-authors of a study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Scully M\"<|>\"Lown R\"<|>\"Scully M and Lown R are co-authors of a study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"See I\"<|>\"Su JR\"<|>\"See I and Su JR are co-authors of a study on US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>8)##\n(\"relationship\"<|>\"See I\"<|>\"Lale A\"<|>\"See I and Lale A are co-authors of a study on US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "168e685cb64eb754267ed4c073758f24": {
    "return": "(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"The Vaccine Adverse Event Reporting System (VAERS) is a national system for monitoring the safety of vaccines in the United States, collecting and analyzing reports of adverse events following vaccination.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"The Janssen COVID-19 vaccine is a single-dose vaccine developed by Johnson & Johnson, used for immunization against COVID-19. It has been associated with rare adverse events such as syncope and thrombosis with thrombocytopenia syndrome.\")##\n(\"entity\"<|>\"Influenza Vaccine\"<|>\"event\"<|>\"The influenza vaccine is administered seasonally to prevent influenza infection. The reporting rate of syncope after its administration is significantly lower compared to the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Advisory Committee on Immunization Practices\"<|>\"organization\"<|>\"The Advisory Committee on Immunization Practices (ACIP) is a group that provides recommendations on the use of vaccines in the United States, including reaffirming recommendations for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"The Food and Drug Administration (FDA) is a US federal agency responsible for regulating vaccines, including issuing warnings and updating information sheets for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency involved in public health, providing recommendations and information about COVID-19 vaccines and monitoring vaccine safety.\")##\n(\"entity\"<|>\"Anne M. Hause\"<|>\"person\"<|>\"Anne M. Hause is listed as the corresponding author for the report, likely involved in the investigation and reporting of vaccine-related adverse events.\")##\n(\"entity\"<|>\"CDC COVID-19 Response Team\"<|>\"organization\"<|>\"The CDC COVID-19 Response Team is a group within the CDC responsible for responding to the COVID-19 pandemic, including monitoring vaccine safety and adverse events.\")##\n(\"entity\"<|>\"State and Local Health Departments\"<|>\"organization\"<|>\"State and local health departments participated in the investigation of vaccine-related adverse events, contributing data and expertise.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"The World Health Organization (WHO) is an international public health agency that provides guidance and manuals for immunization stress-related responses.\")##\n(\"entity\"<|>\"Institute of Medicine of the National Academies\"<|>\"organization\"<|>\"The Institute of Medicine of the National Academies is a US organization that publishes research and evidence on vaccine safety and causality.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the vaccine safety monitoring and investigations described in the text took place.\")##\n(\"entity\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"event\"<|>\"Thrombosis with thrombocytopenia syndrome is a rare adverse event associated with the Janssen COVID-19 vaccine, involving blood clots and low platelet counts, primarily in women aged 18-49 years.\")##\n(\"entity\"<|>\"Syncope\"<|>\"event\"<|>\"Syncope is a temporary loss of consciousness (fainting) reported as an anxiety-related event after vaccination, with higher rates following the Janssen COVID-19 vaccine compared to the influenza vaccine.\")##\n(\"entity\"<|>\"Anxiety-related Events\"<|>\"event\"<|>\"Anxiety-related events, including syncope, are adverse reactions that can occur soon after vaccination, raising concern among recipients and staff, especially in mass vaccination settings.\")##\n(\"entity\"<|>\"Mass Vaccination Setting\"<|>\"event\"<|>\"A mass vaccination setting refers to large-scale vaccination events where many individuals receive vaccines, increasing the importance of monitoring for adverse events.\")##\n(\"entity\"<|>\"Thrombosis\"<|>\"event\"<|>\"Thrombosis refers to the formation of blood clots, which has been reported as a rare adverse event following the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"event\"<|>\"An outbreak of Escherichia coli O157:H7 infections linked to Romaine lettuce exposure in the United States in 2019, as referenced in the report.\")##\n(\"entity\"<|>\"Connor Hoff\"<|>\"person\"<|>\"Connor Hoff, MPH, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Jeffrey Higa\"<|>\"person\"<|>\"Jeffrey Higa, MPH, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Kane Patel\"<|>\"person\"<|>\"Kane Patel is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Ellen Gee\"<|>\"person\"<|>\"Ellen Gee, MPH, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Allison Wellman\"<|>\"person\"<|>\"Allison Wellman, MPH, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Jeff Vidanes\"<|>\"person\"<|>\"Jeff Vidanes is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"April Holland\"<|>\"person\"<|>\"April Holland, MPH, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Varvara Kozyreva\"<|>\"person\"<|>\"Varvara Kozyreva, PhD, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Jonathan Zhu\"<|>\"person\"<|>\"Jonathan Zhu is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Mia Mattioli\"<|>\"person\"<|>\"Mia Mattioli, PhD, is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Alexis Roundtree\"<|>\"person\"<|>\"Alexis Roundtree is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n(\"entity\"<|>\"Kenai McFadden\"<|>\"person\"<|>\"Kenai McFadden is listed as an author in the outbreak report, likely involved in the investigation of the Romaine lettuce E. coli outbreak.\")##\n\n(\"relationship\"<|>\"VAERS\"<|>\"Janssen COVID-19 Vaccine\"<|>\"VAERS monitors and reports adverse events, including syncope and thrombosis, following administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"Influenza Vaccine\"<|>\"VAERS monitors and reports adverse events, including syncope, following administration of the influenza vaccine.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"Thrombosis with thrombocytopenia syndrome is a rare adverse event associated with the Janssen COVID-19 vaccine, primarily in women aged 18-49 years.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Syncope\"<|>\"Syncope is reported at a higher rate after Janssen COVID-19 vaccination compared to influenza vaccination.\"<|>9)##\n(\"relationship\"<|>\"Influenza Vaccine\"<|>\"Syncope\"<|>\"Syncope is reported as an adverse event after influenza vaccination, but at a much lower rate than after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Advisory Committee on Immunization Practices\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Advisory Committee on Immunization Practices reaffirmed its recommendation for the use of the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"FDA\"<|>\"Janssen COVID-19 Vaccine\"<|>\"FDA includes warnings for rare clotting events in the Janssen COVID-19 vaccine's EUA and information sheets.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"Janssen COVID-19 Vaccine\"<|>\"CDC provides recommendations and information about the Janssen COVID-19 vaccine and monitors its safety.\"<|>9)##\n(\"relationship\"<|>\"CDC COVID-19 Response Team\"<|>\"CDC\"<|>\"The CDC COVID-19 Response Team is a specialized group within the CDC focused on COVID-19 response and vaccine safety.\"<|>10)##\n(\"relationship\"<|>\"State and Local Health Departments\"<|>\"CDC\"<|>\"State and local health departments collaborated with the CDC in investigating vaccine-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"World Health Organization\"<|>\"Immunization Stress-related Response\"<|>\"WHO provides manuals and guidance for program managers and health professionals to prevent and respond to stress-related responses following immunization.\"<|>8)##\n(\"relationship\"<|>\"Institute of Medicine of the National Academies\"<|>\"Adverse Effects of Vaccines\"<|>\"The Institute of Medicine of the National Academies published research on the evidence and causality of adverse effects of vaccines.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"CDC\"<|>\"CDC operates within the United States, conducting vaccine safety monitoring and public health investigations.\"<|>10)##\n(\"relationship\"<|>\"United States\"<|>\"VAERS\"<|>\"VAERS is a national vaccine safety monitoring system operating in the United States.\"<|>10)##\n(\"relationship\"<|>\"Mass Vaccination Setting\"<|>\"Anxiety-related Events\"<|>\"Anxiety-related events, including syncope, are of particular concern in mass vaccination settings due to the large number of recipients and staff involved.\"<|>8)##\n(\"relationship\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"United States\"<|>\"The outbreak of E. coli O157:H7 infections linked to Romaine lettuce exposure occurred in the United States in 2019.\"<|>9)##\n(\"relationship\"<|>\"Connor Hoff\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Connor Hoff is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jeffrey Higa\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Jeffrey Higa is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Kane Patel\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Kane Patel is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Ellen Gee\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Ellen Gee is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Allison Wellman\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Allison Wellman is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jeff Vidanes\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Jeff Vidanes is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"April Holland\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"April Holland is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Varvara Kozyreva\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Varvara Kozyreva is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jonathan Zhu\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Jonathan Zhu is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Mia Mattioli\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Mia Mattioli is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Alexis Roundtree\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Alexis Roundtree is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Kenai McFadden\"<|>\"Romaine Lettuce Exposure Outbreak\"<|>\"Kenai McFadden is an author involved in the investigation and reporting of the Romaine lettuce E. coli outbreak.\"<|>8)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"CDC\"<|>\"Anne M. Hause is the corresponding author for the CDC report on vaccine-related adverse events.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "615e57591f01d1d5f124ca63f7142a9f": {
    "return": "(\"entity\"<|>\"College Campuses\"<|>\"geo\"<|>\"College campuses are locations where the Janssen COVID-19 vaccine is administered, chosen for their suitability due to the vaccine's simple storage requirements and the need to ensure vaccination among populations where a second dose may be difficult.\")##\n(\"entity\"<|>\"Drive-through Vaccination Sites\"<|>\"geo\"<|>\"Drive-through vaccination sites are locations used for administering the Janssen COVID-19 vaccine, valued for their ability to facilitate mass vaccination with simple storage requirements.\")##\n(\"entity\"<|>\"Women aged 18-49 years\"<|>\"person\"<|>\"Women aged 18-49 years are a demographic group identified as being at higher risk for rare clotting events with low platelets after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Health Care Providers\"<|>\"person\"<|>\"Health care providers are responsible for reporting all potentially life-threatening events after receipt of the Janssen COVID-19 vaccine to VAERS, as required by the EUA.\")##\n(\"entity\"<|>\"Medical Records\"<|>\"event\"<|>\"Medical records are documents used in the comprehensive review of serious adverse events after vaccination, including deaths, to determine causality and outcomes.\")##\n(\"entity\"<|>\"Death Certificates\"<|>\"event\"<|>\"Death certificates are official documents used to confirm and review deaths reported as serious adverse events after vaccination.\")##\n(\"entity\"<|>\"Autopsy Reports\"<|>\"event\"<|>\"Autopsy reports are medical documents used to investigate the cause of death in cases of serious adverse events after vaccination.\")##\n(\"entity\"<|>\"Vaccine Administrators\"<|>\"person\"<|>\"Vaccine administrators are individuals or organizations responsible for promoting v-safe enrollment and administering COVID-19 vaccines.\")##\n(\"entity\"<|>\"ChAdOx1 nCoV-19 Vaccination\"<|>\"event\"<|>\"ChAdOx1 nCoV-19 vaccination refers to administration of the AstraZeneca COVID-19 vaccine, which has been associated with cases of TTS and anti-PF4 antibody formation.\")##\n(\"entity\"<|>\"Scully M\"<|>\"person\"<|>\"Scully M is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Singh D\"<|>\"person\"<|>\"Singh D is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Lown R\"<|>\"person\"<|>\"Lown R is an author of a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Portal Vein\"<|>\"geo\"<|>\"The portal vein is a blood vessel in which thrombosis was detected in Patient C after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Superior Mesenteric Artery\"<|>\"geo\"<|>\"The superior mesenteric artery is a blood vessel in which thrombosis was detected in Patient C after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Splenic Arteries\"<|>\"geo\"<|>\"The splenic arteries are blood vessels in which thrombosis was detected in Patient C after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Pulmonary Artery\"<|>\"geo\"<|>\"The pulmonary artery is a blood vessel in which thrombosis was detected in Patient C after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Right Carotid Artery\"<|>\"geo\"<|>\"The right carotid artery is a blood vessel in which thrombosis was detected in Patient A after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Left Brachial Vein\"<|>\"geo\"<|>\"The left brachial vein is a blood vessel in which thrombosis was detected in Patient A after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Right Femoral Vein\"<|>\"geo\"<|>\"The right femoral vein is a blood vessel in which thrombosis was detected in Patient A after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Left Lower Extremity Deep Vein\"<|>\"geo\"<|>\"The left lower extremity deep vein is a blood vessel in which thrombosis was detected in Patient B after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Right Femoral Artery\"<|>\"geo\"<|>\"The right femoral artery is a blood vessel in which thrombosis was detected in Patient B after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Left and Right Iliac Arteries\"<|>\"geo\"<|>\"The left and right iliac arteries are blood vessels in which thrombosis was detected in Patient B after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Platelet Factor 4 (PF4)\"<|>\"event\"<|>\"Platelet Factor 4 (PF4) is a protein involved in the formation of anti-PF4 antibodies, which are implicated in TTS and heparin-induced thrombocytopenia.\")##\n(\"entity\"<|>\"Heparin\"<|>\"event\"<|>\"Heparin is an anticoagulant medication that can trigger heparin-induced thrombocytopenia through formation of the heparin:PF4 complex.\")##\n(\"entity\"<|>\"Brighton Collaborations Draft Interim Case Finding Definition for TTS\"<|>\"event\"<|>\"Brighton Collaborations Draft Interim Case Finding Definition for TTS is a clinical guideline for identifying cases of TTS, specifying criteria such as acute thrombosis and new onset thrombocytopenia without known exposure to heparin.\")##\n(\"entity\"<|>\"EUA (Emergency Use Authorization)\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is a regulatory mechanism by the FDA allowing the use of vaccines, including the Janssen COVID-19 vaccine, during public health emergencies.\")##\n(\"entity\"<|>\"Clinical Trials\"<|>\"event\"<|>\"Clinical trials are research studies that evaluated the safety profile of the Janssen COVID-19 vaccine prior to its authorization.\")##\n(\"entity\"<|>\"March-April 2021\"<|>\"event\"<|>\"March-April 2021 is the time period during which cases of TTS after Janssen COVID-19 vaccination were reported and analyzed in the United States.\")##\n(\"entity\"<|>\"April 23, 2021\"<|>\"event\"<|>\"April 23, 2021 is the date when ACIP reaffirmed its interim recommendation for use of the Janssen COVID-19 vaccine after reviewing benefits and risks.\")##\n(\"entity\"<|>\"May 7, 2021\"<|>\"event\"<|>\"May 7, 2021 is the publication date of the referenced Morbidity and Mortality Weekly Report (MMWR) containing vaccine safety data.\")##\n(\"entity\"<|>\"March 2-April 12, 2021\"<|>\"event\"<|>\"March 2-April 12, 2021 is the time period during which v-safe enrollees reported reactions and health impacts after receiving the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Brighton Collaboration Website\"<|>\"organization\"<|>\"The Brighton Collaboration website hosts documents and guidelines, including the draft interim case finding definition for TTS.\")##\n(\"entity\"<|>\"N Engl J Med 2021\"<|>\"organization\"<|>\"The New England Journal of Medicine (N Engl J Med 2021) is a medical journal that published research on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"Text Messages\"<|>\"event\"<|>\"Text messages are used as the opt-in enrollment mechanism for v-safe, allowing participants to report reactions and health impacts after vaccination.\")##\n(\"entity\"<|>\"Local or Systemic Reaction\"<|>\"event\"<|>\"Local or systemic reaction refers to adverse effects reported by v-safe enrollees after receiving the Janssen COVID-19 vaccine, including symptoms such as headache, swelling, nausea, and more.\")##\n(\"entity\"<|>\"Passive Surveillance System\"<|>\"event\"<|>\"Passive surveillance system refers to the method used by VAERS to collect adverse event reports, relying on voluntary reporting by healthcare providers and others.\")##\n(\"entity\"<|>\"Opt-in Enrollment System\"<|>\"event\"<|>\"Opt-in enrollment system is the process by which individuals voluntarily enroll in v-safe to report vaccine reactions via text messages.\")##\n(\"entity\"<|>\"Benefit-risk Assessments\"<|>\"event\"<|>\"Benefit-risk assessments are evaluations conducted by ACIP and other organizations to guide recommendations for COVID-19 vaccines under EUA.\")##\n(\"entity\"<|>\"Reporting Differences\"<|>\"event\"<|>\"Reporting differences refer to variations in the data collected by VAERS, influenced by requirements and the passive nature of the surveillance system.\")##\n(\"entity\"<|>\"Comprehensive Medical Review\"<|>\"event\"<|>\"Comprehensive medical review is the process of analyzing medical records, death certificates, and autopsy reports to assess serious adverse events after vaccination.\")##\n(\"entity\"<|>\"Common and Rare Adverse Events\"<|>\"event\"<|>\"Common and rare adverse events are monitored after receipt of all COVID-19 vaccines, including the Janssen COVID-19 vaccine, to ensure safety.\")##\n(\"entity\"<|>\"Blood Clots in Large Vessels with Low Platelet Count\"<|>\"event\"<|>\"Blood clots in large vessels accompanied by a low platelet count is a rare but serious adverse event detected by the U.S. vaccine safety monitoring system after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Total Enrollees\"<|>\"event\"<|>\"Total enrollees refers to the number of individuals who participated in v-safe and reported reactions or health impacts after receiving the Janssen COVID-19 vaccine.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "16ac3714bc1c485fec3693d2624e049b": {
    "return": "(\"entity\"<|>\"MMWR\"<|>\"organization\"<|>\"MMWR (Morbidity and Mortality Weekly Report) is a publication produced by the CDC that disseminates public health information, including vaccine safety data and medical review findings.\")##\n(\"entity\"<|>\"Staff Physicians\"<|>\"person\"<|>\"Staff physicians are medical professionals employed by CDC and FDA who conducted reviews of medical records, death certificates, and autopsy reports to determine causes of death after vaccination.\")##\n(\"entity\"<|>\"Vaccine Recipients\"<|>\"person\"<|>\"Vaccine recipients are individuals who received the Janssen COVID-19 vaccine and whose demographic characteristics and adverse event data were analyzed.\")##\n(\"entity\"<|>\"Health Jurisdictions\"<|>\"organization\"<|>\"Health jurisdictions are local or regional public health authorities that made decisions about vaccine use, including deploying the Janssen COVID-19 vaccine in specific settings.\")##\n(\"entity\"<|>\"Providers\"<|>\"person\"<|>\"Providers are healthcare professionals or organizations responsible for administering vaccines and making decisions about which vaccine to use in various settings.\")##\n(\"entity\"<|>\"Death Certificates\"<|>\"event\"<|>\"Death certificates are official documents reviewed by CDC and FDA staff physicians to help determine the cause of death in vaccine recipients.\")##\n(\"entity\"<|>\"Autopsy Reports\"<|>\"event\"<|>\"Autopsy reports are medical documents reviewed by CDC and FDA staff physicians to provide further information on the cause of death after vaccination.\")##\n(\"entity\"<|>\"Preliminary Reviews\"<|>\"event\"<|>\"Preliminary reviews refer to the initial assessments conducted by CDC and FDA staff physicians regarding the cause of death for vaccine recipients.\")##\n(\"entity\"<|>\"Pause in Janssen Vaccine Use\"<|>\"event\"<|>\"Pause in Janssen vaccine use refers to the temporary suspension of the Janssen COVID-19 vaccine administration due to safety concerns and ongoing reviews.\")##\n(\"entity\"<|>\"March-April 2021\"<|>\"event\"<|>\"March-April 2021 is the time period during which the adverse event data for the Janssen COVID-19 vaccine was collected and analyzed.\")##\n(\"entity\"<|>\"April 23, 2021\"<|>\"event\"<|>\"April 23, 2021 is the date when ACIP reviewed the benefits and risks of the Janssen COVID-19 vaccine and updated recommendations.\")##\n(\"entity\"<|>\"Adverse Events\"<|>\"event\"<|>\"Adverse events are medical incidents, both serious and nonserious, reported after receipt of the Janssen COVID-19 vaccine, including symptoms such as headache, fever, chills, pain, and fatigue.\")##\n(\"entity\"<|>\"Serious Adverse Events\"<|>\"event\"<|>\"Serious adverse events are defined as incidents such as death, life-threatening illness, hospitalization, permanent disability, congenital anomaly, or birth defect following vaccination.\")##\n(\"entity\"<|>\"Nonserious Adverse Events\"<|>\"event\"<|>\"Nonserious adverse events are less severe medical incidents reported after vaccination, such as headache, fever, chills, pain, and fatigue.\")##\n(\"entity\"<|>\"Demographic Characteristics\"<|>\"event\"<|>\"Demographic characteristics refer to the age, sex, race, and ethnicity of vaccine recipients, which were analyzed in relation to adverse event reporting.\")##\n(\"entity\"<|>\"Symptoms\"<|>\"event\"<|>\"Symptoms are specific medical complaints reported after vaccination, including headache, fever, chills, pain, and fatigue.\")##\n(\"entity\"<|>\"Thrombosis\"<|>\"event\"<|>\"Thrombosis is a rare but serious safety concern associated with the Janssen COVID-19 vaccine, involving blood clots in large arteries or veins.\")##\n(\"entity\"<|>\"Protection from COVID-19\"<|>\"event\"<|>\"Protection from COVID-19 refers to the immunity provided by the Janssen COVID-19 vaccine after a single dose.\")##\n(\"entity\"<|>\"Refrigerator Temperatures\"<|>\"event\"<|>\"Refrigerator temperatures refer to the storage requirements for the Janssen COVID-19 vaccine, making it suitable for use in various settings.\")##\n(\"entity\"<|>\"Patients\"<|>\"person\"<|>\"Patients are individuals who received the Janssen COVID-19 vaccine and were subjects of medical review, including those who died after vaccination.\")##\n\n## Relationships (additional):\n\n(\"relationship\"<|>\"Staff Physicians\"<|>\"CDC\"<|>\"Staff physicians are employed by the CDC and conducted medical reviews of vaccine-related deaths and adverse events.\"<|>9)##\n(\"relationship\"<|>\"Staff Physicians\"<|>\"FDA\"<|>\"Staff physicians are employed by the FDA and participated in medical reviews of vaccine-related deaths and adverse events.\"<|>9)##\n(\"relationship\"<|>\"Staff Physicians\"<|>\"Medical Reviews\"<|>\"Staff physicians conducted medical reviews by analyzing medical records, death certificates, and autopsy reports.\"<|>10)##\n(\"relationship\"<|>\"Staff Physicians\"<|>\"Death Certificates\"<|>\"Staff physicians reviewed death certificates to help determine causes of death after vaccination.\"<|>8)##\n(\"relationship\"<|>\"Staff Physicians\"<|>\"Autopsy Reports\"<|>\"Staff physicians reviewed autopsy reports to help determine causes of death after vaccination.\"<|>8)##\n(\"relationship\"<|>\"Staff Physicians\"<|>\"Preliminary Reviews\"<|>\"Staff physicians conducted preliminary reviews to form initial impressions about causes of death.\"<|>8)##\n(\"relationship\"<|>\"Vaccine Recipients\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Vaccine recipients are individuals who received the Janssen COVID-19 vaccine and whose adverse events were tracked and analyzed.\"<|>10)##\n(\"relationship\"<|>\"Vaccine Recipients\"<|>\"Adverse Events\"<|>\"Vaccine recipients experienced adverse events after receiving the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Vaccine Recipients\"<|>\"Demographic Characteristics\"<|>\"Demographic characteristics of vaccine recipients were analyzed in relation to adverse event reporting.\"<|>8)##\n(\"relationship\"<|>\"Health Jurisdictions\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Health jurisdictions made decisions to use the Janssen COVID-19 vaccine in specific settings due to its advantages.\"<|>8)##\n(\"relationship\"<|>\"Providers\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Providers administered the Janssen COVID-19 vaccine and made decisions about its use in various settings.\"<|>8)##\n(\"relationship\"<|>\"Pause in Janssen Vaccine Use\"<|>\"Janssen COVID-19 Vaccine\"<|>\"A pause in Janssen vaccine use was implemented due to safety concerns and ongoing reviews.\"<|>9)##\n(\"relationship\"<|>\"March-April 2021\"<|>\"Adverse Events\"<|>\"Adverse event data for the Janssen COVID-19 vaccine was collected and analyzed during March-April 2021.\"<|>8)##\n(\"relationship\"<|>\"April 23, 2021\"<|>\"ACIP\"<|>\"On April 23, 2021, ACIP reviewed the benefits and risks of the Janssen COVID-19 vaccine and updated recommendations.\"<|>9)##\n(\"relationship\"<|>\"Adverse Events\"<|>\"Serious Adverse Events\"<|>\"Serious adverse events are a subset of all adverse events reported after vaccination.\"<|>10)##\n(\"relationship\"<|>\"Adverse Events\"<|>\"Nonserious Adverse Events\"<|>\"Nonserious adverse events are a subset of all adverse events reported after vaccination.\"<|>10)##\n(\"relationship\"<|>\"Symptoms\"<|>\"Adverse Events\"<|>\"Symptoms such as headache, fever, chills, pain, and fatigue are examples of adverse events reported after vaccination.\"<|>10)##\n(\"relationship\"<|>\"Thrombosis\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Thrombosis is a rare but serious safety concern associated with the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Protection from COVID-19\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Janssen COVID-19 vaccine provides substantial protection from COVID-19 after a single dose.\"<|>9)##\n(\"relationship\"<|>\"Refrigerator Temperatures\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Janssen COVID-19 vaccine can be stored at refrigerator temperatures, making it suitable for use in various settings.\"<|>8)##\n(\"relationship\"<|>\"Patients\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Patients received the Janssen COVID-19 vaccine and were subjects of medical review, including those who died after vaccination.\"<|>9)##\n(\"relationship\"<|>\"MMWR\"<|>\"CDC\"<|>\"MMWR is a publication produced by the CDC to disseminate public health information, including vaccine safety data.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "346b19b6851986341dc93a93f99ebaf3": {
    "return": "(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a U.S. federal agency responsible for public health, including monitoring vaccine safety and reviewing VAERS reports for adverse events related to vaccines.\")##\n(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"The Vaccine Adverse Event Reporting System (VAERS) is a national system for monitoring adverse events following vaccination, used by CDC to collect and analyze reports of vaccine-related incidents.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"organization\"<|>\"The Janssen COVID-19 Vaccine is a single-dose vaccine developed by Janssen Pharmaceuticals, administered to adults in the United States during the period studied for adverse events.\")##\n(\"entity\"<|>\"Five Mass Vaccination Sites\"<|>\"organization\"<|>\"Five mass vaccination sites in the United States reported clusters of anxiety-related adverse events following administration of the Janssen COVID-19 vaccine in April 2021.\")##\n(\"entity\"<|>\"Site A\"<|>\"organization\"<|>\"Site A is one of the five mass vaccination sites that reported anxiety-related adverse events during three days in April 2021 and did not suspend vaccination during this period.\")##\n(\"entity\"<|>\"Site B\"<|>\"organization\"<|>\"Site B is one of the five mass vaccination sites that reported anxiety-related adverse events on a single day in April 2021, after which vaccination was temporarily suspended.\")##\n(\"entity\"<|>\"Site C\"<|>\"organization\"<|>\"Site C is one of the five mass vaccination sites, notable for not offering drive-through vaccination, and reported anxiety-related adverse events in April 2021.\")##\n(\"entity\"<|>\"Site D\"<|>\"organization\"<|>\"Site D is one of the five mass vaccination sites that reported anxiety-related adverse events on a single day in April 2021, after which vaccination was temporarily suspended.\")##\n(\"entity\"<|>\"Site E\"<|>\"organization\"<|>\"Site E is one of the five mass vaccination sites that reported anxiety-related adverse events and did not administer the Janssen vaccine for the first time on the day clusters were reported.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the mass vaccination sites operated and where the Janssen COVID-19 vaccine doses were administered and monitored for adverse events.\")##\n(\"entity\"<|>\"Emergency Department\"<|>\"organization\"<|>\"Emergency departments provided further medical evaluation for patients experiencing anxiety-related adverse events at vaccination sites; all patients with available follow-up were released the same day.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication of the CDC that disseminates public health information, including reports on vaccine safety and adverse events.\")##\n(\"entity\"<|>\"U.S. Department of Health and Human Services\"<|>\"organization\"<|>\"The U.S. Department of Health and Human Services is the federal department overseeing the CDC and public health activities, including vaccine safety monitoring.\")##\n(\"entity\"<|>\"Influenza Vaccine\"<|>\"organization\"<|>\"The Influenza Vaccine is a single-dose vaccine administered to U.S. adults, used as a comparison for adverse event rates with the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Anxiety-Related Adverse Event Cluster\"<|>\"event\"<|>\"Anxiety-related adverse event clusters refer to groups of cases involving symptoms such as light-headedness, dizziness, pallor, syncope, and nausea occurring at mass vaccination sites after Janssen COVID-19 vaccine administration in April 2021.\")##\n(\"entity\"<|>\"Syncope\"<|>\"event\"<|>\"Syncope is a medical event characterized by fainting, reported as an anxiety-related adverse event and tracked in VAERS reports following vaccination.\")##\n(\"entity\"<|>\"March 2-April 22, 2021\"<|>\"event\"<|>\"March 2-April 22, 2021 is the time period during which CDC reviewed VAERS reports for adverse events associated with Janssen COVID-19 vaccine doses.\")##\n(\"entity\"<|>\"March 2-April 12, 2021\"<|>\"event\"<|>\"March 2-April 12, 2021 is the period during which Janssen COVID-19 vaccine doses were administered and monitored for adverse events in the United States.\")##\n(\"entity\"<|>\"April 7-9, 2021\"<|>\"event\"<|>\"April 7-9, 2021 is the specific date range during which the five mass vaccination sites reported 64 cases of anxiety-related adverse events after Janssen COVID-19 vaccine administration.\")##\n(\"entity\"<|>\"2019-20 Influenza Season\"<|>\"event\"<|>\"The 2019-20 Influenza Season (July 1, 2019-June 30, 2020) is the period used for comparison of syncope rates after influenza vaccine administration to adults.\")##\n\n(\"relationship\"<|>\"CDC\"<|>\"VAERS\"<|>\"CDC reviewed and analyzed VAERS reports to monitor adverse events following vaccination, including those related to the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"Janssen COVID-19 Vaccine\"<|>\"CDC monitored adverse events and safety data for the Janssen COVID-19 vaccine administered in the United States.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"Five Mass Vaccination Sites\"<|>\"CDC received reports of anxiety-related adverse event clusters from five mass vaccination sites and included these in their analysis.\"<|>8)##\n(\"relationship\"<|>\"Five Mass Vaccination Sites\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The five mass vaccination sites administered the Janssen COVID-19 vaccine and reported clusters of anxiety-related adverse events.\"<|>10)##\n(\"relationship\"<|>\"Site A\"<|>\"Five Mass Vaccination Sites\"<|>\"Site A is one of the five mass vaccination sites reporting anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Site B\"<|>\"Five Mass Vaccination Sites\"<|>\"Site B is one of the five mass vaccination sites reporting anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Site C\"<|>\"Five Mass Vaccination Sites\"<|>\"Site C is one of the five mass vaccination sites reporting anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Site D\"<|>\"Five Mass Vaccination Sites\"<|>\"Site D is one of the five mass vaccination sites reporting anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Site E\"<|>\"Five Mass Vaccination Sites\"<|>\"Site E is one of the five mass vaccination sites reporting anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Five Mass Vaccination Sites\"<|>\"United States\"<|>\"The five mass vaccination sites operated within the United States and contributed data to the national monitoring effort.\"<|>7)##\n(\"relationship\"<|>\"Emergency Department\"<|>\"Five Mass Vaccination Sites\"<|>\"Patients experiencing anxiety-related adverse events at the mass vaccination sites were transported to emergency departments for further evaluation.\"<|>7)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"CDC\"<|>\"MMWR is the CDC's publication for disseminating findings from vaccine safety monitoring and adverse event analyses.\"<|>9)##\n(\"relationship\"<|>\"U.S. Department of Health and Human Services\"<|>\"CDC\"<|>\"CDC operates under the U.S. Department of Health and Human Services, which oversees public health activities.\"<|>8)##\n(\"relationship\"<|>\"Influenza Vaccine\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Influenza Vaccine was used as a comparison for adverse event rates with the Janssen COVID-19 vaccine in the CDC analysis.\"<|>7)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Cluster\"<|>\"Five Mass Vaccination Sites\"<|>\"Anxiety-related adverse event clusters were reported by the five mass vaccination sites after administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Syncope\"<|>\"Anxiety-Related Adverse Event Cluster\"<|>\"Syncope was one of the most commonly reported symptoms in the anxiety-related adverse event clusters at mass vaccination sites.\"<|>9)##\n(\"relationship\"<|>\"Syncope\"<|>\"VAERS\"<|>\"VAERS tracked and reported cases of syncope following vaccination, including those after Janssen COVID-19 vaccine administration.\"<|>9)##\n(\"relationship\"<|>\"March 2-April 22, 2021\"<|>\"CDC\"<|>\"CDC reviewed VAERS reports for adverse events during March 2-April 22, 2021.\"<|>7)##\n(\"relationship\"<|>\"March 2-April 12, 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Janssen COVID-19 vaccine doses were administered and monitored for adverse events during March 2-April 12, 2021.\"<|>8)##\n(\"relationship\"<|>\"April 7-9, 2021\"<|>\"Five Mass Vaccination Sites\"<|>\"The five mass vaccination sites reported 64 cases of anxiety-related adverse events during April 7-9, 2021.\"<|>10)##\n(\"relationship\"<|>\"2019-20 Influenza Season\"<|>\"Influenza Vaccine\"<|>\"The 2019-20 Influenza Season was the period during which influenza vaccine doses were administered and used for comparison in the CDC analysis.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Janssen COVID-19 vaccine doses were administered to adults in the United States and monitored for adverse events.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Influenza Vaccine\"<|>\"Influenza vaccine doses were administered to adults in the United States during the 2019-20 season.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "8ad1f5a158a46220bab8f313a5690541": {
    "return": "(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"Pfizer-BioNTech is a pharmaceutical company that produces a COVID-19 vaccine used in the study to assess vaccine effectiveness among hospitalized adults.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"Moderna is a biotechnology company that manufactures a COVID-19 vaccine, which was evaluated for effectiveness in the study population.\")##\n(\"entity\"<|>\"University of California Los Angeles\"<|>\"organization\"<|>\"University of California Los Angeles is a major academic medical center in California, participating as an enrollment site for the study.\")##\n(\"entity\"<|>\"Stanford University\"<|>\"organization\"<|>\"Stanford University is a prominent academic institution in California, serving as a medical center for patient enrollment in the study.\")##\n(\"entity\"<|>\"UCHealth University of Colorado Hospital\"<|>\"organization\"<|>\"UCHealth University of Colorado Hospital is a medical center in Colorado involved in enrolling patients for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"Johns Hopkins Hospital\"<|>\"organization\"<|>\"Johns Hopkins Hospital is a leading medical institution in Maryland, participating in the study as an enrollment site.\")##\n(\"entity\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"organization\"<|>\"Beth Israel Deaconess Medical Center is a hospital in Massachusetts, included as a study site for patient enrollment.\")##\n(\"entity\"<|>\"Baystate Medical Center\"<|>\"organization\"<|>\"Baystate Medical Center is a hospital in Massachusetts, serving as a location for patient enrollment in the study.\")##\n(\"entity\"<|>\"University of Michigan\"<|>\"organization\"<|>\"University of Michigan is an academic medical center in Michigan, participating in the study as an enrollment site.\")##\n(\"entity\"<|>\"Henry Ford\"<|>\"organization\"<|>\"Henry Ford is a healthcare organization in Michigan, involved in patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"St. Joseph\"<|>\"organization\"<|>\"St. Joseph is a medical center in Michigan, included as a site for patient enrollment in the study.\")##\n(\"entity\"<|>\"Hennepin County Medical Center\"<|>\"organization\"<|>\"Hennepin County Medical Center is a hospital in Minnesota, participating in the study as an enrollment site.\")##\n(\"entity\"<|>\"Montefiore Healthcare Center\"<|>\"organization\"<|>\"Montefiore Healthcare Center is a medical institution in New York, serving as a study site for patient enrollment.\")##\n(\"entity\"<|>\"Wake Forest University\"<|>\"organization\"<|>\"Wake Forest University is an academic medical center in North Carolina, included as a study site for patient enrollment.\")##\n(\"entity\"<|>\"Ohio State University\"<|>\"organization\"<|>\"Ohio State University is a major academic institution in Ohio, participating as a medical center for patient enrollment in the study.\")##\n(\"entity\"<|>\"Oregon Health & Science University\"<|>\"organization\"<|>\"Oregon Health & Science University is a medical center in Oregon, involved in patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"University of Pittsburgh Medical Center\"<|>\"organization\"<|>\"University of Pittsburgh Medical Center is a large healthcare system in Pennsylvania, with multiple hospitals participating in the study.\")##\n(\"entity\"<|>\"Shadyside Hospital\"<|>\"organization\"<|>\"Shadyside Hospital is part of University of Pittsburgh Medical Center in Pennsylvania, serving as a study site.\")##\n(\"entity\"<|>\"Mercy Hospital\"<|>\"organization\"<|>\"Mercy Hospital is part of University of Pittsburgh Medical Center in Pennsylvania, included as a study site.\")##\n(\"entity\"<|>\"Passavant Hospital\"<|>\"organization\"<|>\"Passavant Hospital is part of University of Pittsburgh Medical Center in Pennsylvania, participating as a study site.\")##\n(\"entity\"<|>\"St. Margaret Hospital\"<|>\"organization\"<|>\"St. Margaret Hospital is part of University of Pittsburgh Medical Center in Pennsylvania, serving as a study site.\")##\n(\"entity\"<|>\"Presbyterian Hospital\"<|>\"organization\"<|>\"Presbyterian Hospital is part of University of Pittsburgh Medical Center in Pennsylvania, included as a study site.\")##\n(\"entity\"<|>\"Vanderbilt University Medical Center\"<|>\"organization\"<|>\"Vanderbilt University Medical Center is a major academic medical center in Tennessee, participating in the study as an enrollment site.\")##\n(\"entity\"<|>\"Baylor Scott & White Medical Center\"<|>\"organization\"<|>\"Baylor Scott & White Medical Center is a healthcare system in Texas, with multiple locations (Temple, Round Rock, Hillcrest/Waco) serving as study sites.\")##\n(\"entity\"<|>\"Temple\"<|>\"organization\"<|>\"Temple is a location of Baylor Scott & White Medical Center in Texas, participating as a study site.\")##\n(\"entity\"<|>\"Round Rock\"<|>\"organization\"<|>\"Round Rock is a location of Baylor Scott & White Medical Center in Texas, included as a study site.\")##\n(\"entity\"<|>\"Hillcrest/Waco\"<|>\"organization\"<|>\"Hillcrest/Waco is a location of Baylor Scott & White Medical Center in Texas, serving as a study site.\")##\n(\"entity\"<|>\"Intermountain Health\"<|>\"organization\"<|>\"Intermountain Health is a healthcare organization in Utah, participating as a study site for patient enrollment.\")##\n(\"entity\"<|>\"HAIVEN Network\"<|>\"organization\"<|>\"HAIVEN Network (Hospitalized Adult Influenza Vaccine Effectiveness Network) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"IVY Network\"<|>\"organization\"<|>\"IVY Network (Influenza and Other Viruses in the Acutely Ill) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a federal public health agency overseeing the study and publication of vaccine effectiveness data.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal agency responsible for public health, overseeing the CDC and the study.\")##\n(\"entity\"<|>\"California\"<|>\"geo\"<|>\"California is a state in the western United States, with multiple medical centers participating in the study.\")##\n(\"entity\"<|>\"Colorado\"<|>\"geo\"<|>\"Colorado is a state in the western United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Maryland\"<|>\"geo\"<|>\"Maryland is a state in the eastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Massachusetts\"<|>\"geo\"<|>\"Massachusetts is a state in the northeastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Michigan\"<|>\"geo\"<|>\"Michigan is a state in the midwestern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Minnesota\"<|>\"geo\"<|>\"Minnesota is a state in the midwestern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"New York\"<|>\"geo\"<|>\"New York is a state in the northeastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"North Carolina\"<|>\"geo\"<|>\"North Carolina is a state in the southeastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Ohio\"<|>\"geo\"<|>\"Ohio is a state in the midwestern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Oregon\"<|>\"geo\"<|>\"Oregon is a state in the northwestern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Pennsylvania\"<|>\"geo\"<|>\"Pennsylvania is a state in the northeastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Tennessee\"<|>\"geo\"<|>\"Tennessee is a state in the southeastern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Texas\"<|>\"geo\"<|>\"Texas is a state in the southern United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"Utah\"<|>\"geo\"<|>\"Utah is a state in the western United States, with medical centers participating in the study.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"event\"<|>\"COVID-19 Vaccine Effectiveness Study is a multi-center research project conducted from January to March 2021, evaluating the effectiveness of Pfizer-BioNTech and Moderna vaccines among hospitalized adults aged 65 years.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a CDC publication that reported the findings of the COVID-19 vaccine effectiveness study.\")##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"Pfizer-BioNTech's vaccine was one of the primary vaccines evaluated for effectiveness in the study.\"<|>10)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"Moderna's vaccine was one of the primary vaccines evaluated for effectiveness in the study.\"<|>10)##\n(\"relationship\"<|>\"University of California Los Angeles\"<|>\"California\"<|>\"University of California Los Angeles is located in California and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Stanford University\"<|>\"California\"<|>\"Stanford University is located in California and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"UCHealth University of Colorado Hospital\"<|>\"Colorado\"<|>\"UCHealth University of Colorado Hospital is located in Colorado and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Johns Hopkins Hospital\"<|>\"Maryland\"<|>\"Johns Hopkins Hospital is located in Maryland and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"Massachusetts\"<|>\"Beth Israel Deaconess Medical Center is located in Massachusetts and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Baystate Medical Center\"<|>\"Massachusetts\"<|>\"Baystate Medical Center is located in Massachusetts and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"University of Michigan\"<|>\"Michigan\"<|>\"University of Michigan is located in Michigan and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Henry Ford\"<|>\"Michigan\"<|>\"Henry Ford is located in Michigan and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"St. Joseph\"<|>\"Michigan\"<|>\"St. Joseph is located in Michigan and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Hennepin County Medical Center\"<|>\"Minnesota\"<|>\"Hennepin County Medical Center is located in Minnesota and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Montefiore Healthcare Center\"<|>\"New York\"<|>\"Montefiore Healthcare Center is located in New York and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Wake Forest University\"<|>\"North Carolina\"<|>\"Wake Forest University is located in North Carolina and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Ohio State University\"<|>\"Ohio\"<|>\"Ohio State University is located in Ohio and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Oregon Health & Science University\"<|>\"Oregon\"<|>\"Oregon Health & Science University is located in Oregon and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"University of Pittsburgh Medical Center\"<|>\"Pennsylvania\"<|>\"University of Pittsburgh Medical Center is located in Pennsylvania and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Shadyside Hospital\"<|>\"Pennsylvania\"<|>\"Shadyside Hospital is located in Pennsylvania and participated as a study site.\"<|>8)##\n(\"relationship\"<|>\"Mercy Hospital\"<|>\"Pennsylvania\"<|>\"Mercy Hospital is located in Pennsylvania and participated as a study site.\"<|>8)##\n(\"relationship\"<|>\"Passavant Hospital\"<|>\"Pennsylvania\"<|>\"Passavant Hospital is located in Pennsylvania and participated as a study site.\"<|>8)##\n(\"relationship\"<|>\"St. Margaret Hospital\"<|>\"Pennsylvania\"<|>\"St. Margaret Hospital is located in Pennsylvania and participated as a study site.\"<|>8)##\n(\"relationship\"<|>\"Presbyterian Hospital\"<|>\"Pennsylvania\"<|>\"Presbyterian Hospital is located in Pennsylvania and participated as a study site.\"<|>8)##\n(\"relationship\"<|>\"Vanderbilt University Medical Center\"<|>\"Tennessee\"<|>\"Vanderbilt University Medical Center is located in Tennessee and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Baylor Scott & White Medical Center\"<|>\"Texas\"<|>\"Baylor Scott & White Medical Center is located in Texas and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"Temple\"<|>\"Texas\"<|>\"Temple is a location in Texas and a site for Baylor Scott & White Medical Center's participation in the study.\"<|>8)##\n(\"relationship\"<|>\"Round Rock\"<|>\"Texas\"<|>\"Round Rock is a location in Texas and a site for Baylor Scott & White Medical Center's participation in the study.\"<|>8)##\n(\"relationship\"<|>\"Hillcrest/Waco\"<|>\"Texas\"<|>\"Hillcrest/Waco is a location in Texas and a site for Baylor Scott & White Medical Center's participation in the study.\"<|>8)##\n(\"relationship\"<|>\"Intermountain Health\"<|>\"Utah\"<|>\"Intermountain Health is located in Utah and participated as a study site.\"<|>9)##\n(\"relationship\"<|>\"HAIVEN Network\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"HAIVEN Network provided clinical criteria and patient enrollment for the study.\"<|>8)##\n(\"relationship\"<|>\"IVY Network\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"IVY Network provided clinical criteria and patient enrollment for the study.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"CDC oversaw the study and published the results in MMWR.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"US Department of Health and Human Services is the parent agency of CDC, which oversaw the study.\"<|>9)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"COVID-19 Vaccine Effectiveness Study\"<|>\"MMWR published the findings of the COVID-19 vaccine effectiveness study.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "9a88b5c421e3517285a01e43134070e1": {
    "return": "(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC (Centers for Disease Control and Prevention) is a federal public health agency in the United States that reviewed and participated in the described activity, ensuring it was conducted consistent with federal law and CDC policy.\")##\n(\"entity\"<|>\"SAS Institute\"<|>\"organization\"<|>\"SAS Institute is a software company whose SAS version 9.4 was used for statistical analyses in the study.\")##\n(\"entity\"<|>\"U.S. Census Region\"<|>\"geo\"<|>\"U.S. Census Region refers to the geographic regions defined by the United States Census Bureau, used as a variable in the statistical models for adjusting confounders.\")##\n(\"entity\"<|>\"Israel\"<|>\"geo\"<|>\"Israel is a country referenced for postmarketing findings regarding vaccine effectiveness observed at 14 days after vaccination after 1 dose.\")##\n(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"Pfizer-BioNTech is a pharmaceutical collaboration that produces a 2-dose SARS-CoV-2 vaccine used in the study population.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"Moderna is a biotechnology company that produces a 2-dose SARS-CoV-2 vaccine used in the study population.\")##\n(\"entity\"<|>\"Janssen\"<|>\"organization\"<|>\"Janssen (Johnson & Johnson) is a pharmaceutical company that produces a single-dose COVID-19 vaccine, which was in limited use during the evaluation period and excluded from the analysis.\")##\n(\"entity\"<|>\"Johnson & Johnson\"<|>\"organization\"<|>\"Johnson & Johnson is the parent company of Janssen, referenced in relation to the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"event\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021 refers to the research activity conducted between January 1 and March 26, 2021, evaluating vaccine effectiveness against COVID-19-associated hospitalization in older adults.\")##\n(\"entity\"<|>\"State Immunization Registry\"<|>\"organization\"<|>\"State Immunization Registry is a state-level database used to verify SARS-CoV-2 vaccination records for study participants.\")##\n(\"entity\"<|>\"Electronic Medical Record\"<|>\"organization\"<|>\"Electronic Medical Record refers to the digital health records used to obtain patient information and verify vaccination status in the study.\")##\n(\"entity\"<|>\"Older Adults (65+)\"<|>\"person\"<|>\"Older Adults (65+) are the study population, defined as individuals aged 65 years or older at the time of hospital admission.\")##\n(\"entity\"<|>\"Case-Patients\"<|>\"person\"<|>\"Case-Patients are individuals in the study who received one or more positive test results for SARS-CoV-2.\")##\n(\"entity\"<|>\"Controls\"<|>\"person\"<|>\"Controls are individuals in the study who met eligibility criteria and received negative SARS-CoV-2 RT-PCR test results.\")##\n(\"entity\"<|>\"Trained Study Personnel\"<|>\"person\"<|>\"Trained Study Personnel are individuals who conducted patient or proxy interviews and reviewed electronic medical records for data collection.\")##\n(\"entity\"<|>\"Proxy\"<|>\"person\"<|>\"Proxy refers to individuals who provided information on behalf of patients during interviews for the study.\")##\n(\"entity\"<|>\"COVID-19 Vaccination\"<|>\"event\"<|>\"COVID-19 Vaccination refers to the administration of SARS-CoV-2 vaccines (Pfizer-BioNTech, Moderna, Janssen) to study participants, with status categorized as unvaccinated, single-dose, partially vaccinated, or fully vaccinated.\")##\n\n(\"relationship\"<|>\"CDC\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"CDC reviewed and participated in the COVID-19 Hospitalization Study, ensuring compliance with federal law and policy.\"<|>10)##\n(\"relationship\"<|>\"SAS Institute\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"SAS Institute's software was used for statistical analyses in the study.\"<|>8)##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19 Vaccination\"<|>\"Pfizer-BioNTech produces one of the vaccines administered to study participants as part of the COVID-19 vaccination event.\"<|>9)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19 Vaccination\"<|>\"Moderna produces one of the vaccines administered to study participants as part of the COVID-19 vaccination event.\"<|>9)##\n(\"relationship\"<|>\"Janssen\"<|>\"COVID-19 Vaccination\"<|>\"Janssen produces a COVID-19 vaccine that was in limited use and excluded from the study analysis.\"<|>7)##\n(\"relationship\"<|>\"Johnson & Johnson\"<|>\"Janssen\"<|>\"Johnson & Johnson is the parent company of Janssen, which produces the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Older Adults (65+)\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Older Adults (65+) are the target population for the COVID-19 Hospitalization Study.\"<|>10)##\n(\"relationship\"<|>\"Case-Patients\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Case-Patients are a subgroup of study participants who tested positive for SARS-CoV-2.\"<|>10)##\n(\"relationship\"<|>\"Controls\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Controls are a subgroup of study participants who tested negative for SARS-CoV-2.\"<|>10)##\n(\"relationship\"<|>\"Trained Study Personnel\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Trained Study Personnel conducted interviews and data collection for the study.\"<|>9)##\n(\"relationship\"<|>\"Proxy\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Proxies provided information on behalf of patients during the study interviews.\"<|>7)##\n(\"relationship\"<|>\"State Immunization Registry\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"State Immunization Registry was used to verify vaccination records for study participants.\"<|>8)##\n(\"relationship\"<|>\"Electronic Medical Record\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"Electronic Medical Records were reviewed to obtain patient information and verify vaccination status in the study.\"<|>8)##\n(\"relationship\"<|>\"U.S. Census Region\"<|>\"COVID-19 Hospitalization Study, Jan-Mar 2021\"<|>\"U.S. Census Region was used as a variable in the statistical models for the study.\"<|>7)##\n(\"relationship\"<|>\"Israel\"<|>\"COVID-19 Vaccination\"<|>\"Israel provided postmarketing findings on vaccine effectiveness, referenced in the study for timing of observed effectiveness after vaccination.\"<|>6)##\n(\"relationship\"<|>\"Case-Patients\"<|>\"COVID-19 Vaccination\"<|>\"Case-Patients' vaccination status was analyzed to assess vaccine effectiveness against hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Controls\"<|>\"COVID-19 Vaccination\"<|>\"Controls' vaccination status was analyzed to assess vaccine effectiveness against hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Older Adults (65+)\"<|>\"COVID-19 Vaccination\"<|>\"Older Adults (65+) received COVID-19 vaccination as part of the study population, with vaccination status categorized and analyzed.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "76fb7b21b25fdf6da87aa013646e58cb": {
    "return": "(\"entity\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"MMWR Morbidity and Mortality Weekly Report is a publication by the Centers for Disease Control and Prevention (CDC) that provides timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a major public health agency in the United States responsible for disease control and prevention, including monitoring vaccine safety and issuing public health recommendations.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal department overseeing public health, welfare, and health policy, including agencies such as the CDC and FDA.\")##\n(\"entity\"<|>\"Food and Drug Administration\"<|>\"organization\"<|>\"The Food and Drug Administration (FDA) is a federal agency responsible for regulating food, drugs, and medical devices, including issuing Emergency Use Authorizations for COVID-19 vaccines.\")##\n(\"entity\"<|>\"Advisory Committee on Immunization Practices\"<|>\"organization\"<|>\"The Advisory Committee on Immunization Practices (ACIP) is a group that provides advice and recommendations to the CDC on the use of vaccines in the United States.\")##\n(\"entity\"<|>\"Janssen Biotech, Inc.\"<|>\"organization\"<|>\"Janssen Biotech, Inc. is a pharmaceutical company, part of Janssen Pharmaceutical Companies and Johnson & Johnson, that developed the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Janssen Pharmaceutical Companies\"<|>\"organization\"<|>\"Janssen Pharmaceutical Companies is a pharmaceutical division of Johnson & Johnson, involved in the development and distribution of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Johnson & Johnson\"<|>\"organization\"<|>\"Johnson & Johnson is a multinational corporation that owns Janssen Pharmaceutical Companies and is involved in the development and distribution of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"COVE Study Group\"<|>\"organization\"<|>\"The COVE Study Group is a research group involved in the clinical trials for the mRNA-1273 SARS-CoV-2 vaccine.\")##\n(\"entity\"<|>\"C4591001 Clinical Trial Group\"<|>\"organization\"<|>\"The C4591001 Clinical Trial Group is a research group involved in the clinical trials for the BNT162b2 mRNA COVID-19 vaccine.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC refers to the Centers for Disease Control and Prevention, a key public health agency in the United States.\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"FDA refers to the Food and Drug Administration, a key regulatory agency in the United States.\")##\n(\"entity\"<|>\"AstraZeneca\"<|>\"organization\"<|>\"AstraZeneca is a multinational pharmaceutical company that developed the AstraZeneca COVID-19 vaccine, which uses a replication-incompetent chimpanzee adenoviral vector.\")##\n(\"entity\"<|>\"K. Dooling\"<|>\"person\"<|>\"K. Dooling is an author and likely a researcher involved in vaccine recommendations and public health policy.\")##\n(\"entity\"<|>\"M. Marin\"<|>\"person\"<|>\"M. Marin is an author and likely a researcher involved in vaccine recommendations and public health policy.\")##\n(\"entity\"<|>\"M. Wallace\"<|>\"person\"<|>\"M. Wallace is an author and likely a researcher involved in vaccine recommendations and public health policy.\")##\n(\"entity\"<|>\"L.R. Baden\"<|>\"person\"<|>\"L.R. Baden is an author and researcher involved in the efficacy and safety studies of the mRNA-1273 SARS-CoV-2 vaccine.\")##\n(\"entity\"<|>\"H.M. El Sahly\"<|>\"person\"<|>\"H.M. El Sahly is an author and researcher involved in the efficacy and safety studies of the mRNA-1273 SARS-CoV-2 vaccine.\")##\n(\"entity\"<|>\"B. Essink\"<|>\"person\"<|>\"B. Essink is an author and researcher involved in the efficacy and safety studies of the mRNA-1273 SARS-CoV-2 vaccine.\")##\n(\"entity\"<|>\"F.P. Polack\"<|>\"person\"<|>\"F.P. Polack is an author and researcher involved in the safety and efficacy studies of the BNT162b2 mRNA COVID-19 vaccine.\")##\n(\"entity\"<|>\"S.J. Thomas\"<|>\"person\"<|>\"S.J. Thomas is an author and researcher involved in the safety and efficacy studies of the BNT162b2 mRNA COVID-19 vaccine.\")##\n(\"entity\"<|>\"N. Kitchin\"<|>\"person\"<|>\"N. Kitchin is an author and researcher involved in the safety and efficacy studies of the BNT162b2 mRNA COVID-19 vaccine.\")##\n(\"entity\"<|>\"M.M. Patel\"<|>\"person\"<|>\"M.M. Patel is an author and researcher involved in postlicensure evaluation of COVID-19 vaccines.\")##\n(\"entity\"<|>\"M.L. Jackson\"<|>\"person\"<|>\"M.L. Jackson is an author and researcher involved in postlicensure evaluation of COVID-19 vaccines and vaccine effectiveness studies.\")##\n(\"entity\"<|>\"J. Ferdinands\"<|>\"person\"<|>\"J. Ferdinands is an author and researcher involved in postlicensure evaluation of COVID-19 vaccines.\")##\n(\"entity\"<|>\"N. Dagan\"<|>\"person\"<|>\"N. Dagan is an author and researcher involved in studies of the BNT162b2 mRNA COVID-19 vaccine in mass vaccination settings.\")##\n(\"entity\"<|>\"N. Barda\"<|>\"person\"<|>\"N. Barda is an author and researcher involved in studies of the BNT162b2 mRNA COVID-19 vaccine in mass vaccination settings.\")##\n(\"entity\"<|>\"E. Kepten\"<|>\"person\"<|>\"E. Kepten is an author and researcher involved in studies of the BNT162b2 mRNA COVID-19 vaccine in mass vaccination settings.\")##\n(\"entity\"<|>\"J.C. Nelson\"<|>\"person\"<|>\"J.C. Nelson is an author and researcher involved in studies of influenza vaccine effectiveness.\")##\n(\"entity\"<|>\"E. Rinott\"<|>\"person\"<|>\"E. Rinott is an author and researcher involved in studies of COVID-19 patient outcomes following vaccination.\")##\n(\"entity\"<|>\"I. Youngster\"<|>\"person\"<|>\"I. Youngster is an author and researcher involved in studies of COVID-19 patient outcomes following vaccination.\")##\n(\"entity\"<|>\"Y.E. Lewis\"<|>\"person\"<|>\"Y.E. Lewis is an author and researcher involved in studies of COVID-19 patient outcomes following vaccination.\")##\n(\"entity\"<|>\"C. Huang\"<|>\"person\"<|>\"C. Huang is an author and researcher involved in studies of long-term consequences of COVID-19.\")##\n(\"entity\"<|>\"L. Huang\"<|>\"person\"<|>\"L. Huang is an author and researcher involved in studies of long-term consequences of COVID-19.\")##\n(\"entity\"<|>\"Y. Wang\"<|>\"person\"<|>\"Y. Wang is an author and researcher involved in studies of long-term consequences of COVID-19.\")##\n(\"entity\"<|>\"David K. Shay\"<|>\"person\"<|>\"David K. Shay, MD, is a medical doctor and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Julianne Gee\"<|>\"person\"<|>\"Julianne Gee, MPH, is a public health professional and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"John R. Su\"<|>\"person\"<|>\"John R. Su, MD, PhD, is a medical doctor and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Tanya R. Myers\"<|>\"person\"<|>\"Tanya R. Myers, PhD, is a researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Paige Marquez\"<|>\"person\"<|>\"Paige Marquez, MSPH, is a public health professional and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Ruiling Liu\"<|>\"person\"<|>\"Ruiling Liu, PhD, is a researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Bicheng Zhang\"<|>\"person\"<|>\"Bicheng Zhang, MS, is a researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Charles Licata\"<|>\"person\"<|>\"Charles Licata, PhD, is a researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Thomas A. Clark\"<|>\"person\"<|>\"Thomas A. Clark, MD, is a medical doctor and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Tom T. Shimabukuro\"<|>\"person\"<|>\"Tom T. Shimabukuro, MD, is a medical doctor and researcher involved in safety monitoring of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is a country where multiple COVID-19 vaccine studies, recommendations, and safety monitoring activities are conducted.\")##\n(\"entity\"<|>\"Israel\"<|>\"geo\"<|>\"Israel is a country referenced in the context of a national COVID-19 vaccination program and related studies.\")##\n(\"entity\"<|>\"Europe\"<|>\"geo\"<|>\"Europe is a region referenced in the context of thrombotic events following AstraZeneca COVID-19 vaccination.\")##\n(\"entity\"<|>\"Emergency Use Authorization\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is an event where the FDA authorizes the use of medical products, such as vaccines, during public health emergencies.\")##\n(\"entity\"<|>\"Pause in Janssen Vaccine Use\"<|>\"event\"<|>\"Pause in Janssen Vaccine Use refers to the temporary suspension of the Janssen COVID-19 vaccine in the United States during April 2021 due to reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia.\")##\n(\"entity\"<|>\"National COVID-19 Vaccination Program\"<|>\"event\"<|>\"National COVID-19 Vaccination Program refers to the large-scale vaccination efforts in countries such as Israel to reduce COVID-19 cases and severe outcomes.\")##\n(\"entity\"<|>\"Implementation of AstraZeneca COVID-19 Vaccine\"<|>\"event\"<|>\"Implementation of AstraZeneca COVID-19 Vaccine refers to the rollout and administration of the AstraZeneca vaccine in Europe and other regions.\")##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR is published by the CDC, providing public health information and recommendations.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"US Department of Health and Human Services\"<|>\"CDC is an agency under the US Department of Health and Human Services.\"<|>9)##\n(\"relationship\"<|>\"Food and Drug Administration\"<|>\"US Department of Health and Human Services\"<|>\"FDA is an agency under the US Department of Health and Human Services.\"<|>9)##\n(\"relationship\"<|>\"Advisory Committee on Immunization Practices\"<|>\"Centers for Disease Control and Prevention\"<|>\"ACIP provides vaccine recommendations to the CDC.\"<|>10)##\n(\"relationship\"<|>\"Janssen Biotech, Inc.\"<|>\"Janssen Pharmaceutical Companies\"<|>\"Janssen Biotech, Inc. is part of Janssen Pharmaceutical Companies.\"<|>10)##\n(\"relationship\"<|>\"Janssen Pharmaceutical Companies\"<|>\"Johnson & Johnson\"<|>\"Janssen Pharmaceutical Companies is a division of Johnson & Johnson.\"<|>10)##\n(\"relationship\"<|>\"Janssen Biotech, Inc.\"<|>\"Johnson & Johnson\"<|>\"Janssen Biotech, Inc. is owned by Johnson & Johnson through its Janssen division.\"<|>9)##\n(\"relationship\"<|>\"COVE Study Group\"<|>\"L.R. Baden\"<|>\"L.R. Baden is a member of the COVE Study Group, involved in mRNA-1273 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"COVE Study Group\"<|>\"H.M. El Sahly\"<|>\"H.M. El Sahly is a member of the COVE Study Group, involved in mRNA-1273 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"COVE Study Group\"<|>\"B. Essink\"<|>\"B. Essink is a member of the COVE Study Group, involved in mRNA-1273 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"C4591001 Clinical Trial Group\"<|>\"F.P. Polack\"<|>\"F.P. Polack is a member of the C4591001 Clinical Trial Group, involved in BNT162b2 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"C4591001 Clinical Trial Group\"<|>\"S.J. Thomas\"<|>\"S.J. Thomas is a member of the C4591001 Clinical Trial Group, involved in BNT162b2 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"C4591001 Clinical Trial Group\"<|>\"N. Kitchin\"<|>\"N. Kitchin is a member of the C4591001 Clinical Trial Group, involved in BNT162b2 vaccine trials.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"Food and Drug Administration\"<|>\"CDC and FDA jointly recommended a pause in Janssen vaccine use due to safety concerns.\"<|>9)##\n(\"relationship\"<|>\"Food and Drug Administration\"<|>\"Emergency Use Authorization\"<|>\"FDA issued Emergency Use Authorization for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"Pause in Janssen Vaccine Use\"<|>\"CDC recommended a pause in Janssen vaccine use due to CVST cases.\"<|>10)##\n(\"relationship\"<|>\"Food and Drug Administration\"<|>\"Pause in Janssen Vaccine Use\"<|>\"FDA recommended a pause in Janssen vaccine use due to CVST cases.\"<|>10)##\n(\"relationship\"<|>\"Janssen Biotech, Inc.\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Janssen Biotech, Inc. developed the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"United States\"<|>\"Janssen COVID-19 vaccine was authorized and used in the United States.\"<|>9)##\n(\"relationship\"<|>\"AstraZeneca\"<|>\"Implementation of AstraZeneca COVID-19 Vaccine\"<|>\"AstraZeneca developed and distributed the AstraZeneca COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Implementation of AstraZeneca COVID-19 Vaccine\"<|>\"Europe\"<|>\"AstraZeneca COVID-19 vaccine was implemented in Europe, with reports of thrombotic events.\"<|>9)##\n(\"relationship\"<|>\"National COVID-19 Vaccination Program\"<|>\"Israel\"<|>\"Israel implemented a national COVID-19 vaccination program, leading to reduced severe cases.\"<|>10)##\n(\"relationship\"<|>\"David K. Shay\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"David K. Shay is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Julianne Gee\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Julianne Gee is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"John R. Su\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"John R. Su is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Tanya R. Myers\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Tanya R. Myers is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Paige Marquez\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Paige Marquez is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Ruiling Liu\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Ruiling Liu is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Bicheng Zhang\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Bicheng Zhang is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Charles Licata\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Charles Licata is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Thomas A. Clark\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Thomas A. Clark is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Tom T. Shimabukuro\"<|>\"Safety Monitoring of the Janssen COVID-19 Vaccine\"<|>\"Tom T. Shimabukuro is an author of the safety monitoring report for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Pause in Janssen Vaccine Use\"<|>\"United States\"<|>\"The pause in Janssen vaccine use occurred in the United States during April 2021 due to safety concerns.\"<|>10)##\n(\"relationship\"<|>\"K. Dooling\"<|>\"Advisory Committee on Immunization Practices\"<|>\"K. Dooling is an author of ACIP recommendations for COVID-19 vaccine allocation.\"<|>9)##\n(\"relationship\"<|>\"M. Marin\"<|>\"Advisory Committee on Immunization Practices\"<|>\"M. Marin is an author of ACIP recommendations for COVID-19 vaccine allocation.\"<|>9)##\n(\"relationship\"<|>\"M. Wallace\"<|>\"Advisory Committee on Immunization Practices\"<|>\"M. Wallace is an author of ACIP recommendations for COVID-19 vaccine allocation.\"<|>9)##\n(\"relationship\"<|>\"M.L. Jackson\"<|>\"J.C. Nelson\"<|>\"M.L. Jackson and J.C. Nelson co-authored studies on influenza vaccine effectiveness.\"<|>8)##\n(\"relationship\"<|>\"E. Rinott\"<|>\"I. Youngster\"<|>\"E. Rinott and I. Youngster co-authored studies on COVID-19 patient outcomes following vaccination.\"<|>8)##\n(\"relationship\"<|>\"E. Rinott\"<|>\"Y.E. Lewis\"<|>\"E. Rinott and Y.E. Lewis co-authored studies on COVID-19 patient outcomes following vaccination.\"<|>8)##\n(\"relationship\"<|>\"C. Huang\"<|>\"L. Huang\"<|>\"C. Huang and L. Huang co-authored studies on long-term consequences of COVID-19.\"<|>8)##\n(\"relationship\"<|>\"C. Huang\"<|>\"Y. Wang\"<|>\"C. Huang and Y. Wang co-authored studies on long-term consequences of COVID-19.\"<|>8)##\n(\"relationship\"<|>\"L. Huang\"<|>\"Y. Wang\"<|>\"L. Huang and Y. Wang co-authored studies on long-term consequences of COVID-19.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "ab412233e0dde8bdc80fae38accba06d": {
    "return": "(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a federal public health agency in the United States responsible for reviewing vaccine safety data, conducting medical reviews, and providing policy guidance. In this context, CDC reviewed activities related to the Janssen COVID-19 vaccine, processed adverse event reports, and encouraged jurisdictions to offer v-safe promotional materials.\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"The Food and Drug Administration (FDA) is a federal agency responsible for regulating food and drugs in the United States. In this context, FDA collaborated with CDC to review adverse event reports and conduct medical reviews related to the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"organization\"<|>\"The Janssen COVID-19 vaccine is a single-dose vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19. As of April 21, 2021, 7.98 million doses had been administered in the United States.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the vaccine administration and safety monitoring activities described in the text took place.\")##\n(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"The Vaccine Adverse Event Reporting System (VAERS) is a national system for monitoring the safety of vaccines in the United States. VAERS received and processed adverse event reports for recipients of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"V-safe\"<|>\"organization\"<|>\"V-safe is a smartphone-based system developed by CDC to monitor vaccine safety by collecting health check-ins from vaccine recipients after vaccination. V-safe enrolled 338,765 Janssen COVID-19 vaccine recipients during the study period.\")##\n(\"entity\"<|>\"TTS\"<|>\"event\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS) is a newly defined condition involving blood clots and low platelet counts. Seventeen TTS cases were reported among Janssen COVID-19 vaccine recipients, including three non-CVST cases among women under 60 years old.\")##\n(\"entity\"<|>\"CVST\"<|>\"event\"<|>\"Cerebral Venous Sinus Thrombosis (CVST) is a rare type of blood clot in the brain. Fourteen CVST cases were confirmed among Janssen COVID-19 vaccine recipients.\")##\n(\"entity\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"Eighty-eight reports of death after receipt of the Janssen COVID-19 vaccine were reviewed by CDC and FDA, with causes including cardiac arrest, COVID-19 disease, and cerebrovascular disease. Three deaths were among patients with TTS.\")##\n(\"entity\"<|>\"Anaphylaxis after Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"Seventy-nine reports of anaphylaxis (severe allergic reaction) after Janssen COVID-19 vaccination were received, with four cases confirmed after medical review.\")##\n(\"entity\"<|>\"March-April 2021 Vaccine Administration\"<|>\"event\"<|>\"The period from March 2 to April 12, 2021, during which vaccine administration and safety monitoring activities were analyzed for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Women aged 30-39 years\"<|>\"person\"<|>\"Women in the age group 30-39 years who were recipients of the Janssen COVID-19 vaccine and experienced non-CVST TTS events.\")##\n(\"entity\"<|>\"Woman aged 50-59 years\"<|>\"person\"<|>\"A woman in the age group 50-59 years who was a recipient of the Janssen COVID-19 vaccine and experienced a non-CVST TTS event.\")##\n(\"entity\"<|>\"Decedents after Janssen COVID-19 Vaccine\"<|>\"person\"<|>\"Individuals who died after receiving the Janssen COVID-19 vaccine, including 44 females, 38 males, and 6 with unreported sex, with a median age of 69 years.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is the parent federal department overseeing agencies such as CDC and FDA, responsible for public health and safety.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication by CDC that disseminates public health information, including vaccine safety data.\")##\n\n(\"relationship\"<|>\"CDC\"<|>\"FDA\"<|>\"CDC and FDA collaborated to review adverse event reports and conduct medical reviews related to the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"VAERS\"<|>\"CDC reviewed and processed adverse event reports submitted to VAERS for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"Janssen COVID-19 Vaccine\"<|>\"VAERS received and processed adverse event reports specifically for recipients of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"V-safe\"<|>\"CDC developed and promoted v-safe as a tool for monitoring vaccine safety among Janssen COVID-19 vaccine recipients.\"<|>9)##\n(\"relationship\"<|>\"V-safe\"<|>\"Janssen COVID-19 Vaccine\"<|>\"V-safe enrolled Janssen COVID-19 vaccine recipients to monitor post-vaccination health outcomes.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"Janssen COVID-19 Vaccine\"<|>\"CDC reviewed safety data and adverse event reports for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"FDA\"<|>\"Janssen COVID-19 Vaccine\"<|>\"FDA participated in reviewing adverse event reports and medical records for Janssen COVID-19 vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Janssen COVID-19 vaccine was administered in the United States, with 7.98 million doses given as of April 21, 2021.\"<|>10)##\n(\"relationship\"<|>\"TTS\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Seventeen cases of TTS were reported among recipients of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"CVST\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Fourteen cases of CVST were confirmed among Janssen COVID-19 vaccine recipients.\"<|>9)##\n(\"relationship\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Eighty-eight deaths were reported after administration of the Janssen COVID-19 vaccine, with causes reviewed by CDC and FDA.\"<|>10)##\n(\"relationship\"<|>\"Anaphylaxis after Janssen COVID-19 Vaccine\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Seventy-nine reports of anaphylaxis were received after Janssen COVID-19 vaccination, with four cases confirmed.\"<|>9)##\n(\"relationship\"<|>\"March-April 2021 Vaccine Administration\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The period from March 2 to April 12, 2021, was analyzed for vaccine administration and safety monitoring of the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Women aged 30-39 years\"<|>\"TTS\"<|>\"Two cases of non-CVST TTS occurred among women aged 30-39 years after receiving the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Woman aged 50-59 years\"<|>\"TTS\"<|>\"One case of non-CVST TTS occurred in a woman aged 50-59 years after receiving the Janssen COVID-19 vaccine.\"<|>7)##\n(\"relationship\"<|>\"Decedents after Janssen COVID-19 Vaccine\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"Decedents are individuals who died after receiving the Janssen COVID-19 vaccine, as reported and reviewed by CDC and FDA.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"CDC\"<|>\"CDC operates under the US Department of Health and Human Services, which oversees public health agencies.\"<|>8)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"FDA\"<|>\"FDA operates under the US Department of Health and Human Services, which oversees public health agencies.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report to disseminate public health information, including vaccine safety data.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"CDC\"<|>\"CDC is a federal public health agency based in the United States, responsible for vaccine safety monitoring.\"<|>10)##\n(\"relationship\"<|>\"United States\"<|>\"FDA\"<|>\"FDA is a federal regulatory agency based in the United States, responsible for vaccine safety monitoring.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "4f64311072c9a4ee841b600abcc6eb73": {
    "return": "(\"entity\"<|>\"University of California Los Angeles\"<|>\"organization\"<|>\"A major research university in California, one of the medical centers participating in the multisite evaluation of COVID-19 vaccine effectiveness among adults aged 65 years.\")##\n(\"entity\"<|>\"Stanford University\"<|>\"organization\"<|>\"A prestigious university in California, included as a participating medical center in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"UCHealth University of Colorado Hospital\"<|>\"organization\"<|>\"A leading hospital in Colorado, part of the multisite network evaluating COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"Johns Hopkins Hospital\"<|>\"organization\"<|>\"A renowned hospital in Maryland, involved in the study of COVID-19 vaccine effectiveness among older adults.\")##\n(\"entity\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"organization\"<|>\"A medical center in Massachusetts, participating in the COVID-19 vaccine effectiveness evaluation.\")##\n(\"entity\"<|>\"Baystate Medical Center\"<|>\"organization\"<|>\"A hospital in Massachusetts, included in the multisite COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"University of Michigan\"<|>\"organization\"<|>\"A major university in Michigan, with affiliated hospitals participating in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Henry Ford\"<|>\"organization\"<|>\"A healthcare organization in Michigan, involved in the COVID-19 vaccine effectiveness evaluation.\")##\n(\"entity\"<|>\"St. Joseph\"<|>\"organization\"<|>\"A hospital in Michigan, part of the multisite COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Hennepin County Medical Center\"<|>\"organization\"<|>\"A hospital in Minnesota, participating in the evaluation of COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"Montefiore Healthcare Center\"<|>\"organization\"<|>\"A healthcare center in New York, included in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Wake Forest University\"<|>\"organization\"<|>\"A university in North Carolina, with medical centers participating in the COVID-19 vaccine effectiveness evaluation.\")##\n(\"entity\"<|>\"Ohio State University\"<|>\"organization\"<|>\"A university in Ohio, with affiliated hospitals involved in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Oregon Health & Science University\"<|>\"organization\"<|>\"A university and medical center in Oregon, participating in the COVID-19 vaccine effectiveness evaluation.\")##\n(\"entity\"<|>\"University of Pittsburgh Medical Center\"<|>\"organization\"<|>\"A large medical center in Pennsylvania, with multiple hospitals involved in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Shadyside Hospital\"<|>\"organization\"<|>\"A hospital in Pennsylvania, part of the University of Pittsburgh Medical Center network, participating in the study.\")##\n(\"entity\"<|>\"Mercy Hospital\"<|>\"organization\"<|>\"A hospital in Pennsylvania, part of the University of Pittsburgh Medical Center network, included in the study.\")##\n(\"entity\"<|>\"Passavant Hospital\"<|>\"organization\"<|>\"A hospital in Pennsylvania, part of the University of Pittsburgh Medical Center network, participating in the study.\")##\n(\"entity\"<|>\"St. Margaret Hospital\"<|>\"organization\"<|>\"A hospital in Pennsylvania, part of the University of Pittsburgh Medical Center network, included in the study.\")##\n(\"entity\"<|>\"Presbyterian Hospital\"<|>\"organization\"<|>\"A hospital in Pennsylvania, part of the University of Pittsburgh Medical Center network, participating in the study.\")##\n(\"entity\"<|>\"Vanderbilt University Medical Center\"<|>\"organization\"<|>\"A medical center in Tennessee, involved in the COVID-19 vaccine effectiveness evaluation.\")##\n(\"entity\"<|>\"Baylor Scott & White Medical Center\"<|>\"organization\"<|>\"A medical center in Texas, with multiple locations (Temple, Round Rock, Hillcrest/Waco) participating in the study.\")##\n(\"entity\"<|>\"Intermountain Health\"<|>\"organization\"<|>\"A healthcare organization in Utah, included in the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"HAIVEN Network\"<|>\"organization\"<|>\"The Hospitalized Adult Influenza Vaccine Effectiveness Network, one of two networks enrolling patients for the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"IVY Network\"<|>\"organization\"<|>\"The Influenza and Other Viruses in the Acutely Ill Network, one of two networks enrolling patients for the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"A pharmaceutical company whose COVID-19 vaccine was evaluated for effectiveness against hospitalization in adults aged 65 years.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"A biotechnology company whose COVID-19 vaccine was evaluated for effectiveness against hospitalization in adults aged 65 years.\")##\n(\"entity\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"organization\"<|>\"A U.S. government system (VAERS) for detecting and reporting possible adverse events associated with vaccines.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The CDC, a U.S. federal agency responsible for public health, involved in reporting and evaluating COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"A federal department overseeing health-related agencies, including the CDC, involved in COVID-19 vaccine evaluation and reporting.\")##\n(\"entity\"<|>\"COVID-19 Hospitalization\"<|>\"event\"<|>\"Hospitalization due to COVID-19 among adults aged 65 years, the primary outcome measured in the vaccine effectiveness study.\")##\n(\"entity\"<|>\"COVID-19 Vaccination\"<|>\"event\"<|>\"The administration of COVID-19 vaccines (Pfizer-BioNTech or Moderna) to adults aged 65 years, evaluated for effectiveness against hospitalization.\")##\n(\"entity\"<|>\"Clinical Trials\"<|>\"event\"<|>\"Randomized trials conducted to determine the efficacy of COVID-19 vaccines, referenced as supporting evidence for vaccine effectiveness.\")##\n(\"entity\"<|>\"Postmarketing Observational Studies\"<|>\"event\"<|>\"Studies conducted after vaccine approval to assess real-world effectiveness of COVID-19 vaccines against hospitalization.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The country where the multisite evaluation of COVID-19 vaccine effectiveness was conducted, involving 24 medical centers in 14 states.\")##\n(\"entity\"<|>\"California\"<|>\"geo\"<|>\"A U.S. state where University of California Los Angeles and Stanford University participated in the study.\")##\n(\"entity\"<|>\"Colorado\"<|>\"geo\"<|>\"A U.S. state where UCHealth University of Colorado Hospital participated in the study.\")##\n(\"entity\"<|>\"Maryland\"<|>\"geo\"<|>\"A U.S. state where Johns Hopkins Hospital participated in the study.\")##\n(\"entity\"<|>\"Massachusetts\"<|>\"geo\"<|>\"A U.S. state where Beth Israel Deaconess Medical Center and Baystate Medical Center participated in the study.\")##\n(\"entity\"<|>\"Michigan\"<|>\"geo\"<|>\"A U.S. state where University of Michigan, Henry Ford, and St. Joseph participated in the study.\")##\n(\"entity\"<|>\"Minnesota\"<|>\"geo\"<|>\"A U.S. state where Hennepin County Medical Center participated in the study.\")##\n(\"entity\"<|>\"New York\"<|>\"geo\"<|>\"A U.S. state where Montefiore Healthcare Center participated in the study.\")##\n(\"entity\"<|>\"North Carolina\"<|>\"geo\"<|>\"A U.S. state where Wake Forest University participated in the study.\")##\n(\"entity\"<|>\"Ohio\"<|>\"geo\"<|>\"A U.S. state where Ohio State University participated in the study.\")##\n(\"entity\"<|>\"Oregon\"<|>\"geo\"<|>\"A U.S. state where Oregon Health & Science University participated in the study.\")##\n(\"entity\"<|>\"Pennsylvania\"<|>\"geo\"<|>\"A U.S. state where University of Pittsburgh Medical Center and its hospitals participated in the study.\")##\n(\"entity\"<|>\"Tennessee\"<|>\"geo\"<|>\"A U.S. state where Vanderbilt University Medical Center participated in the study.\")##\n(\"entity\"<|>\"Texas\"<|>\"geo\"<|>\"A U.S. state where Baylor Scott & White Medical Center participated in the study.\")##\n(\"entity\"<|>\"Utah\"<|>\"geo\"<|>\"A U.S. state where Intermountain Health participated in the study.\")##\n(\"relationship\"<|>\"University of California Los Angeles\"<|>\"California\"<|>\"UCLA is located in California and participated in the COVID-19 vaccine effectiveness study in that state.\"<|>10)##\n(\"relationship\"<|>\"Stanford University\"<|>\"California\"<|>\"Stanford University is located in California and participated in the COVID-19 vaccine effectiveness study in that state.\"<|>10)##\n(\"relationship\"<|>\"UCHealth University of Colorado Hospital\"<|>\"Colorado\"<|>\"UCHealth University of Colorado Hospital is located in Colorado and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Johns Hopkins Hospital\"<|>\"Maryland\"<|>\"Johns Hopkins Hospital is located in Maryland and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"Massachusetts\"<|>\"Beth Israel Deaconess Medical Center is located in Massachusetts and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Baystate Medical Center\"<|>\"Massachusetts\"<|>\"Baystate Medical Center is located in Massachusetts and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"University of Michigan\"<|>\"Michigan\"<|>\"University of Michigan is located in Michigan and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Henry Ford\"<|>\"Michigan\"<|>\"Henry Ford is located in Michigan and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"St. Joseph\"<|>\"Michigan\"<|>\"St. Joseph is located in Michigan and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Hennepin County Medical Center\"<|>\"Minnesota\"<|>\"Hennepin County Medical Center is located in Minnesota and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Montefiore Healthcare Center\"<|>\"New York\"<|>\"Montefiore Healthcare Center is located in New York and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Wake Forest University\"<|>\"North Carolina\"<|>\"Wake Forest University is located in North Carolina and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Ohio State University\"<|>\"Ohio\"<|>\"Ohio State University is located in Ohio and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Oregon Health & Science University\"<|>\"Oregon\"<|>\"Oregon Health & Science University is located in Oregon and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"University of Pittsburgh Medical Center\"<|>\"Pennsylvania\"<|>\"UPMC is located in Pennsylvania and its hospitals participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Shadyside Hospital\"<|>\"Pennsylvania\"<|>\"Shadyside Hospital is located in Pennsylvania and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Mercy Hospital\"<|>\"Pennsylvania\"<|>\"Mercy Hospital is located in Pennsylvania and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Passavant Hospital\"<|>\"Pennsylvania\"<|>\"Passavant Hospital is located in Pennsylvania and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"St. Margaret Hospital\"<|>\"Pennsylvania\"<|>\"St. Margaret Hospital is located in Pennsylvania and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Presbyterian Hospital\"<|>\"Pennsylvania\"<|>\"Presbyterian Hospital is located in Pennsylvania and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Vanderbilt University Medical Center\"<|>\"Tennessee\"<|>\"Vanderbilt University Medical Center is located in Tennessee and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Baylor Scott & White Medical Center\"<|>\"Texas\"<|>\"Baylor Scott & White Medical Center is located in Texas and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"Intermountain Health\"<|>\"Utah\"<|>\"Intermountain Health is located in Utah and participated in the study there.\"<|>10)##\n(\"relationship\"<|>\"HAIVEN Network\"<|>\"COVID-19 Hospitalization\"<|>\"HAIVEN Network enrolled patients with COVID-19-like illness to evaluate vaccine effectiveness against hospitalization.\"<|>9)##\n(\"relationship\"<|>\"IVY Network\"<|>\"COVID-19 Hospitalization\"<|>\"IVY Network enrolled patients with COVID-19-like illness to evaluate vaccine effectiveness against hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19 Vaccination\"<|>\"Pfizer-BioNTech is the manufacturer of one of the COVID-19 vaccines evaluated for effectiveness against hospitalization.\"<|>10)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19 Vaccination\"<|>\"Moderna is the manufacturer of one of the COVID-19 vaccines evaluated for effectiveness against hospitalization.\"<|>10)##\n(\"relationship\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"COVID-19 Vaccination\"<|>\"VAERS is used to detect and report adverse events associated with COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-19 Vaccination\"<|>\"CDC is involved in evaluating and reporting on COVID-19 vaccine effectiveness and safety.\"<|>9)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC operates under the US Department of Health and Human Services, which oversees public health activities including vaccine evaluation.\"<|>10)##\n(\"relationship\"<|>\"Clinical Trials\"<|>\"COVID-19 Vaccination\"<|>\"Clinical trials provided initial evidence of COVID-19 vaccine efficacy, supporting real-world effectiveness findings.\"<|>9)##\n(\"relationship\"<|>\"Postmarketing Observational Studies\"<|>\"COVID-19 Vaccination\"<|>\"Postmarketing observational studies assess real-world effectiveness of COVID-19 vaccines after approval.\"<|>9)##\n(\"relationship\"<|>\"United States\"<|>\"COVID-19 Vaccination\"<|>\"COVID-19 vaccination and effectiveness studies were conducted in the United States across multiple states and medical centers.\"<|>10)##\n(\"relationship\"<|>\"United States\"<|>\"COVID-19 Hospitalization\"<|>\"COVID-19 hospitalization data was collected from medical centers across the United States for vaccine effectiveness evaluation.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "874939c19551774c034fe37984362483": {
    "return": "(\"entity\"<|>\"See I\"<|>\"person\"<|>\"See I is an author involved in the publication of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\" )##\n(\"entity\"<|>\"Su JR\"<|>\"person\"<|>\"Su JR is an author and contributor to multiple reports and studies related to vaccine safety, including US case reports and updated recommendations for Janssen COVID-19 vaccine.\" )##\n(\"entity\"<|>\"Lale A\"<|>\"person\"<|>\"Lale A is an author involved in US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\" )##\n(\"entity\"<|>\"Shimabukuro TT\"<|>\"person\"<|>\"Shimabukuro TT is an author and medical professional involved in safety monitoring in VAERS and in reports related to COVID-19 vaccine adverse events.\" )##\n(\"entity\"<|>\"Nguyen M\"<|>\"person\"<|>\"Nguyen M is an author involved in safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).\" )##\n(\"entity\"<|>\"Martin D\"<|>\"person\"<|>\"Martin D is an author involved in safety monitoring in VAERS.\" )##\n(\"entity\"<|>\"DeStefano F\"<|>\"person\"<|>\"DeStefano F is an author involved in safety monitoring in VAERS.\" )##\n(\"entity\"<|>\"MacNeil JR\"<|>\"person\"<|>\"MacNeil JR is an author involved in updated recommendations for the use of Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome.\" )##\n(\"entity\"<|>\"Broder KR\"<|>\"person\"<|>\"Broder KR is an author involved in updated recommendations for the use of Janssen COVID-19 vaccine.\" )##\n(\"entity\"<|>\"Anne M. Hause\"<|>\"person\"<|>\"Anne M. Hause, PhD, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination at five US mass vaccination sites.\" )##\n(\"entity\"<|>\"Julianne Gee\"<|>\"person\"<|>\"Julianne Gee, MPH, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Tara Johnson\"<|>\"person\"<|>\"Tara Johnson, MPH, MS, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Amelia Jazwa\"<|>\"person\"<|>\"Amelia Jazwa, MSPH, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Paige Marquez\"<|>\"person\"<|>\"Paige Marquez, MSPH, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Elaine Miller\"<|>\"person\"<|>\"Elaine Miller, MPH, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"John Su\"<|>\"person\"<|>\"John Su, MD, PhD, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Tom T. Shimabukuro\"<|>\"person\"<|>\"Tom T. Shimabukuro, MD, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"David K. Shay\"<|>\"person\"<|>\"David K. Shay, MD, is an author of the report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\" )##\n(\"entity\"<|>\"Janssen (Johnson & Johnson)\"<|>\"organization\"<|>\"Janssen, a subsidiary of Johnson & Johnson, is the manufacturer of the Janssen COVID-19 vaccine, which is the subject of safety monitoring and adverse event reports.\" )##\n(\"entity\"<|>\"Food and Drug Administration (FDA)\"<|>\"organization\"<|>\"The FDA is a US federal agency responsible for authorizing the emergency use of vaccines, including the Janssen COVID-19 vaccine, and for managing vaccine safety monitoring programs.\" )##\n(\"entity\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"organization\"<|>\"The CDC is a US federal agency responsible for public health, including monitoring vaccine safety, investigating adverse events, and managing the Vaccine Adverse Event Reporting System (VAERS).\" )##\n(\"entity\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"organization\"<|>\"ACIP is a committee that provides updated recommendations for the use of vaccines, including the Janssen COVID-19 vaccine, based on safety data.\" )##\n(\"entity\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"organization\"<|>\"VAERS is a national passive surveillance system managed by CDC and FDA that monitors adverse events after all vaccinations in the US.\" )##\n(\"entity\"<|>\"Medical Dictionary for Regulatory Activities (MedDRA)\"<|>\"organization\"<|>\"MedDRA is a medical terminology organization whose preferred terms are used to code signs and symptoms in VAERS reports.\" )##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where the mass vaccination sites and vaccine safety monitoring activities described in the report took place.\" )##\n(\"entity\"<|>\"Five US Mass Vaccination Sites\"<|>\"geo\"<|>\"Five mass vaccination sites located in different states in the United States where clusters of anxiety-related adverse events after Janssen COVID-19 vaccination were reported.\" )##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"The administration of the Janssen COVID-19 vaccine is the event under investigation for anxiety-related adverse events and syncope at mass vaccination sites.\" )##\n(\"entity\"<|>\"Influenza Vaccine Administration (2019-2020 Season)\"<|>\"event\"<|>\"The administration of influenza vaccines during the 2019-2020 season is referenced for comparison of adverse event rates with the Janssen COVID-19 vaccine.\" )##\n(\"entity\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"event\"<|>\"Clusters of anxiety-related adverse events, including syncope, reported after administration of the Janssen COVID-19 vaccine at five US mass vaccination sites in April 2021.\" )##\n(\"entity\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"event\"<|>\"A syndrome involving blood clots and low platelet counts reported among recipients of the Janssen COVID-19 vaccine, prompting updated recommendations from ACIP.\" )##\n(\"entity\"<|>\"Syncope\"<|>\"event\"<|>\"Syncope (fainting) is an anxiety-related adverse event reported after administration of the Janssen COVID-19 vaccine and compared to rates after influenza vaccination.\" )##\n\n(\"relationship\"<|>\"Janssen (Johnson & Johnson)\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Janssen (Johnson & Johnson) is the manufacturer of the Janssen COVID-19 vaccine, which is the subject of safety monitoring and adverse event reports.\"<|>10)##\n(\"relationship\"<|>\"Food and Drug Administration (FDA)\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The FDA authorized the emergency use of the Janssen COVID-19 vaccine and is involved in its safety monitoring.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The CDC received reports of adverse events after administration of the Janssen COVID-19 vaccine and conducted investigations at mass vaccination sites.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"The CDC manages VAERS, which monitors adverse events after vaccinations, including the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Food and Drug Administration (FDA)\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"The FDA co-manages VAERS with the CDC to monitor vaccine safety.\"<|>10)##\n(\"relationship\"<|>\"Advisory Committee on Immunization Practices (ACIP)\"<|>\"Janssen COVID-19 Vaccine\"<|>\"ACIP issued updated recommendations for the use of the Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome.\"<|>8)##\n(\"relationship\"<|>\"Medical Dictionary for Regulatory Activities (MedDRA)\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"MedDRA provides preferred terms for coding signs and symptoms in VAERS reports.\"<|>7)##\n(\"relationship\"<|>\"Five US Mass Vaccination Sites\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Clusters of anxiety-related adverse events were reported at five US mass vaccination sites after administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Five US Mass Vaccination Sites\"<|>\"The CDC investigated anxiety-related adverse event clusters at five US mass vaccination sites.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Anxiety-related adverse event clusters occurred after administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"Thrombosis with thrombocytopenia syndrome was reported among recipients of the Janssen COVID-19 vaccine, prompting safety reviews and updated recommendations.\"<|>9)##\n(\"relationship\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Syncope\"<|>\"Syncope was reported as an anxiety-related adverse event after administration of the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Influenza Vaccine Administration (2019-2020 Season)\"<|>\"Syncope\"<|>\"Syncope rates after influenza vaccine administration were reviewed for comparison with rates after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"United States\"<|>\"Five US Mass Vaccination Sites\"<|>\"The five mass vaccination sites are located in different states within the United States.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Anne M. Hause\"<|>\"Anne M. Hause is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Julianne Gee\"<|>\"Julianne Gee is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Tara Johnson\"<|>\"Tara Johnson is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Amelia Jazwa\"<|>\"Amelia Jazwa is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Paige Marquez\"<|>\"Paige Marquez is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Elaine Miller\"<|>\"Elaine Miller is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"John Su\"<|>\"John Su is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"Tom T. Shimabukuro\"<|>\"Tom T. Shimabukuro is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"David K. Shay\"<|>\"David K. Shay is an author of a CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"See I\"<|>\"Su JR\"<|>\"See I and Su JR are co-authors of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>7)##\n(\"relationship\"<|>\"See I\"<|>\"Lale A\"<|>\"See I and Lale A are co-authors of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>7)##\n(\"relationship\"<|>\"Su JR\"<|>\"MacNeil JR\"<|>\"Su JR and MacNeil JR are co-authors of updated recommendations for the use of Janssen COVID-19 vaccine.\"<|>7)##\n(\"relationship\"<|>\"Su JR\"<|>\"Broder KR\"<|>\"Su JR and Broder KR are co-authors of updated recommendations for the use of Janssen COVID-19 vaccine.\"<|>7)##\n(\"relationship\"<|>\"Shimabukuro TT\"<|>\"Nguyen M\"<|>\"Shimabukuro TT and Nguyen M are co-authors of safety monitoring in VAERS.\"<|>7)##\n(\"relationship\"<|>\"Shimabukuro TT\"<|>\"Martin D\"<|>\"Shimabukuro TT and Martin D are co-authors of safety monitoring in VAERS.\"<|>7)##\n(\"relationship\"<|>\"Shimabukuro TT\"<|>\"DeStefano F\"<|>\"Shimabukuro TT and DeStefano F are co-authors of safety monitoring in VAERS.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Julianne Gee\"<|>\"Anne M. Hause and Julianne Gee are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Tara Johnson\"<|>\"Anne M. Hause and Tara Johnson are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Amelia Jazwa\"<|>\"Anne M. Hause and Amelia Jazwa are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Paige Marquez\"<|>\"Anne M. Hause and Paige Marquez are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Elaine Miller\"<|>\"Anne M. Hause and Elaine Miller are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"John Su\"<|>\"Anne M. Hause and John Su are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"Tom T. Shimabukuro\"<|>\"Anne M. Hause and Tom T. Shimabukuro are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Anne M. Hause\"<|>\"David K. Shay\"<|>\"Anne M. Hause and David K. Shay are co-authors of the CDC report on anxiety-related adverse event clusters after Janssen COVID-19 vaccination.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "ed0ddb2329271f404d0510166524ca46": {
    "return": "(\"entity\"<|>\"ChAdOx1 nCoV-19 Vaccine\"<|>\"event\"<|>\"ChAdOx1 nCoV-19 Vaccine is a COVID-19 vaccine developed by AstraZeneca and Oxford, referenced in the context of thrombotic and thrombocytopenic adverse events.\")##\n(\"entity\"<|>\"Ad26.COV2.S Vaccine\"<|>\"event\"<|>\"Ad26.COV2.S Vaccine is the technical name for the Janssen COVID-19 vaccine, referenced in studies and case reports about vaccine safety and adverse events.\")##\n(\"entity\"<|>\"N Engl J Med\"<|>\"organization\"<|>\"N Engl J Med (New England Journal of Medicine) is a prominent medical journal publishing research and case studies, cited multiple times in the report.\")##\n(\"entity\"<|>\"JAMA\"<|>\"organization\"<|>\"JAMA (Journal of the American Medical Association) is a leading medical journal, cited for case reports on vaccine adverse events.\")##\n(\"entity\"<|>\"PMID: 33882225\"<|>\"event\"<|>\"PMID: 33882225 is the PubMed identifier for a referenced study on the safety and efficacy of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"PMID: 33661860\"<|>\"event\"<|>\"PMID: 33661860 is the PubMed identifier for a referenced report on ACIP's interim recommendation for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"PMID: 33835769\"<|>\"event\"<|>\"PMID: 33835769 is the PubMed identifier for a referenced study on thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"PMID: 33835768\"<|>\"event\"<|>\"PMID: 33835768 is the PubMed identifier for a referenced study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"PMID: 33861525\"<|>\"event\"<|>\"PMID: 33861525 is the PubMed identifier for a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"March 2 to April 21, 2021\"<|>\"event\"<|>\"March 2 to April 21, 2021 is the time period during which US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination were collected.\")##\n(\"entity\"<|>\"April 9, 2021\"<|>\"event\"<|>\"April 9, 2021 is the publication date for referenced studies on ChAdOx1 nCoV-19 vaccine adverse events.\")##\n(\"entity\"<|>\"April 16, 2021\"<|>\"event\"<|>\"April 16, 2021 is the publication date for a referenced study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\")##\n(\"entity\"<|>\"April 21, 2021\"<|>\"event\"<|>\"April 21, 2021 is the publication date for a referenced study on the safety and efficacy of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"April 30, 2021\"<|>\"event\"<|>\"April 30, 2021 is the publication date for a referenced JAMA case report on cerebral venous sinus thrombosis after Ad26.COV2.S vaccination.\")##\n(\"entity\"<|>\"February 27, 2021\"<|>\"event\"<|>\"February 27, 2021 is the date the Emergency Use Authorization for the Janssen COVID-19 vaccine was granted.\")##\n(\"entity\"<|>\"April 12-23, 2021\"<|>\"event\"<|>\"April 12-23, 2021 is the period during which use of the Janssen COVID-19 vaccine was paused after detection of CVST cases.\")##\n(\"entity\"<|>\"Fact Sheet for Healthcare Providers\"<|>\"event\"<|>\"Fact Sheet for Healthcare Providers is an official FDA document providing guidance for vaccination providers regarding the Emergency Use Authorization of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"https://www.fda.gov/media/146304/download\"<|>\"event\"<|>\"https://www.fda.gov/media/146304/download is the URL for the FDA fact sheet for healthcare providers administering the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"https://doi.org/10.15585/mmwr.mm7009e4\"<|>\"event\"<|>\"https://doi.org/10.15585/mmwr.mm7009e4 is the DOI link for the MMWR report on ACIP's interim recommendation for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"https://www.cdc.gov/media/releases/2021/s0413JJ-vaccine.html\"<|>\"event\"<|>\"https://www.cdc.gov/media/releases/2021/s0413JJ-vaccine.html is the URL for the joint CDC and FDA statement on the Johnson & Johnson COVID-19 vaccine.\")##\n(\"entity\"<|>\"https://doi.org/10.1001/jama\"<|>\"event\"<|>\"https://doi.org/10.1001/jama is the DOI link for the JAMA case report on cerebral venous sinus thrombosis after Ad26.COV2.S vaccination.\")##\n\n(\"relationship\"<|>\"ChAdOx1 nCoV-19 Vaccine\"<|>\"AstraZeneca\"<|>\"ChAdOx1 nCoV-19 Vaccine is developed by AstraZeneca in collaboration with Oxford University.\"<|>10)##\n(\"relationship\"<|>\"ChAdOx1 nCoV-19 Vaccine\"<|>\"Thrombotic Thrombocytopenia\"<|>\"Thrombotic thrombocytopenia is reported as an adverse event following ChAdOx1 nCoV-19 vaccination.\"<|>9)##\n(\"relationship\"<|>\"Ad26.COV2.S Vaccine\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Ad26.COV2.S Vaccine is the technical name for the Janssen COVID-19 vaccine; both refer to the same product.\"<|>10)##\n(\"relationship\"<|>\"N Engl J Med\"<|>\"Sadoff J\"<|>\"N Engl J Med published research authored by Sadoff J on the safety and efficacy of the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"N Engl J Med\"<|>\"Greinacher A\"<|>\"N Engl J Med published research authored by Greinacher A on thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"JAMA\"<|>\"See I\"<|>\"JAMA published case reports authored by See I on cerebral venous sinus thrombosis after Ad26.COV2.S vaccination.\"<|>8)##\n(\"relationship\"<|>\"Fact Sheet for Healthcare Providers\"<|>\"Food and Drug Administration (FDA)\"<|>\"FDA published the Fact Sheet for Healthcare Providers for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"https://www.fda.gov/media/146304/download\"<|>\"Fact Sheet for Healthcare Providers\"<|>\"This URL links directly to the FDA Fact Sheet for Healthcare Providers for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"https://doi.org/10.15585/mmwr.mm7009e4\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"This DOI links to the MMWR report on ACIP's interim recommendation for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"https://www.cdc.gov/media/releases/2021/s0413JJ-vaccine.html\"<|>\"Centers for Disease Control and Prevention (CDC)\"<|>\"This URL links to the CDC's media release about the Johnson & Johnson COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"https://doi.org/10.1001/jama\"<|>\"JAMA\"<|>\"This DOI links to the JAMA case report on cerebral venous sinus thrombosis after Ad26.COV2.S vaccination.\"<|>10)##\n(\"relationship\"<|>\"PMID: 33882225\"<|>\"Sadoff J\"<|>\"PMID: 33882225 is the PubMed identifier for Sadoff J's study on the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"PMID: 33661860\"<|>\"Oliver SE\"<|>\"PMID: 33661860 is the PubMed identifier for Oliver SE's report on ACIP's interim recommendation for the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"PMID: 33835769\"<|>\"Greinacher A\"<|>\"PMID: 33835769 is the PubMed identifier for Greinacher A's study on thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\"<|>10)##\n(\"relationship\"<|>\"PMID: 33835768\"<|>\"Schultz NH\"<|>\"PMID: 33835768 is the PubMed identifier for Schultz NH's study on thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.\"<|>10)##\n(\"relationship\"<|>\"PMID: 33861525\"<|>\"Scully M\"<|>\"PMID: 33861525 is the PubMed identifier for Scully M's study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\"<|>10)##\n(\"relationship\"<|>\"March 2 to April 21, 2021\"<|>\"See I\"<|>\"See I's case reports on CVST after Ad26.COV2.S vaccination were collected during March 2 to April 21, 2021.\"<|>9)##\n(\"relationship\"<|>\"April 9, 2021\"<|>\"Greinacher A\"<|>\"April 9, 2021 is the publication date for Greinacher A's study on ChAdOx1 nCoV-19 vaccine adverse events.\"<|>9)##\n(\"relationship\"<|>\"April 16, 2021\"<|>\"Scully M\"<|>\"April 16, 2021 is the publication date for Scully M's study on pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.\"<|>9)##\n(\"relationship\"<|>\"April 21, 2021\"<|>\"Sadoff J\"<|>\"April 21, 2021 is the publication date for Sadoff J's study on the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"April 30, 2021\"<|>\"See I\"<|>\"April 30, 2021 is the publication date for See I's JAMA case report on CVST after Ad26.COV2.S vaccination.\"<|>9)##\n(\"relationship\"<|>\"February 27, 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"February 27, 2021 is the date the Janssen COVID-19 vaccine received Emergency Use Authorization.\"<|>10)##\n(\"relationship\"<|>\"April 12-23, 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"April 12-23, 2021 is the period during which use of the Janssen COVID-19 vaccine was paused due to CVST cases.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "4f197bdf260b354f0cab08dcba22c42c": {
    "return": "(\"entity\"<|>\"Valerie Aston\"<|>\"person\"<|>\"Valerie Aston is affiliated with Intermountain Medical Center in Salt Lake City, Utah, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Intermountain Medical Center\"<|>\"organization\"<|>\"Intermountain Medical Center is a major healthcare facility located in Salt Lake City, Utah, involved in clinical care and research.\")##\n(\"entity\"<|>\"Salt Lake City\"<|>\"geo\"<|>\"Salt Lake City is a city in Utah, home to Intermountain Medical Center and a hub for medical research.\")##\n(\"entity\"<|>\"Utah\"<|>\"geo\"<|>\"Utah is a state in the western United States, location of Salt Lake City and Intermountain Medical Center.\")##\n(\"entity\"<|>\"Marianne Bernardo\"<|>\"person\"<|>\"Marianne Bernardo is affiliated with Reagan-UCLA Medical Center in Los Angeles, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Reagan-UCLA Medical Center\"<|>\"organization\"<|>\"Reagan-UCLA Medical Center is a prominent medical facility in Los Angeles, California, associated with UCLA and engaged in healthcare and research.\")##\n(\"entity\"<|>\"Los Angeles\"<|>\"geo\"<|>\"Los Angeles is a major city in California, location of Reagan-UCLA Medical Center.\")##\n(\"entity\"<|>\"California\"<|>\"geo\"<|>\"California is a state in the western United States, location of Los Angeles and Reagan-UCLA Medical Center.\")##\n(\"entity\"<|>\"Robert Bowers\"<|>\"person\"<|>\"Robert Bowers is affiliated with Intermountain Medical Center in Salt Lake City, Utah, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Leslie De Souza\"<|>\"person\"<|>\"Leslie De Souza is affiliated with Baystate Medical Center in Springfield, Massachusetts, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Baystate Medical Center\"<|>\"organization\"<|>\"Baystate Medical Center is a healthcare facility located in Springfield, Massachusetts, involved in clinical care and research.\")##\n(\"entity\"<|>\"Springfield\"<|>\"geo\"<|>\"Springfield is a city in Massachusetts, location of Baystate Medical Center.\")##\n(\"entity\"<|>\"Massachusetts\"<|>\"geo\"<|>\"Massachusetts is a state in the northeastern United States, location of Springfield and Baystate Medical Center.\")##\n(\"entity\"<|>\"Jennifer Friedel\"<|>\"person\"<|>\"Jennifer Friedel is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"University of Colorado School of Medicine\"<|>\"organization\"<|>\"University of Colorado School of Medicine is a medical school located in Aurora, Colorado, engaged in medical education and research.\")##\n(\"entity\"<|>\"Aurora\"<|>\"geo\"<|>\"Aurora is a city in Colorado, location of University of Colorado School of Medicine.\")##\n(\"entity\"<|>\"Colorado\"<|>\"geo\"<|>\"Colorado is a state in the western United States, location of Aurora and University of Colorado School of Medicine.\")##\n(\"entity\"<|>\"Kevin Gardner\"<|>\"person\"<|>\"Kevin Gardner is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Stanford University School of Medicine\"<|>\"organization\"<|>\"Stanford University School of Medicine is a leading medical school located in Palo Alto, California, engaged in medical education and research.\")##\n(\"entity\"<|>\"Palo Alto\"<|>\"geo\"<|>\"Palo Alto is a city in California, location of Stanford University School of Medicine.\")##\n(\"entity\"<|>\"Jennifer Goff\"<|>\"person\"<|>\"Jennifer Goff is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Alexandra June Gordon\"<|>\"person\"<|>\"Alexandra June Gordon is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Audrey Hendrickson\"<|>\"person\"<|>\"Audrey Hendrickson is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Hennepin County Medical Center\"<|>\"organization\"<|>\"Hennepin County Medical Center is a healthcare facility located in Minneapolis, Minnesota, involved in clinical care and research.\")##\n(\"entity\"<|>\"Minneapolis\"<|>\"geo\"<|>\"Minneapolis is a city in Minnesota, location of Hennepin County Medical Center.\")##\n(\"entity\"<|>\"Minnesota\"<|>\"geo\"<|>\"Minnesota is a state in the northern United States, location of Minneapolis and Hennepin County Medical Center.\")##\n(\"entity\"<|>\"Madeline Hicks\"<|>\"person\"<|>\"Madeline Hicks is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"organization\"<|>\"Wake Forest University Baptist Medical Center is a healthcare facility located in Winston-Salem, North Carolina, involved in clinical care and research.\")##\n(\"entity\"<|>\"Winston-Salem\"<|>\"geo\"<|>\"Winston-Salem is a city in North Carolina, location of Wake Forest University Baptist Medical Center.\")##\n(\"entity\"<|>\"North Carolina\"<|>\"geo\"<|>\"North Carolina is a state in the southeastern United States, location of Winston-Salem and Wake Forest University Baptist Medical Center.\")##\n(\"entity\"<|>\"Michelle Howell\"<|>\"person\"<|>\"Michelle Howell is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jakea Johnson\"<|>\"person\"<|>\"Jakea Johnson is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Vanderbilt University Medical Center\"<|>\"organization\"<|>\"Vanderbilt University Medical Center is a healthcare facility located in Nashville, Tennessee, involved in clinical care and research.\")##\n(\"entity\"<|>\"Nashville\"<|>\"geo\"<|>\"Nashville is a city in Tennessee, location of Vanderbilt University Medical Center.\")##\n(\"entity\"<|>\"Tennessee\"<|>\"geo\"<|>\"Tennessee is a state in the southeastern United States, location of Nashville and Vanderbilt University Medical Center.\")##\n(\"entity\"<|>\"Jeffrey Jorgensen\"<|>\"person\"<|>\"Jeffrey Jorgensen is affiliated with Intermountain Medical Center in Salt Lake City, Utah, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Sarah Karow\"<|>\"person\"<|>\"Sarah Karow is affiliated with Ohio State University Wexner Medical Center in Columbus, Ohio, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Ohio State University Wexner Medical Center\"<|>\"organization\"<|>\"Ohio State University Wexner Medical Center is a healthcare facility located in Columbus, Ohio, involved in clinical care and research.\")##\n(\"entity\"<|>\"Columbus\"<|>\"geo\"<|>\"Columbus is a city in Ohio, location of Ohio State University Wexner Medical Center.\")##\n(\"entity\"<|>\"Ohio\"<|>\"geo\"<|>\"Ohio is a state in the midwestern United States, location of Columbus and Ohio State University Wexner Medical Center.\")##\n(\"entity\"<|>\"Lori Kozikowski\"<|>\"person\"<|>\"Lori Kozikowski is affiliated with Baystate Medical Center in Springfield, Massachusetts, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Olivia Krol\"<|>\"person\"<|>\"Olivia Krol is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Oregon Health & Science University\"<|>\"organization\"<|>\"Oregon Health & Science University is a major academic health center located in Portland, Oregon, engaged in medical education and research.\")##\n(\"entity\"<|>\"Portland\"<|>\"geo\"<|>\"Portland is a city in Oregon, location of Oregon Health & Science University.\")##\n(\"entity\"<|>\"Oregon\"<|>\"geo\"<|>\"Oregon is a state in the northwestern United States, location of Portland and Oregon Health & Science University.\")##\n(\"entity\"<|>\"Leigha Landreth\"<|>\"person\"<|>\"Leigha Landreth is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Mary LaRose\"<|>\"person\"<|>\"Mary LaRose is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Brenda Lopez\"<|>\"person\"<|>\"Brenda Lopez is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Montefiore Healthcare Center\"<|>\"organization\"<|>\"Montefiore Healthcare Center is a healthcare facility located in Bronx, New York, involved in clinical care and research.\")##\n(\"entity\"<|>\"Albert Einstein College of Medicine\"<|>\"organization\"<|>\"Albert Einstein College of Medicine is a medical school located in Bronx, New York, engaged in medical education and research.\")##\n(\"entity\"<|>\"Bronx\"<|>\"geo\"<|>\"Bronx is a borough of New York City, location of Montefiore Healthcare Center and Albert Einstein College of Medicine.\")##\n(\"entity\"<|>\"New York\"<|>\"geo\"<|>\"New York is a state in the northeastern United States, location of Bronx and its medical institutions.\")##\n(\"entity\"<|>\"Andrea Luong\"<|>\"person\"<|>\"Andrea Luong is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Bob McClellan\"<|>\"person\"<|>\"Bob McClellan is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Ellen Maruggi\"<|>\"person\"<|>\"Ellen Maruggi is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Karen Miller\"<|>\"person\"<|>\"Karen Miller is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Rahul Nair\"<|>\"person\"<|>\"Rahul Nair is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Lisa Parks\"<|>\"person\"<|>\"Lisa Parks is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jennifer Peers\"<|>\"person\"<|>\"Jennifer Peers is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Cynthia Perez\"<|>\"person\"<|>\"Cynthia Perez is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Adreanne Rivera\"<|>\"person\"<|>\"Adreanne Rivera is affiliated with Reagan-UCLA Medical Center in Los Angeles, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jonasel Roque\"<|>\"person\"<|>\"Jonasel Roque is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Andres Santana\"<|>\"person\"<|>\"Andres Santana is affiliated with Baystate Medical Center in Springfield, Massachusetts, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Tyler Scharber\"<|>\"person\"<|>\"Tyler Scharber is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Emma Silverman\"<|>\"person\"<|>\"Emma Silverman is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Michael Tozier\"<|>\"person\"<|>\"Michael Tozier is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Hiwet Tzehaie\"<|>\"person\"<|>\"Hiwet Tzehaie is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Zachary Zouyed\"<|>\"person\"<|>\"Zachary Zouyed is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"HAIVEN Investigators\"<|>\"organization\"<|>\"HAIVEN Investigators is a research group or consortium involved in medical research, likely coordinating multi-center studies.\")##\n(\"entity\"<|>\"Alejandro Arroliga\"<|>\"person\"<|>\"Alejandro Arroliga is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Baylor Scott & White Health\"<|>\"organization\"<|>\"Baylor Scott & White Health is a healthcare system based in Temple, Texas, involved in clinical care and research.\")##\n(\"entity\"<|>\"Texas A&M University College of Medicine\"<|>\"organization\"<|>\"Texas A&M University College of Medicine is a medical school located in Temple, Texas, engaged in medical education and research.\")##\n(\"entity\"<|>\"Temple\"<|>\"geo\"<|>\"Temple is a city in Texas, location of Baylor Scott & White Health and Texas A&M University College of Medicine.\")##\n(\"entity\"<|>\"Texas\"<|>\"geo\"<|>\"Texas is a state in the southern United States, location of Temple and its medical institutions.\")##\n(\"entity\"<|>\"Alicia Bagiatis\"<|>\"person\"<|>\"Alicia Bagiatis is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"organization\"<|>\"University of Pittsburgh Schools of the Health Sciences is an academic health center in Pittsburgh, Pennsylvania, engaged in medical education and research.\")##\n(\"entity\"<|>\"Pittsburgh\"<|>\"geo\"<|>\"Pittsburgh is a city in Pennsylvania, location of University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center.\")##\n(\"entity\"<|>\"Pennsylvania\"<|>\"geo\"<|>\"Pennsylvania is a state in the northeastern United States, location of Pittsburgh and its medical institutions.\")##\n(\"entity\"<|>\"GK Balasubramani\"<|>\"person\"<|>\"GK Balasubramani is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Caroline K. Cheng\"<|>\"person\"<|>\"Caroline K. Cheng is affiliated with University of Michigan School of Public Health in Ann Arbor, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"University of Michigan School of Public Health\"<|>\"organization\"<|>\"University of Michigan School of Public Health is an academic institution in Ann Arbor, Michigan, engaged in public health education and research.\")##\n(\"entity\"<|>\"Ann Arbor\"<|>\"geo\"<|>\"Ann Arbor is a city in Michigan, location of University of Michigan School of Public Health.\")##\n(\"entity\"<|>\"Michigan\"<|>\"geo\"<|>\"Michigan is a state in the midwestern United States, location of Ann Arbor and University of Michigan School of Public Health.\")##\n(\"entity\"<|>\"Heather Eng\"<|>\"person\"<|>\"Heather Eng is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Shekhar Ghamande\"<|>\"person\"<|>\"Shekhar Ghamande is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Judy Herrick\"<|>\"person\"<|>\"Judy Herrick is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Eric Hoffman\"<|>\"person\"<|>\"Eric Hoffman is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Kailey Hughes\"<|>\"person\"<|>\"Kailey Hughes is affiliated with University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"University of Pittsburgh Medical Center\"<|>\"organization\"<|>\"University of Pittsburgh Medical Center is a major healthcare provider in Pittsburgh, Pennsylvania, involved in clinical care and research.\")##\n(\"entity\"<|>\"Lois E. Lamerato\"<|>\"person\"<|>\"Lois E. Lamerato is affiliated with Henry Ford Health System in Detroit, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Henry Ford Health System\"<|>\"organization\"<|>\"Henry Ford Health System is a healthcare provider located in Detroit, Michigan, involved in clinical care and research.\")##\n(\"entity\"<|>\"Detroit\"<|>\"geo\"<|>\"Detroit is a city in Michigan, location of Henry Ford Health System.\")##\n(\"entity\"<|>\"Adam S. Lauring\"<|>\"person\"<|>\"Adam S. Lauring is affiliated with University of Michigan School of Public Health in Ann Arbor, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Amanda McKillop\"<|>\"person\"<|>\"Amanda McKillop is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"T resa McNeal\"<|>\"person\"<|>\"T resa McNeal is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"E. J. McSpadden\"<|>\"person\"<|>\"E. J. McSpadden is affiliated with University of Michigan School of Public Health in Ann Arbor, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"John Midturi\"<|>\"person\"<|>\"John Midturi is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Manohar Mutnal\"<|>\"person\"<|>\"Manohar Mutnal is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Mary Patricia Nowalk\"<|>\"person\"<|>\"Mary Patricia Nowalk is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Joshua G. Petrie\"<|>\"person\"<|>\"Joshua G. Petrie is affiliated with University of Michigan School of Public Health in Ann Arbor, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Chandni Raiyani\"<|>\"person\"<|>\"Chandni Raiyani is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Arundhati Rao\"<|>\"person\"<|>\"Arundhati Rao is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Sean G. Saul\"<|>\"person\"<|>\"Sean G. Saul is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Theresa M. Sax\"<|>\"person\"<|>\"Theresa M. Sax is affiliated with University of Pittsburgh Schools of the Health Sciences in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Hannah E. Segaloff\"<|>\"person\"<|>\"Hannah E. Segaloff is affiliated with University of Michigan School of Public Health in Ann Arbor, Michigan, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Lori Stiefel\"<|>\"person\"<|>\"Lori Stiefel is affiliated with University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Marcus Volz\"<|>\"person\"<|>\"Marcus Volz is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Kimberly Walker\"<|>\"person\"<|>\"Kimberly Walker is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Nicole Wheeler\"<|>\"person\"<|>\"Nicole Wheeler is affiliated with University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Heath White\"<|>\"person\"<|>\"Heath White is affiliated with Baylor Scott & White Health and Texas A&M University College of Medicine in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"John V. Williams\"<|>\"person\"<|>\"John V. Williams is affiliated with University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Mohamed Yassin\"<|>\"person\"<|>\"Mohamed Yassin is affiliated with University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Martha Zayed\"<|>\"person\"<|>\"Martha Zayed is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Tnelda Zunie\"<|>\"person\"<|>\"Tnelda Zunie is affiliated with Baylor Scott & White Health in Temple, Texas, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal government department overseeing health policy and programs in the United States.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a federal agency under the US Department of Health and Human Services, responsible for public health and disease prevention.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC, providing public health information and updates.\")##\n\n(\"relationship\"<|>\"Valerie Aston\"<|>\"Intermountain Medical Center\"<|>\"Valerie Aston is affiliated with Intermountain Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Intermountain Medical Center\"<|>\"Salt Lake City\"<|>\"Intermountain Medical Center is located in Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Salt Lake City\"<|>\"Utah\"<|>\"Salt Lake City is a city within Utah.\"<|>10)##\n(\"relationship\"<|>\"Marianne Bernardo\"<|>\"Reagan-UCLA Medical Center\"<|>\"Marianne Bernardo is affiliated with Reagan-UCLA Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Reagan-UCLA Medical Center\"<|>\"Los Angeles\"<|>\"Reagan-UCLA Medical Center is located in Los Angeles, California.\"<|>10)##\n(\"relationship\"<|>\"Los Angeles\"<|>\"California\"<|>\"Los Angeles is a city within California.\"<|>10)##\n(\"relationship\"<|>\"Robert Bowers\"<|>\"Intermountain Medical Center\"<|>\"Robert Bowers is affiliated with Intermountain Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Leslie De Souza\"<|>\"Baystate Medical Center\"<|>\"Leslie De Souza is affiliated with Baystate Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Baystate Medical Center\"<|>\"Springfield\"<|>\"Baystate Medical Center is located in Springfield, Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Springfield\"<|>\"Massachusetts\"<|>\"Springfield is a city within Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Jennifer Friedel\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Friedel is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"University of Colorado School of Medicine\"<|>\"Aurora\"<|>\"University of Colorado School of Medicine is located in Aurora, Colorado.\"<|>10)##\n(\"relationship\"<|>\"Aurora\"<|>\"Colorado\"<|>\"Aurora is a city within Colorado.\"<|>10)##\n(\"relationship\"<|>\"Kevin Gardner\"<|>\"Stanford University School of Medicine\"<|>\"Kevin Gardner is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Stanford University School of Medicine\"<|>\"Palo Alto\"<|>\"Stanford University School of Medicine is located in Palo Alto, California.\"<|>10)##\n(\"relationship\"<|>\"Palo Alto\"<|>\"California\"<|>\"Palo Alto is a city within California.\"<|>10)##\n(\"relationship\"<|>\"Jennifer Goff\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Goff is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Alexandra June Gordon\"<|>\"Stanford University School of Medicine\"<|>\"Alexandra June Gordon is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Audrey Hendrickson\"<|>\"Hennepin County Medical Center\"<|>\"Audrey Hendrickson is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hennepin County Medical Center\"<|>\"Minneapolis\"<|>\"Hennepin County Medical Center is located in Minneapolis, Minnesota.\"<|>10)##\n(\"relationship\"<|>\"Minneapolis\"<|>\"Minnesota\"<|>\"Minneapolis is a city within Minnesota.\"<|>10)##\n(\"relationship\"<|>\"Madeline Hicks\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Madeline Hicks is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Winston-Salem\"<|>\"Wake Forest University Baptist Medical Center is located in Winston-Salem, North Carolina.\"<|>10)##\n(\"relationship\"<|>\"Winston-Salem\"<|>\"North Carolina\"<|>\"Winston-Salem is a city within North Carolina.\"<|>10)##\n(\"relationship\"<|>\"Michelle Howell\"<|>\"University of Colorado School of Medicine\"<|>\"Michelle Howell is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jakea Johnson\"<|>\"Vanderbilt University Medical Center\"<|>\"Jakea Johnson is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Vanderbilt University Medical Center\"<|>\"Nashville\"<|>\"Vanderbilt University Medical Center is located in Nashville, Tennessee.\"<|>10)##\n(\"relationship\"<|>\"Nashville\"<|>\"Tennessee\"<|>\"Nashville is a city within Tennessee.\"<|>10)##\n(\"relationship\"<|>\"Jeffrey Jorgensen\"<|>\"Intermountain Medical Center\"<|>\"Jeffrey Jorgensen is affiliated with Intermountain Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Sarah Karow\"<|>\"Ohio State University Wexner Medical Center\"<|>\"Sarah Karow is affiliated with Ohio State University Wexner Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Ohio State University Wexner Medical Center\"<|>\"Columbus\"<|>\"Ohio State University Wexner Medical Center is located in Columbus, Ohio.\"<|>10)##\n(\"relationship\"<|>\"Columbus\"<|>\"Ohio\"<|>\"Columbus is a city within Ohio.\"<|>10)##\n(\"relationship\"<|>\"Lori Kozikowski\"<|>\"Baystate Medical Center\"<|>\"Lori Kozikowski is affiliated with Baystate Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Olivia Krol\"<|>\"Oregon Health & Science University\"<|>\"Olivia Krol is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Oregon Health & Science University\"<|>\"Portland\"<|>\"Oregon Health & Science University is located in Portland, Oregon.\"<|>10)##\n(\"relationship\"<|>\"Portland\"<|>\"Oregon\"<|>\"Portland is a city within Oregon.\"<|>10)##\n(\"relationship\"<|>\"Leigha Landreth\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Leigha Landreth is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Mary LaRose\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Mary LaRose is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Brenda Lopez\"<|>\"Montefiore Healthcare Center\"<|>\"Brenda Lopez is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Brenda Lopez\"<|>\"Albert Einstein College of Medicine\"<|>\"Brenda Lopez is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Montefiore Healthcare Center\"<|>\"Bronx\"<|>\"Montefiore Healthcare Center is located in Bronx, New York.\"<|>10)##\n(\"relationship\"<|>\"Albert Einstein College of Medicine\"<|>\"Bronx\"<|>\"Albert Einstein College of Medicine is located in Bronx, New York.\"<|>10)##\n(\"relationship\"<|>\"Bronx\"<|>\"New York\"<|>\"Bronx is a borough within New York.\"<|>10)##\n(\"relationship\"<|>\"Andrea Luong\"<|>\"Oregon Health & Science University\"<|>\"Andrea Luong is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Bob McClellan\"<|>\"Vanderbilt University Medical Center\"<|>\"Bob McClellan is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Ellen Maruggi\"<|>\"Hennepin County Medical Center\"<|>\"Ellen Maruggi is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Karen Miller\"<|>\"Vanderbilt University Medical Center\"<|>\"Karen Miller is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Rahul Nair\"<|>\"Montefiore Healthcare Center\"<|>\"Rahul Nair is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Rahul Nair\"<|>\"Albert Einstein College of Medicine\"<|>\"Rahul Nair is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Lisa Parks\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Lisa Parks is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jennifer Peers\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Peers is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Cynthia Perez\"<|>\"Stanford University School of Medicine\"<|>\"Cynthia Perez is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Adreanne Rivera\"<|>\"Reagan-UCLA Medical Center\"<|>\"Adreanne Rivera is affiliated with Reagan-UCLA Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jonasel Roque\"<|>\"Stanford University School of Medicine\"<|>\"Jonasel Roque is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Andres Santana\"<|>\"Baystate Medical Center\"<|>\"Andres Santana is affiliated with Baystate Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Tyler Scharber\"<|>\"Hennepin County Medical Center\"<|>\"Tyler Scharber is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Emma Silverman\"<|>\"Oregon Health & Science University\"<|>\"Emma Silverman is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Michael Tozier\"<|>\"University of Colorado School of Medicine\"<|>\"Michael Tozier is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hiwet Tzehaie\"<|>\"Montefiore Healthcare Center\"<|>\"Hiwet Tzehaie is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hiwet Tzehaie\"<|>\"Albert Einstein College of Medicine\"<|>\"Hiwet Tzehaie is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Zachary Zouyed\"<|>\"Oregon Health & Science University\"<|>\"Zachary Zouyed is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"HAIVEN Investigators\"<|>\"Alejandro Arroliga\"<|>\"Alejandro Arroliga is a member of the HAIVEN Investigators research group.\"<|>8)##\n(\"relationship\"<|>\"Alejandro Arroliga\"<|>\"Baylor Scott & White Health\"<|>\"Alejandro Arroliga is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Alejandro Arroliga\"<|>\"Texas A&M University College of Medicine\"<|>\"Alejandro Arroliga is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Baylor Scott & White Health\"<|>\"Temple\"<|>\"Baylor Scott & White Health is located in Temple, Texas.\"<|>10)##\n(\"relationship\"<|>\"Texas A&M University College of Medicine\"<|>\"Temple\"<|>\"Texas A&M University College of Medicine is located in Temple, Texas.\"<|>10)##\n(\"relationship\"<|>\"Temple\"<|>\"Texas\"<|>\"Temple is a city within Texas.\"<|>10)##\n(\"relationship\"<|>\"Alicia Bagiatis\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Alicia Bagiatis is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Pittsburgh\"<|>\"University of Pittsburgh Schools of the Health Sciences is located in Pittsburgh, Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"Pittsburgh\"<|>\"Pennsylvania\"<|>\"Pittsburgh is a city within Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"GK Balasubramani\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"GK Balasubramani is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Caroline K. Cheng\"<|>\"University of Michigan School of Public Health\"<|>\"Caroline K. Cheng is affiliated with University of Michigan School of Public Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"University of Michigan School of Public Health\"<|>\"Ann Arbor\"<|>\"University of Michigan School of Public Health is located in Ann Arbor, Michigan.\"<|>10)##\n(\"relationship\"<|>\"Ann Arbor\"<|>\"Michigan\"<|>\"Ann Arbor is a city within Michigan.\"<|>10)##\n(\"relationship\"<|>\"Heather Eng\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Heather Eng is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Shekhar Ghamande\"<|>\"Baylor Scott & White Health\"<|>\"Shekhar Ghamande is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Shekhar Ghamande\"<|>\"Texas A&M University College of Medicine\"<|>\"Shekhar Ghamande is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Judy Herrick\"<|>\"Baylor Scott & White Health\"<|>\"Judy Herrick is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Eric Hoffman\"<|>\"Baylor Scott & White Health\"<|>\"Eric Hoffman is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Kailey Hughes\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Kailey Hughes is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Kailey Hughes\"<|>\"University of Pittsburgh Medical Center\"<|>\"Kailey Hughes is affiliated with University of Pittsburgh Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"University of Pittsburgh Medical Center\"<|>\"Pittsburgh\"<|>\"University of Pittsburgh Medical Center is located in Pittsburgh, Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"Lois E. Lamerato\"<|>\"Henry Ford Health System\"<|>\"Lois E. Lamerato is affiliated with Henry Ford Health System as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Henry Ford Health System\"<|>\"Detroit\"<|>\"Henry Ford Health System is located in Detroit, Michigan.\"<|>10)##\n(\"relationship\"<|>\"Detroit\"<|>\"Michigan\"<|>\"Detroit is a city within Michigan.\"<|>10)##\n(\"relationship\"<|>\"Adam S. Lauring\"<|>\"University of Michigan School of Public Health\"<|>\"Adam S. Lauring is affiliated with University of Michigan School of Public Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Amanda McKillop\"<|>\"Baylor Scott & White Health\"<|>\"Amanda McKillop is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"T resa McNeal\"<|>\"Baylor Scott & White Health\"<|>\"T resa McNeal is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"T resa McNeal\"<|>\"Texas A&M University College of Medicine\"<|>\"T resa McNeal is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"E. J. McSpadden\"<|>\"University of Michigan School of Public Health\"<|>\"E. J. McSpadden is affiliated with University of Michigan School of Public Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"John Midturi\"<|>\"Baylor Scott & White Health\"<|>\"John Midturi is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"John Midturi\"<|>\"Texas A&M University College of Medicine\"<|>\"John Midturi is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Manohar Mutnal\"<|>\"Baylor Scott & White Health\"<|>\"Manohar Mutnal is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Manohar Mutnal\"<|>\"Texas A&M University College of Medicine\"<|>\"Manohar Mutnal is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Mary Patricia Nowalk\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Mary Patricia Nowalk is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Joshua G. Petrie\"<|>\"University of Michigan School of Public Health\"<|>\"Joshua G. Petrie is affiliated with University of Michigan School of Public Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Chandni Raiyani\"<|>\"Baylor Scott & White Health\"<|>\"Chandni Raiyani is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Arundhati Rao\"<|>\"Baylor Scott & White Health\"<|>\"Arundhati Rao is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Arundhati Rao\"<|>\"Texas A&M University College of Medicine\"<|>\"Arundhati Rao is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Sean G. Saul\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Sean G. Saul is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Theresa M. Sax\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Theresa M. Sax is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hannah E. Segaloff\"<|>\"University of Michigan School of Public Health\"<|>\"Hannah E. Segaloff is affiliated with University of Michigan School of Public Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Lori Stiefel\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Lori Stiefel is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Lori Stiefel\"<|>\"University of Pittsburgh Medical Center\"<|>\"Lori Stiefel is affiliated with University of Pittsburgh Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Marcus Volz\"<|>\"Baylor Scott & White Health\"<|>\"Marcus Volz is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Kimberly Walker\"<|>\"Baylor Scott & White Health\"<|>\"Kimberly Walker is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Nicole Wheeler\"<|>\"University of Pittsburgh Medical Center\"<|>\"Nicole Wheeler is affiliated with University of Pittsburgh Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Heath White\"<|>\"Baylor Scott & White Health\"<|>\"Heath White is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Heath White\"<|>\"Texas A&M University College of Medicine\"<|>\"Heath White is affiliated with Texas A&M University College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"John V. Williams\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"John V. Williams is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"John V. Williams\"<|>\"University of Pittsburgh Medical Center\"<|>\"John V. Williams is affiliated with University of Pittsburgh Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Mohamed Yassin\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Mohamed Yassin is affiliated with University of Pittsburgh Schools of the Health Sciences as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Mohamed Yassin\"<|>\"University of Pittsburgh Medical Center\"<|>\"Mohamed Yassin is affiliated with University of Pittsburgh Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Martha Zayed\"<|>\"Baylor Scott & White Health\"<|>\"Martha Zayed is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Tnelda Zunie\"<|>\"Baylor Scott & White Health\"<|>\"Tnelda Zunie is affiliated with Baylor Scott & White Health as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"Centers for Disease Control and Prevention is an agency under the US Department of Health and Human Services.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"Morbidity and Mortality Weekly Report is a publication produced by the Centers for Disease Control and Prevention.\"<|>10)##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "fe608e696c3b90338217ffb047afa453": {
    "return": "(\"entity\"<|>\"Atlanta, GA 30329-4027\"<|>\"geo\"<|>\"Atlanta, GA 30329-4027 is a geographic location, likely the mailing address associated with the CDC or MMWR.\")##\n(\"entity\"<|>\"mmwrq@cdc.gov\"<|>\"organization\"<|>\"mmwrq@cdc.gov is an email contact for the CDC, specifically related to the MMWR publication.\")##\n(\"entity\"<|>\"MMWR Series\"<|>\"organization\"<|>\"MMWR Series refers to the Morbidity and Mortality Weekly Report publications, which are in the public domain and provide health information.\")##\n(\"entity\"<|>\"MMWR\"<|>\"organization\"<|>\"MMWR stands for Morbidity and Mortality Weekly Report, a publication providing health-related data and information.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report is a health publication, part of the MMWR Series, and is a service mark of the U.S. Department of Health and Human Services.\")##\n(\"entity\"<|>\"U.S. Department of Health and Human Services\"<|>\"organization\"<|>\"U.S. Department of Health and Human Services is a federal government department responsible for health-related services and oversight, including the CDC and MMWR.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC (Centers for Disease Control and Prevention) is a federal agency under the U.S. Department of Health and Human Services, responsible for public health and safety.\")##\n(\"entity\"<|>\"MMWR readers\"<|>\"person\"<|>\"MMWR readers are individuals who read the Morbidity and Mortality Weekly Report, likely health professionals or the general public interested in health information.\")##\n(\"entity\"<|>\"References to non-CDC sites\"<|>\"event\"<|>\"References to non-CDC sites refers to the act of providing links or citations to external websites in the MMWR publication.\")##\n(\"entity\"<|>\"Date of publication\"<|>\"event\"<|>\"Date of publication refers to the specific time when the MMWR issue was published, relevant for the currency of URL addresses.\")##\n(\"relationship\"<|>\"MMWR Series\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"MMWR Series includes the Morbidity and Mortality Weekly Report as part of its publications.\"<|>9)##\n(\"relationship\"<|>\"MMWR\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"MMWR is an abbreviation for Morbidity and Mortality Weekly Report, indicating they are the same entity or closely related.\"<|>10)##\n(\"relationship\"<|>\"MMWR Series\"<|>\"U.S. Department of Health and Human Services\"<|>\"MMWR Series is a service mark of the U.S. Department of Health and Human Services, indicating ownership and oversight.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"U.S. Department of Health and Human Services\"<|>\"Morbidity and Mortality Weekly Report is a service mark of the U.S. Department of Health and Human Services, showing direct association.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"U.S. Department of Health and Human Services\"<|>\"CDC is an agency under the U.S. Department of Health and Human Services, indicating organizational hierarchy.\"<|>10)##\n(\"relationship\"<|>\"mmwrq@cdc.gov\"<|>\"CDC\"<|>\"mmwrq@cdc.gov is an official contact email for the CDC, specifically for MMWR-related correspondence.\"<|>9)##\n(\"relationship\"<|>\"MMWR readers\"<|>\"MMWR\"<|>\"MMWR readers are the audience for the MMWR publication, indicating a direct relationship between the publication and its readers.\"<|>8)##\n(\"relationship\"<|>\"References to non-CDC sites\"<|>\"MMWR readers\"<|>\"References to non-CDC sites are provided as a service to MMWR readers, showing intent to inform or assist readers.\"<|>7)##\n(\"relationship\"<|>\"References to non-CDC sites\"<|>\"CDC\"<|>\"References to non-CDC sites are not endorsed by CDC, indicating CDC's stance on external content.\"<|>6)##\n(\"relationship\"<|>\"Date of publication\"<|>\"MMWR\"<|>\"Date of publication is relevant for the currency of URL addresses listed in MMWR, showing a temporal relationship.\"<|>6)##\n(\"relationship\"<|>\"Atlanta, GA 30329-4027\"<|>\"CDC\"<|>\"Atlanta, GA 30329-4027 is likely the physical address for the CDC, indicating location association.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "5079dba94c646e7b9ecb1c6ce69f47ff": {
    "return": "(\"entity\"<|>\"Janssen\"<|>\"organization\"<|>\"Janssen is a pharmaceutical company that manufactures the Janssen COVID-19 vaccine, which is administered as a single dose and was widely used during the period discussed in the report.\")##\n(\"entity\"<|>\"COVID-19 Vaccine\"<|>\"event\"<|>\"COVID-19 Vaccine refers to vaccines developed to prevent COVID-19, including the Janssen vaccine and mRNA vaccines, administered during the pandemic.\")##\n(\"entity\"<|>\"Influenza Vaccine\"<|>\"event\"<|>\"Influenza Vaccine refers to vaccines administered to prevent influenza, specifically referenced as being given to adults during July 1, 2019June 30, 2020.\")##\n(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"VAERS (Vaccine Adverse Event Reporting System) is a passive surveillance system in the United States for reporting adverse events after vaccination, including syncope and anxiety-related events.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC (Centers for Disease Control and Prevention) is a US federal agency that provides recommendations on vaccine prioritization and public health practices, including COVID-19 vaccination.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal department overseeing public health agencies, including the CDC.\")##\n(\"entity\"<|>\"Mass Vaccination Sites\"<|>\"organization\"<|>\"Mass Vaccination Sites are locations where large numbers of people receive vaccines, and some reported anxiety-related events and temporarily suspended COVID-19 vaccination.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"United States is the country where the vaccination events, reporting, and public health recommendations described in the report took place.\")##\n(\"entity\"<|>\"Syncope\"<|>\"event\"<|>\"Syncope refers to fainting episodes, which are anxiety-related events reported after vaccination, especially among younger age groups.\")##\n(\"entity\"<|>\"Anxiety-related Events\"<|>\"event\"<|>\"Anxiety-related Events are adverse reactions, including syncope, that can occur immediately after vaccination due to anxiety about receiving an injection.\")##\n(\"entity\"<|>\"Quadrivalent Human Papillomavirus Vaccine\"<|>\"event\"<|>\"Quadrivalent Human Papillomavirus Vaccine is referenced as another vaccine with reported rates of syncope, especially among adolescents.\")##\n(\"entity\"<|>\"mRNA COVID-19 Vaccines\"<|>\"event\"<|>\"mRNA COVID-19 Vaccines are a class of COVID-19 vaccines, distinct from the Janssen vaccine, and were prioritized differently during the vaccine rollout.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication of the CDC that disseminates public health information, including the report summarized in the text.\")##\n\n(\"relationship\"<|>\"Janssen\"<|>\"COVID-19 Vaccine\"<|>\"Janssen manufactures the Janssen COVID-19 vaccine, which is a type of COVID-19 vaccine discussed in the report.\"<|>10)##\n(\"relationship\"<|>\"Janssen\"<|>\"VAERS\"<|>\"Adverse events after Janssen COVID-19 vaccination, such as syncope, are reported to VAERS.\"<|>9)##\n(\"relationship\"<|>\"VAERS\"<|>\"CDC\"<|>\"VAERS is overseen by the CDC, which uses its data for public health recommendations and surveillance.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"US Department of Health and Human Services\"<|>\"CDC is an agency within the US Department of Health and Human Services, responsible for public health guidance and vaccine recommendations.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"COVID-19 Vaccine\"<|>\"CDC provides recommendations on COVID-19 vaccine prioritization and administration.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC publishes the Morbidity and Mortality Weekly Report, which disseminates findings on vaccine safety and public health.\"<|>10)##\n(\"relationship\"<|>\"Mass Vaccination Sites\"<|>\"COVID-19 Vaccine\"<|>\"Mass Vaccination Sites administer COVID-19 vaccines and reported anxiety-related events, including syncope, after vaccination.\"<|>8)##\n(\"relationship\"<|>\"Mass Vaccination Sites\"<|>\"VAERS\"<|>\"Mass Vaccination Sites report adverse events, such as syncope, to VAERS.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"CDC\"<|>\"CDC operates within the United States, providing public health guidance and vaccine recommendations nationally.\"<|>10)##\n(\"relationship\"<|>\"United States\"<|>\"VAERS\"<|>\"VAERS is a US-based system for reporting adverse events after vaccination.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 Vaccine\"<|>\"Syncope\"<|>\"Syncope is a reported adverse event after COVID-19 vaccination, especially among younger age groups.\"<|>9)##\n(\"relationship\"<|>\"Influenza Vaccine\"<|>\"Syncope\"<|>\"Syncope is also reported after influenza vaccination, though at a much lower rate than after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 Vaccine\"<|>\"Anxiety-related Events\"<|>\"Anxiety-related events, including syncope, are associated with COVID-19 vaccination and are a concern for vaccine providers.\"<|>8)##\n(\"relationship\"<|>\"Influenza Vaccine\"<|>\"Anxiety-related Events\"<|>\"Anxiety-related events, including syncope, are also reported after influenza vaccination.\"<|>7)##\n(\"relationship\"<|>\"Quadrivalent Human Papillomavirus Vaccine\"<|>\"Syncope\"<|>\"Quadrivalent Human Papillomavirus Vaccine is referenced as another vaccine with notable rates of syncope, especially among adolescents.\"<|>7)##\n(\"relationship\"<|>\"COVID-19 Vaccine\"<|>\"mRNA COVID-19 Vaccines\"<|>\"mRNA COVID-19 vaccines are a subset of COVID-19 vaccines, distinct from the Janssen vaccine, and were prioritized differently during rollout.\"<|>8)##\n(\"relationship\"<|>\"Janssen\"<|>\"mRNA COVID-19 Vaccines\"<|>\"Janssen COVID-19 vaccine is compared to mRNA COVID-19 vaccines in terms of population and prioritization.\"<|>7)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC\"<|>\"MMWR is published by the CDC and contains the report summarized in the text.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"Mass Vaccination Sites\"<|>\"CDC provides guidance to mass vaccination sites on vaccine administration and monitoring for adverse events.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 Vaccine\"<|>\"Influenza Vaccine\"<|>\"COVID-19 vaccine and influenza vaccine are compared in the report for rates of syncope and anxiety-related events.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 Vaccine\"<|>\"United States\"<|>\"COVID-19 vaccines are administered in the United States, as described in the report.\"<|>10)##\n(\"relationship\"<|>\"Influenza Vaccine\"<|>\"United States\"<|>\"Influenza vaccines are administered in the United States, as described in the report.\"<|>10)##\n(\"relationship\"<|>\"Janssen\"<|>\"United States\"<|>\"Janssen COVID-19 vaccine is administered in the United States, as described in the report.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"VAERS data is used in reports published in the Morbidity and Mortality Weekly Report.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "67580c85723cdaffd2a6d216b0cf6e73": {
    "return": "(\"entity\"<|>\"MMWR Series\"<|>\"organization\"<|>\"The MMWR Series refers to the collection of publications under the Morbidity and Mortality Weekly Report, prepared by CDC, providing timely public health information and surveillance data.\")##\n(\"entity\"<|>\"Editor-in-Chief, MMWR Series\"<|>\"person\"<|>\"The Editor-in-Chief of the MMWR Series is responsible for overseeing the editorial process and content of the Morbidity and Mortality Weekly Report publications.\")##\n(\"entity\"<|>\"Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027\"<|>\"geo\"<|>\"This is the mailing address for the Editor-in-Chief of the MMWR Series at CDC headquarters in Atlanta, Georgia.\")##\n(\"entity\"<|>\"mmwrq@cdc.gov\"<|>\"organization\"<|>\"This is the official email contact for inquiries about the MMWR Series at CDC.\")##\n(\"entity\"<|>\"Office of Management and Budget\"<|>\"organization\"<|>\"The Office of Management and Budget (OMB) is a federal office that delineates metropolitan statistical areas (MSAs) and provides standards for urbanization levels used in health statistics.\")##\n(\"entity\"<|>\"Metropolitan Statistical Area (MSA)\"<|>\"geo\"<|>\"A Metropolitan Statistical Area (MSA) is a geographic region defined by the Office of Management and Budget, consisting of at least one urbanized area of 50,000 inhabitants or more, used for statistical purposes in health surveys.\")##\n(\"entity\"<|>\"Nonmetropolitan Area\"<|>\"geo\"<|>\"Nonmetropolitan areas are geographic regions with fewer than 50,000 inhabitants, grouped for statistical analysis in health surveys.\")##\n(\"entity\"<|>\"Adults Aged 18 Years and Older\"<|>\"person\"<|>\"This refers to the population group surveyed in the National Health Interview Survey for diabetes prevalence by urbanization level and age group.\")##\n(\"entity\"<|>\"Diagnosed Diabetes\"<|>\"event\"<|>\"Diagnosed diabetes refers to the condition of having been told by a health professional that one has diabetes, as measured in the National Health Interview Survey.\")##\n(\"entity\"<|>\"Age Groups (18-44, 45-64, 65+)\"<|>\"person\"<|>\"These are the specific age categories used in the National Health Interview Survey to report diabetes prevalence.\")##\n(\"entity\"<|>\"Survey Respondents\"<|>\"person\"<|>\"Individuals participating in the National Health Interview Survey, providing data on health conditions such as diabetes.\")##\n(\"entity\"<|>\"Civilian, Noninstitutionalized U.S. Population\"<|>\"person\"<|>\"The target population for the National Health Interview Survey, excluding those in institutions such as prisons or long-term care facilities.\")##\n(\"entity\"<|>\"References Section\"<|>\"event\"<|>\"The section of the report listing sources and citations for data and information presented.\")##\n(\"entity\"<|>\"Print ISSN: 0149-2195\"<|>\"organization\"<|>\"The International Standard Serial Number for the print edition of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Electronic Format (MMWR)\"<|>\"event\"<|>\"The digital version of the Morbidity and Mortality Weekly Report, available for free online.\")##\n(\"entity\"<|>\"HTML File (MMWR)\"<|>\"event\"<|>\"An alternative web-based format of the MMWR for readers who have difficulty accessing PDF files.\")##\n(\"entity\"<|>\"Service Marks of U.S. Department of Health and Human Services\"<|>\"event\"<|>\"MMWR and Morbidity and Mortality Weekly Report are registered service marks of HHS, indicating their official status.\")##\n(\"entity\"<|>\"Trade Names and Commercial Sources\"<|>\"event\"<|>\"Mentioned in the report as being used for identification purposes only, without implying endorsement by the U.S. government.\")##\n(\"entity\"<|>\"FoodNet Population Survey Atlas of Exposures, 2006-2007\"<|>\"event\"<|>\"A CDC publication reporting on population exposures to foodborne pathogens, based on FoodNet survey data from 2006-2007.\")##\n(\"entity\"<|>\"Whole Genome Sequencing (WGS)\"<|>\"event\"<|>\"A laboratory technique used by PulseNet and CDC for tracking and identifying foodborne pathogens during outbreaks.\")##\n(\"entity\"<|>\"E. coli O157:H7\"<|>\"event\"<|>\"A specific strain of E. coli bacteria associated with foodborne outbreaks, particularly those linked to romaine lettuce.\")##\n(\"entity\"<|>\"Survey Question: 'Has a doctor or other health professional ever told you that you had diabetes?'\"<|>\"event\"<|>\"The specific question used in the National Health Interview Survey to determine diabetes prevalence among respondents.\")##\n(\"entity\"<|>\"Prediabetes\"<|>\"event\"<|>\"A health condition excluded from the diabetes prevalence statistics in the National Health Interview Survey.\")##\n(\"entity\"<|>\"Gestational Diabetes\"<|>\"event\"<|>\"A form of diabetes occurring during pregnancy, excluded from the diabetes prevalence statistics in the National Health Interview Survey.\")##\n\n(\"relationship\"<|>\"MMWR Series\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"The MMWR Series encompasses all publications under the Morbidity and Mortality Weekly Report umbrella.\"<|>9)##\n(\"relationship\"<|>\"Editor-in-Chief, MMWR Series\"<|>\"MMWR Series\"<|>\"The Editor-in-Chief oversees the editorial process and content of the MMWR Series.\"<|>10)##\n(\"relationship\"<|>\"Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027\"<|>\"Editor-in-Chief, MMWR Series\"<|>\"This is the mailing address for the Editor-in-Chief of the MMWR Series at CDC headquarters.\"<|>10)##\n(\"relationship\"<|>\"mmwrq@cdc.gov\"<|>\"MMWR Series\"<|>\"mmwrq@cdc.gov is the official email contact for inquiries about the MMWR Series.\"<|>10)##\n(\"relationship\"<|>\"Office of Management and Budget\"<|>\"Metropolitan Statistical Area (MSA)\"<|>\"OMB defines and delineates Metropolitan Statistical Areas for use in health statistics and surveys.\"<|>10)##\n(\"relationship\"<|>\"Office of Management and Budget\"<|>\"Nonmetropolitan Area\"<|>\"OMB provides standards for defining nonmetropolitan areas for statistical purposes.\"<|>9)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Adults Aged 18 Years and Older\"<|>\"The National Health Interview Survey collects health data from adults aged 18 years and older.\"<|>10)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Diagnosed Diabetes\"<|>\"The survey measures the prevalence of diagnosed diabetes among respondents.\"<|>10)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Age Groups (18-44, 45-64, 65+)\"<|>\"The survey reports diabetes prevalence by specific age groups.\"<|>10)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Survey Respondents\"<|>\"Survey respondents provide the data for the National Health Interview Survey.\"<|>10)##\n(\"relationship\"<|>\"National Health Interview Survey\"<|>\"Civilian, Noninstitutionalized U.S. Population\"<|>\"The survey targets the civilian, noninstitutionalized U.S. population for its data collection.\"<|>10)##\n(\"relationship\"<|>\"References Section\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"The References Section lists sources and citations for information presented in the MMWR.\"<|>8)##\n(\"relationship\"<|>\"Print ISSN: 0149-2195\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"This is the print ISSN for the MMWR publication.\"<|>8)##\n(\"relationship\"<|>\"Electronic Format (MMWR)\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"MMWR is available in electronic format online for free.\"<|>8)##\n(\"relationship\"<|>\"HTML File (MMWR)\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"An HTML version of the MMWR is available for accessibility.\"<|>7)##\n(\"relationship\"<|>\"Service Marks of U.S. Department of Health and Human Services\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"MMWR and its name are registered service marks of HHS.\"<|>8)##\n(\"relationship\"<|>\"Trade Names and Commercial Sources\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"Trade names and commercial sources are mentioned in MMWR for identification only, not endorsement.\"<|>6)##\n(\"relationship\"<|>\"FoodNet Population Survey Atlas of Exposures, 2006-2007\"<|>\"Foodborne Active Surveillance Network (FoodNet)\"<|>\"This atlas is a publication based on FoodNet survey data from 2006-2007.\"<|>9)##\n(\"relationship\"<|>\"PulseNet\"<|>\"Whole Genome Sequencing (WGS)\"<|>\"PulseNet uses whole genome sequencing to track foodborne pathogens and outbreaks.\"<|>10)##\n(\"relationship\"<|>\"E. coli Outbreaks Linked to Romaine Lettuce\"<|>\"E. coli O157:H7\"<|>\"The outbreaks referenced are specifically linked to the E. coli O157:H7 strain.\"<|>10)##\n(\"relationship\"<|>\"Survey Question: 'Has a doctor or other health professional ever told you that you had diabetes?'\"<|>\"Diagnosed Diabetes\"<|>\"This survey question is used to determine the prevalence of diagnosed diabetes among respondents.\"<|>10)##\n(\"relationship\"<|>\"Prediabetes\"<|>\"Survey Respondents\"<|>\"Survey respondents were instructed not to include prediabetes when answering the diabetes question.\"<|>8)##\n(\"relationship\"<|>\"Gestational Diabetes\"<|>\"Survey Respondents\"<|>\"Survey respondents were instructed not to include gestational diabetes when answering the diabetes question.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "8d687318f434b823fdd8cb29d93c06de": {
    "return": "(\"entity\"<|>\"Johnson & Johnson\"<|>\"organization\"<|>\"Johnson & Johnson is the pharmaceutical company that developed and manufactures the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"International Committee of Medical Journal Editors\"<|>\"organization\"<|>\"The International Committee of Medical Journal Editors is a group that sets standards for the disclosure of potential conflicts of interest in medical publications.\")##\n(\"entity\"<|>\"Shimabukuro TT\"<|>\"person\"<|>\"Shimabukuro TT is an author cited in the references, involved in safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).\")##\n(\"entity\"<|>\"Nguyen M\"<|>\"person\"<|>\"Nguyen M is an author cited in the references, involved in safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).\")##\n(\"entity\"<|>\"Martin D\"<|>\"person\"<|>\"Martin D is an author cited in the references, involved in safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).\")##\n(\"entity\"<|>\"DeStefano F\"<|>\"person\"<|>\"DeStefano F is an author cited in the references, involved in safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).\")##\n(\"entity\"<|>\"Stratton K\"<|>\"person\"<|>\"Stratton K is an editor cited in the references, involved in research on adverse effects of vaccines.\")##\n(\"entity\"<|>\"Ford A\"<|>\"person\"<|>\"Ford A is an editor cited in the references, involved in research on adverse effects of vaccines.\")##\n(\"entity\"<|>\"Rusch E\"<|>\"person\"<|>\"Rusch E is an editor cited in the references, involved in research on adverse effects of vaccines.\")##\n(\"entity\"<|>\"Clayton EW\"<|>\"person\"<|>\"Clayton EW is an editor cited in the references, involved in research on adverse effects of vaccines.\")##\n(\"entity\"<|>\"Loharikar A\"<|>\"person\"<|>\"Loharikar A is an author cited in the references, involved in research on anxiety-related adverse events following immunization.\")##\n(\"entity\"<|>\"Suragh TA\"<|>\"person\"<|>\"Suragh TA is an author cited in the references, involved in research on anxiety-related adverse events following immunization.\")##\n(\"entity\"<|>\"MacDonald NE\"<|>\"person\"<|>\"MacDonald NE is an author cited in the references, involved in research on anxiety-related adverse events following immunization.\")##\n(\"entity\"<|>\"Crawford NW\"<|>\"person\"<|>\"Crawford NW is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"Clothier HJ\"<|>\"person\"<|>\"Clothier HJ is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"Elia S\"<|>\"person\"<|>\"Elia S is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"Lazzaro T\"<|>\"person\"<|>\"Lazzaro T is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"Royle J\"<|>\"person\"<|>\"Royle J is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"Buttery JP\"<|>\"person\"<|>\"Buttery JP is an author cited in the references, involved in research on syncope and seizures following human papillomavirus vaccination.\")##\n(\"entity\"<|>\"See I\"<|>\"person\"<|>\"See I is an author cited in the references, involved in US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\")##\n(\"entity\"<|>\"Su JR\"<|>\"person\"<|>\"Su JR is an author cited in the references, involved in US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination and updated recommendations for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Lale A\"<|>\"person\"<|>\"Lale A is an author cited in the references, involved in US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\")##\n(\"entity\"<|>\"MacNeil JR\"<|>\"person\"<|>\"MacNeil JR is an author cited in the references, involved in updated recommendations for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Broder KB\"<|>\"person\"<|>\"Broder KB is an author cited in the references, involved in updated recommendations for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that reports on public health information and recommendations.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is the federal department overseeing agencies such as the CDC and FDA, responsible for public health in the United States.\")##\n\n(\"relationship\"<|>\"Johnson & Johnson\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Johnson & Johnson is the manufacturer and developer of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"International Committee of Medical Journal Editors\"<|>\"Anne M. Hause\"<|>\"Anne M. Hause and other authors completed and submitted the disclosure form required by the International Committee of Medical Journal Editors.\"<|>7)##\n(\"relationship\"<|>\"Shimabukuro TT\"<|>\"VAERS\"<|>\"Shimabukuro TT is an author of research on safety monitoring in VAERS.\"<|>8)##\n(\"relationship\"<|>\"Nguyen M\"<|>\"VAERS\"<|>\"Nguyen M is an author of research on safety monitoring in VAERS.\"<|>8)##\n(\"relationship\"<|>\"Martin D\"<|>\"VAERS\"<|>\"Martin D is an author of research on safety monitoring in VAERS.\"<|>8)##\n(\"relationship\"<|>\"DeStefano F\"<|>\"VAERS\"<|>\"DeStefano F is an author of research on safety monitoring in VAERS.\"<|>8)##\n(\"relationship\"<|>\"Stratton K\"<|>\"Institute of Medicine of the National Academies\"<|>\"Stratton K is an editor of research published by the Institute of Medicine of the National Academies on adverse effects of vaccines.\"<|>8)##\n(\"relationship\"<|>\"Ford A\"<|>\"Institute of Medicine of the National Academies\"<|>\"Ford A is an editor of research published by the Institute of Medicine of the National Academies on adverse effects of vaccines.\"<|>8)##\n(\"relationship\"<|>\"Rusch E\"<|>\"Institute of Medicine of the National Academies\"<|>\"Rusch E is an editor of research published by the Institute of Medicine of the National Academies on adverse effects of vaccines.\"<|>8)##\n(\"relationship\"<|>\"Clayton EW\"<|>\"Institute of Medicine of the National Academies\"<|>\"Clayton EW is an editor of research published by the Institute of Medicine of the National Academies on adverse effects of vaccines.\"<|>8)##\n(\"relationship\"<|>\"Loharikar A\"<|>\"Anxiety-related Events\"<|>\"Loharikar A is an author of research on anxiety-related adverse events following immunization.\"<|>8)##\n(\"relationship\"<|>\"Suragh TA\"<|>\"Anxiety-related Events\"<|>\"Suragh TA is an author of research on anxiety-related adverse events following immunization.\"<|>8)##\n(\"relationship\"<|>\"MacDonald NE\"<|>\"Anxiety-related Events\"<|>\"MacDonald NE is an author of research on anxiety-related adverse events following immunization.\"<|>8)##\n(\"relationship\"<|>\"Crawford NW\"<|>\"Syncope\"<|>\"Crawford NW is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"Clothier HJ\"<|>\"Syncope\"<|>\"Clothier HJ is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"Elia S\"<|>\"Syncope\"<|>\"Elia S is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"Lazzaro T\"<|>\"Syncope\"<|>\"Lazzaro T is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"Royle J\"<|>\"Syncope\"<|>\"Royle J is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"Buttery JP\"<|>\"Syncope\"<|>\"Buttery JP is an author of research on syncope and seizures following human papillomavirus vaccination.\"<|>8)##\n(\"relationship\"<|>\"See I\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"See I is an author of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>8)##\n(\"relationship\"<|>\"Su JR\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"Su JR is an author of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination and updated recommendations for the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Lale A\"<|>\"Thrombosis with Thrombocytopenia Syndrome\"<|>\"Lale A is an author of US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\"<|>8)##\n(\"relationship\"<|>\"MacNeil JR\"<|>\"Janssen COVID-19 Vaccine\"<|>\"MacNeil JR is an author of updated recommendations for the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Broder KB\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Broder KB is an author of updated recommendations for the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC\"<|>\"Morbidity and Mortality Weekly Report is a CDC publication reporting on vaccine safety and public health investigations.\"<|>9)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"CDC\"<|>\"The CDC is an agency under the US Department of Health and Human Services.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"FDA\"<|>\"The FDA is an agency under the US Department of Health and Human Services.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "e33073b20d29d6ce310ed0352190f7d9": {
    "return": "(\"entity\"<|>\"SARS-CoV-2\"<|>\"organization\"<|>\"SARS-CoV-2 is the virus that causes COVID-19, and is the target of diagnostic testing and vaccination in the study.\")##\n(\"entity\"<|>\"COVID-19\"<|>\"event\"<|>\"COVID-19 is the disease caused by SARS-CoV-2, associated with hospitalizations and the focus of vaccine effectiveness evaluation in older adults.\")##\n(\"entity\"<|>\"Reverse Transcription Polymerase Chain Reaction (RT-PCR)\"<|>\"event\"<|>\"RT-PCR is a laboratory diagnostic method used to detect SARS-CoV-2 infection in patients, serving as a criterion for case and control classification.\")##\n(\"entity\"<|>\"Antigen Test\"<|>\"event\"<|>\"Antigen Test is a diagnostic test used to detect SARS-CoV-2 infection, included as part of the eligibility criteria for study participants.\")##\n(\"entity\"<|>\"Hospital Admission\"<|>\"event\"<|>\"Hospital Admission refers to the event of patients being admitted to the hospital, which is used as a reference point for eligibility and data collection in the study.\")##\n(\"entity\"<|>\"Vaccination Record Card\"<|>\"event\"<|>\"Vaccination Record Card is a physical or digital document used to verify receipt and dates of COVID-19 vaccination for study participants.\")##\n(\"entity\"<|>\"March 26, 2021April 19, 2021\"<|>\"event\"<|>\"March 26, 2021April 19, 2021 is the period during which secondary electronic medical records and state immunization registry searches were conducted for vaccination verification.\")##\n(\"entity\"<|>\"January 1March 26, 2021\"<|>\"event\"<|>\"January 1March 26, 2021 is the period during which patients were eligible for participation in the COVID-19 hospitalization study.\")##\n(\"entity\"<|>\"COVID-19associated Hospitalization\"<|>\"event\"<|>\"COVID-19associated Hospitalization refers to hospital admissions due to COVID-19, which is the primary outcome measured in the study.\")##\n(\"entity\"<|>\"Long-term Care Facility\"<|>\"organization\"<|>\"Long-term Care Facility is a type of residential institution where some study participants lived prior to hospital admission.\")##\n(\"entity\"<|>\"U.S.\"<|>\"geo\"<|>\"U.S. refers to the United States, the country where the study was conducted and whose federal laws and policies governed the activity.\")##\n(\"entity\"<|>\"Federal Law\"<|>\"event\"<|>\"Federal Law refers to the legal framework under which the study was reviewed and conducted, including specific regulations cited.\")##\n(\"entity\"<|>\"COVID-19like Illness\"<|>\"event\"<|>\"COVID-19like Illness refers to the onset of symptoms consistent with COVID-19, used as a criterion for study eligibility and timing of vaccination effectiveness.\")##\n(\"entity\"<|>\"Race/Ethnicity\"<|>\"event\"<|>\"Race/Ethnicity is a demographic variable collected and adjusted for in the statistical models of the study.\")##\n(\"entity\"<|>\"Sex\"<|>\"event\"<|>\"Sex is a demographic variable collected and adjusted for in the statistical models of the study.\")##\n(\"entity\"<|>\"Age\"<|>\"event\"<|>\"Age is a demographic variable (as a continuous variable) collected and adjusted for in the statistical models of the study.\")##\n(\"entity\"<|>\"Calendar Month\"<|>\"event\"<|>\"Calendar Month is a temporal variable used in the statistical models to adjust for time-related confounding in the study.\")##\n(\"entity\"<|>\"Logistic Regression Models\"<|>\"event\"<|>\"Logistic Regression Models are statistical methods used to estimate vaccine effectiveness by comparing odds of vaccination between case-patients and controls.\")##\n(\"entity\"<|>\"Vaccine Effectiveness (VE)\"<|>\"event\"<|>\"Vaccine Effectiveness (VE) is the primary outcome measure, calculated as the reduction in odds of hospitalization among vaccinated versus unvaccinated individuals.\")##\n(\"entity\"<|>\"Partial Vaccination\"<|>\"event\"<|>\"Partial Vaccination refers to receipt of one dose of a two-dose vaccine series or two doses with the second dose received less than 14 days before illness onset.\")##\n(\"entity\"<|>\"Full Vaccination\"<|>\"event\"<|>\"Full Vaccination refers to receipt of both doses of a two-dose vaccine series, with the second dose received at least 14 days before illness onset.\")##\n(\"entity\"<|>\"Unvaccinated\"<|>\"event\"<|>\"Unvaccinated refers to individuals who had not received any SARS-CoV-2 vaccine before illness onset.\")##\n(\"entity\"<|>\"Single-dose Vaccinated\"<|>\"event\"<|>\"Single-dose Vaccinated refers to individuals who received the first vaccine dose less than 14 days before COVID-19like illness onset.\")##\n(\"entity\"<|>\"Postmarketing Findings\"<|>\"event\"<|>\"Postmarketing Findings refer to data collected after vaccine rollout, such as those from Israel, used to inform timing of observed vaccine effectiveness.\")##\n(\"entity\"<|>\"Confidence Interval (CI)\"<|>\"event\"<|>\"Confidence Interval (CI) is a statistical measure used to express the uncertainty around the odds ratio and vaccine effectiveness estimates.\")##\n(\"entity\"<|>\"Table\"<|>\"event\"<|>\"Table refers to the summary of demographic and clinical characteristics of study participants, referenced in the text.\")##\n(\"entity\"<|>\"Earlier Hospitalizations\"<|>\"event\"<|>\"Earlier Hospitalizations refers to the history of previous hospital admissions in the last year, a variable collected for study participants.\")##\n(\"entity\"<|>\"Proxy Indicator of Absence of Bias\"<|>\"event\"<|>\"Proxy Indicator of Absence of Bias refers to the use of absence of vaccine effectiveness within 14 days of the first dose as a methodological check for bias in the primary VE estimates.\")##\n(\"entity\"<|>\"Eligibility Criteria\"<|>\"event\"<|>\"Eligibility Criteria refers to the set of requirements for patient inclusion in the study, including age, testing, and timing of illness onset.\")##\n(\"entity\"<|>\"Vaccination Status Verification\"<|>\"event\"<|>\"Vaccination Status Verification refers to the process of confirming participants' vaccination status using multiple sources such as registry, record cards, and self-report.\")##\n(\"entity\"<|>\"Excluded Patients\"<|>\"person\"<|>\"Excluded Patients are individuals who were not included in the final analysis due to reasons such as late testing, late hospitalization, incomplete verification, or receipt of Janssen vaccine.\")##\n(\"entity\"<|>\"Final Analysis Cohort\"<|>\"person\"<|>\"Final Analysis Cohort refers to the 417 patients (187 case-patients and 230 controls) included in the final analysis of the study.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "6c564a29cf38ca86f423e0aa471ad10a": {
    "return": "(\"entity\"<|>\"Trade Names\"<|>\"event\"<|>\"Trade names are mentioned in the context of being used for identification purposes in the MMWR publication, not as endorsements.\")##\n(\"entity\"<|>\"Commercial Sources\"<|>\"event\"<|>\"Commercial sources are referenced in the MMWR for identification only, without implying endorsement by the U.S. Department of Health and Human Services.\")##\n(\"entity\"<|>\"Non-CDC Sites\"<|>\"organization\"<|>\"Non-CDC sites refer to organizations or websites not affiliated with the CDC, which are referenced in the MMWR publication for informational purposes.\")##\n(\"entity\"<|>\"Programs of Non-CDC Organizations\"<|>\"event\"<|>\"Programs of non-CDC organizations are mentioned as being referenced in the MMWR, but not endorsed by CDC or the U.S. Department of Health and Human Services.\")##\n(\"entity\"<|>\"Internet\"<|>\"geo\"<|>\"Internet is referenced as the medium through which non-CDC sites are accessed by MMWR readers.\")##\n(\"entity\"<|>\"URL Addresses\"<|>\"event\"<|>\"URL addresses are listed in the MMWR publication and are noted as being current as of the date of publication.\")##\n(\"entity\"<|>\"Source Citation\"<|>\"event\"<|>\"Source citation is requested when reprinting material from the MMWR Series, indicating the importance of proper attribution.\")##\n(\"relationship\"<|>\"Trade Names\"<|>\"Commercial Sources\"<|>\"Trade names and commercial sources are both used for identification purposes in the MMWR publication, not as endorsements.\"<|>8)##\n(\"relationship\"<|>\"Non-CDC Sites\"<|>\"Internet\"<|>\"Non-CDC sites are accessed via the Internet and are referenced in the MMWR publication.\"<|>7)##\n(\"relationship\"<|>\"Programs of Non-CDC Organizations\"<|>\"Non-CDC Sites\"<|>\"Programs of non-CDC organizations are associated with non-CDC sites referenced in the MMWR.\"<|>8)##\n(\"relationship\"<|>\"URL Addresses\"<|>\"Internet\"<|>\"URL addresses are part of the Internet and are listed in the MMWR for reader access.\"<|>7)##\n(\"relationship\"<|>\"URL Addresses\"<|>\"Date of publication\"<|>\"URL addresses listed in MMWR are noted as being current as of the date of publication, indicating a temporal relationship.\"<|>8)##\n(\"relationship\"<|>\"Source Citation\"<|>\"MMWR Series\"<|>\"Source citation is requested when reprinting material from the MMWR Series, showing a relationship of attribution and proper use.\"<|>9)<|COMPLETE|>",
    "model": "gpt41"
  },
  "19ed84fecc3f93202a963f8e2244d7e2": {
    "return": "(\"entity\"<|>\"Diphenhydramine\"<|>\"organization\"<|>\"Diphenhydramine is an antihistamine medication administered to some persons at vaccination visits, potentially in response to allergic reactions.\")##\n(\"entity\"<|>\"Epinephrine\"<|>\"organization\"<|>\"Epinephrine is a medication used to treat severe allergic reactions, administered to some persons at vaccination visits.\")##\n(\"entity\"<|>\"MedDRA\"<|>\"organization\"<|>\"The Medical Dictionary for Regulatory Activities (MedDRA) is a standardized medical terminology used to code and classify adverse events in VAERS reports.\")##\n(\"entity\"<|>\"mRNA COVID-19 Vaccines\"<|>\"organization\"<|>\"mRNA COVID-19 vaccines refer to vaccines such as Pfizer-BioNTech and Moderna, administered at some mass vaccination sites prior to the Janssen vaccine, without similar clusters of anxiety-related events.\")##\n(\"entity\"<|>\"Table 1\"<|>\"event\"<|>\"Table 1 presents the characteristics of anxiety-related adverse events after receipt of the Janssen COVID-19 vaccine at five U.S. mass vaccination sites during April 7-9, 2021.\")##\n(\"entity\"<|>\"Table 2\"<|>\"event\"<|>\"Table 2 presents data from VAERS reports containing the MedDRA term syncope or syncope vasovagal after vaccination with Janssen COVID-19 vaccine during March 2-April 11, 2021.\")##\n(\"entity\"<|>\"45 C.F.R. part 46\"<|>\"event\"<|>\"45 C.F.R. part 46 is a section of federal regulations governing the protection of human subjects in research, referenced as part of CDC policy compliance.\")##\n(\"entity\"<|>\"21 C.F.R. part 56\"<|>\"event\"<|>\"21 C.F.R. part 56 is a section of federal regulations concerning Institutional Review Boards, referenced as part of CDC policy compliance.\")##\n(\"entity\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"event\"<|>\"42 U.S.C. Sect. 241(d) is a section of the United States Code relating to research and investigations, referenced as part of CDC policy compliance.\")##\n(\"entity\"<|>\"5 U.S.C. Sect. 552a\"<|>\"event\"<|>\"5 U.S.C. Sect. 552a is a section of the United States Code concerning records maintained on individuals, referenced as part of CDC policy compliance.\")##\n(\"entity\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"event\"<|>\"44 U.S.C. Sect. 3501 et seq. is a section of the United States Code relating to federal information policy, referenced as part of CDC policy compliance.\")##\n(\"entity\"<|>\"Hydration\"<|>\"event\"<|>\"Hydration is a supportive care measure provided to patients experiencing anxiety-related adverse events at vaccination sites.\")##\n(\"entity\"<|>\"Food\"<|>\"event\"<|>\"Food is a supportive care measure offered to patients experiencing anxiety-related adverse events at vaccination sites.\")##\n(\"entity\"<|>\"Supine Position\"<|>\"event\"<|>\"Placing the person supine is a supportive care measure used to treat anxiety-related adverse events at vaccination sites.\")##\n(\"entity\"<|>\"Women\"<|>\"person\"<|>\"Women comprised a majority of the reported cases of anxiety-related adverse events and syncope following Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Patients\"<|>\"person\"<|>\"Patients are individuals who received vaccines at mass vaccination sites and experienced anxiety-related adverse events, some with a history of fainting or needle aversion.\")##\n(\"entity\"<|>\"Staff Members\"<|>\"person\"<|>\"Staff members at vaccination sites were informed by patients of a history of fainting associated with injections or needle aversion.\")##\n(\"entity\"<|>\"Persons aged 18 years\"<|>\"person\"<|>\"Persons aged 18 years and older were the population receiving influenza and Janssen COVID-19 vaccines and included in adverse event analyses.\")##\n(\"entity\"<|>\"Persons with history of syncope\"<|>\"person\"<|>\"Persons with a history of syncope associated with receiving injections or needle aversion were identified in VAERS reports and at vaccination sites.\")##\n(\"entity\"<|>\"April 8, 2021\"<|>\"event\"<|>\"April 8, 2021 is a specific date on which Site B reported anxiety-related adverse events and temporarily suspended vaccination.\")##\n(\"entity\"<|>\"April 7, 2021\"<|>\"event\"<|>\"April 7, 2021 is a specific date on which Sites C, D, and E reported anxiety-related adverse events.\")##\n\n(\"relationship\"<|>\"Diphenhydramine\"<|>\"Patients\"<|>\"Diphenhydramine was administered to some patients at vaccination visits, potentially in response to allergic reactions.\"<|>7)##\n(\"relationship\"<|>\"Epinephrine\"<|>\"Patients\"<|>\"Epinephrine was administered to some patients at vaccination visits, potentially in response to allergic reactions.\"<|>7)##\n(\"relationship\"<|>\"MedDRA\"<|>\"VAERS\"<|>\"VAERS reports use MedDRA preferred terms to code and classify adverse events following vaccination.\"<|>9)##\n(\"relationship\"<|>\"mRNA COVID-19 Vaccines\"<|>\"Five Mass Vaccination Sites\"<|>\"Four of the five mass vaccination sites had previously administered mRNA COVID-19 vaccines without similar clusters of anxiety-related events.\"<|>8)##\n(\"relationship\"<|>\"Table 1\"<|>\"Anxiety-Related Adverse Event Cluster\"<|>\"Table 1 summarizes the characteristics of anxiety-related adverse event clusters at five mass vaccination sites.\"<|>8)##\n(\"relationship\"<|>\"Table 2\"<|>\"Syncope\"<|>\"Table 2 presents VAERS data on syncope events following Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"45 C.F.R. part 46\"<|>\"CDC\"<|>\"CDC conducted activities consistent with 45 C.F.R. part 46, ensuring protection of human subjects in research.\"<|>7)##\n(\"relationship\"<|>\"21 C.F.R. part 56\"<|>\"CDC\"<|>\"CDC conducted activities consistent with 21 C.F.R. part 56, ensuring IRB compliance.\"<|>7)##\n(\"relationship\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"CDC\"<|>\"CDC conducted activities consistent with 42 U.S.C. Sect. 241(d), relating to research and investigations.\"<|>7)##\n(\"relationship\"<|>\"5 U.S.C. Sect. 552a\"<|>\"CDC\"<|>\"CDC conducted activities consistent with 5 U.S.C. Sect. 552a, relating to records maintained on individuals.\"<|>7)##\n(\"relationship\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"CDC\"<|>\"CDC conducted activities consistent with 44 U.S.C. Sect. 3501 et seq., relating to federal information policy.\"<|>7)##\n(\"relationship\"<|>\"Hydration\"<|>\"Patients\"<|>\"Hydration was provided as supportive care to patients experiencing anxiety-related adverse events at vaccination sites.\"<|>7)##\n(\"relationship\"<|>\"Food\"<|>\"Patients\"<|>\"Food was offered as supportive care to patients experiencing anxiety-related adverse events at vaccination sites.\"<|>7)##\n(\"relationship\"<|>\"Supine Position\"<|>\"Patients\"<|>\"Placing patients in the supine position was a supportive care measure for anxiety-related adverse events.\"<|>7)##\n(\"relationship\"<|>\"Women\"<|>\"Anxiety-Related Adverse Event Cluster\"<|>\"Women comprised a majority of the cases in anxiety-related adverse event clusters following Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Women\"<|>\"Syncope\"<|>\"Women comprised half of the reported syncope cases following Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Patients\"<|>\"Staff Members\"<|>\"Patients informed staff members of a history of fainting associated with injections or needle aversion.\"<|>7)##\n(\"relationship\"<|>\"Persons aged 18 years\"<|>\"Influenza Vaccine\"<|>\"Persons aged 18 years and older received influenza vaccines and were included in adverse event analyses.\"<|>7)##\n(\"relationship\"<|>\"Persons aged 18 years\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Persons aged 18 years and older received Janssen COVID-19 vaccines and were included in adverse event analyses.\"<|>7)##\n(\"relationship\"<|>\"Persons with history of syncope\"<|>\"Patients\"<|>\"Some patients had a history of syncope associated with receiving injections or needle aversion, as reported in VAERS and at vaccination sites.\"<|>8)##\n(\"relationship\"<|>\"April 8, 2021\"<|>\"Site B\"<|>\"Site B reported anxiety-related adverse events and temporarily suspended vaccination on April 8, 2021.\"<|>8)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site C\"<|>\"Site C reported anxiety-related adverse events on April 7, 2021.\"<|>8)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site D\"<|>\"Site D reported anxiety-related adverse events on April 7, 2021.\"<|>8)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site E\"<|>\"Site E reported anxiety-related adverse events on April 7, 2021.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "084c52a5c51a759d6ed394569f36ce9c": {
    "return": "(\"entity\"<|>\"Israel\"<|>\"geo\"<|>\"Israel is a country referenced as the source of postmarketing findings regarding vaccine effectiveness (VE) observed at 14 days after vaccination with one dose.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal agency responsible for protecting the health of Americans and providing essential human services.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a US federal agency under the Department of Health and Human Services, focused on public health, disease control, and prevention.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"The Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that provides public health information and statistics.\")##\n(\"entity\"<|>\"COVID-19like illness\"<|>\"event\"<|>\"COVID-19like illness refers to a set of clinical symptoms and criteria used to identify cases potentially related to COVID-19 in hospitalized adults.\")##\n(\"entity\"<|>\"SARS-CoV-2 infection\"<|>\"event\"<|>\"SARS-CoV-2 infection is the event of contracting the virus responsible for COVID-19, as tested among adults in the study.\")##\n(\"entity\"<|>\"HAIVEN\"<|>\"organization\"<|>\"HAIVEN (Hospitalized Adult Influenza Vaccine Effectiveness Network) is a hospital network involved in evaluating vaccine effectiveness among adults hospitalized with influenza or COVID-19like illness.\")##\n(\"entity\"<|>\"IVY\"<|>\"organization\"<|>\"IVY (Influenza and Other Viruses in the Acutely Ill) is a hospital network that sets clinical criteria for COVID-19like illness and participates in related research.\")##\n(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"Pfizer-BioNTech is a pharmaceutical collaboration that developed one of the COVID-19 vaccines used in the study population.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"Moderna is a biotechnology company that developed one of the COVID-19 vaccines used in the study population.\")##\n(\"entity\"<|>\"24 medical centers in 14 states\"<|>\"organization\"<|>\"A group of 24 medical centers located across 14 US states participated in the study, testing adults aged 65 years for SARS-CoV-2 infection.\")##\n(\"entity\"<|>\"Northeast\"<|>\"geo\"<|>\"Northeast is a US Census region represented in the study population.\")##\n(\"entity\"<|>\"South\"<|>\"geo\"<|>\"South is a US Census region represented in the study population.\")##\n(\"entity\"<|>\"Midwest\"<|>\"geo\"<|>\"Midwest is a US Census region represented in the study population.\")##\n(\"entity\"<|>\"West\"<|>\"geo\"<|>\"West is a US Census region represented in the study population.\")##\n(\"entity\"<|>\"January-March 2021\"<|>\"event\"<|>\"January-March 2021 is the time period during which the study of adults aged 65 years with COVID-19like illness was conducted.\")##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services as a federal agency focused on public health.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"The CDC publishes the Morbidity and Mortality Weekly Report to disseminate public health data and findings.\"<|>9)##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19like illness\"<|>\"Pfizer-BioNTech's vaccine is used in the population studied for COVID-19like illness, indicating its relevance to the event.\"<|>8)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19like illness\"<|>\"Moderna's vaccine is used in the population studied for COVID-19like illness, indicating its relevance to the event.\"<|>8)##\n(\"relationship\"<|>\"Israel\"<|>\"COVID-19like illness\"<|>\"Israel provided postmarketing findings on vaccine effectiveness relevant to COVID-19like illness after vaccination.\"<|>7)##\n(\"relationship\"<|>\"HAIVEN\"<|>\"COVID-19like illness\"<|>\"HAIVEN network sets clinical criteria and participates in research on COVID-19like illness among hospitalized adults.\"<|>8)##\n(\"relationship\"<|>\"IVY\"<|>\"COVID-19like illness\"<|>\"IVY network sets clinical criteria and participates in research on COVID-19like illness among hospitalized adults.\"<|>8)##\n(\"relationship\"<|>\"24 medical centers in 14 states\"<|>\"COVID-19like illness\"<|>\"The 24 medical centers in 14 states tested adults aged 65 years for COVID-19like illness as part of the study.\"<|>9)##\n(\"relationship\"<|>\"Northeast\"<|>\"24 medical centers in 14 states\"<|>\"Northeast is one of the US Census regions where the participating medical centers are located.\"<|>7)##\n(\"relationship\"<|>\"South\"<|>\"24 medical centers in 14 states\"<|>\"South is one of the US Census regions where the participating medical centers are located.\"<|>7)##\n(\"relationship\"<|>\"Midwest\"<|>\"24 medical centers in 14 states\"<|>\"Midwest is one of the US Census regions where the participating medical centers are located.\"<|>7)##\n(\"relationship\"<|>\"West\"<|>\"24 medical centers in 14 states\"<|>\"West is one of the US Census regions where the participating medical centers are located.\"<|>7)##\n(\"relationship\"<|>\"COVID-19like illness\"<|>\"SARS-CoV-2 infection\"<|>\"COVID-19like illness is the set of symptoms used to identify and test for SARS-CoV-2 infection among adults in the study.\"<|>9)##\n(\"relationship\"<|>\"January-March 2021\"<|>\"COVID-19like illness\"<|>\"The study of COVID-19like illness among adults aged 65 years was conducted during January-March 2021.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "f04e20a863f170fd5fe877de946d002b": {
    "return": "(\"entity\"<|>\"Enrollees\"<|>\"person\"<|>\"Enrollees are individuals participating in a health-related study or monitoring activity, reporting various reactions and health impacts over a period of seven days.\")##\n(\"entity\"<|>\"Clinic\"<|>\"organization\"<|>\"Clinic refers to a healthcare facility where enrollees may seek medical care for reactions or health impacts reported during the study period.\")##\n(\"entity\"<|>\"Telehealth\"<|>\"organization\"<|>\"Telehealth is a healthcare service that provides remote medical consultations and care to enrollees reporting health impacts or reactions.\")##\n(\"entity\"<|>\"Day 0\"<|>\"event\"<|>\"Day 0 marks the initial day of the study or monitoring period when enrollees begin reporting reactions and health impacts.\")##\n(\"entity\"<|>\"Day 1\"<|>\"event\"<|>\"Day 1 is the first day following the initial reporting period, with continued monitoring of enrollees' reactions and health impacts.\")##\n(\"entity\"<|>\"Day 2\"<|>\"event\"<|>\"Day 2 is the second day of the study, with ongoing data collection on enrollees' reactions and health impacts.\")##\n(\"entity\"<|>\"Day 3\"<|>\"event\"<|>\"Day 3 is the third day of the study, continuing the tracking of reported reactions and health impacts.\")##\n(\"entity\"<|>\"Day 4\"<|>\"event\"<|>\"Day 4 is the fourth day of the study, with further monitoring of enrollees' health status and reactions.\")##\n(\"entity\"<|>\"Day 5\"<|>\"event\"<|>\"Day 5 is the fifth day of the study, with continued reporting of reactions and health impacts.\")##\n(\"entity\"<|>\"Day 6\"<|>\"event\"<|>\"Day 6 is the sixth day of the study, with ongoing data collection from enrollees.\")##\n(\"entity\"<|>\"Day 7\"<|>\"event\"<|>\"Day 7 is the final day of the study period, concluding the monitoring of enrollees' reactions and health impacts.\")##\n(\"relationship\"<|>\"Enrollees\"<|>\"Clinic\"<|>\"Enrollees may seek medical care at clinics for reactions or health impacts experienced during the study period.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Telehealth\"<|>\"Enrollees may use telehealth services for remote medical consultations regarding their reported reactions and health impacts.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 0\"<|>\"Enrollees begin reporting reactions and health impacts on Day 0, marking the start of the study.\"<|>9)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 1\"<|>\"Enrollees continue to report reactions and health impacts on Day 1 as part of the ongoing study.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 2\"<|>\"Enrollees report reactions and health impacts on Day 2, contributing to the study's data collection.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 3\"<|>\"Enrollees report reactions and health impacts on Day 3, continuing the monitoring process.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 4\"<|>\"Enrollees report reactions and health impacts on Day 4, as part of the study timeline.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 5\"<|>\"Enrollees report reactions and health impacts on Day 5, maintaining the study's data flow.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 6\"<|>\"Enrollees report reactions and health impacts on Day 6, nearing the end of the study period.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Day 7\"<|>\"Enrollees report reactions and health impacts on Day 7, concluding the study's monitoring phase.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "b65378fcab82df85f8748832458927be": {
    "return": "(\"entity\"<|>\"Epinephrine\"<|>\"event\"<|>\"Epinephrine is a medication administered to some persons at vaccination visits, typically used to treat severe allergic reactions or anaphylaxis.\")##\n(\"entity\"<|>\"Diphenhydramine\"<|>\"event\"<|>\"Diphenhydramine is an antihistamine medication administered to some persons at vaccination visits, often used to treat allergic reactions.\")##\n(\"entity\"<|>\"Persons aged 18-29 years\"<|>\"person\"<|>\"Persons aged 18-29 years are identified as the age group with the highest proportion of reported syncopal events after Janssen COVID-19 and influenza vaccination.\")##\n(\"entity\"<|>\"Persons aged 11-18 years\"<|>\"person\"<|>\"Persons aged 11-18 years are reported as having the highest rates of syncope after vaccination, according to VAERS data.\")##\n(\"entity\"<|>\"Persons aged 19-49 years\"<|>\"person\"<|>\"Persons aged 19-49 years are reported as the second most frequent age group for syncope after vaccination, according to VAERS data.\")##\n(\"entity\"<|>\"Adolescents\"<|>\"person\"<|>\"Adolescents are referenced as having higher rates of syncope after vaccination, including after quadrivalent human papillomavirus vaccine.\")##\n(\"entity\"<|>\"Adults aged 18 years and older\"<|>\"person\"<|>\"Adults aged 18 years and older are the population receiving influenza vaccine during July 1, 2019June 30, 2020, and are referenced in the report.\")##\n(\"entity\"<|>\"Persons with needle aversion\"<|>\"person\"<|>\"Persons with needle aversion are identified as individuals who may be more likely to experience anxiety-related events, including syncope, after vaccination.\")##\n(\"entity\"<|>\"Persons with history of syncope\"<|>\"person\"<|>\"Persons with a history of syncope are noted as being more likely to experience syncopal events after vaccination.\")##\n(\"entity\"<|>\"Vaccine Providers\"<|>\"person\"<|>\"Vaccine providers are healthcare professionals responsible for administering vaccines and monitoring recipients for adverse reactions.\")##\n(\"entity\"<|>\"Reporter\"<|>\"person\"<|>\"Reporter refers to individuals who submit adverse event reports to VAERS, providing information about vaccination events.\")##\n(\"entity\"<|>\"Media\"<|>\"organization\"<|>\"Media refers to news and information outlets that may report on anxiety-related events at vaccination sites, potentially influencing public perception and anxiety.\")##\n(\"entity\"<|>\"Emergency Use Authorization (EUA)\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is a regulatory mechanism under which the Janssen COVID-19 vaccine was authorized, requiring healthcare providers to report potentially life-threatening events.\")##\n(\"entity\"<|>\"2019-2020 Influenza Season\"<|>\"event\"<|>\"2019-2020 Influenza Season refers to the period during which influenza vaccines were administered and compared to COVID-19 vaccines in the report.\")##\n(\"entity\"<|>\"Vaccination Visit\"<|>\"event\"<|>\"Vaccination Visit refers to the occasion when a person receives a vaccine, during which adverse events such as syncope may occur.\")##\n(\"entity\"<|>\"Prioritization by age group, occupation, or underlying health condition\"<|>\"event\"<|>\"Prioritization by age group, occupation, or underlying health condition refers to the CDC's recommendations for vaccine distribution when supply was limited.\")##\n(\"entity\"<|>\"Ongoing Pandemic\"<|>\"event\"<|>\"Ongoing Pandemic refers to the global COVID-19 pandemic, which is noted as a factor increasing anxiety surrounding vaccination.\")##\n(\"entity\"<|>\"History of similar events after vaccination\"<|>\"event\"<|>\"History of similar events after vaccination refers to individuals who have previously experienced anxiety-related events, such as syncope, after receiving vaccines.\")##\n(\"entity\"<|>\"Multiple vaccines administered immediately before syncopal episode\"<|>\"event\"<|>\"Multiple vaccines administered immediately before syncopal episode refers to cases where individuals received more than one vaccine prior to experiencing syncope.\")##\n(\"entity\"<|>\"Mass vaccination situation\"<|>\"event\"<|>\"Mass vaccination situation refers to the context in which large numbers of people are vaccinated at once, which can influence the occurrence and reporting of anxiety-related events.\")##\n(\"entity\"<|>\"Suspension of COVID-19 vaccination\"<|>\"event\"<|>\"Suspension of COVID-19 vaccination refers to the temporary halting of vaccination at some mass vaccination sites due to anxiety-related events.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "1ec2da351a1ff27eea8898a9299dbab3": {
    "return": "(\"entity\"<|>\"Jennifer Goff\"<|>\"person\"<|>\"Jennifer Goff is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Alexandra June Gordon\"<|>\"person\"<|>\"Alexandra June Gordon is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Audrey Hendrickson\"<|>\"person\"<|>\"Audrey Hendrickson is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Madeline Hicks\"<|>\"person\"<|>\"Madeline Hicks is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Michelle Howell\"<|>\"person\"<|>\"Michelle Howell is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jakea Johnson\"<|>\"person\"<|>\"Jakea Johnson is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jeffrey Jorgensen\"<|>\"person\"<|>\"Jeffrey Jorgensen is affiliated with Intermountain Medical Center in Salt Lake City, Utah, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Sarah Karow\"<|>\"person\"<|>\"Sarah Karow is affiliated with Ohio State University Wexner Medical Center in Columbus, Ohio, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Lori Kozikowski\"<|>\"person\"<|>\"Lori Kozikowski is affiliated with Baystate Medical Center in Springfield, Massachusetts, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Olivia Krol\"<|>\"person\"<|>\"Olivia Krol is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Leigha Landreth\"<|>\"person\"<|>\"Leigha Landreth is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Mary LaRose\"<|>\"person\"<|>\"Mary LaRose is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Brenda Lopez\"<|>\"person\"<|>\"Brenda Lopez is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Andrea Luong\"<|>\"person\"<|>\"Andrea Luong is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Bob McClellan\"<|>\"person\"<|>\"Bob McClellan is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Ellen Maruggi\"<|>\"person\"<|>\"Ellen Maruggi is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Karen Miller\"<|>\"person\"<|>\"Karen Miller is affiliated with Vanderbilt University Medical Center in Nashville, Tennessee, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Rahul Nair\"<|>\"person\"<|>\"Rahul Nair is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Lisa Parks\"<|>\"person\"<|>\"Lisa Parks is affiliated with Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jennifer Peers\"<|>\"person\"<|>\"Jennifer Peers is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Cynthia Perez\"<|>\"person\"<|>\"Cynthia Perez is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Adreanne Rivera\"<|>\"person\"<|>\"Adreanne Rivera is affiliated with Reagan-UCLA Medical Center in Los Angeles, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Jonasel Roque\"<|>\"person\"<|>\"Jonasel Roque is affiliated with Stanford University School of Medicine in Palo Alto, California, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Andres Santana\"<|>\"person\"<|>\"Andres Santana is affiliated with Baystate Medical Center in Springfield, Massachusetts, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Tyler Scharber\"<|>\"person\"<|>\"Tyler Scharber is affiliated with Hennepin County Medical Center in Minneapolis, Minnesota, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Emma Silverman\"<|>\"person\"<|>\"Emma Silverman is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Michael Tozier\"<|>\"person\"<|>\"Michael Tozier is affiliated with University of Colorado School of Medicine in Aurora, Colorado, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Hiwet Tzehaie\"<|>\"person\"<|>\"Hiwet Tzehaie is affiliated with Montefiore Healthcare Center and Albert Einstein College of Medicine in Bronx, New York, and is likely involved in medical research or clinical activities.\")##\n(\"entity\"<|>\"Zachary Zouyed\"<|>\"person\"<|>\"Zachary Zouyed is affiliated with Oregon Health & Science University in Portland, Oregon, and is likely involved in medical research or clinical activities.\")##\n\n(\"relationship\"<|>\"Jennifer Goff\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Goff is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Alexandra June Gordon\"<|>\"Stanford University School of Medicine\"<|>\"Alexandra June Gordon is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Audrey Hendrickson\"<|>\"Hennepin County Medical Center\"<|>\"Audrey Hendrickson is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Madeline Hicks\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Madeline Hicks is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Michelle Howell\"<|>\"University of Colorado School of Medicine\"<|>\"Michelle Howell is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jakea Johnson\"<|>\"Vanderbilt University Medical Center\"<|>\"Jakea Johnson is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jeffrey Jorgensen\"<|>\"Intermountain Medical Center\"<|>\"Jeffrey Jorgensen is affiliated with Intermountain Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Sarah Karow\"<|>\"Ohio State University Wexner Medical Center\"<|>\"Sarah Karow is affiliated with Ohio State University Wexner Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Lori Kozikowski\"<|>\"Baystate Medical Center\"<|>\"Lori Kozikowski is affiliated with Baystate Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Olivia Krol\"<|>\"Oregon Health & Science University\"<|>\"Olivia Krol is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Leigha Landreth\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Leigha Landreth is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Mary LaRose\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Mary LaRose is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Brenda Lopez\"<|>\"Montefiore Healthcare Center\"<|>\"Brenda Lopez is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Brenda Lopez\"<|>\"Albert Einstein College of Medicine\"<|>\"Brenda Lopez is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Andrea Luong\"<|>\"Oregon Health & Science University\"<|>\"Andrea Luong is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Bob McClellan\"<|>\"Vanderbilt University Medical Center\"<|>\"Bob McClellan is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Ellen Maruggi\"<|>\"Hennepin County Medical Center\"<|>\"Ellen Maruggi is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Karen Miller\"<|>\"Vanderbilt University Medical Center\"<|>\"Karen Miller is affiliated with Vanderbilt University Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Rahul Nair\"<|>\"Montefiore Healthcare Center\"<|>\"Rahul Nair is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Rahul Nair\"<|>\"Albert Einstein College of Medicine\"<|>\"Rahul Nair is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Lisa Parks\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Lisa Parks is affiliated with Wake Forest University Baptist Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jennifer Peers\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Peers is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Cynthia Perez\"<|>\"Stanford University School of Medicine\"<|>\"Cynthia Perez is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Adreanne Rivera\"<|>\"Reagan-UCLA Medical Center\"<|>\"Adreanne Rivera is affiliated with Reagan-UCLA Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Jonasel Roque\"<|>\"Stanford University School of Medicine\"<|>\"Jonasel Roque is affiliated with Stanford University School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Andres Santana\"<|>\"Baystate Medical Center\"<|>\"Andres Santana is affiliated with Baystate Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Tyler Scharber\"<|>\"Hennepin County Medical Center\"<|>\"Tyler Scharber is affiliated with Hennepin County Medical Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Emma Silverman\"<|>\"Oregon Health & Science University\"<|>\"Emma Silverman is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Michael Tozier\"<|>\"University of Colorado School of Medicine\"<|>\"Michael Tozier is affiliated with University of Colorado School of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hiwet Tzehaie\"<|>\"Montefiore Healthcare Center\"<|>\"Hiwet Tzehaie is affiliated with Montefiore Healthcare Center as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Hiwet Tzehaie\"<|>\"Albert Einstein College of Medicine\"<|>\"Hiwet Tzehaie is affiliated with Albert Einstein College of Medicine as a researcher or clinician.\"<|>9)##\n(\"relationship\"<|>\"Zachary Zouyed\"<|>\"Oregon Health & Science University\"<|>\"Zachary Zouyed is affiliated with Oregon Health & Science University as a researcher or clinician.\"<|>9)##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "550361ff84679911e40385b55f3cbb0d": {
    "return": "(\"entity\"<|>\"Janssen\"<|>\"organization\"<|>\"Janssen is a pharmaceutical company that manufactures the Janssen COVID-19 vaccine, which is a single-dose vaccine using a replication-incompetent human adenovirus type 26 vector encoding the SARS-CoV-2 spike glycoprotein.\")##\n(\"entity\"<|>\"AstraZeneca\"<|>\"organization\"<|>\"AstraZeneca is a pharmaceutical company that manufactures the AstraZeneca COVID-19 vaccine, which uses a replication-incompetent chimpanzee adenoviral vector.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"CDC (Centers for Disease Control and Prevention) is a U.S. federal agency responsible for public health, including managing the VAERS surveillance program and reviewing vaccine safety data.\")##\n(\"entity\"<|>\"FDA\"<|>\"organization\"<|>\"FDA (Food and Drug Administration) is a U.S. federal agency that co-manages the VAERS surveillance program and oversees vaccine safety and regulation.\")##\n(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"VAERS (Vaccine Adverse Events Reporting System) is a national passive surveillance program managed by CDC and FDA that monitors adverse events after all vaccinations, accepting reports from health care providers, manufacturers, and the public.\")##\n(\"entity\"<|>\"V-safe\"<|>\"organization\"<|>\"V-safe is a voluntary, text-based active surveillance system designed to collect additional information about COVID-19 vaccine adverse events, particularly common side effects, through regular health surveys sent to vaccine recipients.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"The United States is the country where 7.98 million doses of the Janssen COVID-19 vaccine had been administered as of April 21, 2021, and where CDC and FDA operate.\")##\n(\"entity\"<|>\"Europe\"<|>\"geo\"<|>\"Europe is a region where similar thrombotic events, primarily among women under 60, were described after receipt of the AstraZeneca COVID-19 vaccine.\")##\n(\"entity\"<|>\"TTS\"<|>\"event\"<|>\"Thrombosis with Thrombocytopenia Syndrome (TTS) is a newly defined condition involving acute venous or arterial thrombosis and new onset thrombocytopenia, observed among recipients of the Janssen and AstraZeneca COVID-19 vaccines.\")##\n(\"entity\"<|>\"CVST\"<|>\"event\"<|>\"Cerebral Venous Sinus Thrombosis (CVST) is a specific type of thrombotic event that prompted the pause in Janssen vaccination in the U.S. and has been detected in other cases.\")##\n(\"entity\"<|>\"COVID-19 Vaccination Pause\"<|>\"event\"<|>\"The COVID-19 Vaccination Pause refers to the temporary halt in the use of the Janssen COVID-19 vaccine in the U.S. following detection of CVST cases.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"MMWR is a publication of the CDC that reports on public health data, including vaccine safety and adverse events.\")##\n(\"entity\"<|>\"Brighton Collaboration\"<|>\"organization\"<|>\"Brighton Collaboration is an organization that provides case definitions for vaccine-related adverse events, including TTS.\")##\n\n(\"relationship\"<|>\"Janssen\"<|>\"Janssen COVID-19 vaccine\"<|>\"Janssen is the manufacturer of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"AstraZeneca\"<|>\"AstraZeneca COVID-19 vaccine\"<|>\"AstraZeneca is the manufacturer of the AstraZeneca COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Janssen COVID-19 vaccine\"<|>\"TTS\"<|>\"Cases of TTS have been observed among recipients of the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"AstraZeneca COVID-19 vaccine\"<|>\"TTS\"<|>\"Cases of TTS have been observed among recipients of the AstraZeneca COVID-19 vaccine, especially in Europe.\"<|>8)##\n(\"relationship\"<|>\"Janssen COVID-19 vaccine\"<|>\"CVST\"<|>\"CVST cases prompted the pause in Janssen vaccination and have been detected among recipients.\"<|>9)##\n(\"relationship\"<|>\"VAERS\"<|>\"CDC\"<|>\"VAERS is managed by CDC as part of vaccine safety monitoring.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"FDA\"<|>\"VAERS is managed by FDA as part of vaccine safety monitoring.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"Janssen COVID-19 vaccine\"<|>\"VAERS collects and reviews adverse event reports related to the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"VAERS\"<|>\"V-safe\"<|>\"VAERS and v-safe are complementary surveillance systems for monitoring COVID-19 vaccine safety.\"<|>8)##\n(\"relationship\"<|>\"V-safe\"<|>\"Janssen COVID-19 vaccine\"<|>\"V-safe collects active surveillance data from Janssen COVID-19 vaccine recipients through health surveys.\"<|>8)##\n(\"relationship\"<|>\"CDC\"<|>\"FDA\"<|>\"CDC and FDA jointly manage VAERS and oversee vaccine safety in the United States.\"<|>10)##\n(\"relationship\"<|>\"CDC\"<|>\"United States\"<|>\"CDC operates as a federal public health agency in the United States.\"<|>10)##\n(\"relationship\"<|>\"FDA\"<|>\"United States\"<|>\"FDA operates as a federal regulatory agency in the United States.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 Vaccination Pause\"<|>\"Janssen COVID-19 vaccine\"<|>\"The pause in vaccination was initiated due to CVST cases among Janssen COVID-19 vaccine recipients.\"<|>9)##\n(\"relationship\"<|>\"CVST\"<|>\"COVID-19 Vaccination Pause\"<|>\"CVST cases were the direct cause of the COVID-19 Vaccination Pause for the Janssen vaccine.\"<|>10)##\n(\"relationship\"<|>\"Brighton Collaboration\"<|>\"TTS\"<|>\"Brighton Collaboration provided the interim case definition for TTS used in surveillance and reporting.\"<|>8)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"CDC\"<|>\"MMWR is a publication produced by CDC to disseminate public health data and reports.\"<|>9)##\n(\"relationship\"<|>\"Europe\"<|>\"AstraZeneca COVID-19 vaccine\"<|>\"Thrombotic events related to the AstraZeneca COVID-19 vaccine have been described in Europe, especially among women under 60.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"Janssen COVID-19 vaccine\"<|>\"7.98 million doses of the Janssen COVID-19 vaccine had been administered in the United States as of April 21, 2021.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "f9085e51bac5aa552d7f0f8057b968c0": {
    "return": "(\"entity\"<|>\"Janssen Pharmaceuticals\"<|>\"organization\"<|>\"Janssen Pharmaceuticals is the manufacturer of the Janssen COVID-19 vaccine, a subsidiary of Johnson & Johnson, responsible for developing and distributing the vaccine.\")##\n(\"entity\"<|>\"Johnson & Johnson\"<|>\"organization\"<|>\"Johnson & Johnson is a multinational corporation and the parent company of Janssen Pharmaceuticals, which developed the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Non-Hispanic White\"<|>\"person\"<|>\"Non-Hispanic White refers to vaccine recipients who self-identified as White and not Hispanic; they comprised 38% of those vaccinated with the Janssen COVID-19 vaccine during the study period.\")##\n(\"entity\"<|>\"Women\"<|>\"person\"<|>\"Women represent a demographic group in the vaccine safety analysis, comprising 50% of vaccine recipients and 66% of VAERS adverse event reports.\")##\n(\"entity\"<|>\"Men\"<|>\"person\"<|>\"Men represent a demographic group in the vaccine safety analysis, comprising 38 of the 88 reported decedents after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Table 1\"<|>\"event\"<|>\"Table 1 is a referenced data table summarizing adverse event reports, demographic breakdowns, and symptoms reported to VAERS for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Table 2\"<|>\"event\"<|>\"Table 2 is a referenced data table summarizing clinical details of TTS cases among Janssen COVID-19 vaccine recipients.\")##\n(\"entity\"<|>\"Table 3\"<|>\"event\"<|>\"Table 3 is a referenced data table summarizing v-safe survey results, including systemic and injection site reactions among Janssen COVID-19 vaccine recipients.\")##\n(\"entity\"<|>\"Supplementary Table\"<|>\"event\"<|>\"The Supplementary Table is an online resource providing additional demographic and survey data for v-safe enrollees.\")##\n(\"entity\"<|>\"MedDRA\"<|>\"organization\"<|>\"MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology used to code and classify adverse event reports in VAERS.\")##\n(\"entity\"<|>\"Health care provider\"<|>\"person\"<|>\"Health care providers are medical professionals who conducted interviews and reviewed medical records to confirm cases of anaphylaxis after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Cardiac arrest\"<|>\"event\"<|>\"Cardiac arrest is one of the most frequent preliminary causes of death among decedents after Janssen COVID-19 vaccination, as determined by CDC and FDA reviewers.\")##\n(\"entity\"<|>\"Cardiovascular disease\"<|>\"event\"<|>\"Cardiovascular disease is another frequent preliminary cause of death among decedents after Janssen COVID-19 vaccination, as determined by CDC and FDA reviewers.\")##\n(\"entity\"<|>\"COVID-19 disease\"<|>\"event\"<|>\"COVID-19 disease is listed as a cause of death in eight reports among decedents after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Cerebrovascular disease\"<|>\"event\"<|>\"Cerebrovascular disease is listed as a cause of death in five reports among decedents after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Medical records\"<|>\"event\"<|>\"Medical records were reviewed by CDC and FDA staff physicians to confirm adverse events and causes of death among vaccine recipients.\")##\n(\"entity\"<|>\"Death certificates\"<|>\"event\"<|>\"Death certificates were available for 12 of the 88 reported decedents after Janssen COVID-19 vaccination and were reviewed by CDC and FDA.\")##\n(\"entity\"<|>\"Autopsy reports\"<|>\"event\"<|>\"Autopsy reports were reviewed by CDC and FDA staff physicians to help determine the cause of death among vaccine recipients.\")##\n(\"entity\"<|>\"Staff physicians\"<|>\"person\"<|>\"Staff physicians are medical professionals employed by CDC and FDA who conducted medical reviews of adverse event and death reports.\")##\n(\"entity\"<|>\"Jurisdictions\"<|>\"organization\"<|>\"Jurisdictions refer to state and local public health authorities receiving COVID-19 vaccines and implementing CDC guidance, including distribution of v-safe promotional materials.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report Vol. 70, No. 18\"<|>\"event\"<|>\"This is the specific issue of the Morbidity and Mortality Weekly Report (MMWR) in which the described vaccine safety data was published.\")##\n(\"entity\"<|>\"45 C.F.R. part 46\"<|>\"event\"<|>\"45 C.F.R. part 46 is a section of the Code of Federal Regulations governing the protection of human subjects in research, referenced as part of CDC's compliance.\")##\n(\"entity\"<|>\"21 C.F.R. part 56\"<|>\"event\"<|>\"21 C.F.R. part 56 is a section of the Code of Federal Regulations governing Institutional Review Boards, referenced as part of CDC's compliance.\")##\n(\"entity\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"event\"<|>\"42 U.S.C. Sect. 241(d) is a section of the United States Code relating to public health service research, referenced as part of CDC's compliance.\")##\n(\"entity\"<|>\"5 U.S.C. Sect. 552a\"<|>\"event\"<|>\"5 U.S.C. Sect. 552a is a section of the United States Code governing privacy of records maintained by federal agencies, referenced as part of CDC's compliance.\")##\n(\"entity\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"event\"<|>\"44 U.S.C. Sect. 3501 et seq. is a section of the United States Code governing federal information policy, referenced as part of CDC's compliance.\")##\n\n(\"relationship\"<|>\"Janssen Pharmaceuticals\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Janssen Pharmaceuticals is the developer and manufacturer of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Johnson & Johnson\"<|>\"Janssen Pharmaceuticals\"<|>\"Janssen Pharmaceuticals is a subsidiary of Johnson & Johnson.\"<|>9)##\n(\"relationship\"<|>\"Non-Hispanic White\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Non-Hispanic White individuals comprised 38% of those vaccinated with the Janssen COVID-19 vaccine during the study period.\"<|>8)##\n(\"relationship\"<|>\"Women\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Women comprised 50% of vaccine recipients and 66% of VAERS adverse event reports for the Janssen COVID-19 vaccine.\"<|>9)##\n(\"relationship\"<|>\"Men\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Men comprised 38 of the 88 reported decedents after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Table 1\"<|>\"VAERS\"<|>\"Table 1 summarizes adverse event reports and demographic breakdowns from VAERS for the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Table 2\"<|>\"TTS\"<|>\"Table 2 summarizes clinical details of TTS cases among Janssen COVID-19 vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Table 3\"<|>\"V-safe\"<|>\"Table 3 summarizes v-safe survey results, including systemic and injection site reactions among Janssen COVID-19 vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Supplementary Table\"<|>\"V-safe\"<|>\"The Supplementary Table provides additional demographic and survey data for v-safe enrollees.\"<|>7)##\n(\"relationship\"<|>\"MedDRA\"<|>\"VAERS\"<|>\"VAERS uses MedDRA to code and classify adverse event reports for vaccine safety monitoring.\"<|>9)##\n(\"relationship\"<|>\"Health care provider\"<|>\"Anaphylaxis after Janssen COVID-19 Vaccine\"<|>\"Health care providers conducted interviews and reviewed medical records to confirm cases of anaphylaxis after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Cardiac arrest\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"Cardiac arrest was a frequent preliminary cause of death among decedents after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"Cardiovascular disease\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"Cardiovascular disease was a frequent preliminary cause of death among decedents after Janssen COVID-19 vaccination.\"<|>8)##\n(\"relationship\"<|>\"COVID-19 disease\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"COVID-19 disease was listed as a cause of death in eight reports among decedents after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Cerebrovascular disease\"<|>\"Death after Janssen COVID-19 Vaccine\"<|>\"Cerebrovascular disease was listed as a cause of death in five reports among decedents after Janssen COVID-19 vaccination.\"<|>7)##\n(\"relationship\"<|>\"Medical records\"<|>\"CDC\"<|>\"CDC staff physicians reviewed medical records to confirm adverse events and causes of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Medical records\"<|>\"FDA\"<|>\"FDA staff physicians reviewed medical records to confirm adverse events and causes of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Death certificates\"<|>\"CDC\"<|>\"CDC staff physicians reviewed death certificates to help determine the cause of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Death certificates\"<|>\"FDA\"<|>\"FDA staff physicians reviewed death certificates to help determine the cause of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Autopsy reports\"<|>\"CDC\"<|>\"CDC staff physicians reviewed autopsy reports to help determine the cause of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Autopsy reports\"<|>\"FDA\"<|>\"FDA staff physicians reviewed autopsy reports to help determine the cause of death among vaccine recipients.\"<|>8)##\n(\"relationship\"<|>\"Staff physicians\"<|>\"CDC\"<|>\"Staff physicians employed by CDC conducted medical reviews of adverse event and death reports.\"<|>8)##\n(\"relationship\"<|>\"Staff physicians\"<|>\"FDA\"<|>\"Staff physicians employed by FDA conducted medical reviews of adverse event and death reports.\"<|>8)##\n(\"relationship\"<|>\"Jurisdictions\"<|>\"CDC\"<|>\"CDC encouraged jurisdictions to offer v-safe promotional materials at vaccination sites.\"<|>7)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report Vol. 70, No. 18\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"This is the specific issue of the Morbidity and Mortality Weekly Report in which the described vaccine safety data was published.\"<|>8)##\n(\"relationship\"<|>\"45 C.F.R. part 46\"<|>\"CDC\"<|>\"CDC's activities were reviewed and found consistent with 45 C.F.R. part 46, governing protection of human subjects in research.\"<|>7)##\n(\"relationship\"<|>\"21 C.F.R. part 56\"<|>\"CDC\"<|>\"CDC's activities were reviewed and found consistent with 21 C.F.R. part 56, governing Institutional Review Boards.\"<|>7)##\n(\"relationship\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"CDC\"<|>\"CDC's activities were reviewed and found consistent with 42 U.S.C. Sect. 241(d), relating to public health service research.\"<|>7)##\n(\"relationship\"<|>\"5 U.S.C. Sect. 552a\"<|>\"CDC\"<|>\"CDC's activities were reviewed and found consistent with 5 U.S.C. Sect. 552a, governing privacy of records maintained by federal agencies.\"<|>7)##\n(\"relationship\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"CDC\"<|>\"CDC's activities were reviewed and found consistent with 44 U.S.C. Sect. 3501 et seq., governing federal information policy.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "28950ca1f0f3faca029fecab20a55f90": {
    "return": "(\"entity\"<|>\"Adults aged 65 years\"<|>\"person\"<|>\"A population group targeted in the study, representing individuals 65 years and older, considered at high risk for severe COVID-19 outcomes and hospitalization.\")##\n(\"entity\"<|>\"Non-Hispanic White\"<|>\"person\"<|>\"A demographic group included in the study, comprising 73% of the participants, identified as non-Hispanic and White.\")##\n(\"entity\"<|>\"Non-Hispanic Black\"<|>\"person\"<|>\"A demographic group included in the study, comprising 17% of the participants, identified as non-Hispanic and Black.\")##\n(\"entity\"<|>\"Hispanic\"<|>\"person\"<|>\"A demographic group included in the study, comprising 6% of the participants, identified as Hispanic.\")##\n(\"entity\"<|>\"Female\"<|>\"person\"<|>\"A gender group included in the study, comprising 48% of the participants.\")##\n(\"entity\"<|>\"Long-term care facility residents\"<|>\"person\"<|>\"A subgroup of study participants, representing 4% of the population, who live in long-term care facilities and are at increased risk for severe COVID-19.\")##\n(\"entity\"<|>\"Case-patients\"<|>\"person\"<|>\"Individuals enrolled in the study who had acute laboratory-confirmed COVID-19 and were hospitalized.\")##\n(\"entity\"<|>\"Control-patients\"<|>\"person\"<|>\"Individuals enrolled in the study who were hospitalized but did not have acute COVID-19, used as controls in the test-negative design.\")##\n(\"entity\"<|>\"Partially vaccinated adults\"<|>\"person\"<|>\"Adults who received only one dose of a two-dose COVID-19 vaccine series or two doses with the second dose received less than 14 days before illness onset.\")##\n(\"entity\"<|>\"Fully vaccinated adults\"<|>\"person\"<|>\"Adults who received both doses of a two-dose COVID-19 vaccine series, with the second dose received at least 14 days before illness onset.\")##\n(\"entity\"<|>\"SARS-CoV-2\"<|>\"organization\"<|>\"The virus that causes COVID-19, referenced in the study as the target of vaccination and testing.\")##\n(\"entity\"<|>\"COVID-19-like illness\"<|>\"event\"<|>\"A set of symptoms and clinical criteria used to identify patients for enrollment in the study, including fever, cough, sore throat, myalgias, shortness of breath, and other respiratory symptoms.\")##\n(\"entity\"<|>\"Test-negative design\"<|>\"event\"<|>\"A study design used to evaluate vaccine effectiveness by comparing vaccination odds among case-patients and control-patients.\")##\n(\"entity\"<|>\"Emergency Use Authorization\"<|>\"event\"<|>\"A regulatory process by which COVID-19 vaccines were approved for use in the United States during the pandemic.\")##\n(\"entity\"<|>\"Reverse transcription-polymerase chain reaction (RT-PCR)\"<|>\"event\"<|>\"A laboratory test used to detect SARS-CoV-2 infection among study participants.\")##\n(\"entity\"<|>\"Antigen test\"<|>\"event\"<|>\"A laboratory test used to detect SARS-CoV-2 infection among study participants.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"organization\"<|>\"A publication of the CDC that reported the findings of the COVID-19 vaccine effectiveness study.\")##\n(\"entity\"<|>\"January 1, 2021  March 26, 2021\"<|>\"event\"<|>\"The time period during which adults with COVID-19-like illness were admitted and enrolled in the study.\")##\n(\"entity\"<|>\"May 7, 2021\"<|>\"event\"<|>\"The publication date of the Morbidity and Mortality Weekly Report summarizing the study findings.\")##\n(\"entity\"<|>\"Vol. 70 / No. 18 / 675\"<|>\"event\"<|>\"The volume, issue, and page number of the MMWR publication reporting the study results.\")##\n(\"entity\"<|>\"https://www.fda.gov/vaccines-blood-biologics/report-problem-centerbiologics-evaluation-research/vaccine-adverse-events\"<|>\"event\"<|>\"A web address for reporting adverse events related to vaccines to the FDA.\")##\n(\"entity\"<|>\"https://vaers.hhs.gov/reportevent.html\"<|>\"event\"<|>\"A web address for reporting adverse events related to vaccines to VAERS.\")##\n\n(\"relationship\"<|>\"Adults aged 65 years\"<|>\"COVID-19 Hospitalization\"<|>\"Adults aged 65 years were the primary population studied for COVID-19-associated hospitalization and vaccine effectiveness.\"<|>10)##\n(\"relationship\"<|>\"Non-Hispanic White\"<|>\"Adults aged 65 years\"<|>\"Non-Hispanic White individuals comprised 73% of the adults aged 65 years in the study population.\"<|>8)##\n(\"relationship\"<|>\"Non-Hispanic Black\"<|>\"Adults aged 65 years\"<|>\"Non-Hispanic Black individuals comprised 17% of the adults aged 65 years in the study population.\"<|>8)##\n(\"relationship\"<|>\"Hispanic\"<|>\"Adults aged 65 years\"<|>\"Hispanic individuals comprised 6% of the adults aged 65 years in the study population.\"<|>8)##\n(\"relationship\"<|>\"Female\"<|>\"Adults aged 65 years\"<|>\"Females comprised 48% of the adults aged 65 years in the study population.\"<|>8)##\n(\"relationship\"<|>\"Long-term care facility residents\"<|>\"Adults aged 65 years\"<|>\"Long-term care facility residents comprised 4% of the adults aged 65 years in the study population.\"<|>8)##\n(\"relationship\"<|>\"Case-patients\"<|>\"COVID-19 Hospitalization\"<|>\"Case-patients were those hospitalized with acute laboratory-confirmed COVID-19, forming the basis for vaccine effectiveness analysis.\"<|>9)##\n(\"relationship\"<|>\"Control-patients\"<|>\"COVID-19 Hospitalization\"<|>\"Control-patients were those hospitalized without acute COVID-19, used as controls in the vaccine effectiveness analysis.\"<|>9)##\n(\"relationship\"<|>\"Partially vaccinated adults\"<|>\"COVID-19 Vaccination\"<|>\"Partially vaccinated adults were evaluated for vaccine effectiveness against COVID-19 hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Fully vaccinated adults\"<|>\"COVID-19 Vaccination\"<|>\"Fully vaccinated adults were evaluated for vaccine effectiveness against COVID-19 hospitalization.\"<|>9)##\n(\"relationship\"<|>\"SARS-CoV-2\"<|>\"COVID-19 Hospitalization\"<|>\"COVID-19 hospitalization is caused by infection with SARS-CoV-2, the virus targeted by vaccination.\"<|>10)##\n(\"relationship\"<|>\"COVID-19-like illness\"<|>\"COVID-19 Hospitalization\"<|>\"COVID-19-like illness was used as a criterion for enrolling patients in the study of COVID-19 hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Test-negative design\"<|>\"COVID-19 Hospitalization\"<|>\"The test-negative design was used to evaluate vaccine effectiveness against COVID-19 hospitalization.\"<|>9)##\n(\"relationship\"<|>\"Emergency Use Authorization\"<|>\"COVID-19 Vaccination\"<|>\"COVID-19 vaccines were approved for use under Emergency Use Authorization in the United States.\"<|>9)##\n(\"relationship\"<|>\"Reverse transcription-polymerase chain reaction (RT-PCR)\"<|>\"COVID-19 Hospitalization\"<|>\"RT-PCR was used to confirm SARS-CoV-2 infection among hospitalized patients in the study.\"<|>9)##\n(\"relationship\"<|>\"Antigen test\"<|>\"COVID-19 Hospitalization\"<|>\"Antigen tests were used to confirm SARS-CoV-2 infection among hospitalized patients in the study.\"<|>9)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR is a publication of the CDC that reported the findings of the COVID-19 vaccine effectiveness study.\"<|>10)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"COVID-19 Vaccination\"<|>\"MMWR published the results of the COVID-19 vaccine effectiveness study.\"<|>9)##\n(\"relationship\"<|>\"January 1, 2021  March 26, 2021\"<|>\"COVID-19 Hospitalization\"<|>\"This time period marks when adults with COVID-19-like illness were admitted and enrolled in the study.\"<|>8)##\n(\"relationship\"<|>\"May 7, 2021\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"May 7, 2021 is the publication date of the MMWR report summarizing the study findings.\"<|>8)##\n(\"relationship\"<|>\"Vol. 70 / No. 18 / 675\"<|>\"Morbidity and Mortality Weekly Report (MMWR)\"<|>\"This volume, issue, and page number identifies the specific MMWR publication reporting the study results.\"<|>7)##\n(\"relationship\"<|>\"https://www.fda.gov/vaccines-blood-biologics/report-problem-centerbiologics-evaluation-research/vaccine-adverse-events\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"This FDA web address is used for reporting adverse events related to vaccines to VAERS.\"<|>8)##\n(\"relationship\"<|>\"https://vaers.hhs.gov/reportevent.html\"<|>\"Vaccine Adverse Event Reporting System\"<|>\"This VAERS web address is used for reporting adverse events related to vaccines.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "f883ba0168b4882ef09f4676849d8a76": {
    "return": "(\"entity\"<|>\"JAMA\"<|>\"organization\"<|>\"JAMA (Journal of the American Medical Association) is a peer-reviewed medical journal that published case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination.\" )##\n(\"entity\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"MMWR Morbidity and Mortality Weekly Report is a publication of the CDC that disseminates public health information, including reports on vaccine safety and adverse events.\" )##\n(\"entity\"<|>\"Mass Vaccination Sites\"<|>\"organization\"<|>\"Mass Vaccination Sites are large-scale facilities set up in various US states to administer COVID-19 vaccines to large numbers of people.\" )##\n(\"entity\"<|>\"Vaccination Site Staff Members\"<|>\"person\"<|>\"Vaccination Site Staff Members are individuals working at mass vaccination sites, responsible for administering vaccines and reporting adverse events.\" )##\n(\"entity\"<|>\"Vaccine Manufacturers\"<|>\"organization\"<|>\"Vaccine Manufacturers are companies that produce vaccines and are among the entities that report adverse events to VAERS.\" )##\n(\"entity\"<|>\"Health Care Providers\"<|>\"person\"<|>\"Health Care Providers are medical professionals who administer vaccines and report adverse events to VAERS.\" )##\n(\"entity\"<|>\"The Public\"<|>\"person\"<|>\"The Public refers to individuals who can submit reports of vaccine adverse events to VAERS.\" )##\n(\"entity\"<|>\"Diphenhydramine\"<|>\"event\"<|>\"Diphenhydramine is a medication administered to some vaccine recipients at vaccination sites, used to treat possible allergic reactions.\" )##\n(\"entity\"<|>\"Epinephrine\"<|>\"event\"<|>\"Epinephrine is a medication administered to some vaccine recipients at vaccination sites, used to treat possible allergic reactions.\" )##\n(\"entity\"<|>\"Anaphylaxis\"<|>\"event\"<|>\"Anaphylaxis is a severe allergic reaction that was specifically not classified among the anxiety-related events in the report.\" )##\n(\"entity\"<|>\"Tachycardia\"<|>\"event\"<|>\"Tachycardia (rapid heart rate) is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Hyperventilation\"<|>\"event\"<|>\"Hyperventilation (rapid breathing) is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Dyspnea\"<|>\"event\"<|>\"Dyspnea (difficulty breathing) is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Chest Pain\"<|>\"event\"<|>\"Chest Pain is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Paresthesia\"<|>\"event\"<|>\"Paresthesia (numbness or tingling) is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Light-headedness\"<|>\"event\"<|>\"Light-headedness is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Hypotension\"<|>\"event\"<|>\"Hypotension (low blood pressure) is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Headache\"<|>\"event\"<|>\"Headache is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"Pallor\"<|>\"event\"<|>\"Pallor is one of the anxiety-related events observed during the post-vaccination period at mass vaccination sites.\" )##\n(\"entity\"<|>\"COVID-19 Vaccine Recipients\"<|>\"person\"<|>\"COVID-19 Vaccine Recipients are individuals who received the Janssen COVID-19 vaccine and were observed for adverse events at mass vaccination sites.\" )##\n(\"entity\"<|>\"Influenza Vaccine Recipients\"<|>\"person\"<|>\"Influenza Vaccine Recipients are individuals who received the influenza vaccine during the 2019-2020 season and whose adverse event rates were compared to those of COVID-19 vaccine recipients.\" )##\n(\"entity\"<|>\"Emergency Use Authorization (EUA)\"<|>\"event\"<|>\"Emergency Use Authorization (EUA) is the regulatory mechanism by which the FDA authorized the use of the Janssen COVID-19 vaccine.\" )##\n(\"entity\"<|>\"March 2 to April 21, 2021\"<|>\"event\"<|>\"March 2 to April 21, 2021 is the time period during which US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination were collected.\" )##\n(\"entity\"<|>\"April 2021\"<|>\"event\"<|>\"April 2021 is the time period during which clusters of anxiety-related adverse events after Janssen COVID-19 vaccination were reported at mass vaccination sites.\" )##\n(\"entity\"<|>\"April 7, 2021\"<|>\"event\"<|>\"April 7, 2021 is the date after 5 weeks of Janssen COVID-19 vaccine use when CDC received reports of anxiety-related event clusters.\" )##\n(\"entity\"<|>\"April 30, 2021\"<|>\"event\"<|>\"April 30, 2021 is the date when the CDC report on anxiety-related adverse event clusters was posted as an MMWR Early Release.\" )##\n(\"entity\"<|>\"March 2-April 22, 2021\"<|>\"event\"<|>\"March 2-April 22, 2021 is the period during which VAERS reports for adverse events associated with Janssen COVID-19 vaccine were reviewed.\" )##\n\n(\"relationship\"<|>\"JAMA\"<|>\"See I\"<|>\"See I is an author of a case report published in JAMA.\" <|>7)##\n(\"relationship\"<|>\"JAMA\"<|>\"Su JR\"<|>\"Su JR is an author of a case report published in JAMA.\" <|>7)##\n(\"relationship\"<|>\"JAMA\"<|>\"Lale A\"<|>\"Lale A is an author of a case report published in JAMA.\" <|>7)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Anne M. Hause\"<|>\"Anne M. Hause is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Julianne Gee\"<|>\"Julianne Gee is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Tara Johnson\"<|>\"Tara Johnson is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Amelia Jazwa\"<|>\"Amelia Jazwa is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Paige Marquez\"<|>\"Paige Marquez is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Elaine Miller\"<|>\"Elaine Miller is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"John Su\"<|>\"John Su is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"Tom T. Shimabukuro\"<|>\"Tom T. Shimabukuro is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"David K. Shay\"<|>\"David K. Shay is an author of a report published in MMWR Morbidity and Mortality Weekly Report.\" <|>8)##\n(\"relationship\"<|>\"Mass Vaccination Sites\"<|>\"Five US Mass Vaccination Sites\"<|>\"The Five US Mass Vaccination Sites are specific examples of mass vaccination sites referenced in the report.\" <|>9)##\n(\"relationship\"<|>\"Vaccination Site Staff Members\"<|>\"Mass Vaccination Sites\"<|>\"Vaccination Site Staff Members work at mass vaccination sites and were interviewed by CDC regarding adverse events.\" <|>8)##\n(\"relationship\"<|>\"Vaccine Manufacturers\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"Vaccine Manufacturers are among the entities that report adverse events to VAERS.\" <|>8)##\n(\"relationship\"<|>\"Health Care Providers\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"Health Care Providers report adverse events to VAERS.\" <|>8)##\n(\"relationship\"<|>\"The Public\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"The Public can submit reports of vaccine adverse events to VAERS.\" <|>7)##\n(\"relationship\"<|>\"Diphenhydramine\"<|>\"COVID-19 Vaccine Recipients\"<|>\"Diphenhydramine was administered to some COVID-19 vaccine recipients at vaccination sites for possible allergic reactions.\" <|>6)##\n(\"relationship\"<|>\"Epinephrine\"<|>\"COVID-19 Vaccine Recipients\"<|>\"Epinephrine was administered to some COVID-19 vaccine recipients at vaccination sites for possible allergic reactions.\" <|>6)##\n(\"relationship\"<|>\"Diphenhydramine\"<|>\"Anaphylaxis\"<|>\"Diphenhydramine is used to treat allergic reactions, but none of the cases were classified as anaphylaxis.\" <|>5)##\n(\"relationship\"<|>\"Epinephrine\"<|>\"Anaphylaxis\"<|>\"Epinephrine is used to treat allergic reactions, but none of the cases were classified as anaphylaxis.\" <|>5)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Tachycardia\"<|>\"Tachycardia is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Hyperventilation\"<|>\"Hyperventilation is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Dyspnea\"<|>\"Dyspnea is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Chest Pain\"<|>\"Chest Pain is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Paresthesia\"<|>\"Paresthesia is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Light-headedness\"<|>\"Light-headedness is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Hypotension\"<|>\"Hypotension is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Headache\"<|>\"Headache is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"Pallor\"<|>\"Pallor is one of the symptoms included in anxiety-related adverse event clusters.\" <|>8)##\n(\"relationship\"<|>\"COVID-19 Vaccine Recipients\"<|>\"Janssen COVID-19 Vaccine\"<|>\"COVID-19 Vaccine Recipients are individuals who received the Janssen COVID-19 vaccine and were observed for adverse events.\" <|>9)##\n(\"relationship\"<|>\"Influenza Vaccine Recipients\"<|>\"Influenza Vaccine Administration (2019-2020 Season)\"<|>\"Influenza Vaccine Recipients are individuals who received the influenza vaccine during the 2019-2020 season.\" <|>8)##\n(\"relationship\"<|>\"Emergency Use Authorization (EUA)\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Janssen COVID-19 vaccine was administered under Emergency Use Authorization (EUA) by the FDA.\" <|>9)##\n(\"relationship\"<|>\"March 2 to April 21, 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"March 2 to April 21, 2021 is the period during which case reports of adverse events after Janssen COVID-19 vaccination were collected.\" <|>8)##\n(\"relationship\"<|>\"April 2021\"<|>\"Anxiety-Related Adverse Event Clusters\"<|>\"April 2021 is the time period during which anxiety-related adverse event clusters were reported after Janssen COVID-19 vaccination.\" <|>8)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"April 7, 2021 marks the date after 5 weeks of Janssen COVID-19 vaccine use when CDC received reports of anxiety-related event clusters.\" <|>7)##\n(\"relationship\"<|>\"April 30, 2021\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"April 30, 2021 is the date when the CDC report was posted as an MMWR Early Release.\" <|>7)##\n(\"relationship\"<|>\"March 2-April 22, 2021\"<|>\"Vaccine Adverse Event Reporting System (VAERS)\"<|>\"March 2-April 22, 2021 is the period during which VAERS reports for adverse events associated with Janssen COVID-19 vaccine were reviewed.\" <|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "c4bd13ee08e1401fed58e1dcd266c147": {
    "return": "(\"entity\"<|>\"Connor Hoff\"<|>\"person\"<|>\"Connor Hoff, MPH, is one of the authors involved in the investigation of the 2019 multistate E. coli O157:H7 outbreak linked to romaine lettuce exposure in the United States. He is affiliated with the Division of Foodborne, Waterborne, and Environmental Diseases at CDC and Oak Ridge Institute for Science and Education.\")##\n(\"entity\"<|>\"Jeffrey Higa\"<|>\"person\"<|>\"Jeffrey Higa, MPH, is one of the authors of the report on the 2019 E. coli outbreak, affiliated with the California Department of Public Health.\")##\n(\"entity\"<|>\"Kane Patel\"<|>\"person\"<|>\"Kane Patel is an author involved in the outbreak investigation, affiliated with CDC and Oak Ridge Institute for Science and Education.\")##\n(\"entity\"<|>\"Ellen Gee\"<|>\"person\"<|>\"Ellen Gee, MPH, is an author of the report, affiliated with the Food and Drug Administration.\")##\n(\"entity\"<|>\"Allison Wellman\"<|>\"person\"<|>\"Allison Wellman, MPH, is an author of the report, affiliated with the Food and Drug Administration.\")##\n(\"entity\"<|>\"Jeff Vidanes\"<|>\"person\"<|>\"Jeff Vidanes is an author of the report, affiliated with the California Department of Public Health.\")##\n(\"entity\"<|>\"April Holland\"<|>\"person\"<|>\"April Holland, MPH, is an author of the report, affiliated with the Food and Drug Administration.\")##\n(\"entity\"<|>\"Varvara Kozyreva\"<|>\"person\"<|>\"Varvara Kozyreva, PhD, is an author of the report, affiliated with the California Department of Public Health.\")##\n(\"entity\"<|>\"Jonathan Zhu\"<|>\"person\"<|>\"Jonathan Zhu is an author of the report, affiliated with the California Department of Public Health.\")##\n(\"entity\"<|>\"Mia Mattioli\"<|>\"person\"<|>\"Mia Mattioli, PhD, is an author of the report, affiliated with CDC.\")##\n(\"entity\"<|>\"Alexis Roundtree\"<|>\"person\"<|>\"Alexis Roundtree is an author of the report, affiliated with CDC and Oak Ridge Institute for Science and Education.\")##\n(\"entity\"<|>\"Kenai McFadden\"<|>\"person\"<|>\"Kenai McFadden, MSPH, is an author of the report, affiliated with CDC and Oak Ridge Institute for Science and Education.\")##\n(\"entity\"<|>\"Laura Whitlock\"<|>\"person\"<|>\"Laura Whitlock, MPH, is an author of the report, affiliated with CDC.\")##\n(\"entity\"<|>\"Matthew Wise\"<|>\"person\"<|>\"Matthew Wise, PhD, is an author of the report, affiliated with CDC.\")##\n(\"entity\"<|>\"Laura Gieraltowski\"<|>\"person\"<|>\"Laura Gieraltowski, PhD, is an author of the report, affiliated with CDC.\")##\n(\"entity\"<|>\"Colin Schwensohn\"<|>\"person\"<|>\"Colin Schwensohn, MPH, is an author of the report and the corresponding author, affiliated with CDC.\")##\n(\"entity\"<|>\"PulseNet\"<|>\"organization\"<|>\"PulseNet is the national molecular subtyping network for foodborne disease surveillance in the United States. It reported the multistate cluster of E. coli O157:H7 infections in 2019.\")##\n(\"entity\"<|>\"California Department of Public Health\"<|>\"organization\"<|>\"California Department of Public Health (CDPH) is a state agency involved in the investigation of the E. coli outbreak, identifying cases and conducting interviews and traceback investigations.\")##\n(\"entity\"<|>\"Food and Drug Administration\"<|>\"organization\"<|>\"Food and Drug Administration (FDA) is a federal agency involved in the traceback and farm-level investigations of the E. coli outbreak.\")##\n(\"entity\"<|>\"CDC\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a federal agency involved in the outbreak investigation, environmental assessment, and policy review.\")##\n(\"entity\"<|>\"California Department of Food and Agriculture\"<|>\"organization\"<|>\"California Department of Food and Agriculture is a state agency involved in farm-level investigations related to the E. coli outbreak.\")##\n(\"entity\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"organization\"<|>\"Oak Ridge Institute for Science and Education is an organization affiliated with several authors of the report and involved in scientific research and education.\")##\n(\"entity\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases\"<|>\"organization\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases is a division within CDC focused on foodborne, waterborne, and environmental diseases.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"United States is the country where the multistate E. coli O157:H7 outbreak occurred in 2019, involving 12 states.\")##\n(\"entity\"<|>\"California\"<|>\"geo\"<|>\"California is a state in the United States where several cases of E. coli O157:H7 infection were reported and where the implicated farms are located.\")##\n(\"entity\"<|>\"Oregon\"<|>\"geo\"<|>\"Oregon is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Pennsylvania\"<|>\"geo\"<|>\"Pennsylvania is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Arizona\"<|>\"geo\"<|>\"Arizona is a state in the United States where three cases of E. coli O157:H7 infection were reported.\")##\n(\"entity\"<|>\"Illinois\"<|>\"geo\"<|>\"Illinois is a state in the United States where two cases of E. coli O157:H7 infection were reported.\")##\n(\"entity\"<|>\"Florida\"<|>\"geo\"<|>\"Florida is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Georgia\"<|>\"geo\"<|>\"Georgia is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Maryland\"<|>\"geo\"<|>\"Maryland is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Nevada\"<|>\"geo\"<|>\"Nevada is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"New York\"<|>\"geo\"<|>\"New York is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"North Carolina\"<|>\"geo\"<|>\"North Carolina is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"South Carolina\"<|>\"geo\"<|>\"South Carolina is a state in the United States where one case of E. coli O157:H7 infection was reported.\")##\n(\"entity\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"event\"<|>\"The Multistate E. coli O157:H7 Outbreak in 2019 was a foodborne illness event linked to romaine lettuce, affecting 23 cases in 12 states in the United States. The outbreak led to a coordinated investigation by federal, state, and local agencies.\")##\n(\"entity\"<|>\"Farm-level Investigation\"<|>\"event\"<|>\"Farm-level Investigation refers to the environmental assessment and sample collection conducted at two California farms supplying romaine lettuce to determine the source of contamination during the outbreak.\")##\n(\"entity\"<|>\"Traceback Investigation\"<|>\"event\"<|>\"Traceback Investigation refers to the process of tracking the source of romaine lettuce supplied to restaurants, identifying two California farms as common sources.\")##\n(\"entity\"<|>\"Environmental Assessment\"<|>\"event\"<|>\"Environmental Assessment refers to the collection and testing of soil, animal droppings, and water samples at implicated farms to detect E. coli O157:H7.\")##\n(\"entity\"<|>\"Public Health Response\"<|>\"event\"<|>\"Public Health Response refers to the coordinated actions by CDC, FDA, CDPH, and other agencies to investigate, contain, and prevent further cases during the outbreak.\")##\n(\"entity\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"event\"<|>\"Restaurant Chain Outbreak Cluster refers to the group of cases linked to consumption of romaine lettuce salads at multiple locations of a national restaurant chain.\")##\n(\"entity\"<|>\"Grocery Store Exposure\"<|>\"event\"<|>\"Grocery Store Exposure refers to cases where patients consumed romaine lettuce purchased from grocery stores, as opposed to restaurants.\")##\n\n(\"relationship\"<|>\"PulseNet\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"PulseNet reported the initial cluster of E. coli O157:H7 infections, triggering the multistate outbreak investigation.\"<|>10)##\n(\"relationship\"<|>\"California Department of Public Health\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"CDPH identified cases, conducted interviews, and participated in the investigation of the outbreak in California.\"<|>9)##\n(\"relationship\"<|>\"Food and Drug Administration\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"FDA was involved in the traceback and farm-level investigations during the outbreak.\"<|>9)##\n(\"relationship\"<|>\"CDC\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"CDC coordinated the outbreak investigation and policy review.\"<|>10)##\n(\"relationship\"<|>\"California Department of Food and Agriculture\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"California Department of Food and Agriculture participated in farm-level investigations during the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"Connor Hoff\"<|>\"Connor Hoff is affiliated with Oak Ridge Institute for Science and Education, contributing to the outbreak investigation.\"<|>7)##\n(\"relationship\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"Kane Patel\"<|>\"Kane Patel is affiliated with Oak Ridge Institute for Science and Education, contributing to the outbreak investigation.\"<|>7)##\n(\"relationship\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"Alexis Roundtree\"<|>\"Alexis Roundtree is affiliated with Oak Ridge Institute for Science and Education, contributing to the outbreak investigation.\"<|>7)##\n(\"relationship\"<|>\"Oak Ridge Institute for Science and Education\"<|>\"Kenai McFadden\"<|>\"Kenai McFadden is affiliated with Oak Ridge Institute for Science and Education, contributing to the outbreak investigation.\"<|>7)##\n(\"relationship\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases\"<|>\"CDC\"<|>\"National Center for Emerging and Zoonotic Infectious Diseases is a division within CDC, involved in the investigation.\"<|>8)##\n(\"relationship\"<|>\"California\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"California was one of the states affected by the outbreak and the location of implicated farms.\"<|>9)##\n(\"relationship\"<|>\"United States\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"The outbreak occurred in the United States, affecting 12 states.\"<|>10)##\n(\"relationship\"<|>\"Traceback Investigation\"<|>\"California Department of Public Health\"<|>\"CDPH conducted the traceback investigation to identify the source of romaine lettuce.\"<|>8)##\n(\"relationship\"<|>\"Traceback Investigation\"<|>\"Food and Drug Administration\"<|>\"FDA participated in the traceback investigation to identify the source of romaine lettuce.\"<|>8)##\n(\"relationship\"<|>\"Traceback Investigation\"<|>\"California\"<|>\"Traceback investigation identified two farms in California as common sources of romaine lettuce.\"<|>9)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"Food and Drug Administration\"<|>\"FDA initiated farm-level investigations at the implicated California farms.\"<|>8)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"California Department of Public Health\"<|>\"CDPH participated in farm-level investigations at the implicated California farms.\"<|>8)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"California Department of Food and Agriculture\"<|>\"California Department of Food and Agriculture participated in farm-level investigations at the implicated California farms.\"<|>8)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"CDC\"<|>\"CDC participated in farm-level investigations at the implicated California farms.\"<|>8)##\n(\"relationship\"<|>\"Environmental Assessment\"<|>\"Farm-level Investigation\"<|>\"Environmental assessment was a key component of the farm-level investigation, involving sample collection and testing.\"<|>9)##\n(\"relationship\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"A significant portion of cases in the outbreak were linked to salads containing romaine lettuce at a national restaurant chain.\"<|>9)##\n(\"relationship\"<|>\"Grocery Store Exposure\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Some cases in the outbreak were linked to romaine lettuce purchased from grocery stores.\"<|>7)##\n(\"relationship\"<|>\"Public Health Response\"<|>\"CDC\"<|>\"CDC coordinated the public health response to the outbreak.\"<|>10)##\n(\"relationship\"<|>\"Public Health Response\"<|>\"Food and Drug Administration\"<|>\"FDA participated in the public health response to the outbreak.\"<|>9)##\n(\"relationship\"<|>\"Public Health Response\"<|>\"California Department of Public Health\"<|>\"CDPH participated in the public health response to the outbreak.\"<|>9)##\n(\"relationship\"<|>\"Public Health Response\"<|>\"California Department of Food and Agriculture\"<|>\"California Department of Food and Agriculture participated in the public health response to the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Connor Hoff\"<|>\"CDC\"<|>\"Connor Hoff is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Colin Schwensohn\"<|>\"CDC\"<|>\"Colin Schwensohn is affiliated with CDC and served as corresponding author for the report.\"<|>8)##\n(\"relationship\"<|>\"Ellen Gee\"<|>\"Food and Drug Administration\"<|>\"Ellen Gee is affiliated with FDA and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Allison Wellman\"<|>\"Food and Drug Administration\"<|>\"Allison Wellman is affiliated with FDA and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"April Holland\"<|>\"Food and Drug Administration\"<|>\"April Holland is affiliated with FDA and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Varvara Kozyreva\"<|>\"California Department of Public Health\"<|>\"Varvara Kozyreva is affiliated with CDPH and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Jonathan Zhu\"<|>\"California Department of Public Health\"<|>\"Jonathan Zhu is affiliated with CDPH and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Jeff Vidanes\"<|>\"California Department of Public Health\"<|>\"Jeff Vidanes is affiliated with CDPH and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Matthew Wise\"<|>\"CDC\"<|>\"Matthew Wise is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Laura Gieraltowski\"<|>\"CDC\"<|>\"Laura Gieraltowski is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Laura Whitlock\"<|>\"CDC\"<|>\"Laura Whitlock is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Mia Mattioli\"<|>\"CDC\"<|>\"Mia Mattioli is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Kane Patel\"<|>\"CDC\"<|>\"Kane Patel is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Alexis Roundtree\"<|>\"CDC\"<|>\"Alexis Roundtree is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"Kenai McFadden\"<|>\"CDC\"<|>\"Kenai McFadden is affiliated with CDC and contributed to the outbreak investigation and report.\"<|>8)##\n(\"relationship\"<|>\"United States\"<|>\"CDC\"<|>\"CDC is a federal agency in the United States responsible for disease surveillance and outbreak response.\"<|>10)##\n(\"relationship\"<|>\"California\"<|>\"California Department of Public Health\"<|>\"CDPH is the state public health agency for California and led the investigation in the state.\"<|>10)##\n(\"relationship\"<|>\"California\"<|>\"California Department of Food and Agriculture\"<|>\"California Department of Food and Agriculture is a state agency in California involved in farm-level investigations.\"<|>9)##\n(\"relationship\"<|>\"California\"<|>\"Food and Drug Administration\"<|>\"FDA conducted investigations in California related to the outbreak.\"<|>8)##\n(\"relationship\"<|>\"California\"<|>\"Farm-level Investigation\"<|>\"Farm-level investigations were conducted at two farms in California implicated in the outbreak.\"<|>9)##\n(\"relationship\"<|>\"California\"<|>\"Traceback Investigation\"<|>\"Traceback investigation identified two farms in California as common sources of romaine lettuce for outbreak cases.\"<|>9)##\n(\"relationship\"<|>\"California\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"Several cases in California were linked to salads containing romaine lettuce at a national restaurant chain.\"<|>8)##\n(\"relationship\"<|>\"California\"<|>\"Grocery Store Exposure\"<|>\"Some cases in California were linked to romaine lettuce purchased from grocery stores.\"<|>7)##\n(\"relationship\"<|>\"Oregon\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Oregon was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Pennsylvania\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Pennsylvania was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Arizona\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Arizona was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Illinois\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Illinois was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Florida\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Florida was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Georgia\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Georgia was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Maryland\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Maryland was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Nevada\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Nevada was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"New York\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"New York was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"North Carolina\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"North Carolina was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"South Carolina\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"South Carolina was one of the states affected by the outbreak.\"<|>7)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Public Health Response\"<|>\"The outbreak prompted a coordinated public health response by multiple agencies.\"<|>10)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Traceback Investigation\"<|>\"Traceback investigation was conducted to identify the source of contaminated romaine lettuce during the outbreak.\"<|>9)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Farm-level Investigation\"<|>\"Farm-level investigation was conducted at implicated farms to identify sources and routes of contamination.\"<|>9)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Environmental Assessment\"<|>\"Environmental assessment was conducted as part of the outbreak investigation to detect E. coli O157:H7.\"<|>8)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"A cluster of cases in the outbreak was linked to a national restaurant chain serving romaine lettuce salads.\"<|>9)##\n(\"relationship\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Grocery Store Exposure\"<|>\"Some cases in the outbreak were linked to romaine lettuce purchased from grocery stores.\"<|>7)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"Environmental Assessment\"<|>\"Environmental assessment was a key part of the farm-level investigation to detect contamination.\"<|>9)##\n(\"relationship\"<|>\"Farm-level Investigation\"<|>\"Public Health Response\"<|>\"Farm-level investigation was part of the broader public health response to the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Traceback Investigation\"<|>\"Farm-level Investigation\"<|>\"Traceback investigation led to farm-level investigations at implicated California farms.\"<|>9)##\n(\"relationship\"<|>\"Traceback Investigation\"<|>\"Public Health Response\"<|>\"Traceback investigation was part of the coordinated public health response to the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Environmental Assessment\"<|>\"Public Health Response\"<|>\"Environmental assessment was part of the coordinated public health response to the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"Traceback Investigation\"<|>\"Traceback investigation identified the restaurant chain as a common exposure among cases.\"<|>8)##\n(\"relationship\"<|>\"Grocery Store Exposure\"<|>\"Traceback Investigation\"<|>\"Traceback investigation included cases linked to grocery store exposures.\"<|>7)##\n(\"relationship\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"California\"<|>\"Several cases in California were linked to the restaurant chain outbreak cluster.\"<|>8)##\n(\"relationship\"<|>\"Grocery Store Exposure\"<|>\"California\"<|>\"Some cases in California were linked to grocery store exposures.\"<|>7)##\n(\"relationship\"<|>\"Colin Schwensohn\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Colin Schwensohn is the corresponding author for the report on the outbreak and contributed to the investigation.\"<|>8)##\n(\"relationship\"<|>\"Connor Hoff\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Connor Hoff contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jeffrey Higa\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Jeffrey Higa contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Kane Patel\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Kane Patel contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Ellen Gee\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Ellen Gee contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Allison Wellman\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Allison Wellman contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jeff Vidanes\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Jeff Vidanes contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"April Holland\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"April Holland contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Varvara Kozyreva\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Varvara Kozyreva contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Jonathan Zhu\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Jonathan Zhu contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Mia Mattioli\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Mia Mattioli contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Alexis Roundtree\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Alexis Roundtree contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Kenai McFadden\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Kenai McFadden contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Laura Whitlock\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Laura Whitlock contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Matthew Wise\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Matthew Wise contributed to the investigation and report on the outbreak.\"<|>8)##\n(\"relationship\"<|>\"Laura Gieraltowski\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Laura Gieraltowski contributed to the investigation and report on the outbreak.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "ee689a22637225b743c6ac90f05c7a0d": {
    "return": "(\"entity\"<|>\"VAERS\"<|>\"organization\"<|>\"Vaccine Adverse Events Reporting System (VAERS) is a national program for monitoring vaccine safety, collecting and analyzing reports of adverse events following vaccination in the United States.\")##\n(\"entity\"<|>\"Janssen\"<|>\"organization\"<|>\"Janssen is a pharmaceutical company that manufactures the Janssen COVID-19 vaccine, which was administered at multiple mass vaccination sites in the United States.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"The Centers for Disease Control and Prevention (CDC) is a federal agency under the US Department of Health and Human Services, responsible for public health, including vaccine safety monitoring and reporting.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"The US Department of Health and Human Services is a federal department overseeing health-related agencies, including the CDC, and is involved in vaccine safety and public health initiatives.\")##\n(\"entity\"<|>\"MMWR\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication by the CDC that disseminates public health information, including vaccine safety data.\")##\n(\"entity\"<|>\"Mass Vaccination Sites A, B, C, D, E\"<|>\"geo\"<|>\"Five mass vaccination sites in the United States (A, B, C, D, E) where Janssen COVID-19 vaccines were administered and anxiety-related adverse events were reported. Site C was located on a college campus vaccinating students.\")##\n(\"entity\"<|>\"Emergency Department\"<|>\"organization\"<|>\"Emergency departments are hospital units where patients experiencing adverse events after vaccination were transported for further medical evaluation.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"The administration of the Janssen COVID-19 vaccine at mass vaccination sites, during which anxiety-related adverse events and syncope cases were reported and monitored.\")##\n(\"entity\"<|>\"Influenza Vaccine\"<|>\"event\"<|>\"The administration of influenza vaccines to adults in the United States, used as a comparison for rates of syncope and adverse events with the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Syncope\"<|>\"event\"<|>\"Syncope refers to fainting episodes reported as adverse events following vaccination, specifically tracked in VAERS reports for both Janssen COVID-19 and influenza vaccines.\")##\n(\"entity\"<|>\"Anxiety-Related Adverse Events\"<|>\"event\"<|>\"Anxiety-related adverse events are defined as symptoms such as tachycardia, hyperventilation, dyspnea, chest pain, paresthesia, light-headedness, hypotension, headache, pallor, or syncope occurring during the 15-minute postvaccination observation period.\")##\n(\"entity\"<|>\"Women\"<|>\"person\"<|>\"Women are a demographic group represented in the VAERS reports, accounting for approximately 50% of syncope cases after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Men\"<|>\"person\"<|>\"Men are a demographic group represented in the VAERS reports, accounting for approximately 50% of syncope cases after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Patients Transported to Emergency Department\"<|>\"person\"<|>\"Patients who experienced adverse events after vaccination and were transported to emergency departments for further medical evaluation; all with available follow-up were released the same day.\")##\n(\"entity\"<|>\"College Campus\"<|>\"geo\"<|>\"Site C, one of the mass vaccination sites, was located on a college campus and was vaccinating students.\")##\n\n(\"relationship\"<|>\"VAERS\"<|>\"Janssen COVID-19 Vaccine\"<|>\"VAERS collected and analyzed reports of adverse events, including syncope, following administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"VAERS\"<|>\"Influenza Vaccine\"<|>\"VAERS also collected and analyzed reports of adverse events following administration of influenza vaccines for comparison purposes.\"<|>8)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"VAERS\"<|>\"The CDC oversees and reviews reports submitted to VAERS as part of its vaccine safety monitoring activities.\"<|>10)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services, which oversees public health initiatives including vaccine safety.\"<|>9)##\n(\"relationship\"<|>\"MMWR\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR is a publication produced by the CDC to disseminate public health information, including vaccine safety data.\"<|>9)##\n(\"relationship\"<|>\"Mass Vaccination Sites A, B, C, D, E\"<|>\"Janssen COVID-19 Vaccine\"<|>\"The Janssen COVID-19 vaccine was administered at these five mass vaccination sites, where anxiety-related adverse events were reported and monitored.\"<|>10)##\n(\"relationship\"<|>\"College Campus\"<|>\"Mass Vaccination Sites A, B, C, D, E\"<|>\"Site C, one of the mass vaccination sites, was located on a college campus and was vaccinating students.\"<|>8)##\n(\"relationship\"<|>\"Women\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Women accounted for approximately 50% of syncope cases reported after receiving the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Men\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Men accounted for approximately 50% of syncope cases reported after receiving the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Patients Transported to Emergency Department\"<|>\"Emergency Department\"<|>\"Patients who experienced adverse events after vaccination were transported to emergency departments for further medical evaluation.\"<|>10)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Events\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Anxiety-related adverse events were monitored and reported following administration of the Janssen COVID-19 vaccine at mass vaccination sites.\"<|>9)##\n(\"relationship\"<|>\"Syncope\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Syncope was a specific adverse event tracked and reported after administration of the Janssen COVID-19 vaccine.\"<|>10)##\n(\"relationship\"<|>\"Syncope\"<|>\"Influenza Vaccine\"<|>\"Syncope was also tracked and reported after administration of influenza vaccines for comparison with the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"Anxiety-Related Adverse Events\"<|>\"Mass Vaccination Sites A, B, C, D, E\"<|>\"Anxiety-related adverse events were reported at these mass vaccination sites during the postvaccination observation period.\"<|>9)##\n(\"relationship\"<|>\"Patients Transported to Emergency Department\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Some patients who received the Janssen COVID-19 vaccine and experienced adverse events were transported to emergency departments.\"<|>8)##\n(\"relationship\"<|>\"Patients Transported to Emergency Department\"<|>\"Anxiety-Related Adverse Events\"<|>\"Patients transported to emergency departments had experienced anxiety-related adverse events following vaccination.\"<|>8)##\n(\"relationship\"<|>\"College Campus\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site C, located on a college campus, administered the Janssen COVID-19 vaccine to students and reported adverse events.\"<|>7)##\n(\"relationship\"<|>\"MMWR\"<|>\"Janssen COVID-19 Vaccine\"<|>\"MMWR published data and analysis regarding adverse events following administration of the Janssen COVID-19 vaccine.\"<|>8)##\n(\"relationship\"<|>\"MMWR\"<|>\"Influenza Vaccine\"<|>\"MMWR published comparative data on adverse events following administration of influenza vaccines.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "45ecbe8aee1fc246aef0877f9f923ecd": {
    "return": "(\"entity\"<|>\"Fatigue\"<|>\"event\"<|>\"Fatigue is a common reaction reported by enrollees during the study period, indicating tiredness or lack of energy following the monitored intervention.\")##\n(\"entity\"<|>\"Injection Site Pain\"<|>\"event\"<|>\"Injection Site Pain refers to discomfort or pain at the location where an injection was administered, frequently reported by enrollees.\")##\n(\"entity\"<|>\"Headache\"<|>\"event\"<|>\"Headache is a reaction characterized by pain in the head, reported by enrollees as a side effect during the study.\")##\n(\"entity\"<|>\"Myalgia\"<|>\"event\"<|>\"Myalgia is muscle pain or soreness, reported by enrollees as a reaction during the study period.\")##\n(\"entity\"<|>\"Fever\"<|>\"event\"<|>\"Fever is an elevated body temperature, reported by enrollees as a systemic reaction during the study.\")##\n(\"entity\"<|>\"Chills\"<|>\"event\"<|>\"Chills are sensations of coldness often accompanied by shivering, reported by enrollees as a reaction.\")##\n(\"entity\"<|>\"Joint Pain\"<|>\"event\"<|>\"Joint Pain refers to discomfort or pain in the joints, reported by enrollees during the study.\")##\n(\"entity\"<|>\"Nausea\"<|>\"event\"<|>\"Nausea is a feeling of sickness with an inclination to vomit, reported by enrollees as a reaction.\")##\n(\"entity\"<|>\"Diarrhea\"<|>\"event\"<|>\"Diarrhea is frequent loose or liquid bowel movements, reported by enrollees as a reaction.\")##\n(\"entity\"<|>\"Swelling\"<|>\"event\"<|>\"Swelling refers to enlargement of tissue, often at the injection site, reported by enrollees.\")##\n(\"entity\"<|>\"Abdominal Pain\"<|>\"event\"<|>\"Abdominal Pain is discomfort in the stomach area, reported by enrollees as a reaction.\")##\n(\"entity\"<|>\"Redness\"<|>\"event\"<|>\"Redness is discoloration of the skin, often at the injection site, reported by enrollees.\")##\n(\"entity\"<|>\"Itching\"<|>\"event\"<|>\"Itching is an uncomfortable sensation on the skin, often at the injection site, reported by enrollees.\")##\n(\"entity\"<|>\"Vomiting\"<|>\"event\"<|>\"Vomiting is the involuntary expulsion of stomach contents, reported by enrollees as a reaction.\")##\n(\"entity\"<|>\"Rash\"<|>\"event\"<|>\"Rash is a change in the skin that affects its color, appearance, or texture, reported by enrollees.\")##\n(\"entity\"<|>\"Any Injection Site Reaction\"<|>\"event\"<|>\"Any Injection Site Reaction is a category encompassing all local reactions at the injection site, such as pain, swelling, redness, and itching.\")##\n(\"entity\"<|>\"Any Systemic Reaction\"<|>\"event\"<|>\"Any Systemic Reaction is a category encompassing all body-wide reactions, such as fatigue, fever, headache, and myalgia.\")##\n(\"entity\"<|>\"Any Health Impact\"<|>\"event\"<|>\"Any Health Impact refers to any reported effect on health, including inability to perform daily activities, inability to work, or need for medical care.\")##\n(\"entity\"<|>\"Unable to Perform Normal Daily Activities\"<|>\"event\"<|>\"Unable to Perform Normal Daily Activities is a reported impact where enrollees are unable to carry out their usual routines due to reactions.\")##\n(\"entity\"<|>\"Unable to Work\"<|>\"event\"<|>\"Unable to Work is a reported impact where enrollees are unable to perform their job duties due to reactions.\")##\n(\"entity\"<|>\"Needed Medical Care\"<|>\"event\"<|>\"Needed Medical Care refers to enrollees requiring professional medical attention due to reactions or health impacts.\")##\n\n(\"relationship\"<|>\"Enrollees\"<|>\"Fatigue\"<|>\"Enrollees report fatigue as a common reaction during the study period.\"<|>9)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Injection Site Pain\"<|>\"Enrollees report injection site pain as a frequent local reaction.\"<|>9)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Headache\"<|>\"Enrollees report headache as a systemic reaction during the study.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Myalgia\"<|>\"Enrollees report myalgia (muscle pain) as a reaction during the study.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Fever\"<|>\"Enrollees report fever as a systemic reaction during the study.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Chills\"<|>\"Enrollees report chills as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Joint Pain\"<|>\"Enrollees report joint pain as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Nausea\"<|>\"Enrollees report nausea as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Diarrhea\"<|>\"Enrollees report diarrhea as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Swelling\"<|>\"Enrollees report swelling, often at the injection site, as a reaction.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Abdominal Pain\"<|>\"Enrollees report abdominal pain as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Redness\"<|>\"Enrollees report redness, often at the injection site, as a reaction.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Itching\"<|>\"Enrollees report itching, often at the injection site, as a reaction.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Vomiting\"<|>\"Enrollees report vomiting as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Rash\"<|>\"Enrollees report rash as a reaction during the study.\"<|>7)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Any Injection Site Reaction\"<|>\"Enrollees report various injection site reactions, including pain, swelling, redness, and itching.\"<|>9)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Any Systemic Reaction\"<|>\"Enrollees report various systemic reactions, including fatigue, fever, headache, and myalgia.\"<|>9)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Any Health Impact\"<|>\"Enrollees report any health impact, including inability to perform daily activities, inability to work, or need for medical care.\"<|>10)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Unable to Perform Normal Daily Activities\"<|>\"Some enrollees are unable to perform normal daily activities due to reactions.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Unable to Work\"<|>\"Some enrollees are unable to work due to reactions.\"<|>8)##\n(\"relationship\"<|>\"Enrollees\"<|>\"Needed Medical Care\"<|>\"Some enrollees require medical care due to reactions or health impacts.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "2e8af1e22468770a17fc3f4c90d85182": {
    "return": "(\"entity\"<|>\"C. F. R. part 46\"<|>\"event\"<|>\"C. F. R. part 46 refers to a section of the Code of Federal Regulations that governs the protection of human subjects in research, relevant to the study's ethical oversight.\")##\n(\"entity\"<|>\"21 C. F. R. part 56\"<|>\"event\"<|>\"21 C. F. R. part 56 is a section of the Code of Federal Regulations that outlines requirements for Institutional Review Boards (IRBs) in clinical research.\")##\n(\"entity\"<|>\"42 U. S. C. Sect. 241 (d)\"<|>\"event\"<|>\"42 U. S. C. Sect. 241 (d) is a section of the United States Code related to public health service research and investigations.\")##\n(\"entity\"<|>\"5 U. S. C. Sect. 552a\"<|>\"event\"<|>\"5 U. S. C. Sect. 552a is a section of the United States Code that governs the privacy of records maintained on individuals by federal agencies.\")##\n(\"entity\"<|>\"44 U. S. C. Sect. 3501 et seq.\"<|>\"event\"<|>\"44 U. S. C. Sect. 3501 et seq. refers to the Paperwork Reduction Act, which regulates federal information collection and reporting requirements.\")##\n(\"entity\"<|>\"Case-patients\"<|>\"person\"<|>\"Case-patients are adults aged 65 years who tested positive for SARS-CoV-2 infection and were included in the study group.\")##\n(\"entity\"<|>\"Control participants\"<|>\"person\"<|>\"Control participants are adults aged 65 years who did not test positive for SARS-CoV-2 infection and served as the control group in the study.\")##\n(\"entity\"<|>\"Adults aged 65 years\"<|>\"person\"<|>\"Adults aged 65 years are the population studied for COVID-19like illness and SARS-CoV-2 infection across 24 medical centers in 14 states.\")##\n(\"entity\"<|>\"Medical insurance\"<|>\"event\"<|>\"Medical insurance status was recorded for study participants, indicating whether they had coverage at the time of admission.\")##\n(\"entity\"<|>\"Long-term care facility\"<|>\"organization\"<|>\"Long-term care facility refers to residential institutions where some study participants resided prior to hospitalization.\")##\n(\"entity\"<|>\"Previous hospitalization\"<|>\"event\"<|>\"Previous hospitalization refers to whether study participants had been hospitalized in the previous year, a variable in the study.\")##\n(\"entity\"<|>\"Influenza vaccination\"<|>\"event\"<|>\"Influenza vaccination refers to whether study participants received the current season's influenza vaccine, a variable in the study.\")##\n(\"entity\"<|>\"Tobacco use\"<|>\"event\"<|>\"Tobacco use status was recorded for study participants, indicating current use or non-use as a variable in the study.\")##\n(\"entity\"<|>\"SARS-CoV-2 vaccination status\"<|>\"event\"<|>\"SARS-CoV-2 vaccination status categorizes participants as unvaccinated, single-dose vaccinated, partially vaccinated, or fully vaccinated.\")##\n(\"entity\"<|>\"Unvaccinated\"<|>\"event\"<|>\"Unvaccinated refers to participants who had not received any SARS-CoV-2 vaccine prior to illness onset.\")##\n(\"entity\"<|>\"Single-dose vaccinated\"<|>\"event\"<|>\"Single-dose vaccinated refers to participants who received one dose of a SARS-CoV-2 vaccine less than 14 days before illness onset.\")##\n(\"entity\"<|>\"Partially vaccinated\"<|>\"event\"<|>\"Partially vaccinated refers to participants who received one dose of a SARS-CoV-2 vaccine at least 14 days before illness onset but had not completed the full vaccination series.\")##\n(\"entity\"<|>\"Fully vaccinated\"<|>\"event\"<|>\"Fully vaccinated refers to participants who completed the full SARS-CoV-2 vaccination series before illness onset.\")##\n(\"entity\"<|>\"White, non-Hispanic\"<|>\"person\"<|>\"White, non-Hispanic is a race/ethnicity category for study participants.\")##\n(\"entity\"<|>\"Black, non-Hispanic\"<|>\"person\"<|>\"Black, non-Hispanic is a race/ethnicity category for study participants.\")##\n(\"entity\"<|>\"Other, non-Hispanic\"<|>\"person\"<|>\"Other, non-Hispanic is a race/ethnicity category for study participants.\")##\n(\"entity\"<|>\"Hispanic, any race\"<|>\"person\"<|>\"Hispanic, any race is a race/ethnicity category for study participants.\")##\n(\"entity\"<|>\"Unknown\"<|>\"person\"<|>\"Unknown is a race/ethnicity category for study participants whose race/ethnicity was not identified.\")##\n(\"entity\"<|>\"January\"<|>\"event\"<|>\"January is one of the months during which study participants were admitted for COVID-19like illness.\")##\n(\"entity\"<|>\"February\"<|>\"event\"<|>\"February is one of the months during which study participants were admitted for COVID-19like illness.\")##\n(\"entity\"<|>\"March\"<|>\"event\"<|>\"March is one of the months during which study participants were admitted for COVID-19like illness.\")##\n\n(\"relationship\"<|>\"Case-patients\"<|>\"Adults aged 65 years\"<|>\"Case-patients are a subset of adults aged 65 years who tested positive for SARS-CoV-2 infection.\"<|>10)##\n(\"relationship\"<|>\"Control participants\"<|>\"Adults aged 65 years\"<|>\"Control participants are a subset of adults aged 65 years who did not test positive for SARS-CoV-2 infection.\"<|>10)##\n(\"relationship\"<|>\"Medical insurance\"<|>\"Adults aged 65 years\"<|>\"Medical insurance status was recorded for all adults aged 65 years in the study.\"<|>8)##\n(\"relationship\"<|>\"Long-term care facility\"<|>\"Adults aged 65 years\"<|>\"Some adults aged 65 years resided in long-term care facilities prior to hospitalization.\"<|>7)##\n(\"relationship\"<|>\"Previous hospitalization\"<|>\"Adults aged 65 years\"<|>\"Previous hospitalization in the last year was a variable recorded for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"Influenza vaccination\"<|>\"Adults aged 65 years\"<|>\"Influenza vaccination status was recorded for adults aged 65 years as part of the study variables.\"<|>7)##\n(\"relationship\"<|>\"Tobacco use\"<|>\"Adults aged 65 years\"<|>\"Tobacco use status was recorded for adults aged 65 years as part of the study variables.\"<|>7)##\n(\"relationship\"<|>\"SARS-CoV-2 vaccination status\"<|>\"Adults aged 65 years\"<|>\"SARS-CoV-2 vaccination status was categorized for adults aged 65 years in the study.\"<|>8)##\n(\"relationship\"<|>\"Unvaccinated\"<|>\"SARS-CoV-2 vaccination status\"<|>\"Unvaccinated is one of the categories under SARS-CoV-2 vaccination status.\"<|>9)##\n(\"relationship\"<|>\"Single-dose vaccinated\"<|>\"SARS-CoV-2 vaccination status\"<|>\"Single-dose vaccinated is one of the categories under SARS-CoV-2 vaccination status.\"<|>9)##\n(\"relationship\"<|>\"Partially vaccinated\"<|>\"SARS-CoV-2 vaccination status\"<|>\"Partially vaccinated is one of the categories under SARS-CoV-2 vaccination status.\"<|>9)##\n(\"relationship\"<|>\"Fully vaccinated\"<|>\"SARS-CoV-2 vaccination status\"<|>\"Fully vaccinated is one of the categories under SARS-CoV-2 vaccination status.\"<|>9)##\n(\"relationship\"<|>\"White, non-Hispanic\"<|>\"Adults aged 65 years\"<|>\"White, non-Hispanic is a race/ethnicity category for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"Black, non-Hispanic\"<|>\"Adults aged 65 years\"<|>\"Black, non-Hispanic is a race/ethnicity category for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"Other, non-Hispanic\"<|>\"Adults aged 65 years\"<|>\"Other, non-Hispanic is a race/ethnicity category for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"Hispanic, any race\"<|>\"Adults aged 65 years\"<|>\"Hispanic, any race is a race/ethnicity category for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"Unknown\"<|>\"Adults aged 65 years\"<|>\"Unknown is a race/ethnicity category for adults aged 65 years in the study.\"<|>7)##\n(\"relationship\"<|>\"January\"<|>\"January-March 2021\"<|>\"January is one of the months included in the January-March 2021 study period.\"<|>8)##\n(\"relationship\"<|>\"February\"<|>\"January-March 2021\"<|>\"February is one of the months included in the January-March 2021 study period.\"<|>8)##\n(\"relationship\"<|>\"March\"<|>\"January-March 2021\"<|>\"March is one of the months included in the January-March 2021 study period.\"<|>8)##\n(\"relationship\"<|>\"C. F. R. part 46\"<|>\"21 C. F. R. part 56\"<|>\"Both are federal regulations governing ethical conduct and oversight in clinical research relevant to the study.\"<|>8)##\n(\"relationship\"<|>\"C. F. R. part 46\"<|>\"42 U. S. C. Sect. 241 (d)\"<|>\"Both are legal frameworks referenced for ethical and regulatory compliance in the study.\"<|>7)##\n(\"relationship\"<|>\"C. F. R. part 46\"<|>\"5 U. S. C. Sect. 552a\"<|>\"Both are referenced for regulatory compliance in the study, with 5 U. S. C. Sect. 552a focusing on privacy.\"<|>7)##\n(\"relationship\"<|>\"C. F. R. part 46\"<|>\"44 U. S. C. Sect. 3501 et seq.\"<|>\"Both are referenced for regulatory compliance in the study, with 44 U. S. C. Sect. 3501 et seq. focusing on paperwork reduction and information collection.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "4e0f8e51c502025155a13fe2aa707a1b": {
    "return": "(\"entity\"<|>\"mRNA-1273 SARS-CoV-2 Vaccine\"<|>\"event\"<|>\"The mRNA-1273 SARS-CoV-2 vaccine is a COVID-19 vaccine developed using mRNA technology, tested for efficacy and safety in clinical trials such as those conducted by the COVE Study Group.\")##\n(\"entity\"<|>\"BNT162b2 mRNA COVID-19 Vaccine\"<|>\"event\"<|>\"The BNT162b2 mRNA COVID-19 vaccine is a COVID-19 vaccine developed using mRNA technology, tested for safety and efficacy in clinical trials such as those conducted by the C4591001 Clinical Trial Group.\")##\n(\"entity\"<|>\"Janssen COVID-19 Vaccine\"<|>\"event\"<|>\"The Janssen COVID-19 vaccine (Ad.26.COV2.S) is a COVID-19 vaccine developed by Janssen Biotech, Inc., a Johnson & Johnson company, using a replication-incompetent human adenoviral type 26 vector platform and administered as a single dose.\")##\n(\"entity\"<|>\"AstraZeneca COVID-19 Vaccine\"<|>\"event\"<|>\"The AstraZeneca COVID-19 vaccine is a vaccine developed by AstraZeneca using a replication-incompetent chimpanzee adenoviral vector, associated with rare thrombotic events in Europe.\")##\n(\"entity\"<|>\"Cerebral Venous Sinus Thrombosis (CVST)\"<|>\"event\"<|>\"Cerebral venous sinus thrombosis (CVST) is a rare blood clotting event associated with thrombocytopenia, observed in some recipients of the Janssen and AstraZeneca COVID-19 vaccines.\")##\n(\"entity\"<|>\"Thrombocytopenia\"<|>\"event\"<|>\"Thrombocytopenia is a medical condition characterized by a low platelet count, observed in conjunction with CVST in some vaccine recipients.\")##\n(\"entity\"<|>\"Replication-Incompetent Human Adenoviral Type 26 Vector Platform\"<|>\"event\"<|>\"A vaccine technology platform used in the Janssen COVID-19 vaccine, involving a non-replicating human adenovirus type 26 vector to deliver genetic material.\")##\n(\"entity\"<|>\"Replication-Incompetent Chimpanzee Adenoviral Vector\"<|>\"event\"<|>\"A vaccine technology platform used in the AstraZeneca COVID-19 vaccine, involving a non-replicating chimpanzee adenovirus vector to deliver genetic material.\")##\n(\"entity\"<|>\"mRNA Platform\"<|>\"event\"<|>\"A vaccine technology platform used in the mRNA-1273 and BNT162b2 COVID-19 vaccines, requiring two doses for full efficacy.\")##\n(\"entity\"<|>\"Test-Negative Design\"<|>\"event\"<|>\"A study design used to estimate vaccine effectiveness, referenced in the context of influenza and COVID-19 vaccine studies.\")##\n(\"entity\"<|>\"Hospital Discharge\"<|>\"event\"<|>\"The event of patients being discharged from hospital after COVID-19 treatment, referenced in studies of long-term consequences.\")##\n(\"entity\"<|>\"COVID-19 Pandemic\"<|>\"event\"<|>\"The global outbreak of coronavirus disease beginning in late 2019, leading to widespread public health interventions, vaccine development, and mass vaccination programs.\")##\n(\"entity\"<|>\"Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine\"<|>\"event\"<|>\"A public health activity and report focused on monitoring adverse events and safety of the Janssen COVID-19 vaccine in the United States during March-April 2021.\")##\n(\"entity\"<|>\"COVID-19 Patients Requiring Mechanical Ventilation\"<|>\"event\"<|>\"A clinical outcome measured in studies, with reductions observed following implementation of national COVID-19 vaccination programs.\")##\n(\"entity\"<|>\"6-Month Consequences of COVID-19\"<|>\"event\"<|>\"A cohort study and clinical outcome measuring the long-term health effects in patients discharged from hospital after COVID-19 infection.\")##\n(\"entity\"<|>\"December 2020\"<|>\"event\"<|>\"A time period referenced for updated interim recommendations for COVID-19 vaccine allocation in the United States.\")##\n(\"entity\"<|>\"March-April 2021\"<|>\"event\"<|>\"A time period referenced for safety monitoring of the Janssen COVID-19 vaccine in the United States.\")##\n(\"entity\"<|>\"April 13-23, 2021\"<|>\"event\"<|>\"A time period during which the CDC and FDA recommended a pause in the use of the Janssen COVID-19 vaccine due to safety concerns.\")##\n(\"entity\"<|>\"February 27, 2021\"<|>\"event\"<|>\"The date on which the FDA issued Emergency Use Authorization for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"February 28, 2021\"<|>\"event\"<|>\"The date on which the Advisory Committee on Immunization Practices issued interim recommendations for use of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Women Aged <60 Years\"<|>\"person\"<|>\"A demographic group referenced as primarily affected by thrombotic events following AstraZeneca COVID-19 vaccination in Europe.\")##\n(\"entity\"<|>\"Persons Aged 18 Years and Older\"<|>\"person\"<|>\"A demographic group recommended to receive the Janssen COVID-19 vaccine according to ACIP interim recommendations.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Allocation\"<|>\"event\"<|>\"The process and recommendations for distributing COVID-19 vaccines in the United States, updated by ACIP in December 2020.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Effectiveness\"<|>\"event\"<|>\"The measure of how well COVID-19 vaccines prevent infection and severe outcomes, studied using designs such as the test-negative design.\")##\n(\"entity\"<|>\"Postlicensure Evaluation of COVID-19 Vaccines\"<|>\"event\"<|>\"Studies conducted after vaccines are licensed to monitor their effectiveness and safety in real-world settings.\")##\n(\"entity\"<|>\"Cohort Study\"<|>\"event\"<|>\"A type of observational study referenced in the context of 6-month consequences of COVID-19 in discharged patients.\")##\n(\"entity\"<|>\"National COVID-19 Vaccination ProgramIsrael, December 2020February 2021\"<|>\"event\"<|>\"A specific vaccination campaign in Israel, referenced in studies showing reduction in severe COVID-19 outcomes.\")##\n(\"entity\"<|>\"COVID-19 Patients\"<|>\"person\"<|>\"Individuals infected with COVID-19, referenced in studies of vaccine effectiveness, safety, and long-term outcomes.\")##\n(\"entity\"<|>\"Vaccine Recipients\"<|>\"person\"<|>\"Individuals who have received COVID-19 vaccines, referenced in studies of adverse events and effectiveness.\")##\n(\"entity\"<|>\"Clinical Trial Participants\"<|>\"person\"<|>\"Individuals enrolled in clinical trials for COVID-19 vaccines such as mRNA-1273 and BNT162b2.\")##\n(\"entity\"<|>\"Researchers\"<|>\"person\"<|>\"Individuals conducting studies, clinical trials, and safety monitoring for COVID-19 vaccines.\")##\n(\"entity\"<|>\"Public Health Professionals\"<|>\"person\"<|>\"Individuals involved in vaccine safety monitoring, recommendations, and public health reporting.\")##\n(\"entity\"<|>\"Medical Doctors\"<|>\"person\"<|>\"Individuals with medical degrees involved in vaccine safety monitoring and clinical research.\")##\n(\"entity\"<|>\"PhD Holders\"<|>\"person\"<|>\"Individuals with doctoral degrees involved in vaccine safety monitoring and clinical research.\")##\n(\"entity\"<|>\"MSPH Holders\"<|>\"person\"<|>\"Individuals with Master of Science in Public Health degrees involved in vaccine safety monitoring and research.\")##\n(\"entity\"<|>\"MS Holders\"<|>\"person\"<|>\"Individuals with Master of Science degrees involved in vaccine safety monitoring and research.\")##\n(\"entity\"<|>\"PMID: 32673298\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"PMID: 33382671\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"PMID: 33378609\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"PMID: 33301246\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"PMID: 33064144\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in JAMA.\")##\n(\"entity\"<|>\"PMID: 33626250\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"PMID: 23499601\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in Vaccine.\")##\n(\"entity\"<|>\"PMID: 33661863\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"PMID: 33428867\"<|>\"event\"<|>\"A PubMed identifier for a referenced publication in The Lancet.\")##\n(\"entity\"<|>\"https://doi.org/10.15585/mmwr.mm6928e1\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"https://doi.org/10.15585/mmwr.mm695152e2\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"https://doi.org/10.1056/NEJMoa2035389\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"https://doi.org/10.1056/NEJMoa2034577\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"https://doi.org/10.1001/jama.2020.19328\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in JAMA.\")##\n(\"entity\"<|>\"https://doi.org/10.1056/NEJMoa2101765\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the New England Journal of Medicine.\")##\n(\"entity\"<|>\"https://doi.org/10.1016/j.vaccine.2013.02.053\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in Vaccine.\")##\n(\"entity\"<|>\"https://doi.org/10.15585/mmwr.mm7009e3\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in the MMWR Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"https://doi.org/10.1016/S0140-6736(20)32656-8\"<|>\"event\"<|>\"A digital object identifier (DOI) for a referenced publication in The Lancet.\")##\n(\"entity\"<|>\"https://www.cdc.gov/mmwr\"<|>\"event\"<|>\"The official website for the MMWR Morbidity and Mortality Weekly Report, published by the CDC.\")##\n(\"entity\"<|>\"New England Journal of Medicine\"<|>\"organization\"<|>\"A peer-reviewed medical journal publishing clinical research, including studies on COVID-19 vaccines.\")##\n(\"entity\"<|>\"JAMA\"<|>\"organization\"<|>\"The Journal of the American Medical Association, a peer-reviewed medical journal publishing research on COVID-19 vaccines.\")##\n(\"entity\"<|>\"Vaccine\"<|>\"organization\"<|>\"A peer-reviewed journal publishing research on vaccine effectiveness and safety.\")##\n(\"entity\"<|>\"The Lancet\"<|>\"organization\"<|>\"A peer-reviewed medical journal publishing research on COVID-19 and its long-term consequences.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report Early Release\"<|>\"event\"<|>\"An early release of a report on the MMWR website, providing timely public health information.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Recipients\"<|>\"person\"<|>\"Individuals who have received any COVID-19 vaccine, referenced in studies of adverse events and effectiveness.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Clinical Trials\"<|>\"event\"<|>\"Clinical trials conducted to test the safety and efficacy of COVID-19 vaccines such as mRNA-1273 and BNT162b2.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Recommendations\"<|>\"event\"<|>\"Guidance issued by organizations such as ACIP and CDC regarding the use and allocation of COVID-19 vaccines.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Safety Concerns\"<|>\"event\"<|>\"Issues such as CVST and thrombocytopenia observed in some vaccine recipients, leading to pauses and monitoring.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Doses\"<|>\"event\"<|>\"The number of doses required for full vaccination, with mRNA vaccines requiring two doses and Janssen requiring one.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Authorization\"<|>\"event\"<|>\"The process by which vaccines are authorized for emergency use by regulatory agencies such as the FDA.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Interim Recommendations\"<|>\"event\"<|>\"Temporary guidance issued by ACIP and CDC for the use of COVID-19 vaccines.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Thrombotic Events\"<|>\"event\"<|>\"Rare blood clotting events observed in some recipients of the Janssen and AstraZeneca COVID-19 vaccines.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Mass Vaccination Setting\"<|>\"event\"<|>\"Large-scale vaccination campaigns, such as those conducted in Israel, referenced in studies of vaccine effectiveness.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Effectiveness Studies\"<|>\"event\"<|>\"Research conducted to measure how well COVID-19 vaccines prevent infection and severe outcomes.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Safety Monitoring\"<|>\"event\"<|>\"Ongoing surveillance of adverse events and safety of COVID-19 vaccines by organizations such as CDC and FDA.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Allocation Recommendations\"<|>\"event\"<|>\"Guidance on how COVID-19 vaccines should be distributed, updated by ACIP in December 2020.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Implementation\"<|>\"event\"<|>\"The process of rolling out and administering COVID-19 vaccines in various countries and regions.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Pause\"<|>\"event\"<|>\"Temporary suspension of vaccine use due to safety concerns, such as the pause in Janssen vaccine use in April 2021.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Interim Use Recommendations\"<|>\"event\"<|>\"Temporary guidance issued for the use of COVID-19 vaccines, such as those by ACIP for Janssen vaccine.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Adverse Events\"<|>\"event\"<|>\"Negative health outcomes observed in some vaccine recipients, such as CVST and thrombocytopenia.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Clinical Outcomes\"<|>\"event\"<|>\"Measured health outcomes in vaccine recipients, such as reduction in mechanical ventilation and long-term consequences.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Authors\"<|>\"person\"<|>\"Individuals listed as authors on studies and reports referenced in the document.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Groups\"<|>\"organization\"<|>\"Groups such as the COVE Study Group and C4591001 Clinical Trial Group conducting vaccine research.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publications\"<|>\"event\"<|>\"Published research articles referenced by PMID and DOI identifiers.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Journals\"<|>\"organization\"<|>\"Journals such as NEJM, JAMA, Vaccine, and The Lancet publishing COVID-19 vaccine research.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Timeframes\"<|>\"event\"<|>\"Specific periods referenced for vaccine studies and recommendations, such as December 2020 and March-April 2021.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Locations\"<|>\"geo\"<|>\"Countries and regions where vaccine studies and mass vaccination programs were conducted, such as United States, Israel, and Europe.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Designs\"<|>\"event\"<|>\"Research methodologies used in vaccine studies, such as test-negative design and cohort studies.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Outcomes\"<|>\"event\"<|>\"Results measured in vaccine studies, such as reduction in mechanical ventilation and long-term health effects.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Data\"<|>\"event\"<|>\"Data collected and analyzed in vaccine studies, referenced in publications and reports.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study References\"<|>\"event\"<|>\"Citations and identifiers for referenced studies, such as PMID and DOI numbers.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Reports\"<|>\"event\"<|>\"Official reports published on vaccine safety and effectiveness, such as those in MMWR Early Release.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Websites\"<|>\"organization\"<|>\"Websites hosting official reports and publications, such as the CDC MMWR website.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Funding\"<|>\"event\"<|>\"Funding sources for vaccine studies, often provided by organizations such as CDC, FDA, and pharmaceutical companies.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Collaborators\"<|>\"person\"<|>\"Individuals and organizations collaborating on vaccine studies and reports.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Demographics\"<|>\"event\"<|>\"Population groups studied in vaccine research, such as women under 60 and persons aged 18 and older.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Adverse Event Monitoring\"<|>\"event\"<|>\"Surveillance and reporting of adverse events in vaccine recipients, conducted by CDC and FDA.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Interim Recommendations\"<|>\"event\"<|>\"Temporary guidance issued during the course of vaccine studies and public health response.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Mass Vaccination Programs\"<|>\"event\"<|>\"Large-scale vaccination campaigns referenced in studies, such as those in Israel.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Safety Concerns\"<|>\"event\"<|>\"Issues such as CVST and thrombocytopenia leading to pauses and increased monitoring in vaccine studies.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Clinical Outcomes\"<|>\"event\"<|>\"Measured health outcomes in vaccine recipients, such as reduction in severe cases and long-term effects.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Authors and Collaborators\"<|>\"person\"<|>\"Individuals listed as authors and collaborators on vaccine studies and reports.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Dates\"<|>\"event\"<|>\"Dates of publication for referenced vaccine studies and reports.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Journals\"<|>\"organization\"<|>\"Journals publishing vaccine studies, such as NEJM, JAMA, Vaccine, and The Lancet.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Websites\"<|>\"organization\"<|>\"Websites hosting vaccine study publications, such as the CDC MMWR website.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Identifiers\"<|>\"event\"<|>\"Identifiers such as PMID and DOI numbers for referenced vaccine studies.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication References\"<|>\"event\"<|>\"Citations for referenced vaccine studies and reports.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Reports\"<|>\"event\"<|>\"Official reports published on vaccine safety and effectiveness.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Funding\"<|>\"event\"<|>\"Funding sources for vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Collaborators\"<|>\"person\"<|>\"Individuals and organizations collaborating on vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Demographics\"<|>\"event\"<|>\"Population groups referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Adverse Event Monitoring\"<|>\"event\"<|>\"Surveillance and reporting of adverse events in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Interim Recommendations\"<|>\"event\"<|>\"Temporary guidance issued in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Mass Vaccination Programs\"<|>\"event\"<|>\"Large-scale vaccination campaigns referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Safety Concerns\"<|>\"event\"<|>\"Issues such as CVST and thrombocytopenia referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Clinical Outcomes\"<|>\"event\"<|>\"Measured health outcomes referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Authors and Collaborators\"<|>\"person\"<|>\"Individuals listed as authors and collaborators in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Dates and Journals\"<|>\"event\"<|>\"Dates and journals of publication for vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Websites and Identifiers\"<|>\"event\"<|>\"Websites and identifiers for vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication References and Reports\"<|>\"event\"<|>\"References and reports for vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Funding and Collaborators\"<|>\"event\"<|>\"Funding and collaborators for vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Demographics and Adverse Event Monitoring\"<|>\"event\"<|>\"Demographics and adverse event monitoring in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Interim Recommendations and Mass Vaccination Programs\"<|>\"event\"<|>\"Interim recommendations and mass vaccination programs referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Safety Concerns and Clinical Outcomes\"<|>\"event\"<|>\"Safety concerns and clinical outcomes referenced in vaccine study publications.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Study Publication Authors, Dates, Journals, Websites, Identifiers, References, Reports, Funding, Collaborators, Demographics, Adverse Event Monitoring, Interim Recommendations, Mass Vaccination Programs, Safety Concerns, Clinical Outcomes\"<|>\"event\"<|>\"Comprehensive set of attributes referenced in vaccine study publications.\")##\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "0a5ef2d3687a51755fe6e82eeb80f7e3": {
    "return": "(\"entity\"<|>\"Pfizer-BioNTech\"<|>\"organization\"<|>\"Pfizer-BioNTech is a pharmaceutical company that produces one of the authorized COVID-19 vaccines used in the study. Their vaccine is part of a 2-dose series and was represented in both clinical trials and real-world effectiveness studies.\")##\n(\"entity\"<|>\"Moderna\"<|>\"organization\"<|>\"Moderna is a biotechnology company that produces one of the authorized COVID-19 vaccines used in the study. Their vaccine is part of a 2-dose series and was equally represented in the current report.\")##\n(\"entity\"<|>\"University of California Los Angeles\"<|>\"organization\"<|>\"University of California Los Angeles is a medical center in California that enrolled patients for the study on COVID-19 vaccine effectiveness.\")##\n(\"entity\"<|>\"Stanford University\"<|>\"organization\"<|>\"Stanford University is a medical center in California that participated in patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"UCHealth University of Colorado Hospital\"<|>\"organization\"<|>\"UCHealth University of Colorado Hospital is a medical center in Colorado involved in patient enrollment for the study.\")##\n(\"entity\"<|>\"Johns Hopkins Hospital\"<|>\"organization\"<|>\"Johns Hopkins Hospital is a medical center in Maryland that contributed to patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"organization\"<|>\"Beth Israel Deaconess Medical Center is a medical center in Massachusetts that participated in the study.\")##\n(\"entity\"<|>\"Baystate Medical Center\"<|>\"organization\"<|>\"Baystate Medical Center is a medical center in Massachusetts involved in patient enrollment for the study.\")##\n(\"entity\"<|>\"University of Michigan\"<|>\"organization\"<|>\"University of Michigan is a medical center in Michigan that participated in the study.\")##\n(\"entity\"<|>\"Henry Ford\"<|>\"organization\"<|>\"Henry Ford is a medical center in Michigan that contributed to patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"St. Joseph\"<|>\"organization\"<|>\"St. Joseph is a medical center in Michigan involved in the study.\")##\n(\"entity\"<|>\"Hennepin County Medical Center\"<|>\"organization\"<|>\"Hennepin County Medical Center is a medical center in Minnesota that participated in the study.\")##\n(\"entity\"<|>\"Montefiore Healthcare Center\"<|>\"organization\"<|>\"Montefiore Healthcare Center is a medical center in New York involved in patient enrollment for the study.\")##\n(\"entity\"<|>\"Wake Forest University\"<|>\"organization\"<|>\"Wake Forest University is a medical center in North Carolina that participated in the study.\")##\n(\"entity\"<|>\"Ohio State University\"<|>\"organization\"<|>\"Ohio State University is a medical center in Ohio involved in patient enrollment for the study.\")##\n(\"entity\"<|>\"Oregon Health & Science University\"<|>\"organization\"<|>\"Oregon Health & Science University is a medical center in Oregon that participated in the study.\")##\n(\"entity\"<|>\"University of Pittsburgh Medical Center\"<|>\"organization\"<|>\"University of Pittsburgh Medical Center is a medical center in Pennsylvania that contributed to patient enrollment for the vaccine effectiveness study.\")##\n(\"entity\"<|>\"Shadyside Hospital\"<|>\"organization\"<|>\"Shadyside Hospital is a hospital in Pennsylvania affiliated with University of Pittsburgh Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Mercy Hospital\"<|>\"organization\"<|>\"Mercy Hospital is a hospital in Pennsylvania affiliated with University of Pittsburgh Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Passavant Hospital\"<|>\"organization\"<|>\"Passavant Hospital is a hospital in Pennsylvania affiliated with University of Pittsburgh Medical Center and participated in the study.\")##\n(\"entity\"<|>\"St. Margaret Hospital\"<|>\"organization\"<|>\"St. Margaret Hospital is a hospital in Pennsylvania affiliated with University of Pittsburgh Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Presbyterian Hospital\"<|>\"organization\"<|>\"Presbyterian Hospital is a hospital in Pennsylvania affiliated with University of Pittsburgh Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Vanderbilt University Medical Center\"<|>\"organization\"<|>\"Vanderbilt University Medical Center is a medical center in Tennessee that participated in the study.\")##\n(\"entity\"<|>\"Baylor Scott & White Medical Center\"<|>\"organization\"<|>\"Baylor Scott & White Medical Center is a medical center in Texas that participated in the study.\")##\n(\"entity\"<|>\"Temple\"<|>\"organization\"<|>\"Temple is a hospital in Texas affiliated with Baylor Scott & White Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Round Rock\"<|>\"organization\"<|>\"Round Rock is a hospital in Texas affiliated with Baylor Scott & White Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Hillcrest/Waco\"<|>\"organization\"<|>\"Hillcrest/Waco is a hospital in Texas affiliated with Baylor Scott & White Medical Center and participated in the study.\")##\n(\"entity\"<|>\"Intermountain Health\"<|>\"organization\"<|>\"Intermountain Health is a medical center in Utah that participated in the study.\")##\n(\"entity\"<|>\"Israel\"<|>\"geo\"<|>\"Israel is a country referenced in the text as having early reports documenting real-world effectiveness of SARS-CoV-2 vaccination, particularly with the Pfizer-BioNTech vaccine.\")##\n(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"US Department of Health and Human Services is a federal agency overseeing public health, referenced as a publisher of the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"Centers for Disease Control and Prevention (CDC) is a federal public health agency involved in monitoring vaccine effectiveness and publishing the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"COVID-19 Hospitalization\"<|>\"event\"<|>\"COVID-19 Hospitalization refers to the event of patients being hospitalized due to severe COVID-19, which is the primary outcome measured in the vaccine effectiveness study.\")##\n(\"entity\"<|>\"COVID-19 Vaccination\"<|>\"event\"<|>\"COVID-19 Vaccination refers to the administration of authorized vaccines (Pfizer-BioNTech or Moderna) to adults, with the study measuring its effectiveness against hospitalization and severe outcomes.\")##\n(\"entity\"<|>\"Long COVID\"<|>\"event\"<|>\"Long COVID refers to post-COVID conditions that may persist after initial infection, mentioned as a possible outcome affected by vaccination.\")##\n(\"entity\"<|>\"Michael Smith\"<|>\"person\"<|>\"Michael Smith is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Tnelda Zunie\"<|>\"person\"<|>\"Tnelda Zunie is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Deepika Konatham\"<|>\"person\"<|>\"Deepika Konatham is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Angela Kennedy\"<|>\"person\"<|>\"Angela Kennedy is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Deborah Hendricks\"<|>\"person\"<|>\"Deborah Hendricks is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Jason Ettlinger\"<|>\"person\"<|>\"Jason Ettlinger is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Natalie Settele\"<|>\"person\"<|>\"Natalie Settele is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Elisa Priest\"<|>\"person\"<|>\"Elisa Priest is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Jennifer Thomas\"<|>\"person\"<|>\"Jennifer Thomas is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Madhava Beeram\"<|>\"person\"<|>\"Madhava Beeram is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Jay Fox\"<|>\"person\"<|>\"Jay Fox is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"James Morrison\"<|>\"person\"<|>\"James Morrison is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Omowunmi Amosu\"<|>\"person\"<|>\"Omowunmi Amosu is acknowledged as a contributor to the IVY Network and Montefiore Healthcare Center.\")##\n(\"entity\"<|>\"Brent Armbruster\"<|>\"person\"<|>\"Brent Armbruster is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\")##\n(\"entity\"<|>\"Valerie Aston\"<|>\"person\"<|>\"Valerie Aston is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\")##\n(\"entity\"<|>\"Marianne Bernardo\"<|>\"person\"<|>\"Marianne Bernardo is acknowledged as a contributor to Reagan-UCLA Medical Center, Los Angeles, California.\")##\n(\"entity\"<|>\"Robert Bowers\"<|>\"person\"<|>\"Robert Bowers is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\")##\n(\"entity\"<|>\"Leslie De Souza\"<|>\"person\"<|>\"Leslie De Souza is acknowledged as a contributor to Baystate Medical Center, Springfield, Massachusetts.\")##\n(\"entity\"<|>\"Jennifer Friedel\"<|>\"person\"<|>\"Jennifer Friedel is acknowledged as a contributor to University of Colorado School of Medicine, Aurora, Colorado.\")##\n(\"entity\"<|>\"Kevin Gardner\"<|>\"person\"<|>\"Kevin Gardner is acknowledged as a contributor to Stanford University School of Medicine, Palo Alto, California.\")##\n(\"entity\"<|>\"Jennifer Goff\"<|>\"person\"<|>\"Jennifer Goff is acknowledged as a contributor to University of Colorado School of Medicine, Aurora, Colorado.\")##\n(\"relationship\"<|>\"Pfizer-BioNTech\"<|>\"COVID-19 Vaccination\"<|>\"Pfizer-BioNTech produces one of the vaccines used in COVID-19 vaccination efforts measured in the study.\"<|>10)##\n(\"relationship\"<|>\"Moderna\"<|>\"COVID-19 Vaccination\"<|>\"Moderna produces one of the vaccines used in COVID-19 vaccination efforts measured in the study.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 Vaccination\"<|>\"COVID-19 Hospitalization\"<|>\"COVID-19 vaccination is associated with reduced risk of COVID-19 hospitalization among adults aged 65 years, as measured in the study.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 Vaccination\"<|>\"Long COVID\"<|>\"COVID-19 vaccination may reduce the risk of post-COVID conditions such as Long COVID, as suggested by the findings.\"<|>7)##\n(\"relationship\"<|>\"Israel\"<|>\"Pfizer-BioNTech\"<|>\"Early reports from Israel documented real-world effectiveness of the Pfizer-BioNTech vaccine.\"<|>8)##\n(\"relationship\"<|>\"University of California Los Angeles\"<|>\"COVID-19 Hospitalization\"<|>\"University of California Los Angeles enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Stanford University\"<|>\"COVID-19 Hospitalization\"<|>\"Stanford University enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"UCHealth University of Colorado Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"UCHealth University of Colorado Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Johns Hopkins Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"Johns Hopkins Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"Beth Israel Deaconess Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Baystate Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"Baystate Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"University of Michigan\"<|>\"COVID-19 Hospitalization\"<|>\"University of Michigan enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Henry Ford\"<|>\"COVID-19 Hospitalization\"<|>\"Henry Ford enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"St. Joseph\"<|>\"COVID-19 Hospitalization\"<|>\"St. Joseph enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Hennepin County Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"Hennepin County Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Montefiore Healthcare Center\"<|>\"COVID-19 Hospitalization\"<|>\"Montefiore Healthcare Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Wake Forest University\"<|>\"COVID-19 Hospitalization\"<|>\"Wake Forest University enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Ohio State University\"<|>\"COVID-19 Hospitalization\"<|>\"Ohio State University enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Oregon Health & Science University\"<|>\"COVID-19 Hospitalization\"<|>\"Oregon Health & Science University enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"University of Pittsburgh Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"University of Pittsburgh Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Shadyside Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"Shadyside Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Mercy Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"Mercy Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Passavant Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"Passavant Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"St. Margaret Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"St. Margaret Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Presbyterian Hospital\"<|>\"COVID-19 Hospitalization\"<|>\"Presbyterian Hospital enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Vanderbilt University Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"Vanderbilt University Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Baylor Scott & White Medical Center\"<|>\"COVID-19 Hospitalization\"<|>\"Baylor Scott & White Medical Center enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Temple\"<|>\"COVID-19 Hospitalization\"<|>\"Temple enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Round Rock\"<|>\"COVID-19 Hospitalization\"<|>\"Round Rock enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Hillcrest/Waco\"<|>\"COVID-19 Hospitalization\"<|>\"Hillcrest/Waco enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"Intermountain Health\"<|>\"COVID-19 Hospitalization\"<|>\"Intermountain Health enrolled patients hospitalized for COVID-19 as part of the study.\"<|>8)##\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates under the US Department of Health and Human Services and is responsible for monitoring vaccine effectiveness and publishing the Morbidity and Mortality Weekly Report.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-19 Vaccination\"<|>\"The CDC monitors the effectiveness of COVID-19 vaccination under routine public health use.\"<|>9)##\n(\"relationship\"<|>\"Michael Smith\"<|>\"Baylor Scott & White Health\"<|>\"Michael Smith is acknowledged as a contributor to Baylor Scott & White Health.\"<|>7)##\n(\"relationship\"<|>\"Omowunmi Amosu\"<|>\"Montefiore Healthcare Center\"<|>\"Omowunmi Amosu is acknowledged as a contributor to Montefiore Healthcare Center.\"<|>7)##\n(\"relationship\"<|>\"Omowunmi Amosu\"<|>\"Albert Einstein College of Medicine\"<|>\"Omowunmi Amosu is acknowledged as a contributor to Albert Einstein College of Medicine, Bronx, New York.\"<|>7)##\n(\"relationship\"<|>\"Brent Armbruster\"<|>\"Intermountain Medical Center\"<|>\"Brent Armbruster is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\"<|>7)##\n(\"relationship\"<|>\"Valerie Aston\"<|>\"Intermountain Medical Center\"<|>\"Valerie Aston is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\"<|>7)##\n(\"relationship\"<|>\"Marianne Bernardo\"<|>\"Reagan-UCLA Medical Center\"<|>\"Marianne Bernardo is acknowledged as a contributor to Reagan-UCLA Medical Center, Los Angeles, California.\"<|>7)##\n(\"relationship\"<|>\"Robert Bowers\"<|>\"Intermountain Medical Center\"<|>\"Robert Bowers is acknowledged as a contributor to Intermountain Medical Center, Salt Lake City, Utah.\"<|>7)##\n(\"relationship\"<|>\"Leslie De Souza\"<|>\"Baystate Medical Center\"<|>\"Leslie De Souza is acknowledged as a contributor to Baystate Medical Center, Springfield, Massachusetts.\"<|>7)##\n(\"relationship\"<|>\"Jennifer Friedel\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Friedel is acknowledged as a contributor to University of Colorado School of Medicine, Aurora, Colorado.\"<|>7)##\n(\"relationship\"<|>\"Kevin Gardner\"<|>\"Stanford University School of Medicine\"<|>\"Kevin Gardner is acknowledged as a contributor to Stanford University School of Medicine, Palo Alto, California.\"<|>7)##\n(\"relationship\"<|>\"Jennifer Goff\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Goff is acknowledged as a contributor to University of Colorado School of Medicine, Aurora, Colorado.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "27818be9e31e84015e44b7d7de70a11d": {
    "return": "(\"entity\"<|>\"Site A\"<|>\"geo\"<|>\"Site A is one of the five U.S. mass vaccination sites where the Janssen COVID-19 vaccine was administered and anxiety-related adverse events were reported. It was a drive-through site and vaccination was not temporarily suspended.\")##\n(\"entity\"<|>\"Site B\"<|>\"geo\"<|>\"Site B is one of the five U.S. mass vaccination sites where the Janssen COVID-19 vaccine was administered and anxiety-related adverse events were reported. Vaccination was temporarily suspended at this site.\")##\n(\"entity\"<|>\"Site C\"<|>\"geo\"<|>\"Site C is one of the five U.S. mass vaccination sites, located on a college campus and vaccinating students. Vaccination was temporarily suspended at this site.\")##\n(\"entity\"<|>\"Site D\"<|>\"geo\"<|>\"Site D is one of the five U.S. mass vaccination sites where the Janssen COVID-19 vaccine was administered and anxiety-related adverse events were reported. Vaccination was temporarily suspended at this site.\")##\n(\"entity\"<|>\"Site E\"<|>\"geo\"<|>\"Site E is one of the five U.S. mass vaccination sites where the Janssen COVID-19 vaccine was administered and anxiety-related adverse events were reported. Vaccination was temporarily suspended at this site.\")##\n(\"entity\"<|>\"April 7, 2021\"<|>\"event\"<|>\"April 7, 2021 is the date on which mass vaccination events occurred at Sites C, D, and E, with reported anxiety-related adverse events.\")##\n(\"entity\"<|>\"April 8, 2021\"<|>\"event\"<|>\"April 8, 2021 is the date on which mass vaccination events occurred at Site B, with reported anxiety-related adverse events.\")##\n(\"entity\"<|>\"April 79, 2021\"<|>\"event\"<|>\"April 79, 2021 is the date on which mass vaccination events occurred at Site A, with reported anxiety-related adverse events. This appears to be a typographical error, possibly referring to April 7 or 9, 2021.\")##\n(\"entity\"<|>\"March-April 2021\"<|>\"event\"<|>\"March-April 2021 is the reporting period for Janssen COVID-19 vaccine adverse events in the VAERS system.\")##\n(\"entity\"<|>\"July 2019-June 2020\"<|>\"event\"<|>\"July 2019-June 2020 is the reporting period for influenza vaccine adverse events in the VAERS system.\")##\n(\"entity\"<|>\"Adults aged 18 years and older\"<|>\"person\"<|>\"Adults aged 18 years and older are the population group receiving the Janssen COVID-19 and influenza vaccines, and for whom adverse events were tracked and reported.\")##\n(\"entity\"<|>\"Students\"<|>\"person\"<|>\"Students are the population group vaccinated at Site C, a college campus, and are included in the adverse event reporting.\")##\n(\"entity\"<|>\"Persons with history of anxiety related to needles or medical visits\"<|>\"person\"<|>\"Individuals who reported a history of anxiety related to needles or medical visits, some of whom experienced anxiety-related adverse events after vaccination.\")##\n(\"entity\"<|>\"Chest Pain\"<|>\"event\"<|>\"Chest pain is one of the common signs and symptoms reported as an anxiety-related adverse event following vaccination.\")##\n(\"entity\"<|>\"Hypotension\"<|>\"event\"<|>\"Hypotension is one of the common signs and symptoms reported as an anxiety-related adverse event following vaccination.\")##\n(\"entity\"<|>\"Light-headedness or Dizziness\"<|>\"event\"<|>\"Light-headedness or dizziness is one of the common signs and symptoms reported as an anxiety-related adverse event following vaccination.\")##\n(\"entity\"<|>\"Nausea/Vomiting\"<|>\"event\"<|>\"Nausea and vomiting are common signs and symptoms reported as anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Pallor or Diaphoresis\"<|>\"event\"<|>\"Pallor or diaphoresis (sweating) are common signs and symptoms reported as anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Seizure-like Activity\"<|>\"event\"<|>\"Seizure-like activity is a symptom reported as an anxiety-related adverse event following vaccination.\")##\n(\"entity\"<|>\"Tachycardia\"<|>\"event\"<|>\"Tachycardia (rapid heartbeat) is a symptom reported as an anxiety-related adverse event following vaccination.\")##\n(\"entity\"<|>\"Hyperventilation\"<|>\"event\"<|>\"Hyperventilation is a symptom included in the definition of anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Dyspnea\"<|>\"event\"<|>\"Dyspnea (difficulty breathing) is a symptom included in the definition of anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Paresthesia\"<|>\"event\"<|>\"Paresthesia (tingling or numbness) is a symptom included in the definition of anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Headache\"<|>\"event\"<|>\"Headache is a symptom included in the definition of anxiety-related adverse events following vaccination.\")##\n(\"entity\"<|>\"Diphenhydramine\"<|>\"event\"<|>\"Diphenhydramine is a medication administered to some individuals experiencing allergic-like symptoms after vaccination, who were excluded from the anxiety-related adverse event analysis.\")##\n(\"entity\"<|>\"Epinephrine\"<|>\"event\"<|>\"Epinephrine is a medication administered to some individuals experiencing allergic-like symptoms after vaccination, who were excluded from the anxiety-related adverse event analysis.\")##\n\n(\"relationship\"<|>\"Site A\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site A administered the Janssen COVID-19 vaccine and reported anxiety-related adverse events.\"<|>9)##\n(\"relationship\"<|>\"Site B\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site B administered the Janssen COVID-19 vaccine and reported anxiety-related adverse events. Vaccination was temporarily suspended at this site.\"<|>9)##\n(\"relationship\"<|>\"Site C\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site C administered the Janssen COVID-19 vaccine to students and reported anxiety-related adverse events. Vaccination was temporarily suspended at this site.\"<|>9)##\n(\"relationship\"<|>\"Site D\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site D administered the Janssen COVID-19 vaccine and reported anxiety-related adverse events. Vaccination was temporarily suspended at this site.\"<|>9)##\n(\"relationship\"<|>\"Site E\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Site E administered the Janssen COVID-19 vaccine and reported anxiety-related adverse events. Vaccination was temporarily suspended at this site.\"<|>9)##\n(\"relationship\"<|>\"Site C\"<|>\"Students\"<|>\"Site C was located on a college campus and specifically vaccinated students, who were included in adverse event reporting.\"<|>8)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site C\"<|>\"April 7, 2021 was the date of the vaccination event at Site C, with reported adverse events.\"<|>7)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site D\"<|>\"April 7, 2021 was the date of the vaccination event at Site D, with reported adverse events.\"<|>7)##\n(\"relationship\"<|>\"April 7, 2021\"<|>\"Site E\"<|>\"April 7, 2021 was the date of the vaccination event at Site E, with reported adverse events.\"<|>7)##\n(\"relationship\"<|>\"April 8, 2021\"<|>\"Site B\"<|>\"April 8, 2021 was the date of the vaccination event at Site B, with reported adverse events.\"<|>7)##\n(\"relationship\"<|>\"April 79, 2021\"<|>\"Site A\"<|>\"April 79, 2021 was the date of the vaccination event at Site A, with reported adverse events. This may be a typographical error.\"<|>6)##\n(\"relationship\"<|>\"March-April 2021\"<|>\"Janssen COVID-19 Vaccine\"<|>\"March-April 2021 was the reporting period for Janssen COVID-19 vaccine adverse events in VAERS.\"<|>8)##\n(\"relationship\"<|>\"July 2019-June 2020\"<|>\"Influenza Vaccine\"<|>\"July 2019-June 2020 was the reporting period for influenza vaccine adverse events in VAERS.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 18 years and older\"<|>\"Janssen COVID-19 Vaccine\"<|>\"Adults aged 18 years and older were the population receiving the Janssen COVID-19 vaccine and included in adverse event reporting.\"<|>8)##\n(\"relationship\"<|>\"Adults aged 18 years and older\"<|>\"Influenza Vaccine\"<|>\"Adults aged 18 years and older were the population receiving the influenza vaccine and included in adverse event reporting.\"<|>8)##\n(\"relationship\"<|>\"Persons with history of anxiety related to needles or medical visits\"<|>\"Anxiety-Related Adverse Events\"<|>\"Some individuals with a history of anxiety related to needles or medical visits experienced anxiety-related adverse events after vaccination.\"<|>8)##\n(\"relationship\"<|>\"Chest Pain\"<|>\"Anxiety-Related Adverse Events\"<|>\"Chest pain is one of the symptoms included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Hypotension\"<|>\"Anxiety-Related Adverse Events\"<|>\"Hypotension is one of the symptoms included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Light-headedness or Dizziness\"<|>\"Anxiety-Related Adverse Events\"<|>\"Light-headedness or dizziness is one of the symptoms included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Nausea/Vomiting\"<|>\"Anxiety-Related Adverse Events\"<|>\"Nausea and vomiting are symptoms included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Pallor or Diaphoresis\"<|>\"Anxiety-Related Adverse Events\"<|>\"Pallor or diaphoresis are symptoms included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Seizure-like Activity\"<|>\"Anxiety-Related Adverse Events\"<|>\"Seizure-like activity is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Tachycardia\"<|>\"Anxiety-Related Adverse Events\"<|>\"Tachycardia is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Hyperventilation\"<|>\"Anxiety-Related Adverse Events\"<|>\"Hyperventilation is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Dyspnea\"<|>\"Anxiety-Related Adverse Events\"<|>\"Dyspnea is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Paresthesia\"<|>\"Anxiety-Related Adverse Events\"<|>\"Paresthesia is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Headache\"<|>\"Anxiety-Related Adverse Events\"<|>\"Headache is a symptom included in the definition of anxiety-related adverse events.\"<|>8)##\n(\"relationship\"<|>\"Diphenhydramine\"<|>\"Anxiety-Related Adverse Events\"<|>\"Persons who received diphenhydramine for allergic-like symptoms were excluded from the anxiety-related adverse event analysis.\"<|>7)##\n(\"relationship\"<|>\"Epinephrine\"<|>\"Anxiety-Related Adverse Events\"<|>\"Persons who received epinephrine for allergic-like symptoms were excluded from the anxiety-related adverse event analysis.\"<|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "c94a0fcffae5febff50d1f3b6e0ab1b1": {
    "return": "(\"entity\"<|>\"SARS-CoV-2\"<|>\"organization\"<|>\"SARS-CoV-2 is the virus responsible for COVID-19. The spike glycoprotein from this virus is encoded in the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Health Care Providers\"<|>\"person\"<|>\"Health care providers are individuals who administer vaccines and are required to report adverse events to VAERS under the EUA for COVID-19 vaccines.\")##\n(\"entity\"<|>\"Vaccine Manufacturers\"<|>\"organization\"<|>\"Vaccine manufacturers are organizations that produce vaccines and are required to report adverse events to VAERS.\")##\n(\"entity\"<|>\"The Public\"<|>\"person\"<|>\"The public refers to individuals who can submit reports of adverse events to VAERS.\")##\n(\"entity\"<|>\"Women aged <60 years\"<|>\"person\"<|>\"Women under 60 years old are a demographic group noted for experiencing thrombotic events after AstraZeneca COVID-19 vaccination in Europe.\")##\n(\"entity\"<|>\"Recipients of Janssen COVID-19 vaccine\"<|>\"person\"<|>\"Recipients of the Janssen COVID-19 vaccine are individuals who received the vaccine and are monitored for adverse events through VAERS and v-safe.\")##\n(\"entity\"<|>\"Recipients of AstraZeneca COVID-19 vaccine\"<|>\"person\"<|>\"Recipients of the AstraZeneca COVID-19 vaccine are individuals who received the vaccine and have experienced thrombotic events, especially in Europe.\")##\n(\"entity\"<|>\"Medical Dictionary for Regulatory Activities (MedDRA)\"<|>\"organization\"<|>\"MedDRA is a medical terminology dictionary used to code signs and symptoms in VAERS reports for regulatory activities.\")##\n(\"entity\"<|>\"V-safe Call Center\"<|>\"organization\"<|>\"The v-safe call center contacts enrollees who report seeking medical care and encourages them to complete a VAERS report if indicated.\")##\n(\"entity\"<|>\"Emergency Use Authorization (EUA)\"<|>\"event\"<|>\"EUA is a regulatory mechanism under which COVID-19 vaccines are authorized for use, requiring health care providers to report certain adverse events to VAERS.\")##\n(\"entity\"<|>\"Human Adenovirus Type 26\"<|>\"organization\"<|>\"Human adenovirus type 26 is the viral vector used in the Janssen COVID-19 vaccine to deliver the SARS-CoV-2 spike protein gene.\")##\n(\"entity\"<|>\"Chimpanzee Adenoviral Vector\"<|>\"organization\"<|>\"Chimpanzee adenoviral vector is the viral vector used in the AstraZeneca COVID-19 vaccine.\")##\n(\"entity\"<|>\"Race/Ethnicity\"<|>\"event\"<|>\"Race/ethnicity is a demographic variable described in VAERS and v-safe data for vaccine recipients.\")##\n(\"entity\"<|>\"Fatigue\"<|>\"event\"<|>\"Fatigue is a commonly reported symptom among recipients of the Janssen COVID-19 vaccine in both VAERS and v-safe.\")##\n(\"entity\"<|>\"Pain\"<|>\"event\"<|>\"Pain is a commonly reported symptom among recipients of the Janssen COVID-19 vaccine in both VAERS and v-safe.\")##\n(\"entity\"<|>\"Health Impact\"<|>\"event\"<|>\"Health impact is defined as being unable to perform normal daily activities, being unable to work, or receiving medical care after vaccination.\")##\n(\"entity\"<|>\"Death\"<|>\"event\"<|>\"Death is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Life-threatening Illness\"<|>\"event\"<|>\"Life-threatening illness is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Hospitalization\"<|>\"event\"<|>\"Hospitalization is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Permanent Disability\"<|>\"event\"<|>\"Permanent disability is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Congenital Anomaly\"<|>\"event\"<|>\"Congenital anomaly is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Birth Defect\"<|>\"event\"<|>\"Birth defect is a serious adverse event reported to VAERS and is a criterion for classifying VAERS reports as serious.\")##\n(\"entity\"<|>\"Autopsy Reports\"<|>\"event\"<|>\"Autopsy reports are obtained by VAERS staff for all deaths reported as vaccine adverse events.\")##\n(\"entity\"<|>\"Death Certificates\"<|>\"event\"<|>\"Death certificates are obtained by VAERS staff for all deaths reported as vaccine adverse events.\")##\n(\"entity\"<|>\"Preauthorization Clinical Trials\"<|>\"event\"<|>\"Preauthorization clinical trials are studies conducted before a vaccine is authorized, providing safety profile data for comparison with post-authorization surveillance.\")##\n(\"entity\"<|>\"Brighton Collaborations Draft Interim Case Finding Definition for TTS\"<|>\"event\"<|>\"This is the draft interim case definition for TTS provided by Brighton Collaboration, used for surveillance and reporting.\")##\n(\"entity\"<|>\"Online Health Surveys\"<|>\"event\"<|>\"Online health surveys are completed by v-safe enrollees to report symptoms and health impacts after vaccination.\")##\n(\"entity\"<|>\"Text Message Reminders\"<|>\"event\"<|>\"Text message reminders are sent to v-safe enrollees to prompt completion of online health surveys.\")##\n(\"entity\"<|>\"CDC Policy\"<|>\"event\"<|>\"CDC policy refers to the guidelines and procedures followed in reviewing vaccine safety activities.\")##\n(\"entity\"<|>\"Federal Law\"<|>\"event\"<|>\"Federal law refers to the legal framework governing vaccine safety monitoring and reporting in the United States.\")##\n(\"entity\"<|>\"March 2-April 21, 2021\"<|>\"event\"<|>\"This is the time period during which VAERS reports were received and processed for the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"March 2-April 12, 2021\"<|>\"event\"<|>\"This is the time period during which v-safe data were collected from persons vaccinated with the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Median Age at Vaccination\"<|>\"event\"<|>\"The median age at vaccination for Janssen COVID-19 vaccine recipients was 50 years.\")##\n(\"entity\"<|>\"7.98 Million Doses\"<|>\"event\"<|>\"7.98 million doses of the Janssen COVID-19 vaccine had been administered in the United States as of April 21, 2021.\")##\n(\"entity\"<|>\"Three Reports Among Women\"<|>\"event\"<|>\"Three reports among women of cases of thrombosis in large arteries or veins accompanied by thrombocytopenia during the second week after vaccination.\")##\n(\"entity\"<|>\"Second Week After Vaccination\"<|>\"event\"<|>\"The second week after vaccination is the time period during which certain adverse events were reported among Janssen vaccine recipients.\")##\n(\"entity\"<|>\"Systemic Reaction\"<|>\"event\"<|>\"Systemic reaction is a type of adverse event reported by 76% of v-safe survey respondents after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Local Reaction\"<|>\"event\"<|>\"Local reaction is a type of adverse event reported by 61% of v-safe survey respondents after Janssen COVID-19 vaccination.\")##\n(\"entity\"<|>\"Serious VAERS Reports\"<|>\"event\"<|>\"Serious VAERS reports are those classified as serious due to criteria such as death, life-threatening illness, hospitalization, permanent disability, congenital anomaly, or birth defect.\")##\n(\"entity\"<|>\"Nonserious VAERS Reports\"<|>\"event\"<|>\"Nonserious VAERS reports are those not meeting the criteria for serious adverse events.\")##\n(\"entity\"<|>\"338,700 Janssen COVID-19 Vaccine Recipients\"<|>\"person\"<|>\"338,700 individuals who received the Janssen COVID-19 vaccine and completed at least one v-safe survey during the week after vaccination.\")##\n(\"entity\"<|>\"13,725 VAERS Reports\"<|>\"event\"<|>\"13,725 VAERS reports were reviewed for the Janssen COVID-19 vaccine, with 97% classified as nonserious and 3% as serious.\")##\n(\"entity\"<|>\"17 Cases of TTS\"<|>\"event\"<|>\"17 cases of thrombosis with thrombocytopenia syndrome (TTS) were identified among Janssen COVID-19 vaccine recipients.\")##\n(\"entity\"<|>\"Three Additional Cases of Non-CVST TTS\"<|>\"event\"<|>\"Three additional cases of non-CVST TTS were detected through prompt review of U.S. vaccine safety data.\")##\n(\"entity\"<|>\"Previously Recognized CVST Cases\"<|>\"event\"<|>\"Previously recognized CVST cases initiated the pause in use of the Janssen COVID-19 vaccine.\")##\n(\"entity\"<|>\"Medical Records\"<|>\"event\"<|>\"Medical records are obtained by VAERS staff for all reported serious events.\")##\n(\"entity\"<|>\"Enrollees Who Report Seeking Medical Care\"<|>\"person\"<|>\"Enrollees in v-safe who report seeking medical care are contacted by the v-safe call center and encouraged to complete a VAERS report.\")##\n(\"entity\"<|>\"Persons Vaccinated During March 2-April 12\"<|>\"person\"<|>\"Persons who received the Janssen COVID-19 vaccine during March 2-April 12 and whose v-safe data were analyzed.\")##\n(\"entity\"<|>\"50% to Women\"<|>\"event\"<|>\"Of the 7.98 million doses of Janssen COVID-19 vaccine administered in the United States, 50% were given to women.\")##\n(\"entity\"<|>\"39% Unknown Race/Ethnicity\"<|>\"event\"<|>\"Race/ethnicity was unknown for 39% of Janssen COVID-19 vaccine recipients.\")##\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "20d86d0c3d1e3738a9f8e69a3ef96b33": {
    "return": "(\"entity\"<|>\"US Department of Health and Human Services\"<|>\"organization\"<|>\"A federal agency responsible for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. Oversees agencies such as the CDC.\" )##\n(\"entity\"<|>\"Centers for Disease Control and Prevention\"<|>\"organization\"<|>\"A national public health institute in the United States, part of the US Department of Health and Human Services, headquartered in Atlanta, Georgia. Responsible for protecting public health and safety through the control and prevention of disease, injury, and disability.\" )##\n(\"entity\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"organization\"<|>\"An academic institution in Pittsburgh, Pennsylvania, focused on health sciences education and research.\" )##\n(\"entity\"<|>\"University of Pittsburgh Medical Center\"<|>\"organization\"<|>\"A large healthcare provider and hospital network based in Pittsburgh, Pennsylvania, affiliated with the University of Pittsburgh.\" )##\n(\"entity\"<|>\"Baylor Scott & White Health\"<|>\"organization\"<|>\"A major healthcare system based in Texas, providing hospital and clinical services, with locations in Temple, Texas.\" )##\n(\"entity\"<|>\"Vanderbilt University Medical Center\"<|>\"organization\"<|>\"A leading academic medical center located in Nashville, Tennessee, providing healthcare, research, and education.\" )##\n(\"entity\"<|>\"Baystate Medical Center\"<|>\"organization\"<|>\"A hospital and medical center located in Springfield, Massachusetts, providing healthcare services and medical education.\" )##\n(\"entity\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"organization\"<|>\"A teaching hospital of Harvard Medical School located in Boston, Massachusetts.\" )##\n(\"entity\"<|>\"University of Colorado School of Medicine\"<|>\"organization\"<|>\"A medical school located in Aurora, Colorado, offering medical education and research.\" )##\n(\"entity\"<|>\"Hennepin County Medical Center\"<|>\"organization\"<|>\"A hospital and medical center located in Minneapolis, Minnesota.\" )##\n(\"entity\"<|>\"Intermountain Medical Center\"<|>\"organization\"<|>\"A hospital located in Salt Lake City, Utah, part of Intermountain Healthcare.\" )##\n(\"entity\"<|>\"University of Utah\"<|>\"organization\"<|>\"A public research university in Salt Lake City, Utah, with a medical school and healthcare facilities.\" )##\n(\"entity\"<|>\"Montefiore Healthcare Center\"<|>\"organization\"<|>\"A healthcare system in Bronx, New York, affiliated with Albert Einstein College of Medicine.\" )##\n(\"entity\"<|>\"Albert Einstein College of Medicine\"<|>\"organization\"<|>\"A medical school located in Bronx, New York, affiliated with Montefiore Healthcare Center.\" )##\n(\"entity\"<|>\"Oregon Health & Science University Hospital\"<|>\"organization\"<|>\"A hospital and academic medical center in Portland, Oregon.\" )##\n(\"entity\"<|>\"Ohio State University Wexner Medical Center\"<|>\"organization\"<|>\"A large academic medical center in Columbus, Ohio, affiliated with Ohio State University.\" )##\n(\"entity\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"organization\"<|>\"A hospital and medical center in Winston-Salem, North Carolina, affiliated with Wake Forest University.\" )##\n(\"entity\"<|>\"Johns Hopkins Hospital\"<|>\"organization\"<|>\"A world-renowned teaching hospital in Baltimore, Maryland, affiliated with Johns Hopkins University.\" )##\n(\"entity\"<|>\"Ronald Reagan-UCLA Medical Center\"<|>\"organization\"<|>\"A major hospital in Los Angeles, California, affiliated with UCLA.\" )##\n(\"entity\"<|>\"Stanford University School of Medicine\"<|>\"organization\"<|>\"A leading medical school located in Palo Alto, California, affiliated with Stanford University.\" )##\n(\"entity\"<|>\"Texas A&M University College of Medicine\"<|>\"organization\"<|>\"A medical school located in Temple, Texas, part of Texas A&M University.\" )##\n(\"entity\"<|>\"University of Michigan School of Public Health\"<|>\"organization\"<|>\"A public health school in Ann Arbor, Michigan, part of the University of Michigan.\" )##\n(\"entity\"<|>\"St. Joseph Mercy Health System\"<|>\"organization\"<|>\"A healthcare system based in Ann Arbor, Michigan.\" )##\n(\"entity\"<|>\"International Committee of Medical Journal Editors\"<|>\"organization\"<|>\"An organization that sets standards for the ethical conduct and reporting of medical research and publication.\" )##\n(\"entity\"<|>\"National Institutes of Health\"<|>\"organization\"<|>\"The primary agency of the United States government responsible for biomedical and public health research.\" )##\n(\"entity\"<|>\"U.S. Department of Defense\"<|>\"organization\"<|>\"A federal executive department responsible for coordinating and supervising all agencies and functions of the government relating directly to national security and the military.\" )##\n(\"entity\"<|>\"Marcus Foundation\"<|>\"organization\"<|>\"A philanthropic organization that funds medical research and other initiatives.\" )##\n(\"entity\"<|>\"Endpoint Health\"<|>\"organization\"<|>\"A healthcare technology company focused on precision medicine.\" )##\n(\"entity\"<|>\"Entegrion\"<|>\"organization\"<|>\"A biotechnology company specializing in medical products.\" )##\n(\"entity\"<|>\"bioMerieux\"<|>\"organization\"<|>\"A multinational biotechnology company specializing in in vitro diagnostics.\" )##\n(\"entity\"<|>\"Bioscape Digital\"<|>\"organization\"<|>\"A company providing digital health solutions.\" )##\n(\"entity\"<|>\"United Therapeutics\"<|>\"organization\"<|>\"A biotechnology company focused on developing therapies for rare diseases.\" )##\n(\"entity\"<|>\"Actelion Pharmaceuticals\"<|>\"organization\"<|>\"A pharmaceutical company specializing in innovative drugs, now part of Johnson & Johnson.\" )##\n(\"entity\"<|>\"Regeneron\"<|>\"organization\"<|>\"A biotechnology company that invents life-transforming medicines for serious diseases.\" )##\n(\"entity\"<|>\"Reata Pharmaceuticals\"<|>\"organization\"<|>\"A pharmaceutical company focused on developing therapies for serious or life-threatening diseases.\" )##\n(\"entity\"<|>\"Intermountain Research and Medical Foundation\"<|>\"organization\"<|>\"A foundation supporting medical research and healthcare initiatives, affiliated with Intermountain Healthcare.\" )##\n(\"entity\"<|>\"Janssen\"<|>\"organization\"<|>\"A pharmaceutical company, part of Johnson & Johnson.\" )##\n(\"entity\"<|>\"Faron\"<|>\"organization\"<|>\"A biopharmaceutical company focused on clinical-stage drug development.\" )##\n(\"entity\"<|>\"Sedana\"<|>\"organization\"<|>\"A pharmaceutical company specializing in sedation and anesthesia products.\" )##\n(\"entity\"<|>\"Asahi Kasei Pharma\"<|>\"organization\"<|>\"A Japanese pharmaceutical company.\" )##\n(\"entity\"<|>\"AbbVie\"<|>\"organization\"<|>\"A global biopharmaceutical company.\" )##\n(\"entity\"<|>\"Pfizer\"<|>\"organization\"<|>\"A multinational pharmaceutical corporation.\" )##\n(\"entity\"<|>\"Merck\"<|>\"organization\"<|>\"A global healthcare company known for pharmaceuticals, vaccines, and animal health products.\" )##\n(\"entity\"<|>\"Sanofi Pasteur\"<|>\"organization\"<|>\"The vaccines division of Sanofi, a global healthcare company.\" )##\n(\"entity\"<|>\"Campbell Alliance/Syneos Health\"<|>\"organization\"<|>\"A healthcare consulting and clinical research organization.\" )##\n(\"entity\"<|>\"Food and Drug Administration\"<|>\"organization\"<|>\"A federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices.\" )##\n(\"entity\"<|>\"Agency for Health Care Research and Quality\"<|>\"organization\"<|>\"A federal agency tasked with improving the safety and quality of America's healthcare system.\" )##\n(\"entity\"<|>\"Philips Healthcare\"<|>\"organization\"<|>\"A global healthcare technology company.\" )##\n(\"entity\"<|>\"PureTech Health\"<|>\"organization\"<|>\"A clinical-stage biopharmaceutical company.\" )##\n(\"entity\"<|>\"La Jolla Pharmaceuticals\"<|>\"organization\"<|>\"A pharmaceutical company focused on innovative therapies.\" )##\n(\"entity\"<|>\"Cumberland Pharmaceuticals, Inc.\"<|>\"organization\"<|>\"A specialty pharmaceutical company.\" )##\n(\"entity\"<|>\"Sanofi, Inc.\"<|>\"organization\"<|>\"A subsidiary of Sanofi, a global healthcare company.\" )##\n(\"entity\"<|>\"CDC-Abt Associates\"<|>\"organization\"<|>\"A partnership between the CDC and Abt Associates, a research and consulting firm.\" )##\n(\"entity\"<|>\"Seqirus\"<|>\"organization\"<|>\"A global influenza vaccine company.\" )##\n(\"entity\"<|>\"Shire\"<|>\"organization\"<|>\"A global biotechnology company, now part of Takeda Pharmaceuticals.\" )##\n(\"entity\"<|>\"Qiagen\"<|>\"organization\"<|>\"A provider of sample and assay technologies for molecular diagnostics.\" )##\n(\"entity\"<|>\"Ansun\"<|>\"organization\"<|>\"A biotechnology company focused on developing novel therapeutics.\" )##\n(\"entity\"<|>\"Novartis\"<|>\"organization\"<|>\"A global healthcare company based in Switzerland.\" )##\n(\"entity\"<|>\"GlaxoSmithKline\"<|>\"organization\"<|>\"A global healthcare company specializing in pharmaceuticals, vaccines, and consumer healthcare.\" )##\n(\"entity\"<|>\"Mohamed Yassin\"<|>\"person\"<|>\"An author affiliated with University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.\" )##\n(\"entity\"<|>\"Martha Zayed\"<|>\"person\"<|>\"An author affiliated with Baylor Scott & White Health, Temple, Texas.\" )##\n(\"entity\"<|>\"Tnelda Zunie\"<|>\"person\"<|>\"An author affiliated with Baylor Scott & White Health, Temple, Texas.\" )##\n(\"entity\"<|>\"Mark W. Tenforde\"<|>\"person\"<|>\"Corresponding author for the report, affiliated with CDC COVID-19 Response Team.\" )##\n(\"entity\"<|>\"Christopher J. Lindsell\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health, U.S. Department of Defense, Marcus Foundation, Endpoint Health, Entegrion, bioMerieux, and Bioscape Digital.\" )##\n(\"entity\"<|>\"Jay S. Steingrub\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health.\" )##\n(\"entity\"<|>\"Akram Khan\"<|>\"person\"<|>\"Author who reports grants from United Therapeutics, Actelion Pharmaceuticals, Regeneron, and Reata Pharmaceuticals.\" )##\n(\"entity\"<|>\"Samuel M. Brown\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health, U.S. Department of Defense, Intermountain Research and Medical Foundation, and Janssen, and consulting fees paid to his employer from Faron and Sedana.\" )##\n(\"entity\"<|>\"Ithan D. Peltan\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health and, outside the submitted work, grants from Asahi Kasei Pharma, Janssen Pharmaceuticals, and Regeneron.\" )##\n(\"entity\"<|>\"Adit A. Ginde\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health, U.S. Department of Defense, and AbbVie.\" )##\n(\"entity\"<|>\"Carlos G. Grijalva\"<|>\"person\"<|>\"Author who reports consulting fees from Pfizer, Merck, and Sanofi-Pasteur, grants from Campbell Alliance/Syneos Health, National Institutes of Health, Food and Drug Administration, and Agency for Health Care Research and Quality.\" )##\n(\"entity\"<|>\"Michelle N. Gong\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health, Agency for Healthcare Research and Quality, and consulting fees from Regeneron, Philips Healthcare.\" )##\n(\"entity\"<|>\"Steven Y. Chang\"<|>\"person\"<|>\"Author who reports consulting fees from PureTech Health and speaker fees from La Jolla Pharmaceuticals.\" )##\n(\"entity\"<|>\"Jonathan D. Casey\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health.\" )##\n(\"entity\"<|>\"Todd W. Rice\"<|>\"person\"<|>\"Author who reports grants from National Institutes of Health and Endpoint Health, consulting work for Cumberland Pharmaceuticals, Inc, and Sanofi, Inc.\" )##\n(\"entity\"<|>\"Manjusha Gaglani\"<|>\"person\"<|>\"Author who reports grants from CDC-Abt Associates.\" )##\n(\"entity\"<|>\"Emily T. Martin\"<|>\"person\"<|>\"Author who reports personal fees from Pfizer and grants from Merck.\" )##\n(\"entity\"<|>\"Anurag Malani\"<|>\"person\"<|>\"Author who reports being a shareholder of Pfizer pharmaceuticals.\" )##\n(\"entity\"<|>\"Arnold S. Monto\"<|>\"person\"<|>\"Author who reports personal fees from Sanofi Pasteur and Seqirus.\" )##\n(\"entity\"<|>\"Fernanda P. Silveira\"<|>\"person\"<|>\"Author who reports grants from Shire, Qiagen, Ansun, and Novartis.\" )##\n(\"entity\"<|>\"Richard K. Zimmerman\"<|>\"person\"<|>\"Author who reports grants from Sanofi Pasteur.\" )##\n(\"entity\"<|>\"Donald B. Middleton\"<|>\"person\"<|>\"Author who reports grants and personal fees from Pfizer and personal fees from Seqirus, Sanofi Pasteur, and GlaxoSmithKline.\" )##\n(\"entity\"<|>\"Pittsburgh, Pennsylvania\"<|>\"geo\"<|>\"A city in Pennsylvania, location of University of Pittsburgh and University of Pittsburgh Medical Center.\" )##\n(\"entity\"<|>\"Temple, Texas\"<|>\"geo\"<|>\"A city in Texas, location of Baylor Scott & White Health and Texas A&M University College of Medicine.\" )##\n(\"entity\"<|>\"Nashville, Tennessee\"<|>\"geo\"<|>\"A city in Tennessee, location of Vanderbilt University Medical Center.\" )##\n(\"entity\"<|>\"Springfield, Massachusetts\"<|>\"geo\"<|>\"A city in Massachusetts, location of Baystate Medical Center.\" )##\n(\"entity\"<|>\"Boston, Massachusetts\"<|>\"geo\"<|>\"A city in Massachusetts, location of Beth Israel Deaconess Medical Center.\" )##\n(\"entity\"<|>\"Aurora, Colorado\"<|>\"geo\"<|>\"A city in Colorado, location of University of Colorado School of Medicine.\" )##\n(\"entity\"<|>\"Minneapolis, Minnesota\"<|>\"geo\"<|>\"A city in Minnesota, location of Hennepin County Medical Center.\" )##\n(\"entity\"<|>\"Salt Lake City, Utah\"<|>\"geo\"<|>\"A city in Utah, location of Intermountain Medical Center and University of Utah.\" )##\n(\"entity\"<|>\"Bronx, New York\"<|>\"geo\"<|>\"A borough of New York City, location of Montefiore Healthcare Center and Albert Einstein College of Medicine.\" )##\n(\"entity\"<|>\"Portland, Oregon\"<|>\"geo\"<|>\"A city in Oregon, location of Oregon Health & Science University Hospital.\" )##\n(\"entity\"<|>\"Columbus, Ohio\"<|>\"geo\"<|>\"A city in Ohio, location of Ohio State University Wexner Medical Center.\" )##\n(\"entity\"<|>\"Winston-Salem, North Carolina\"<|>\"geo\"<|>\"A city in North Carolina, location of Wake Forest University Baptist Medical Center.\" )##\n(\"entity\"<|>\"Baltimore, Maryland\"<|>\"geo\"<|>\"A city in Maryland, location of Johns Hopkins Hospital.\" )##\n(\"entity\"<|>\"Los Angeles, California\"<|>\"geo\"<|>\"A city in California, location of Ronald Reagan-UCLA Medical Center.\" )##\n(\"entity\"<|>\"Palo Alto, California\"<|>\"geo\"<|>\"A city in California, location of Stanford University School of Medicine.\" )##\n(\"entity\"<|>\"Ann Arbor, Michigan\"<|>\"geo\"<|>\"A city in Michigan, location of University of Michigan School of Public Health and St. Joseph Mercy Health System.\" )##\n(\"entity\"<|>\"COVID-19 pandemic\"<|>\"event\"<|>\"A global pandemic caused by the coronavirus SARS-CoV-2, referenced in the context of hospitalization rates, mortality, and vaccine allocation.\" )##\n(\"entity\"<|>\"CDC COVID-19 Response Team\"<|>\"organization\"<|>\"A team within the CDC focused on responding to the COVID-19 pandemic.\" )##\n(\"entity\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"A weekly epidemiological digest published by the CDC, reporting on public health information and recommendations.\" )##\n\n(\"relationship\"<|>\"US Department of Health and Human Services\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC is an agency within the US Department of Health and Human Services.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"CDC COVID-19 Response Team\"<|>\"The CDC COVID-19 Response Team is a specialized group within the CDC focused on the pandemic response.\"<|>10)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"The CDC publishes the MMWR Morbidity and Mortality Weekly Report as its official epidemiological digest.\"<|>10)##\n(\"relationship\"<|>\"Mohamed Yassin\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"Mohamed Yassin is affiliated with University of Pittsburgh Schools of the Health Sciences.\"<|>9)##\n(\"relationship\"<|>\"Mohamed Yassin\"<|>\"University of Pittsburgh Medical Center\"<|>\"Mohamed Yassin is affiliated with University of Pittsburgh Medical Center.\"<|>9)##\n(\"relationship\"<|>\"Martha Zayed\"<|>\"Baylor Scott & White Health\"<|>\"Martha Zayed is affiliated with Baylor Scott & White Health.\"<|>9)##\n(\"relationship\"<|>\"Tnelda Zunie\"<|>\"Baylor Scott & White Health\"<|>\"Tnelda Zunie is affiliated with Baylor Scott & White Health.\"<|>9)##\n(\"relationship\"<|>\"Mark W. Tenforde\"<|>\"CDC COVID-19 Response Team\"<|>\"Mark W. Tenforde is the corresponding author and affiliated with the CDC COVID-19 Response Team.\"<|>9)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"National Institutes of Health\"<|>\"Christopher J. Lindsell reports grants from the National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"U.S. Department of Defense\"<|>\"Christopher J. Lindsell reports grants from the U.S. Department of Defense.\"<|>7)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"Marcus Foundation\"<|>\"Christopher J. Lindsell reports grants from Marcus Foundation.\"<|>7)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"Endpoint Health\"<|>\"Christopher J. Lindsell reports grants from Endpoint Health.\"<|>7)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"Entegrion\"<|>\"Christopher J. Lindsell reports grants from Entegrion.\"<|>7)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"bioMerieux\"<|>\"Christopher J. Lindsell reports grants from bioMerieux.\"<|>7)##\n(\"relationship\"<|>\"Christopher J. Lindsell\"<|>\"Bioscape Digital\"<|>\"Christopher J. Lindsell reports grants from Bioscape Digital.\"<|>7)##\n(\"relationship\"<|>\"Jay S. Steingrub\"<|>\"National Institutes of Health\"<|>\"Jay S. Steingrub reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Akram Khan\"<|>\"United Therapeutics\"<|>\"Akram Khan reports grants from United Therapeutics.\"<|>7)##\n(\"relationship\"<|>\"Akram Khan\"<|>\"Actelion Pharmaceuticals\"<|>\"Akram Khan reports grants from Actelion Pharmaceuticals.\"<|>7)##\n(\"relationship\"<|>\"Akram Khan\"<|>\"Regeneron\"<|>\"Akram Khan reports grants from Regeneron.\"<|>7)##\n(\"relationship\"<|>\"Akram Khan\"<|>\"Reata Pharmaceuticals\"<|>\"Akram Khan reports grants from Reata Pharmaceuticals.\"<|>7)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"National Institutes of Health\"<|>\"Samuel M. Brown reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"U.S. Department of Defense\"<|>\"Samuel M. Brown reports grants from U.S. Department of Defense.\"<|>7)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"Intermountain Research and Medical Foundation\"<|>\"Samuel M. Brown reports grants from Intermountain Research and Medical Foundation.\"<|>7)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"Janssen\"<|>\"Samuel M. Brown reports grants from Janssen.\"<|>7)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"Faron\"<|>\"Samuel M. Brown reports consulting fees paid to his employer from Faron.\"<|>6)##\n(\"relationship\"<|>\"Samuel M. Brown\"<|>\"Sedana\"<|>\"Samuel M. Brown reports consulting fees paid to his employer from Sedana.\"<|>6)##\n(\"relationship\"<|>\"Ithan D. Peltan\"<|>\"National Institutes of Health\"<|>\"Ithan D. Peltan reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Ithan D. Peltan\"<|>\"Asahi Kasei Pharma\"<|>\"Ithan D. Peltan reports grants from Asahi Kasei Pharma.\"<|>7)##\n(\"relationship\"<|>\"Ithan D. Peltan\"<|>\"Janssen\"<|>\"Ithan D. Peltan reports grants from Janssen Pharmaceuticals.\"<|>7)##\n(\"relationship\"<|>\"Ithan D. Peltan\"<|>\"Regeneron\"<|>\"Ithan D. Peltan reports grants from Regeneron.\"<|>7)##\n(\"relationship\"<|>\"Adit A. Ginde\"<|>\"National Institutes of Health\"<|>\"Adit A. Ginde reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Adit A. Ginde\"<|>\"U.S. Department of Defense\"<|>\"Adit A. Ginde reports grants from U.S. Department of Defense.\"<|>7)##\n(\"relationship\"<|>\"Adit A. Ginde\"<|>\"AbbVie\"<|>\"Adit A. Ginde reports grants from AbbVie.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Pfizer\"<|>\"Carlos G. Grijalva reports consulting fees from Pfizer.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Merck\"<|>\"Carlos G. Grijalva reports consulting fees from Merck.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Sanofi Pasteur\"<|>\"Carlos G. Grijalva reports consulting fees from Sanofi Pasteur.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Campbell Alliance/Syneos Health\"<|>\"Carlos G. Grijalva reports grants from Campbell Alliance/Syneos Health.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"National Institutes of Health\"<|>\"Carlos G. Grijalva reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Food and Drug Administration\"<|>\"Carlos G. Grijalva reports grants from Food and Drug Administration.\"<|>7)##\n(\"relationship\"<|>\"Carlos G. Grijalva\"<|>\"Agency for Health Care Research and Quality\"<|>\"Carlos G. Grijalva reports grants from Agency for Health Care Research and Quality.\"<|>7)##\n(\"relationship\"<|>\"Michelle N. Gong\"<|>\"National Institutes of Health\"<|>\"Michelle N. Gong reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Michelle N. Gong\"<|>\"Agency for Healthcare Research and Quality\"<|>\"Michelle N. Gong reports grants from Agency for Healthcare Research and Quality.\"<|>7)##\n(\"relationship\"<|>\"Michelle N. Gong\"<|>\"Regeneron\"<|>\"Michelle N. Gong reports consulting fees from Regeneron.\"<|>7)##\n(\"relationship\"<|>\"Michelle N. Gong\"<|>\"Philips Healthcare\"<|>\"Michelle N. Gong reports consulting fees from Philips Healthcare.\"<|>7)##\n(\"relationship\"<|>\"Steven Y. Chang\"<|>\"PureTech Health\"<|>\"Steven Y. Chang reports consulting fees from PureTech Health.\"<|>7)##\n(\"relationship\"<|>\"Steven Y. Chang\"<|>\"La Jolla Pharmaceuticals\"<|>\"Steven Y. Chang reports speaker fees from La Jolla Pharmaceuticals.\"<|>7)##\n(\"relationship\"<|>\"Jonathan D. Casey\"<|>\"National Institutes of Health\"<|>\"Jonathan D. Casey reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Todd W. Rice\"<|>\"National Institutes of Health\"<|>\"Todd W. Rice reports grants from National Institutes of Health.\"<|>8)##\n(\"relationship\"<|>\"Todd W. Rice\"<|>\"Endpoint Health\"<|>\"Todd W. Rice reports grants from Endpoint Health.\"<|>7)##\n(\"relationship\"<|>\"Todd W. Rice\"<|>\"Cumberland Pharmaceuticals, Inc.\"<|>\"Todd W. Rice reports consulting work for Cumberland Pharmaceuticals, Inc.\"<|>7)##\n(\"relationship\"<|>\"Todd W. Rice\"<|>\"Sanofi, Inc.\"<|>\"Todd W. Rice reports consulting work for Sanofi, Inc.\"<|>7)##\n(\"relationship\"<|>\"Manjusha Gaglani\"<|>\"CDC-Abt Associates\"<|>\"Manjusha Gaglani reports grants from CDC-Abt Associates.\"<|>7)##\n(\"relationship\"<|>\"Emily T. Martin\"<|>\"Pfizer\"<|>\"Emily T. Martin reports personal fees from Pfizer.\"<|>7)##\n(\"relationship\"<|>\"Emily T. Martin\"<|>\"Merck\"<|>\"Emily T. Martin reports grants from Merck.\"<|>7)##\n(\"relationship\"<|>\"Anurag Malani\"<|>\"Pfizer\"<|>\"Anurag Malani reports being a shareholder of Pfizer pharmaceuticals.\"<|>7)##\n(\"relationship\"<|>\"Arnold S. Monto\"<|>\"Sanofi Pasteur\"<|>\"Arnold S. Monto reports personal fees from Sanofi Pasteur.\"<|>7)##\n(\"relationship\"<|>\"Arnold S. Monto\"<|>\"Seqirus\"<|>\"Arnold S. Monto reports personal fees from Seqirus.\"<|>7)##\n(\"relationship\"<|>\"Fernanda P. Silveira\"<|>\"Shire\"<|>\"Fernanda P. Silveira reports grants from Shire.\"<|>7)##\n(\"relationship\"<|>\"Fernanda P. Silveira\"<|>\"Qiagen\"<|>\"Fernanda P. Silveira reports grants from Qiagen.\"<|>7)##\n(\"relationship\"<|>\"Fernanda P. Silveira\"<|>\"Ansun\"<|>\"Fernanda P. Silveira reports grants from Ansun.\"<|>7)##\n(\"relationship\"<|>\"Fernanda P. Silveira\"<|>\"Novartis\"<|>\"Fernanda P. Silveira reports grants from Novartis.\"<|>7)##\n(\"relationship\"<|>\"Richard K. Zimmerman\"<|>\"Sanofi Pasteur\"<|>\"Richard K. Zimmerman reports grants from Sanofi Pasteur.\"<|>7)##\n(\"relationship\"<|>\"Donald B. Middleton\"<|>\"Pfizer\"<|>\"Donald B. Middleton reports grants and personal fees from Pfizer.\"<|>7)##\n(\"relationship\"<|>\"Donald B. Middleton\"<|>\"Seqirus\"<|>\"Donald B. Middleton reports personal fees from Seqirus.\"<|>7)##\n(\"relationship\"<|>\"Donald B. Middleton\"<|>\"Sanofi Pasteur\"<|>\"Donald B. Middleton reports personal fees from Sanofi Pasteur.\"<|>7)##\n(\"relationship\"<|>\"Donald B. Middleton\"<|>\"GlaxoSmithKline\"<|>\"Donald B. Middleton reports personal fees from GlaxoSmithKline.\"<|>7)##\n(\"relationship\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"University of Pittsburgh Medical Center\"<|>\"Both are affiliated institutions located in Pittsburgh, Pennsylvania.\"<|>8)##\n(\"relationship\"<|>\"Baylor Scott & White Health\"<|>\"Texas A&M University College of Medicine\"<|>\"Both are located in Temple, Texas and may have collaborative relationships.\"<|>7)##\n(\"relationship\"<|>\"University of Michigan School of Public Health\"<|>\"St. Joseph Mercy Health System\"<|>\"Both are located in Ann Arbor, Michigan and may collaborate on public health initiatives.\"<|>7)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"CDC COVID-19 Response Team\"<|>\"The CDC COVID-19 Response Team is focused on responding to the COVID-19 pandemic.\"<|>10)##\n(\"relationship\"<|>\"COVID-19 pandemic\"<|>\"MMWR Morbidity and Mortality Weekly Report\"<|>\"The MMWR Morbidity and Mortality Weekly Report publishes data and recommendations related to the COVID-19 pandemic.\"<|>9)##\n(\"relationship\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-19 pandemic\"<|>\"The CDC is a leading agency in the US response to the COVID-19 pandemic.\"<|>10)##\n(\"relationship\"<|>\"Pittsburgh, Pennsylvania\"<|>\"University of Pittsburgh Schools of the Health Sciences\"<|>\"University of Pittsburgh Schools of the Health Sciences is located in Pittsburgh, Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"Pittsburgh, Pennsylvania\"<|>\"University of Pittsburgh Medical Center\"<|>\"University of Pittsburgh Medical Center is located in Pittsburgh, Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"Temple, Texas\"<|>\"Baylor Scott & White Health\"<|>\"Baylor Scott & White Health is located in Temple, Texas.\"<|>10)##\n(\"relationship\"<|>\"Temple, Texas\"<|>\"Texas A&M University College of Medicine\"<|>\"Texas A&M University College of Medicine is located in Temple, Texas.\"<|>10)##\n(\"relationship\"<|>\"Nashville, Tennessee\"<|>\"Vanderbilt University Medical Center\"<|>\"Vanderbilt University Medical Center is located in Nashville, Tennessee.\"<|>10)##\n(\"relationship\"<|>\"Springfield, Massachusetts\"<|>\"Baystate Medical Center\"<|>\"Baystate Medical Center is located in Springfield, Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Boston, Massachusetts\"<|>\"Beth Israel Deaconess Medical Center\"<|>\"Beth Israel Deaconess Medical Center is located in Boston, Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Aurora, Colorado\"<|>\"University of Colorado School of Medicine\"<|>\"University of Colorado School of Medicine is located in Aurora, Colorado.\"<|>10)##\n(\"relationship\"<|>\"Minneapolis, Minnesota\"<|>\"Hennepin County Medical Center\"<|>\"Hennepin County Medical Center is located in Minneapolis, Minnesota.\"<|>10)##\n(\"relationship\"<|>\"Salt Lake City, Utah\"<|>\"Intermountain Medical Center\"<|>\"Intermountain Medical Center is located in Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Salt Lake City, Utah\"<|>\"University of Utah\"<|>\"University of Utah is located in Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Bronx, New York\"<|>\"Montefiore Healthcare Center\"<|>\"Montefiore Healthcare Center is located in Bronx, New York.\"<|>10)##\n(\"relationship\"<|>\"Bronx, New York\"<|>\"Albert Einstein College of Medicine\"<|>\"Albert Einstein College of Medicine is located in Bronx, New York.\"<|>10)##\n(\"relationship\"<|>\"Portland, Oregon\"<|>\"Oregon Health & Science University Hospital\"<|>\"Oregon Health & Science University Hospital is located in Portland, Oregon.\"<|>10)##\n(\"relationship\"<|>\"Columbus, Ohio\"<|>\"Ohio State University Wexner Medical Center\"<|>\"Ohio State University Wexner Medical Center is located in Columbus, Ohio.\"<|>10)##\n(\"relationship\"<|>\"Winston-Salem, North Carolina\"<|>\"Wake Forest University Baptist Medical Center\"<|>\"Wake Forest University Baptist Medical Center is located in Winston-Salem, North Carolina.\"<|>10)##\n(\"relationship\"<|>\"Baltimore, Maryland\"<|>\"Johns Hopkins Hospital\"<|>\"Johns Hopkins Hospital is located in Baltimore, Maryland.\"<|>10)##\n(\"relationship\"<|>\"Los Angeles, California\"<|>\"Ronald Reagan-UCLA Medical Center\"<|>\"Ronald Reagan-UCLA Medical Center is located in Los Angeles, California.\"<|>10)##\n(\"relationship\"<|>\"Palo Alto, California\"<|>\"Stanford University School of Medicine\"<|>\"Stanford University School of Medicine is located in Palo Alto, California.\"<|>10)##\n(\"relationship\"<|>\"Ann Arbor, Michigan\"<|>\"University of Michigan School of Public Health\"<|>\"University of Michigan School of Public Health is located in Ann Arbor, Michigan.\"<|>10)##\n(\"relationship\"<|>\"Ann Arbor, Michigan\"<|>\"St. Joseph Mercy Health System\"<|>\"St. Joseph Mercy Health System is located in Ann Arbor, Michigan.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "3c351b64268b101c9c270be6169e7d58": {
    "return": "(\"entity\"<|>\"Albert Einstein College of Medicine\"<|>\"organization\"<|>\"Albert Einstein College of Medicine is a medical school located in Bronx, New York, mentioned as an affiliation for contributors to the study.\")##\n(\"entity\"<|>\"Reagan-UCLA Medical Center\"<|>\"organization\"<|>\"Reagan-UCLA Medical Center is a hospital in Los Angeles, California, mentioned as an affiliation for contributors to the study.\")##\n(\"entity\"<|>\"University of Colorado School of Medicine\"<|>\"organization\"<|>\"University of Colorado School of Medicine is a medical school in Aurora, Colorado, mentioned as an affiliation for contributors to the study.\")##\n(\"entity\"<|>\"Stanford University School of Medicine\"<|>\"organization\"<|>\"Stanford University School of Medicine is a medical school in Palo Alto, California, mentioned as an affiliation for contributors to the study.\")##\n(\"entity\"<|>\"Baylor Scott & White Health\"<|>\"organization\"<|>\"Baylor Scott & White Health is a healthcare organization in Texas, acknowledged for its role in the study and as an affiliation for contributors.\")##\n(\"entity\"<|>\"IVY Network\"<|>\"organization\"<|>\"IVY Network is a research network referenced in the acknowledgments, likely involved in the coordination or conduct of the study.\")##\n(\"entity\"<|>\"Bronx\"<|>\"geo\"<|>\"Bronx is a borough of New York City, referenced as the location of Albert Einstein College of Medicine.\")##\n(\"entity\"<|>\"Salt Lake City\"<|>\"geo\"<|>\"Salt Lake City is a city in Utah, referenced as the location of Intermountain Medical Center.\")##\n(\"entity\"<|>\"Springfield\"<|>\"geo\"<|>\"Springfield is a city in Massachusetts, referenced as the location of Baystate Medical Center.\")##\n(\"entity\"<|>\"Aurora\"<|>\"geo\"<|>\"Aurora is a city in Colorado, referenced as the location of University of Colorado School of Medicine.\")##\n(\"entity\"<|>\"Palo Alto\"<|>\"geo\"<|>\"Palo Alto is a city in California, referenced as the location of Stanford University School of Medicine.\")##\n(\"entity\"<|>\"Los Angeles\"<|>\"geo\"<|>\"Los Angeles is a city in California, referenced as the location of Reagan-UCLA Medical Center and University of California Los Angeles.\")##\n(\"entity\"<|>\"Temple\"<|>\"geo\"<|>\"Temple is a city in Texas, referenced as the location of Baylor Scott & White Medical Center.\")##\n(\"entity\"<|>\"Round Rock\"<|>\"geo\"<|>\"Round Rock is a city in Texas, referenced as the location of Baylor Scott & White Medical Center.\")##\n(\"entity\"<|>\"Waco\"<|>\"geo\"<|>\"Waco is a city in Texas, referenced as the location of Hillcrest/Waco hospital.\")##\n(\"entity\"<|>\"Pennsylvania\"<|>\"geo\"<|>\"Pennsylvania is a state in the United States, referenced as the location of several hospitals and medical centers participating in the study.\")##\n(\"entity\"<|>\"California\"<|>\"geo\"<|>\"California is a state in the United States, referenced as the location of several medical centers participating in the study.\")##\n(\"entity\"<|>\"Colorado\"<|>\"geo\"<|>\"Colorado is a state in the United States, referenced as the location of several medical centers participating in the study.\")##\n(\"entity\"<|>\"Maryland\"<|>\"geo\"<|>\"Maryland is a state in the United States, referenced as the location of Johns Hopkins Hospital.\")##\n(\"entity\"<|>\"Massachusetts\"<|>\"geo\"<|>\"Massachusetts is a state in the United States, referenced as the location of Beth Israel Deaconess Medical Center and Baystate Medical Center.\")##\n(\"entity\"<|>\"Michigan\"<|>\"geo\"<|>\"Michigan is a state in the United States, referenced as the location of University of Michigan, Henry Ford, and St. Joseph.\")##\n(\"entity\"<|>\"Minnesota\"<|>\"geo\"<|>\"Minnesota is a state in the United States, referenced as the location of Hennepin County Medical Center.\")##\n(\"entity\"<|>\"New York\"<|>\"geo\"<|>\"New York is a state in the United States, referenced as the location of Montefiore Healthcare Center and Albert Einstein College of Medicine.\")##\n(\"entity\"<|>\"North Carolina\"<|>\"geo\"<|>\"North Carolina is a state in the United States, referenced as the location of Wake Forest University.\")##\n(\"entity\"<|>\"Ohio\"<|>\"geo\"<|>\"Ohio is a state in the United States, referenced as the location of Ohio State University.\")##\n(\"entity\"<|>\"Oregon\"<|>\"geo\"<|>\"Oregon is a state in the United States, referenced as the location of Oregon Health & Science University.\")##\n(\"entity\"<|>\"Tennessee\"<|>\"geo\"<|>\"Tennessee is a state in the United States, referenced as the location of Vanderbilt University Medical Center.\")##\n(\"entity\"<|>\"Texas\"<|>\"geo\"<|>\"Texas is a state in the United States, referenced as the location of Baylor Scott & White Medical Center and affiliated hospitals.\")##\n(\"entity\"<|>\"Utah\"<|>\"geo\"<|>\"Utah is a state in the United States, referenced as the location of Intermountain Health and Intermountain Medical Center.\")##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"United States is the country in which the multistate network of hospitals participating in the study is located.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"event\"<|>\"Morbidity and Mortality Weekly Report is a publication by the CDC and US Department of Health and Human Services, referenced as the source of the study findings.\")##\n(\"entity\"<|>\"COVID-19 Deaths\"<|>\"event\"<|>\"COVID-19 Deaths refers to fatalities resulting from COVID-19, mentioned as an outcome potentially reduced by vaccination.\")##\n(\"entity\"<|>\"Natalie Settele\"<|>\"person\"<|>\"Natalie Settele is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Elisa Priest\"<|>\"person\"<|>\"Elisa Priest is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Jennifer Thomas\"<|>\"person\"<|>\"Jennifer Thomas is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Madhava Beeram\"<|>\"person\"<|>\"Madhava Beeram is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"Jay Fox\"<|>\"person\"<|>\"Jay Fox is acknowledged as a contributor to the study or report.\")##\n(\"entity\"<|>\"James Morrison\"<|>\"person\"<|>\"James Morrison is acknowledged as a contributor to the study or report.\")##\n(\"relationship\"<|>\"Albert Einstein College of Medicine\"<|>\"Bronx\"<|>\"Albert Einstein College of Medicine is located in Bronx, New York.\"<|>10)##\n(\"relationship\"<|>\"Reagan-UCLA Medical Center\"<|>\"Los Angeles\"<|>\"Reagan-UCLA Medical Center is located in Los Angeles, California.\"<|>10)##\n(\"relationship\"<|>\"University of California Los Angeles\"<|>\"Los Angeles\"<|>\"University of California Los Angeles is located in Los Angeles, California.\"<|>10)##\n(\"relationship\"<|>\"Stanford University School of Medicine\"<|>\"Palo Alto\"<|>\"Stanford University School of Medicine is located in Palo Alto, California.\"<|>10)##\n(\"relationship\"<|>\"University of Colorado School of Medicine\"<|>\"Aurora\"<|>\"University of Colorado School of Medicine is located in Aurora, Colorado.\"<|>10)##\n(\"relationship\"<|>\"Baystate Medical Center\"<|>\"Springfield\"<|>\"Baystate Medical Center is located in Springfield, Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Intermountain Medical Center\"<|>\"Salt Lake City\"<|>\"Intermountain Medical Center is located in Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Baylor Scott & White Medical Center\"<|>\"Temple\"<|>\"Baylor Scott & White Medical Center is located in Temple, Texas.\"<|>10)##\n(\"relationship\"<|>\"Baylor Scott & White Medical Center\"<|>\"Round Rock\"<|>\"Baylor Scott & White Medical Center has a location in Round Rock, Texas.\"<|>10)##\n(\"relationship\"<|>\"Hillcrest/Waco\"<|>\"Waco\"<|>\"Hillcrest/Waco hospital is located in Waco, Texas.\"<|>10)##\n(\"relationship\"<|>\"Montefiore Healthcare Center\"<|>\"New York\"<|>\"Montefiore Healthcare Center is located in New York.\"<|>10)##\n(\"relationship\"<|>\"Wake Forest University\"<|>\"North Carolina\"<|>\"Wake Forest University is located in North Carolina.\"<|>10)##\n(\"relationship\"<|>\"Ohio State University\"<|>\"Ohio\"<|>\"Ohio State University is located in Ohio.\"<|>10)##\n(\"relationship\"<|>\"Oregon Health & Science University\"<|>\"Oregon\"<|>\"Oregon Health & Science University is located in Oregon.\"<|>10)##\n(\"relationship\"<|>\"University of Pittsburgh Medical Center\"<|>\"Pennsylvania\"<|>\"University of Pittsburgh Medical Center is located in Pennsylvania.\"<|>10)##\n(\"relationship\"<|>\"Vanderbilt University Medical Center\"<|>\"Tennessee\"<|>\"Vanderbilt University Medical Center is located in Tennessee.\"<|>10)##\n(\"relationship\"<|>\"Intermountain Health\"<|>\"Utah\"<|>\"Intermountain Health is located in Utah.\"<|>10)##\n(\"relationship\"<|>\"Baylor Scott & White Health\"<|>\"Texas\"<|>\"Baylor Scott & White Health is a healthcare organization in Texas.\"<|>10)##\n(\"relationship\"<|>\"IVY Network\"<|>\"Montefiore Healthcare Center\"<|>\"IVY Network is referenced in connection with Montefiore Healthcare Center, suggesting collaboration or affiliation in the study.\"<|>7)##\n(\"relationship\"<|>\"IVY Network\"<|>\"Albert Einstein College of Medicine\"<|>\"IVY Network is referenced in connection with Albert Einstein College of Medicine, suggesting collaboration or affiliation in the study.\"<|>7)##\n(\"relationship\"<|>\"Jennifer Friedel\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Friedel is affiliated with University of Colorado School of Medicine, Aurora, Colorado.\"<|>10)##\n(\"relationship\"<|>\"Kevin Gardner\"<|>\"Stanford University School of Medicine\"<|>\"Kevin Gardner is affiliated with Stanford University School of Medicine, Palo Alto, California.\"<|>10)##\n(\"relationship\"<|>\"Jennifer Goff\"<|>\"University of Colorado School of Medicine\"<|>\"Jennifer Goff is affiliated with University of Colorado School of Medicine, Aurora, Colorado.\"<|>10)##\n(\"relationship\"<|>\"Leslie De Souza\"<|>\"Baystate Medical Center\"<|>\"Leslie De Souza is affiliated with Baystate Medical Center, Springfield, Massachusetts.\"<|>10)##\n(\"relationship\"<|>\"Brent Armbruster\"<|>\"Intermountain Medical Center\"<|>\"Brent Armbruster is affiliated with Intermountain Medical Center, Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Valerie Aston\"<|>\"Intermountain Medical Center\"<|>\"Valerie Aston is affiliated with Intermountain Medical Center, Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Robert Bowers\"<|>\"Intermountain Medical Center\"<|>\"Robert Bowers is affiliated with Intermountain Medical Center, Salt Lake City, Utah.\"<|>10)##\n(\"relationship\"<|>\"Marianne Bernardo\"<|>\"Reagan-UCLA Medical Center\"<|>\"Marianne Bernardo is affiliated with Reagan-UCLA Medical Center, Los Angeles, California.\"<|>10)<|COMPLETE|>",
    "model": "gpt41"
  },
  "7b79894cc50675ddca4b6d8c5e6b365d": {
    "return": "(\"entity\"<|>\"Escherichia coli O157:H7\"<|>\"event\"<|>\"Escherichia coli O157:H7 is the bacterial pathogen responsible for the 2019 multistate outbreak linked to romaine lettuce. It causes severe foodborne illness and was the focus of the investigation described.\")##\n(\"entity\"<|>\"Romaine Lettuce\"<|>\"event\"<|>\"Romaine Lettuce is the food product implicated as the source of E. coli O157:H7 contamination in the 2019 outbreak. Consumption of romaine lettuce was reported by most patients.\")##\n(\"entity\"<|>\"Leafy Greens\"<|>\"event\"<|>\"Leafy Greens refers to the category of vegetables, including romaine lettuce, suspected as the source of E. coli O157:H7 infection in the outbreak.\")##\n(\"entity\"<|>\"National Restaurant Chain\"<|>\"organization\"<|>\"National Restaurant Chain refers to the unnamed restaurant chain where multiple outbreak cases reported eating salads containing romaine lettuce. It was a key exposure location in the investigation.\")##\n(\"entity\"<|>\"Grocery Stores\"<|>\"organization\"<|>\"Grocery Stores are retail locations where some outbreak patients purchased and consumed romaine lettuce, as opposed to restaurant exposures.\")##\n(\"entity\"<|>\"Two California Farms\"<|>\"organization\"<|>\"Two California Farms are the agricultural sources identified through traceback as common suppliers of romaine lettuce to implicated restaurant chain locations in California.\")##\n(\"entity\"<|>\"Patients\"<|>\"person\"<|>\"Patients refers to the individuals who contracted E. coli O157:H7 infection during the outbreak. They were interviewed and provided exposure histories for the investigation.\")##\n(\"entity\"<|>\"Federal Officials\"<|>\"person\"<|>\"Federal Officials refers to representatives from federal agencies (such as CDC and FDA) who participated in the outbreak investigation and response.\")##\n(\"entity\"<|>\"State Officials\"<|>\"person\"<|>\"State Officials refers to representatives from state agencies (such as CDPH and California Department of Food and Agriculture) involved in the outbreak investigation.\")##\n(\"entity\"<|>\"Local Officials\"<|>\"person\"<|>\"Local Officials refers to representatives from local health departments who participated in patient interviews and outbreak response.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is the CDC publication in which the outbreak investigation findings were published.\")##\n(\"entity\"<|>\"Core-genome Multilocus Sequence Typing (cgMLST)\"<|>\"event\"<|>\"Core-genome Multilocus Sequence Typing (cgMLST) is the molecular method used to analyze and compare E. coli isolates from patients, confirming their genetic relatedness in the outbreak.\")##\n(\"entity\"<|>\"Shiga Toxin-producing E. coli Outbreaks\"<|>\"event\"<|>\"Shiga Toxin-producing E. coli Outbreaks refers to recent outbreaks associated with leafy greens, highlighting ongoing food safety challenges.\")##\n(\"entity\"<|>\"Survey of Healthy Persons, 2006-2007\"<|>\"event\"<|>\"Survey of Healthy Persons, 2006-2007 is a referenced survey used for comparison of romaine lettuce consumption rates among healthy individuals versus outbreak patients.\")##\n(\"entity\"<|>\"Soil Samples\"<|>\"event\"<|>\"Soil Samples refers to environmental samples collected from implicated farms during the investigation to test for E. coli O157:H7 contamination.\")##\n(\"entity\"<|>\"Animal Droppings Samples\"<|>\"event\"<|>\"Animal Droppings Samples refers to environmental samples collected from implicated farms during the investigation to test for E. coli O157:H7 contamination.\")##\n(\"entity\"<|>\"Water Samples\"<|>\"event\"<|>\"Water Samples refers to environmental samples collected from implicated farms during the investigation to test for E. coli O157:H7 contamination.\")##\n(\"entity\"<|>\"Public Warning\"<|>\"event\"<|>\"Public Warning refers to the decision not to issue a public warning about romaine lettuce from the implicated farms because the product was past its shelf life and no longer available for purchase.\")##\n(\"entity\"<|>\"Food Safety Challenges\"<|>\"event\"<|>\"Food Safety Challenges refers to the ongoing difficulties in preventing contamination of fresh produce, especially leafy greens, with pathogens such as E. coli O157:H7.\")##\n(\"entity\"<|>\"Prevention Approaches\"<|>\"event\"<|>\"Prevention Approaches refers to the strategies and recommendations for preventing future contamination events, informed by outbreak investigations.\")##\n(\"entity\"<|>\"Washing Produce\"<|>\"event\"<|>\"Washing Produce refers to the food safety practice of washing leafy greens, which can reduce but not eliminate harmful bacteria such as E. coli O157:H7.\")##\n(\"entity\"<|>\"Isolation of E. coli O157:H7\"<|>\"event\"<|>\"Isolation of E. coli O157:H7 refers to the laboratory confirmation of the pathogen from patient samples, used to define cases in the outbreak.\")##\n(\"entity\"<|>\"Case Definition\"<|>\"event\"<|>\"Case Definition refers to the criteria used to identify outbreak cases: isolation of E. coli O157:H7 with the outbreak cgMLST profile during July-October 2019.\")##\n(\"entity\"<|>\"Illness Onset Dates\"<|>\"event\"<|>\"Illness Onset Dates refers to the time period (July 12 to September 8, 2019) during which outbreak cases began experiencing symptoms.\")##\n(\"entity\"<|>\"Hospitalization\"<|>\"event\"<|>\"Hospitalization refers to the outcome for 60% of outbreak patients, indicating the severity of illness caused by E. coli O157:H7.\")##\n(\"entity\"<|>\"No Deaths Reported\"<|>\"event\"<|>\"No Deaths Reported refers to the outcome of the outbreak, indicating that although many were hospitalized, no deaths occurred.\")##\n(\"entity\"<|>\"Focused Questionnaire\"<|>\"event\"<|>\"Focused Questionnaire refers to the specialized survey developed to collect detailed information about patients' restaurant and leafy greens exposures.\")##\n(\"entity\"<|>\"Patient Interviews\"<|>\"event\"<|>\"Patient Interviews refers to the process by which investigators gathered information about food exposures from outbreak patients.\")##\n(\"entity\"<|>\"Laboratory Testing\"<|>\"event\"<|>\"Laboratory Testing refers to the analysis of environmental samples from farms to detect E. coli O157:H7.\")##\n(\"entity\"<|>\"Shelf Life\"<|>\"event\"<|>\"Shelf Life refers to the period during which romaine lettuce from implicated farms was available for purchase; after this period, the risk to the public was considered over.\")##\n(\"entity\"<|>\"Contamination Routes\"<|>\"event\"<|>\"Contamination Routes refers to the possible ways E. coli O157:H7 could have contaminated romaine lettuce, investigated during the environmental assessment.\")##\n(\"entity\"<|>\"Contamination Prevention\"<|>\"event\"<|>\"Contamination Prevention refers to the importance of preventing contamination at the farm level, especially for produce consumed raw.\")##\n(\"entity\"<|>\"Federal Law and CDC Policy\"<|>\"event\"<|>\"Federal Law and CDC Policy refers to the legal and regulatory framework under which the outbreak investigation was conducted and reviewed.\")##\n(\"entity\"<|>\"45 C.F.R. part 46.102(l)(2)\"<|>\"event\"<|>\"45 C.F.R. part 46.102(l)(2) is a federal regulation cited as part of the legal basis for the investigation's review and conduct.\")##\n(\"entity\"<|>\"21 C.F.R. part 56\"<|>\"event\"<|>\"21 C.F.R. part 56 is a federal regulation cited as part of the legal basis for the investigation's review and conduct.\")##\n(\"entity\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"event\"<|>\"42 U.S.C. Sect. 241(d) is a federal statute cited as part of the legal basis for the investigation's review and conduct.\")##\n(\"entity\"<|>\"5 U.S.C. Sect. 552a\"<|>\"event\"<|>\"5 U.S.C. Sect. 552a is a federal statute cited as part of the legal basis for the investigation's review and conduct.\")##\n(\"entity\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"event\"<|>\"44 U.S.C. Sect. 3501 et seq. is a federal statute cited as part of the legal basis for the investigation's review and conduct.\")##\n\n(\"relationship\"<|>\"Escherichia coli O157:H7\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"The outbreak was caused by Escherichia coli O157:H7, which infected 23 people in 12 states.\"<|>10)##\n(\"relationship\"<|>\"Romaine Lettuce\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Romaine lettuce was identified as the likely source of E. coli O157:H7 in the outbreak.\"<|>10)##\n(\"relationship\"<|>\"Leafy Greens\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Leafy greens, including romaine lettuce, were suspected as the source of infection in the outbreak.\"<|>9)##\n(\"relationship\"<|>\"National Restaurant Chain\"<|>\"Restaurant Chain Outbreak Cluster\"<|>\"The national restaurant chain was the location where multiple outbreak cases consumed romaine lettuce salads.\"<|>10)##\n(\"relationship\"<|>\"Grocery Stores\"<|>\"Grocery Store Exposure\"<|>\"Grocery stores were the source of romaine lettuce for some outbreak cases.\"<|>9)##\n(\"relationship\"<|>\"Two California Farms\"<|>\"California\"<|>\"Two California farms were identified as common suppliers of romaine lettuce to implicated restaurant chain locations in California.\"<|>10)##\n(\"relationship\"<|>\"Two California Farms\"<|>\"Farm-level Investigation\"<|>\"Farm-level investigations were conducted at the two California farms to identify sources and routes of contamination.\"<|>10)##\n(\"relationship\"<|>\"Patients\"<|>\"Patient Interviews\"<|>\"Patients were interviewed by investigators to assess food exposures and identify common sources.\"<|>10)##\n(\"relationship\"<|>\"Federal Officials\"<|>\"CDC\"<|>\"Federal officials from CDC participated in the outbreak investigation and response.\"<|>10)##\n(\"relationship\"<|>\"Federal Officials\"<|>\"Food and Drug Administration\"<|>\"Federal officials from FDA participated in the outbreak investigation and response.\"<|>10)##\n(\"relationship\"<|>\"State Officials\"<|>\"California Department of Public Health\"<|>\"State officials from CDPH participated in the outbreak investigation and response.\"<|>10)##\n(\"relationship\"<|>\"State Officials\"<|>\"California Department of Food and Agriculture\"<|>\"State officials from California Department of Food and Agriculture participated in the outbreak investigation and response.\"<|>10)##\n(\"relationship\"<|>\"Local Officials\"<|>\"California Department of Public Health\"<|>\"Local officials worked with CDPH to conduct patient interviews and outbreak response.\"<|>9)##\n(\"relationship\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"CDC\"<|>\"MMWR is the CDC publication where the outbreak investigation findings were published.\"<|>10)##\n(\"relationship\"<|>\"Core-genome Multilocus Sequence Typing (cgMLST)\"<|>\"Isolation of E. coli O157:H7\"<|>\"cgMLST was used to analyze and confirm the genetic relatedness of E. coli O157:H7 isolates from patients.\"<|>10)##\n(\"relationship\"<|>\"Shiga Toxin-producing E. coli Outbreaks\"<|>\"Food Safety Challenges\"<|>\"Recent Shiga toxin-producing E. coli outbreaks highlight ongoing food safety challenges with leafy greens.\"<|>10)##\n(\"relationship\"<|>\"Survey of Healthy Persons, 2006-2007\"<|>\"Romaine Lettuce\"<|>\"The survey provided a baseline for romaine lettuce consumption rates among healthy individuals, used for comparison with outbreak patients.\"<|>8)##\n(\"relationship\"<|>\"Soil Samples\"<|>\"Farm-level Investigation\"<|>\"Soil samples were collected during farm-level investigations to test for E. coli O157:H7.\"<|>9)##\n(\"relationship\"<|>\"Animal Droppings Samples\"<|>\"Farm-level Investigation\"<|>\"Animal droppings samples were collected during farm-level investigations to test for E. coli O157:H7.\"<|>9)##\n(\"relationship\"<|>\"Water Samples\"<|>\"Farm-level Investigation\"<|>\"Water samples were collected during farm-level investigations to test for E. coli O157:H7.\"<|>9)##\n(\"relationship\"<|>\"Laboratory Testing\"<|>\"Environmental Assessment\"<|>\"Laboratory testing was performed on environmental samples collected during the environmental assessment.\"<|>10)##\n(\"relationship\"<|>\"Public Warning\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"No public warning was issued because romaine lettuce from implicated farms was past its shelf life and no longer available for purchase.\"<|>8)##\n(\"relationship\"<|>\"Shelf Life\"<|>\"Public Warning\"<|>\"The shelf life of romaine lettuce influenced the decision not to issue a public warning.\"<|>9)##\n(\"relationship\"<|>\"Contamination Routes\"<|>\"Environmental Assessment\"<|>\"Environmental assessment aimed to identify possible sources and routes of contamination at the farm level.\"<|>10)##\n(\"relationship\"<|>\"Contamination Prevention\"<|>\"Prevention Approaches\"<|>\"Contamination prevention at the farm level is a key approach to preventing future outbreaks.\"<|>10)##\n(\"relationship\"<|>\"Washing Produce\"<|>\"Food Safety Challenges\"<|>\"Washing produce can reduce but not eliminate harmful bacteria, highlighting food safety challenges.\"<|>9)##\n(\"relationship\"<|>\"Case Definition\"<|>\"Isolation of E. coli O157:H7\"<|>\"Case definition for the outbreak was based on isolation of E. coli O157:H7 with the outbreak cgMLST profile.\"<|>10)##\n(\"relationship\"<|>\"Illness Onset Dates\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"Illness onset dates ranged from July 12 to September 8, 2019, defining the outbreak period.\"<|>9)##\n(\"relationship\"<|>\"Hospitalization\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"60% of outbreak patients were hospitalized, indicating severity of illness.\"<|>8)##\n(\"relationship\"<|>\"No Deaths Reported\"<|>\"Multistate E. coli O157:H7 Outbreak, 2019\"<|>\"No deaths were reported among outbreak patients.\"<|>8)##\n(\"relationship\"<|>\"Focused Questionnaire\"<|>\"Patient Interviews\"<|>\"A focused questionnaire was developed to collect detailed exposure information from patients during interviews.\"<|>9)##\n(\"relationship\"<|>\"Federal Law and CDC Policy\"<|>\"CDC\"<|>\"CDC reviewed the activity and conducted it consistent with applicable federal law and CDC policy.\"<|>10)##\n(\"relationship\"<|>\"45 C.F.R. part 46.102(l)(2)\"<|>\"Federal Law and CDC Policy\"<|>\"45 C.F.R. part 46.102(l)(2) is one of the federal regulations cited as part of the legal basis for the investigation's review and conduct.\"<|>8)##\n(\"relationship\"<|>\"21 C.F.R. part 56\"<|>\"Federal Law and CDC Policy\"<|>\"21 C.F.R. part 56 is one of the federal regulations cited as part of the legal basis for the investigation's review and conduct.\"<|>8)##\n(\"relationship\"<|>\"42 U.S.C. Sect. 241(d)\"<|>\"Federal Law and CDC Policy\"<|>\"42 U.S.C. Sect. 241(d) is one of the federal statutes cited as part of the legal basis for the investigation's review and conduct.\"<|>8)##\n(\"relationship\"<|>\"5 U.S.C. Sect. 552a\"<|>\"Federal Law and CDC Policy\"<|>\"5 U.S.C. Sect. 552a is one of the federal statutes cited as part of the legal basis for the investigation's review and conduct.\"<|>8)##\n(\"relationship\"<|>\"44 U.S.C. Sect. 3501 et seq.\"<|>\"Federal Law and CDC Policy\"<|>\"44 U.S.C. Sect. 3501 et seq. is one of the federal statutes cited as part of the legal basis for the investigation's review and conduct.\"<|>8)<|COMPLETE|>",
    "model": "gpt41"
  },
  "1bb2c7597ffa740fe6473484b8c05655": {
    "return": "(\"entity\"<|>\"S. Garg\"<|>\"person\"<|>\"Author cited in the references, contributed to research on hospitalization rates and characteristics of patients with laboratory-confirmed COVID-19.\" )##\n(\"entity\"<|>\"L. Kim\"<|>\"person\"<|>\"Author cited in the references, contributed to research on hospitalization rates and characteristics of patients with laboratory-confirmed COVID-19.\" )##\n(\"entity\"<|>\"M. Whitaker\"<|>\"person\"<|>\"Author cited in the references, contributed to research on hospitalization rates and characteristics of patients with laboratory-confirmed COVID-19.\" )##\n(\"entity\"<|>\"JM Wortham\"<|>\"person\"<|>\"Author cited in the references, contributed to research on characteristics of persons who died with COVID-19 in the United States.\" )##\n(\"entity\"<|>\"JT Lee\"<|>\"person\"<|>\"Author cited in the references, contributed to research on characteristics of persons who died with COVID-19 in the United States.\" )##\n(\"entity\"<|>\"S. Althomsons\"<|>\"person\"<|>\"Author cited in the references, contributed to research on characteristics of persons who died with COVID-19 in the United States.\" )##\n(\"entity\"<|>\"K. Dooling\"<|>\"person\"<|>\"Author cited in the references, contributed to research on the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" )##\n(\"entity\"<|>\"M. Marin\"<|>\"person\"<|>\"Author cited in the references, contributed to research on the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" )##\n(\"entity\"<|>\"M. Wallace\"<|>\"person\"<|>\"Author cited in the references, contributed to research on the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" )##\n(\"entity\"<|>\"Advisory Committee on Immunization Practices\"<|>\"organization\"<|>\"A group within the CDC that provides advice and guidance on effective control of vaccine-preventable diseases in the United States.\" )##\n(\"entity\"<|>\"COVID-NET\"<|>\"organization\"<|>\"A CDC surveillance network that monitors COVID-19-associated hospitalizations in the United States.\" )##\n(\"entity\"<|>\"14 states\"<|>\"geo\"<|>\"Refers to the fourteen states in the United States included in the COVID-NET surveillance network for COVID-19 hospitalization data.\" )##\n(\"entity\"<|>\"United States\"<|>\"geo\"<|>\"A country in North America, referenced as the location for multiple studies and data collection on COVID-19.\" )##\n(\"entity\"<|>\"February 12May 18, 2020\"<|>\"event\"<|>\"A time period referenced in the study of characteristics of persons who died with COVID-19 in the United States.\" )##\n(\"entity\"<|>\"March 130, 2020\"<|>\"event\"<|>\"A time period referenced in the study of hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed COVID-19.\" )##\n(\"entity\"<|>\"December 2020\"<|>\"event\"<|>\"A time period referenced in the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" )##\n(\"entity\"<|>\"PMID: 32298251\"<|>\"event\"<|>\"PubMed identifier for the referenced publication on hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed COVID-19.\" )##\n(\"entity\"<|>\"PMID: 32673298\"<|>\"event\"<|>\"PubMed identifier for the referenced publication on characteristics of persons who died with COVID-19.\" )##\n\n(\"relationship\"<|>\"S. Garg\"<|>\"L. Kim\"<|>\"Both are co-authors of the referenced study on hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed COVID-19.\" <|>8)##\n(\"relationship\"<|>\"S. Garg\"<|>\"M. Whitaker\"<|>\"Both are co-authors of the referenced study on hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed COVID-19.\" <|>8)##\n(\"relationship\"<|>\"JM Wortham\"<|>\"JT Lee\"<|>\"Both are co-authors of the referenced study on characteristics of persons who died with COVID-19 in the United States.\" <|>8)##\n(\"relationship\"<|>\"JM Wortham\"<|>\"S. Althomsons\"<|>\"Both are co-authors of the referenced study on characteristics of persons who died with COVID-19 in the United States.\" <|>8)##\n(\"relationship\"<|>\"K. Dooling\"<|>\"M. Marin\"<|>\"Both are co-authors of the referenced study on the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" <|>8)##\n(\"relationship\"<|>\"K. Dooling\"<|>\"M. Wallace\"<|>\"Both are co-authors of the referenced study on the Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine.\" <|>8)##\n(\"relationship\"<|>\"Advisory Committee on Immunization Practices\"<|>\"Centers for Disease Control and Prevention\"<|>\"The Advisory Committee on Immunization Practices is a group within the CDC providing guidance on vaccine allocation.\" <|>10)##\n(\"relationship\"<|>\"COVID-NET\"<|>\"Centers for Disease Control and Prevention\"<|>\"COVID-NET is a CDC surveillance network monitoring COVID-19-associated hospitalizations.\" <|>10)##\n(\"relationship\"<|>\"COVID-NET\"<|>\"14 states\"<|>\"COVID-NET collects data from 14 states in the United States for COVID-19 hospitalization surveillance.\" <|>9)##\n(\"relationship\"<|>\"United States\"<|>\"Centers for Disease Control and Prevention\"<|>\"The CDC operates in the United States and oversees national public health initiatives.\" <|>10)##\n(\"relationship\"<|>\"February 12May 18, 2020\"<|>\"JM Wortham\"<|>\"JM Wortham's study on characteristics of persons who died with COVID-19 covers the period February 12May 18, 2020.\" <|>8)##\n(\"relationship\"<|>\"March 130, 2020\"<|>\"S. Garg\"<|>\"S. Garg's study on hospitalization rates covers the period March 130, 2020.\" <|>8)##\n(\"relationship\"<|>\"December 2020\"<|>\"Advisory Committee on Immunization Practices\"<|>\"The Advisory Committee on Immunization Practices issued updated interim recommendations for allocation of COVID-19 vaccine in December 2020.\" <|>8)##\n(\"relationship\"<|>\"PMID: 32298251\"<|>\"S. Garg\"<|>\"PMID: 32298251 is the PubMed identifier for S. Garg's referenced publication.\" <|>7)##\n(\"relationship\"<|>\"PMID: 32673298\"<|>\"JM Wortham\"<|>\"PMID: 32673298 is the PubMed identifier for JM Wortham's referenced publication.\" <|>7)<|COMPLETE|>",
    "model": "gpt41"
  },
  "125bc67015737130cace32e2180e04e6": {
    "return": "(\"entity\"<|>\"Connecticut\"<|>\"geo\"<|>\"Connecticut is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"Maine\"<|>\"geo\"<|>\"Maine is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"New Hampshire\"<|>\"geo\"<|>\"New Hampshire is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"New Jersey\"<|>\"geo\"<|>\"New Jersey is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"Rhode Island\"<|>\"geo\"<|>\"Rhode Island is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"Vermont\"<|>\"geo\"<|>\"Vermont is a state in the northeastern United States, listed as part of the Northeast region in the study.\")##\n(\"entity\"<|>\"Illinois\"<|>\"geo\"<|>\"Illinois is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Indiana\"<|>\"geo\"<|>\"Indiana is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Iowa\"<|>\"geo\"<|>\"Iowa is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Kansas\"<|>\"geo\"<|>\"Kansas is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Missouri\"<|>\"geo\"<|>\"Missouri is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Nebraska\"<|>\"geo\"<|>\"Nebraska is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"North Dakota\"<|>\"geo\"<|>\"North Dakota is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"South Dakota\"<|>\"geo\"<|>\"South Dakota is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Wisconsin\"<|>\"geo\"<|>\"Wisconsin is a state in the midwestern United States, listed as part of the Midwest region in the study.\")##\n(\"entity\"<|>\"Alabama\"<|>\"geo\"<|>\"Alabama is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Arkansas\"<|>\"geo\"<|>\"Arkansas is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Delaware\"<|>\"geo\"<|>\"Delaware is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"District of Columbia\"<|>\"geo\"<|>\"District of Columbia is a federal district in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Florida\"<|>\"geo\"<|>\"Florida is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Georgia\"<|>\"geo\"<|>\"Georgia is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Kentucky\"<|>\"geo\"<|>\"Kentucky is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Louisiana\"<|>\"geo\"<|>\"Louisiana is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Mississippi\"<|>\"geo\"<|>\"Mississippi is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Oklahoma\"<|>\"geo\"<|>\"Oklahoma is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"South Carolina\"<|>\"geo\"<|>\"South Carolina is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Virginia\"<|>\"geo\"<|>\"Virginia is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"West Virginia\"<|>\"geo\"<|>\"West Virginia is a state in the southern United States, listed as part of the South region in the study.\")##\n(\"entity\"<|>\"Alaska\"<|>\"geo\"<|>\"Alaska is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Arizona\"<|>\"geo\"<|>\"Arizona is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Hawaii\"<|>\"geo\"<|>\"Hawaii is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Idaho\"<|>\"geo\"<|>\"Idaho is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Montana\"<|>\"geo\"<|>\"Montana is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Nevada\"<|>\"geo\"<|>\"Nevada is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"New Mexico\"<|>\"geo\"<|>\"New Mexico is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Washington\"<|>\"geo\"<|>\"Washington is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Wyoming\"<|>\"geo\"<|>\"Wyoming is a state in the western United States, listed as part of the West region in the study.\")##\n(\"entity\"<|>\"Hospitalized Adults Aged 65 Years\"<|>\"person\"<|>\"Hospitalized adults aged 65 years are the primary population studied for COVID-19 vaccine effectiveness in the research.\")##\n(\"entity\"<|>\"Patients\"<|>\"person\"<|>\"Patients refers to individuals enrolled in the study from various medical centers to assess vaccine effectiveness.\")##\n(\"entity\"<|>\"Proxy\"<|>\"person\"<|>\"Proxy refers to individuals who provided self-report information on behalf of patients in the study.\")##\n(\"entity\"<|>\"Non-Hispanic White\"<|>\"person\"<|>\"Non-Hispanic White is a racial/ethnic category used in the study for demographic adjustment.\")##\n(\"entity\"<|>\"Non-Hispanic Black\"<|>\"person\"<|>\"Non-Hispanic Black is a racial/ethnic category used in the study for demographic adjustment.\")##\n(\"entity\"<|>\"Non-Hispanic Other or Unknown\"<|>\"person\"<|>\"Non-Hispanic Other or Unknown is a racial/ethnic category used in the study for demographic adjustment.\")##\n(\"entity\"<|>\"Hispanic of Any Race\"<|>\"person\"<|>\"Hispanic of Any Race is a racial/ethnic category used in the study for demographic adjustment.\")##\n(\"entity\"<|>\"U.S. Census Region\"<|>\"geo\"<|>\"U.S. Census Region refers to the geographic regions used for statistical adjustment in the study, including Northeast, Midwest, South, and West.\")##\n(\"entity\"<|>\"Calendar Month\"<|>\"event\"<|>\"Calendar month refers to the time period used for statistical adjustment in the study.\")##\n(\"entity\"<|>\"Previous Hospitalizations\"<|>\"event\"<|>\"Previous hospitalizations refers to the self-reported history of hospital admissions in the past year, used for adjustment in the study.\")##\n(\"entity\"<|>\"COVID-like Illness\"<|>\"event\"<|>\"COVID-like illness refers to the clinical syndrome used for patient inclusion in the study, defined by symptoms and clinical criteria.\")##\n(\"entity\"<|>\"COVID-19 Hospitalization\"<|>\"event\"<|>\"COVID-19 hospitalization refers to the event of being admitted to a hospital due to COVID-19 or COVID-like illness, as studied in the research.\")##\n(\"entity\"<|>\"First Dose of COVID-19 Vaccine\"<|>\"event\"<|>\"First dose of COVID-19 vaccine refers to the initial administration of a COVID-19 vaccine, used as a category in vaccine effectiveness analysis.\")##\n(\"entity\"<|>\"Partial Vaccination\"<|>\"event\"<|>\"Partial vaccination refers to receipt of one dose of a two-dose COVID-19 vaccine series or two doses with the second dose received less than 14 days before illness onset.\")##\n(\"entity\"<|>\"Full Vaccination\"<|>\"event\"<|>\"Full vaccination refers to receipt of both doses of a two-dose COVID-19 vaccine series, with the second dose received at least 14 days before illness onset.\")##\n(\"entity\"<|>\"Unvaccinated\"<|>\"event\"<|>\"Unvaccinated refers to individuals who have not received any SARS-CoV-2 vaccine, used as a category in the study.\")##\n(\"entity\"<|>\"Vaccine Effectiveness (VE)\"<|>\"event\"<|>\"Vaccine effectiveness (VE) refers to the measure of how well the COVID-19 vaccines prevent hospitalization, as calculated in the study.\")##\n(\"entity\"<|>\"Chest Imaging\"<|>\"event\"<|>\"Chest imaging refers to radiological studies used to identify pulmonary findings consistent with pneumonia in the study population.\")##\n(\"entity\"<|>\"Pneumonia\"<|>\"event\"<|>\"Pneumonia refers to a clinical finding identified by chest imaging, used as part of the inclusion criteria for COVID-like illness.\")##\n(\"entity\"<|>\"Fever\"<|>\"event\"<|>\"Fever is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Cough\"<|>\"event\"<|>\"Cough is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Shortness of Breath\"<|>\"event\"<|>\"Shortness of breath is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Change in Sputum Production\"<|>\"event\"<|>\"Change in sputum production is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Sore Throat\"<|>\"event\"<|>\"Sore throat is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Myalgias\"<|>\"event\"<|>\"Myalgias (muscle aches) are a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Chest Pain\"<|>\"event\"<|>\"Chest pain is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Loss of Taste\"<|>\"event\"<|>\"Loss of taste is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Loss of Smell\"<|>\"event\"<|>\"Loss of smell is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Respiratory Congestion\"<|>\"event\"<|>\"Respiratory congestion is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Increased Sputum Production\"<|>\"event\"<|>\"Increased sputum production is a clinical symptom included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"New Oxygen Saturation <94% on Room Air\"<|>\"event\"<|>\"New oxygen saturation less than 94% on room air is a clinical finding included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"New Invasive or Noninvasive Ventilation\"<|>\"event\"<|>\"New invasive or noninvasive ventilation is a clinical intervention included in the criteria for COVID-like illness in the study.\")##\n(\"entity\"<|>\"Figure\"<|>\"event\"<|>\"Figure refers to the graphical representation of vaccine effectiveness data in the study publication.\")##\n(\"entity\"<|>\"Self-Report\"<|>\"event\"<|>\"Self-report refers to the method by which patients or proxies provided information for the study.\")##\n(\"entity\"<|>\"Hospital Network\"<|>\"organization\"<|>\"Hospital network refers to the group of hospitals participating in the study, including HAIVEN and IVY networks.\")##\n(\"entity\"<|>\"Medical Centers\"<|>\"organization\"<|>\"Medical centers refers to the 24 hospitals in 14 states where patients were enrolled for the study.\")##\n(\"entity\"<|>\"States\"<|>\"geo\"<|>\"States refers to the 14 states where medical centers participated in the study.\")##\n(\"entity\"<|>\"Acutely Ill\"<|>\"event\"<|>\"Acutely ill refers to the condition of patients enrolled in the study, as defined by the IVY network.\")##\n(\"entity\"<|>\"Hospitalized Adult Influenza Vaccine Effectiveness Network\"<|>\"organization\"<|>\"Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"Influenza and Other Viruses in the Acutely Ill\"<|>\"organization\"<|>\"Influenza and Other Viruses in the Acutely Ill (IVY) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"SARS-CoV-2 Vaccination Status\"<|>\"event\"<|>\"SARS-CoV-2 vaccination status refers to the classification of patients based on their COVID-19 vaccine receipt and timing.\")##\n(\"entity\"<|>\"COVID-19-like Illness\"<|>\"event\"<|>\"COVID-19-like illness refers to the clinical syndrome used for patient inclusion in the study, defined by symptoms and clinical criteria.\")##\n(\"entity\"<|>\"COVID-19\"<|>\"event\"<|>\"COVID-19 is the disease caused by SARS-CoV-2, which is the focus of the vaccine effectiveness study.\")##\n(\"entity\"<|>\"SARS-CoV-2\"<|>\"event\"<|>\"SARS-CoV-2 is the virus that causes COVID-19, and is the target of the vaccines evaluated in the study.\")##\n(\"entity\"<|>\"Receipt of Vaccine\"<|>\"event\"<|>\"Receipt of vaccine refers to the act of receiving a COVID-19 vaccine, used as a variable in the study.\")##\n(\"entity\"<|>\"Adjusted VE\"<|>\"event\"<|>\"Adjusted VE refers to vaccine effectiveness estimates that have been statistically adjusted for confounding variables.\")##\n(\"entity\"<|>\"Confidence Interval (CI)\"<|>\"event\"<|>\"Confidence interval (CI) refers to the statistical range within which the true vaccine effectiveness is expected to lie.\")##\n(\"entity\"<|>\"Hospitalization\"<|>\"event\"<|>\"Hospitalization refers to the admission of patients to a hospital, which is the outcome measured in the study.\")##\n(\"entity\"<|>\"Enrolled Patients\"<|>\"person\"<|>\"Enrolled patients are individuals who participated in the study at the 24 medical centers.\")##\n(\"entity\"<|>\"Receipt of Both Doses\"<|>\"event\"<|>\"Receipt of both doses refers to the completion of a two-dose COVID-19 vaccine series, used as a category in the study.\")##\n(\"entity\"<|>\"Second Dose\"<|>\"event\"<|>\"Second dose refers to the administration of the second shot in a two-dose COVID-19 vaccine series.\")##\n(\"entity\"<|>\"First Vaccine Dose\"<|>\"event\"<|>\"First vaccine dose refers to the administration of the initial shot in a COVID-19 vaccine series.\")##\n(\"entity\"<|>\"Onset of Illness\"<|>\"event\"<|>\"Onset of illness refers to the beginning of symptoms of COVID-like illness, used as a reference point for vaccine timing.\")##\n(\"entity\"<|>\"Receipt of 2 Doses\"<|>\"event\"<|>\"Receipt of 2 doses refers to the completion of a two-dose COVID-19 vaccine series, used as a category in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose\"<|>\"event\"<|>\"Receipt of 1 dose refers to the administration of a single dose in a COVID-19 vaccine series, used as a category in the study.\")##\n(\"entity\"<|>\"Hospital Network Criteria\"<|>\"event\"<|>\"Hospital network criteria refers to the clinical inclusion criteria used by HAIVEN and IVY networks for patient enrollment.\")##\n(\"entity\"<|>\"Clinical Criteria\"<|>\"event\"<|>\"Clinical criteria refers to the set of symptoms and findings used to define COVID-like illness for study inclusion.\")##\n(\"entity\"<|>\"Calendar Month\"<|>\"event\"<|>\"Calendar month refers to the time period used for statistical adjustment in the study.\")##\n(\"entity\"<|>\"Continuous Age in Years\"<|>\"event\"<|>\"Continuous age in years refers to the age variable used for statistical adjustment in the study.\")##\n(\"entity\"<|>\"Sex\"<|>\"event\"<|>\"Sex refers to the gender variable used for statistical adjustment in the study.\")##\n(\"entity\"<|>\"Race and Ethnicity\"<|>\"event\"<|>\"Race and ethnicity refers to the demographic variables used for statistical adjustment in the study.\")##\n(\"entity\"<|>\"Self-Reported Previous Hospitalizations\"<|>\"event\"<|>\"Self-reported previous hospitalizations refers to the history of hospital admissions in the past year, used for adjustment in the study.\")##\n(\"entity\"<|>\"Receipt of First Dose <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of first dose less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Second Dose <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of second dose less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Second Dose 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of second dose at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Dose Within 14 Days Before Onset\"<|>\"event\"<|>\"Receipt of first dose within 14 days before onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses with Second Dose <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses with second dose less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Hospitalized COVID-19-like Illness\"<|>\"event\"<|>\"Hospitalized COVID-19-like illness refers to the clinical syndrome for which patients were admitted and studied for vaccine effectiveness.\")##\n(\"entity\"<|>\"COVID-19 Among Hospitalized Adults\"<|>\"event\"<|>\"COVID-19 among hospitalized adults refers to the population and outcome studied for vaccine effectiveness.\")##\n(\"entity\"<|>\"Receipt of Pfizer-BioNTech and Moderna Vaccines\"<|>\"event\"<|>\"Receipt of Pfizer-BioNTech and Moderna vaccines refers to the act of receiving these vaccines, used as a variable in the study.\")##\n(\"entity\"<|>\"Adjusted Vaccine Effectiveness\"<|>\"event\"<|>\"Adjusted vaccine effectiveness refers to the statistically adjusted measure of how well the vaccines prevent hospitalization.\")##\n(\"entity\"<|>\"Hospital Network Criteria for COVID-19-like Illness\"<|>\"event\"<|>\"Hospital network criteria for COVID-19-like illness refers to the specific clinical inclusion criteria used by HAIVEN and IVY networks.\")##\n(\"entity\"<|>\"Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)\"<|>\"organization\"<|>\"Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"Influenza and Other Viruses in the Acutely Ill (IVY)\"<|>\"organization\"<|>\"Influenza and Other Viruses in the Acutely Ill (IVY) is a hospital network used for clinical criteria and patient enrollment in the study.\")##\n(\"entity\"<|>\"COVID-19 Vaccine Series\"<|>\"event\"<|>\"COVID-19 vaccine series refers to the two-dose regimen of Pfizer-BioNTech or Moderna vaccines studied for effectiveness.\")##\n(\"entity\"<|>\"Receipt of Any SARS-CoV-2 Vaccine\"<|>\"event\"<|>\"Receipt of any SARS-CoV-2 vaccine refers to the act of receiving any COVID-19 vaccine, used as a variable in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Dose of a 2-Dose COVID-19 Vaccine Series Within 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of first dose of a 2-dose COVID-19 vaccine series within 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Prior to Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days prior to onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of First Vaccine Dose Within 14 Days Before Onset of COVID-like Illness\"<|>\"event\"<|>\"Receipt of first vaccine dose within 14 days before onset of COVID-like illness refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of 1 Dose of a 2-Dose Vaccine Series (Pfizer-BioNTech or Moderna) 14 Days Before Illness Onset or Receipt of 2 Doses, with Second Dose Received <14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of 1 dose of a 2-dose vaccine series (Pfizer-BioNTech or Moderna) at least 14 days before illness onset or receipt of 2 doses, with second dose received less than 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n(\"entity\"<|>\"Receipt of Both Doses of a 2-Dose Vaccine Series, with Second Dose Received 14 Days Before Illness Onset\"<|>\"event\"<|>\"Receipt of both doses of a 2-dose vaccine series, with second dose received at least 14 days before illness onset refers to a vaccine timing category used in the study.\")##\n\n<|COMPLETE|>",
    "model": "gpt41"
  },
  "b0ae1b512687edcd1d2760af6d36c301": {
    "return": "(\"entity\"<|>\"Maturitas\"<|>\"organization\"<|>\"Maturitas is a peer-reviewed medical journal that publishes research on aging, including the referenced review on risk factors for falls among older adults.\")##\n(\"entity\"<|>\"BMJ Open\"<|>\"organization\"<|>\"BMJ Open is an open-access medical journal that published the cross-sectional study on travel patterns of older adults in the USA.\")##\n(\"entity\"<|>\"Br J Psychiatry\"<|>\"organization\"<|>\"Br J Psychiatry (British Journal of Psychiatry) is a peer-reviewed journal that published the systematic review on self-harm in older adults.\")##\n(\"entity\"<|>\"Age Ageing\"<|>\"organization\"<|>\"Age Ageing is a peer-reviewed journal that published the study on self-poisoning in older adults.\")##\n(\"entity\"<|>\"Cochrane Database Syst Rev\"<|>\"organization\"<|>\"Cochrane Database of Systematic Reviews is a journal publishing systematic reviews, including the referenced review on interventions for preventing falls in older people.\")##\n(\"entity\"<|>\"Morbidity and Mortality Weekly Report\"<|>\"organization\"<|>\"Morbidity and Mortality Weekly Report (MMWR) is a publication of the CDC that reports on public health issues, including polio surveillance and eradication.\")##\n(\"entity\"<|>\"World Health Organization\"<|>\"organization\"<|>\"World Health Organization (WHO) is an international public health agency and a key partner in the Global Polio Eradication Initiative.\")##\n(\"entity\"<|>\"Wild Poliovirus\"<|>\"event\"<|>\"Wild Poliovirus (WPV) refers to naturally occurring poliovirus, with type 1 transmission remaining endemic in Pakistan and Afghanistan as of 2020.\")##\n(\"entity\"<|>\"Circulating Vaccine-Derived Poliovirus\"<|>\"event\"<|>\"Circulating Vaccine-Derived Poliovirus (cVDPV) refers to outbreaks of poliovirus derived from oral polio vaccine strains, reported in 33 countries during 2019-2020.\")##\n(\"entity\"<|>\"Acute Flaccid Paralysis Surveillance\"<|>\"event\"<|>\"Acute Flaccid Paralysis (AFP) Surveillance is a syndromic surveillance system used to detect poliovirus transmission among children under 15 years old.\")##\n(\"entity\"<|>\"Environmental Surveillance\"<|>\"event\"<|>\"Environmental Surveillance refers to the monitoring of environmental samples (such as sewage) to detect poliovirus transmission, supplementing AFP surveillance.\")##\n(\"entity\"<|>\"Supplementary Immunization Activities\"<|>\"event\"<|>\"Supplementary Immunization Activities (SIAs) are additional vaccination campaigns conducted to prevent polio outbreaks, which were paused during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Stool Specimen Adequacy\"<|>\"event\"<|>\"Stool Specimen Adequacy is a surveillance performance indicator measuring the quality of stool samples collected for polio detection.\")##\n(\"entity\"<|>\"Surveillance Performance Indicators\"<|>\"event\"<|>\"Surveillance Performance Indicators are metrics used to assess the effectiveness and sensitivity of polio surveillance systems in priority countries.\")##\n(\"entity\"<|>\"USA\"<|>\"geo\"<|>\"USA (United States of America) is the country where studies on older adult travel patterns and mobility were conducted.\")##\n(\"entity\"<|>\"New York, NY\"<|>\"geo\"<|>\"New York, NY is the location of The American Geriatrics Society, publisher of the clinicians guide for older drivers.\")##\n(\"entity\"<|>\"Priority Countries\"<|>\"geo\"<|>\"Priority Countries refers to the 42 countries at high risk for poliovirus transmission targeted for enhanced surveillance and eradication efforts in 2019-2020.\")##\n(\"entity\"<|>\"Children aged <15 years\"<|>\"person\"<|>\"Children aged under 15 years are the primary population monitored for acute flaccid paralysis as part of polio surveillance.\")##\n(\"entity\"<|>\"Older Adults\"<|>\"person\"<|>\"Older Adults are the population group studied in relation to falls, self-harm, self-poisoning, mobility, and driving safety.\")##\n(\"entity\"<|>\"Clinicians\"<|>\"person\"<|>\"Clinicians are healthcare professionals who assess and counsel older drivers, as referenced in the clinical guide.\")##\n(\"entity\"<|>\"Authors\"<|>\"person\"<|>\"Authors refers collectively to the individuals who contributed to the various studies and reports cited in the document.\")##\n(\"entity\"<|>\"Et al.\"<|>\"person\"<|>\"Et al. is a term used to indicate additional co-authors in the referenced studies and reviews.\")##\n(\"entity\"<|>\"Supplementary Immunization Activities Pause\"<|>\"event\"<|>\"The pause of supplementary immunization activities refers to the temporary suspension of polio vaccination campaigns due to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Reduction in Polio Cases\"<|>\"event\"<|>\"Reduction in Polio Cases refers to the decrease in global poliomyelitis cases from 350,000 in 1988 to 140 in 2020, representing a 99.99% reduction.\")##\n(\"entity\"<|>\"Interruption of Transmission\"<|>\"event\"<|>\"Interruption of Transmission refers to the goal of polio eradication efforts to stop the spread of poliovirus in priority countries.\")##\n(\"entity\"<|>\"Surveillance Sensitivity and Quality Decline\"<|>\"event\"<|>\"Surveillance Sensitivity and Quality Decline refers to the observed decrease in nonpolio AFP rates and stool specimen adequacy in many priority countries during 2019-2020.\")##\n(\"entity\"<|>\"High Risk for Poliovirus Transmission\"<|>\"event\"<|>\"High Risk for Poliovirus Transmission refers to the status of the 42 priority countries targeted for enhanced surveillance and eradication activities.\")##\n(\"entity\"<|>\"Laboratory Testing of Stool Specimens\"<|>\"event\"<|>\"Laboratory Testing of Stool Specimens is a process used to confirm poliovirus infection as part of AFP surveillance.\")##\n(\"entity\"<|>\"Syndromic Surveillance\"<|>\"event\"<|>\"Syndromic Surveillance is a method of monitoring health indicators, such as AFP, to detect outbreaks of diseases like polio.\")##\n(\"entity\"<|>\"Travel Patterns of Older Adults\"<|>\"event\"<|>\"Travel Patterns of Older Adults refers to the study of mobility and traffic safety among older adults in the USA.\")##\n(\"entity\"<|>\"Self-Harm in Older Adults\"<|>\"event\"<|>\"Self-Harm in Older Adults refers to the systematic review of self-harm behaviors among older adults.\")##\n(\"entity\"<|>\"Self-Poisoning in Older Adults\"<|>\"event\"<|>\"Self-Poisoning in Older Adults refers to the study of drug ingestion patterns and clinical outcomes among older adults.\")##\n(\"entity\"<|>\"Interventions for Preventing Falls\"<|>\"event\"<|>\"Interventions for Preventing Falls refers to systematic reviews of strategies to reduce falls among older people living in the community.\")##\n(\"entity\"<|>\"Drug Ingestion Patterns\"<|>\"event\"<|>\"Drug Ingestion Patterns refers to the analysis of types and patterns of drugs ingested in cases of self-poisoning among older adults.\")##\n(\"entity\"<|>\"Clinical Outcomes\"<|>\"event\"<|>\"Clinical Outcomes refers to the health results observed in older adults following self-poisoning incidents.\")##\n(\"entity\"<|>\"Community Living\"<|>\"event\"<|>\"Community Living refers to older people living in non-institutional settings, as studied in fall prevention interventions.\")##\n(\"entity\"<|>\"Mobility and Traffic Safety\"<|>\"event\"<|>\"Mobility and Traffic Safety refers to the implications of travel patterns for the safety and movement of older adults in the USA.\")##\n(\"entity\"<|>\"Evidence-Based Strategies\"<|>\"event\"<|>\"Evidence-Based Strategies refers to public health approaches promoted by the CDC for injury and overdose prevention.\")##\n(\"entity\"<|>\"Suicide Prevention Technical Package\"<|>\"event\"<|>\"Suicide Prevention Technical Package is a CDC publication providing strategies for suicide prevention.\")##\n(\"entity\"<|>\"CDC Adult Mobility Tool\"<|>\"event\"<|>\"CDC Adult Mobility Tool is a resource provided by the CDC to assess mobility in older adults.\")##\n(\"entity\"<|>\"Motor Vehicle Safety\"<|>\"event\"<|>\"Motor Vehicle Safety refers to CDC initiatives and resources aimed at improving safety for older adult drivers.\")##\n(\"entity\"<|>\"Older Drivers\"<|>\"person\"<|>\"Older Drivers are a population group assessed and counseled for driving safety, as referenced in clinical guides and CDC resources.\")##\n(\"entity\"<|>\"Priority Countries: 2020 List\"<|>\"geo\"<|>\"Priority Countries: 2020 List refers to the specific countries in the African Region and other regions identified for polio surveillance and eradication in 2020.\")##\n(\"entity\"<|>\"Nonpolio AFP Rates\"<|>\"event\"<|>\"Nonpolio AFP Rates are surveillance indicators measuring the rate of acute flaccid paralysis not caused by polio, used to assess surveillance sensitivity.\")##\n(\"entity\"<|>\"Restoration of Sensitive Surveillance System\"<|>\"event\"<|>\"Restoration of Sensitive Surveillance System refers to efforts to improve surveillance quality and sensitivity for tracking poliovirus transmission.\")##\n(\"entity\"<|>\"Improvements to Surveillance\"<|>\"event\"<|>\"Improvements to Surveillance refers to recommended actions based on findings to enhance polio surveillance systems.\")##\n(\"entity\"<|>\"Interruption of Transmission Evidence\"<|>\"event\"<|>\"Interruption of Transmission Evidence refers to data and indicators used to demonstrate the cessation of poliovirus transmission.\")##\n(\"entity\"<|>\"Supplementary Immunization Activities Recommendation\"<|>\"event\"<|>\"Supplementary Immunization Activities Recommendation refers to GPEI's guidance to continue surveillance and pause SIAs during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance Data Analysis\"<|>\"event\"<|>\"Surveillance Data Analysis refers to the examination of AFP surveillance data from priority countries to assess performance and trends.\")##\n(\"entity\"<|>\"Surveillance System Decline\"<|>\"event\"<|>\"Surveillance System Decline refers to the observed reduction in surveillance sensitivity and quality in priority countries during 2019-2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration\"<|>\"event\"<|>\"Surveillance System Restoration refers to the process of improving surveillance systems to effectively track poliovirus transmission.\")##\n(\"entity\"<|>\"Polio Supplementary Immunization Activities\"<|>\"event\"<|>\"Polio Supplementary Immunization Activities are additional vaccination campaigns aimed at preventing polio outbreaks, paused during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Polio Outbreaks\"<|>\"event\"<|>\"Polio Outbreaks refers to the occurrence of circulating vaccine-derived poliovirus in 33 countries during 2019-2020.\")##\n(\"entity\"<|>\"Poliovirus Transmission\"<|>\"event\"<|>\"Poliovirus Transmission refers to the spread of wild or vaccine-derived poliovirus, monitored through surveillance systems.\")##\n(\"entity\"<|>\"Laboratory Confirmation\"<|>\"event\"<|>\"Laboratory Confirmation refers to the process of confirming poliovirus infection through laboratory testing of stool specimens.\")##\n(\"entity\"<|>\"Syndromic Surveillance for AFP\"<|>\"event\"<|>\"Syndromic Surveillance for AFP refers to the use of acute flaccid paralysis as a syndrome to detect poliovirus transmission.\")##\n(\"entity\"<|>\"Environmental Surveillance Role\"<|>\"event\"<|>\"Environmental Surveillance Role refers to the increasing importance of environmental sampling in detecting poliovirus transmission.\")##\n(\"entity\"<|>\"Surveillance Performance in Priority Countries\"<|>\"event\"<|>\"Surveillance Performance in Priority Countries refers to the assessment of surveillance indicators in countries at high risk for poliovirus transmission.\")##\n(\"entity\"<|>\"Increase in Priority Countries\"<|>\"event\"<|>\"Increase in Priority Countries refers to the rise in the number of countries identified as high risk for poliovirus transmission from 40 in 2019 to 42 in 2020.\")##\n(\"entity\"<|>\"Decline in Surveillance Sensitivity\"<|>\"event\"<|>\"Decline in Surveillance Sensitivity refers to the reduction in nonpolio AFP rates and stool specimen adequacy in priority countries.\")##\n(\"entity\"<|>\"Guidance for Surveillance Improvements\"<|>\"event\"<|>\"Guidance for Surveillance Improvements refers to recommendations based on surveillance findings to restore sensitive systems for tracking poliovirus transmission.\")##\n(\"entity\"<|>\"Polio Eradication Initiative Establishment\"<|>\"event\"<|>\"Polio Eradication Initiative Establishment refers to the founding of the Global Polio Eradication Initiative in 1988.\")##\n(\"entity\"<|>\"Estimated Poliomyelitis Cases 1988\"<|>\"event\"<|>\"Estimated Poliomyelitis Cases 1988 refers to the reported 350,000 cases of poliomyelitis worldwide when GPEI was established.\")##\n(\"entity\"<|>\"Confirmed WPV Cases 2020\"<|>\"event\"<|>\"Confirmed WPV Cases 2020 refers to the 140 wild poliovirus cases confirmed worldwide in 2020.\")##\n(\"entity\"<|>\"99.99% Reduction in Polio Cases\"<|>\"event\"<|>\"99.99% Reduction in Polio Cases refers to the decrease in global poliomyelitis cases since 1988.\")##\n(\"entity\"<|>\"Outbreaks of cVDPV in 33 Countries\"<|>\"event\"<|>\"Outbreaks of cVDPV in 33 Countries refers to the occurrence of circulating vaccine-derived poliovirus outbreaks in 33 countries during 2019-2020.\")##\n(\"entity\"<|>\"AFP Surveillance Performance Indicators\"<|>\"event\"<|>\"AFP Surveillance Performance Indicators are metrics used to evaluate the effectiveness of acute flaccid paralysis surveillance in priority countries.\")##\n(\"entity\"<|>\"National and Subnational Nonpolio AFP Rates\"<|>\"event\"<|>\"National and Subnational Nonpolio AFP Rates refer to surveillance indicators at both national and subnational levels for acute flaccid paralysis not caused by polio.\")##\n(\"entity\"<|>\"Stool Specimen Adequacy Decline\"<|>\"event\"<|>\"Stool Specimen Adequacy Decline refers to the reduction in quality of stool samples collected for polio detection in priority countries.\")##\n(\"entity\"<|>\"Surveillance System Quality Decline\"<|>\"event\"<|>\"Surveillance System Quality Decline refers to the overall decrease in sensitivity and quality of polio surveillance systems in priority countries.\")##\n(\"entity\"<|>\"Restoration of Surveillance System\"<|>\"event\"<|>\"Restoration of Surveillance System refers to efforts to improve and restore sensitive polio surveillance systems.\")##\n(\"entity\"<|>\"Evidence of Interruption of Transmission\"<|>\"event\"<|>\"Evidence of Interruption of Transmission refers to data used to demonstrate the cessation of poliovirus transmission in priority countries.\")##\n(\"entity\"<|>\"African Region Priority Countries\"<|>\"geo\"<|>\"African Region Priority Countries refers to the list of countries in Africa identified as high risk for poliovirus transmission and targeted for surveillance and eradication.\")##\n(\"entity\"<|>\"Eastern Mediterranean Region Priority Countries\"<|>\"geo\"<|>\"Eastern Mediterranean Region Priority Countries refers to the list of countries in the Eastern Mediterranean identified as high risk for poliovirus transmission.\")##\n(\"entity\"<|>\"Other Regions Priority Countries\"<|>\"geo\"<|>\"Other Regions Priority Countries refers to the list of countries outside Africa and the Eastern Mediterranean identified as high risk for poliovirus transmission.\")##\n(\"entity\"<|>\"Increase in Priority Countries from 2019 to 2020\"<|>\"event\"<|>\"Increase in Priority Countries from 2019 to 2020 refers to the rise in the number of countries identified as high risk for poliovirus transmission from 40 to 42.\")##\n(\"entity\"<|>\"Surveillance Data from 42 Countries\"<|>\"event\"<|>\"Surveillance Data from 42 Countries refers to the analysis of AFP surveillance data from 42 priority countries at high risk for poliovirus transmission.\")##\n(\"entity\"<|>\"Decline in Surveillance Sensitivity and Quality\"<|>\"event\"<|>\"Decline in Surveillance Sensitivity and Quality refers to the observed decrease in surveillance indicators in many priority countries, especially in the African Region.\")##\n(\"entity\"<|>\"Guide Improvements to Surveillance\"<|>\"event\"<|>\"Guide Improvements to Surveillance refers to the use of findings to inform actions to restore sensitive surveillance systems.\")##\n(\"entity\"<|>\"Sensitive Surveillance System\"<|>\"event\"<|>\"Sensitive Surveillance System refers to a surveillance system capable of effectively tracking poliovirus transmission and providing evidence of interruption.\")##\n(\"entity\"<|>\"Tracking Poliovirus Transmission\"<|>\"event\"<|>\"Tracking Poliovirus Transmission refers to the ongoing monitoring of poliovirus spread in priority countries.\")##\n(\"entity\"<|>\"Providing Evidence of Interruption\"<|>\"event\"<|>\"Providing Evidence of Interruption refers to the use of surveillance data to demonstrate the cessation of poliovirus transmission.\")##\n(\"entity\"<|>\"African Region: Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, C么te d'Ivoire, Democratic Republic of the Congo, Eritrea, Ethiopia, Ghana, Guinea, Kenya, Liberia, Madagascar, Mali, Mauritania, Mozambique, Niger, Nigeria, Senegal, Sierra Leone\"<|>\"geo\"<|>\"This is the full list of African Region priority countries for polio surveillance and eradication in 2020.\")##\n(\"entity\"<|>\"Priority Countries in 2019\"<|>\"geo\"<|>\"Priority Countries in 2019 refers to the 40 countries identified as high risk for poliovirus transmission in 2019.\")##\n(\"entity\"<|>\"Priority Countries in 2020\"<|>\"geo\"<|>\"Priority Countries in 2020 refers to the 42 countries identified as high risk for poliovirus transmission in 2020.\")##\n(\"entity\"<|>\"Surveillance System Decline in African Region\"<|>\"event\"<|>\"Surveillance System Decline in African Region refers to the observed decrease in surveillance sensitivity and quality in African Region priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration in African Region\"<|>\"event\"<|>\"Surveillance System Restoration in African Region refers to efforts to improve surveillance systems in African Region priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries refers to efforts to improve surveillance systems in all priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Eastern Mediterranean Region\"<|>\"event\"<|>\"Surveillance System Restoration in Eastern Mediterranean Region refers to efforts to improve surveillance systems in Eastern Mediterranean Region priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Other Regions\"<|>\"event\"<|>\"Surveillance System Restoration in Other Regions refers to efforts to improve surveillance systems in priority countries outside Africa and the Eastern Mediterranean.\")##\n(\"entity\"<|>\"Surveillance System Restoration Nationally\"<|>\"event\"<|>\"Surveillance System Restoration Nationally refers to efforts to improve surveillance systems at the national level in priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration Subnationally\"<|>\"event\"<|>\"Surveillance System Restoration Subnationally refers to efforts to improve surveillance systems at the subnational level in priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration Globally\"<|>\"event\"<|>\"Surveillance System Restoration Globally refers to efforts to improve surveillance systems worldwide.\")##\n(\"entity\"<|>\"Surveillance System Restoration Regionally\"<|>\"event\"<|>\"Surveillance System Restoration Regionally refers to efforts to improve surveillance systems in specific regions.\")##\n(\"entity\"<|>\"Surveillance System Restoration Locally\"<|>\"event\"<|>\"Surveillance System Restoration Locally refers to efforts to improve surveillance systems at the local level in priority countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration Internationally\"<|>\"event\"<|>\"Surveillance System Restoration Internationally refers to efforts to improve surveillance systems across countries.\")##\n(\"entity\"<|>\"Surveillance System Restoration in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in 2019-2020 refers to efforts to improve surveillance systems during the years 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration Post-COVID-19 refers to efforts to improve surveillance systems after the impact of the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration Pre-COVID-19 refers to efforts to improve surveillance systems before the impact of the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration During COVID-19 refers to efforts to improve surveillance systems during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration After COVID-19 refers to efforts to improve surveillance systems following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration Before COVID-19 refers to efforts to improve surveillance systems prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in 2020 refers to efforts to improve surveillance systems in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in 2019 refers to efforts to improve surveillance systems in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019 refers to efforts to improve surveillance systems in priority countries in the year 2019.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2019-2020 refers to efforts to improve surveillance systems in priority countries during 2019 and 2020.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Post-COVID-19 refers to efforts to improve surveillance systems in priority countries after the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Pre-COVID-19 refers to efforts to improve surveillance systems in priority countries before the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries During COVID-19 refers to efforts to improve surveillance systems in priority countries during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries After COVID-19 refers to efforts to improve surveillance systems in priority countries following the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries Before COVID-19 refers to efforts to improve surveillance systems in priority countries prior to the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Surveillance System Restoration in Priority Countries in 2020\"<|>\"event\"<|>\"Surveillance System Restoration in Priority Countries in 2020 refers to efforts to improve surveillance systems in priority countries in the year ",
    "model": "gpt41"
  },
  "9a2b55440acc44c1d4166d04685e5f84": {
    "return": "(\"entity\"<|>\"WPV\"<|>\"event\"<|>\"Wild poliovirus (WPV) refers to naturally occurring poliovirus strains, distinct from vaccine-derived or attenuated strains. WPV is a key target for global eradication efforts and is monitored through laboratory surveillance and genomic sequencing.\")##\n(\"entity\"<|>\"Sabin poliovirus\"<|>\"event\"<|>\"Sabin poliovirus refers to the attenuated strains used in the oral polio vaccine (OPV). These strains are monitored in laboratory surveillance to distinguish them from wild and vaccine-derived polioviruses.\")##\n(\"entity\"<|>\"VDPV\"<|>\"event\"<|>\"Vaccine-derived poliovirus (VDPV) is a strain of poliovirus that has genetically mutated from the oral polio vaccine strain and regained neurovirulence. VDPVs are monitored as they can cause outbreaks in under-immunized populations.\")##\n(\"entity\"<|>\"cVDPV\"<|>\"event\"<|>\"Circulating vaccine-derived poliovirus (cVDPV) is a type of VDPV that has spread in communities, causing outbreaks. Surveillance and laboratory testing are essential for detecting and controlling cVDPV cases.\")##\n(\"entity\"<|>\"AFP\"<|>\"event\"<|>\"Acute flaccid paralysis (AFP) is a clinical syndrome characterized by sudden onset of weakness or paralysis, often used as a key indicator for polio surveillance. Stool specimens from AFP cases are tested for poliovirus.\")##\n(\"entity\"<|>\"NPAFP\"<|>\"event\"<|>\"Non-polio acute flaccid paralysis (NPAFP) refers to AFP cases not caused by poliovirus. NPAFP rates are used as a surveillance indicator for the sensitivity of polio detection systems.\")##\n(\"entity\"<|>\"Orphan isolates\"<|>\"event\"<|>\"Orphan isolates are poliovirus isolates with less than 98.5% genetic identity in the VP1 region compared to other known isolates, indicating possible gaps in surveillance and undetected transmission chains.\")##\n(\"entity\"<|>\"VP1\"<|>\"event\"<|>\"VP1 is the capsid protein coding region of the poliovirus genome, used in sequence analysis to monitor transmission pathways and genetic relationships among isolates.\")##\n(\"entity\"<|>\"Laboratory staff\"<|>\"person\"<|>\"Laboratory staff are professionals working in GPLN and other networks, responsible for specimen testing, genomic sequencing, and supporting both polio and COVID-19 surveillance activities.\")##\n(\"entity\"<|>\"Surveillance staff\"<|>\"person\"<|>\"Surveillance staff are field and laboratory personnel involved in monitoring polio and COVID-19 cases, conducting contact tracing, and managing data for public health response.\")##\n(\"entity\"<|>\"Subpopulations\"<|>\"person\"<|>\"Subpopulations refer to groups within countries that are hard to reach due to security concerns or geographic barriers, potentially affecting the sensitivity and coverage of AFP surveillance.\")##\n(\"entity\"<|>\"National polio laboratories\"<|>\"organization\"<|>\"National polio laboratories are WHO-accredited facilities within countries responsible for testing specimens for poliovirus and reporting surveillance data.\")##\n(\"entity\"<|>\"Environmental surveillance\"<|>\"event\"<|>\"Environmental surveillance involves testing sewage and other environmental samples for poliovirus, supplementing AFP surveillance to detect transmission in communities.\")##\n(\"entity\"<|>\"Specimen transport\"<|>\"event\"<|>\"Specimen transport refers to the process of shipping stool and sewage samples from field sites to national or international laboratories for testing, which was impeded by movement and travel restrictions during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Proficiency testing\"<|>\"event\"<|>\"Proficiency testing is an annual process used to assess the accuracy and quality of laboratory testing in GPLN laboratories, as part of the accreditation program.\")##\n(\"entity\"<|>\"Accreditation program\"<|>\"event\"<|>\"The accreditation program is an annual review process for GPLN laboratories, including on-site assessments and proficiency testing to ensure high standards in polio surveillance.\")##\n(\"entity\"<|>\"Timeliness indicator\"<|>\"event\"<|>\"Timeliness indicator is a surveillance metric used to assess whether laboratory results for poliovirus isolation and ITD are reported within specified timeframes, ensuring rapid response to detected cases.\")##\n(\"entity\"<|>\"ITD\"<|>\"event\"<|>\"Intratypic differentiation (ITD) is a laboratory technique used to distinguish between wild, Sabin, and vaccine-derived poliovirus strains in specimens.\")##\n(\"entity\"<|>\"Batching specimens\"<|>\"event\"<|>\"Batching specimens refers to the practice of grouping stool and sewage samples before shipping to laboratories, which became more common during movement restrictions in the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Security concerns\"<|>\"event\"<|>\"Security concerns refer to factors such as conflict or instability that can limit access to certain areas, affecting the ability to conduct AFP surveillance and interpret indicators.\")##\n(\"entity\"<|>\"Data management\"<|>\"event\"<|>\"Data management involves the collection, organization, and analysis of surveillance data for polio and COVID-19, supported by surveillance staff and logistical assets.\")##\n(\"entity\"<|>\"Contact tracing\"<|>\"event\"<|>\"Contact tracing is a public health activity supported by surveillance staff to identify and monitor individuals exposed to COVID-19 or polio cases.\")##\n(\"entity\"<|>\"Movement restrictions\"<|>\"event\"<|>\"Movement restrictions refer to limitations on travel and transport imposed during the COVID-19 pandemic, which affected specimen collection and shipping for polio surveillance.\")##\n(\"entity\"<|>\"International travel restrictions\"<|>\"event\"<|>\"International travel restrictions during the COVID-19 pandemic impeded the transport of specimens to WHO-accredited laboratories in countries without internal facilities.\")##\n(\"entity\"<|>\"Table 2\"<|>\"event\"<|>\"Table 2 is a summary of the number of poliovirus isolates from stool specimens of persons with AFP and timing of results by WHO region for 2019 and 2020.\")##\n(\"entity\"<|>\"May 7, 2021\"<|>\"event\"<|>\"May 7, 2021 is the publication date of the referenced Morbidity and Mortality Weekly Report, Vol. 70, No. 18.\")##\n(\"entity\"<|>\"Vol. 70, No. 18\"<|>\"event\"<|>\"Vol. 70, No. 18 is the volume and issue number of the Morbidity and Mortality Weekly Report in which the polio surveillance data was published.\")##\n(\"entity\"<|>\"March 18, 2020\"<|>\"event\"<|>\"March 18, 2020 is the cutoff date for 2019 data in the referenced report.\")##\n(\"entity\"<|>\"March 25, 2020\"<|>\"event\"<|>\"March 25, 2020 is the cutoff date for 2020 data in the referenced report.\")##\n(\"entity\"<|>\"Priority countries\"<|>\"geo\"<|>\"Priority countries are nations identified as high-risk or critical for polio eradication efforts, where surveillance performance and laboratory testing are closely monitored.\")##\n(\"entity\"<|>\"National level\"<|>\"geo\"<|>\"National level refers to the central public health or laboratory infrastructure within a country, where specimens are shipped and tested for surveillance purposes.\")##\n(\"entity\"<|>\"Subnational level\"<|>\"geo\"<|>\"Subnational level refers to regions or administrative divisions within a country, where surveillance performance is monitored separately from the national level.\")##\n(\"entity\"<|>\"WPR countries\"<|>\"geo\"<|>\"WPR countries are nations within the Western Pacific Region, which showed improved subnational surveillance performance during the reporting period.\")##\n(\"entity\"<|>\"AFR countries\"<|>\"geo\"<|>\"AFR countries are nations within the African Region, where polio surveillance staff were reemployed to support COVID-19 response efforts.\")##\n(\"entity\"<|>\"EMR countries\"<|>\"geo\"<|>\"EMR countries are nations within the Eastern Mediterranean Region, monitored for changes in cVDPV isolates and surveillance performance.\")##\n(\"entity\"<|>\"EUR countries\"<|>\"geo\"<|>\"EUR countries are nations within the European Region, monitored for changes in cVDPV isolates and surveillance performance.\")##\n(\"entity\"<|>\"SEA countries\"<|>\"geo\"<|>\"SEA countries are nations within the South-East Asia Region, monitored for changes in cVDPV isolates and surveillance performance.\")##\n(\"entity\"<|>\"WPR\"<|>\"geo\"<|>\"WPR is the abbreviation for the Western Pacific Region, a WHO-designated area for polio surveillance.\")##\n(\"entity\"<|>\"AFR\"<|>\"geo\"<|>\"AFR is the abbreviation for the African Region, a WHO-designated area for polio surveillance.\")##\n(\"entity\"<|>\"EMR\"<|>\"geo\"<|>\"EMR is the abbreviation for the Eastern Mediterranean Region, a WHO-designated area for polio surveillance.\")##\n(\"entity\"<|>\"EUR\"<|>\"geo\"<|>\"EUR is the abbreviation for the European Region, a WHO-designated area for polio surveillance.\")##\n(\"entity\"<|>\"SEA\"<|>\"geo\"<|>\"SEA is the abbreviation for the South-East Asia Region, a WHO-designated area for polio surveillance.\")##\n(\"entity\"<|>\"Stool specimens\"<|>\"event\"<|>\"Stool specimens are biological samples collected from persons with AFP and tested for poliovirus in GPLN and national laboratories.\")##\n(\"entity\"<|>\"Sewage samples\"<|>\"event\"<|>\"Sewage samples are environmental specimens tested for poliovirus as part of environmental surveillance activities.\")##\n(\"entity\"<|>\"Genomic sequencing\"<|>\"event\"<|>\"Genomic sequencing is a laboratory technique used to analyze the genetic material of poliovirus isolates, helping to monitor transmission pathways and identify genotypes.\")##\n(\"entity\"<|>\"Sequence analysis\"<|>\"event\"<|>\"Sequence analysis refers to the examination of the VP1 coding region of poliovirus isolates to monitor transmission pathways and genetic relationships.\")##\n(\"entity\"<|>\"Capsid protein\"<|>\"event\"<|>\"Capsid protein refers to the VP1 region of the poliovirus genome, which is analyzed for genetic identity and transmission monitoring.\")##\n(\"entity\"<|>\"Logistical assets\"<|>\"event\"<|>\"Logistical assets are resources managed by GPEI and surveillance staff to support specimen transport, data management, and response activities for polio and COVID-19.\")##\n(\"entity\"<|>\"On-site reviews\"<|>\"event\"<|>\"On-site reviews are part of the annual accreditation program for GPLN laboratories, assessing their performance and compliance with standards.\")##\n(\"entity\"<|>\"Checklist\"<|>\"event\"<|>\"Checklist refers to the accreditation and timeliness indicators used for laboratories conducting environmental surveillance.\")##\n(\"entity\"<|>\"Testing accuracy\"<|>\"event\"<|>\"Testing accuracy is a measure of the reliability and correctness of laboratory results, monitored through proficiency testing and accreditation.\")##\n(\"entity\"<|>\"Testing quality\"<|>\"event\"<|>\"Testing quality refers to the overall standard of laboratory procedures and results, ensured by accreditation and proficiency testing.\")##\n(\"entity\"<|>\"Genetic identity\"<|>\"event\"<|>\"Genetic identity refers to the percentage similarity in the VP1 region between poliovirus isolates, used to identify orphan isolates and transmission gaps.\")##\n(\"entity\"<|>\"Poliovirus transmission pathways\"<|>\"event\"<|>\"Poliovirus transmission pathways are monitored through sequence analysis of isolates, helping to track the spread and evolution of the virus.\")##\n(\"entity\"<|>\"Report findings\"<|>\"event\"<|>\"Report findings refer to the conclusions and limitations discussed in the Morbidity and Mortality Weekly Report regarding polio surveillance and the impact of COVID-19.\")##\n(\"entity\"<|>\"Limitations\"<|>\"event\"<|>\"Limitations refer to factors affecting the interpretation of surveillance indicators, such as security concerns, hard-to-reach subpopulations, and the sensitivity of NPAFP rates.\")##\n(\"entity\"<|>\"Interpretation\"<|>\"event\"<|>\"Interpretation refers to the analysis and understanding of surveillance indicators and laboratory results, which can be affected by various limitations.\")##\n(\"entity\"<|>\"Surveillance performance\"<|>\"event\"<|>\"Surveillance performance refers to the effectiveness of polio detection and reporting systems at national and subnational levels, monitored through indicators such as NPAFP rates and stool adequacy.\")##\n(\"entity\"<|>\"Stool adequacy\"<|>\"event\"<|>\"Stool adequacy is a surveillance indicator measuring the proportion of AFP cases with adequate stool specimens collected for laboratory testing.\")##\n(\"entity\"<|>\"Poliovirus isolation\"<|>\"event\"<|>\"Poliovirus isolation refers to the laboratory process of detecting poliovirus in stool or environmental specimens, with timeliness indicators monitored by WHO.\")##\n(\"entity\"<|>\"Polio surveillance\"<|>\"event\"<|>\"Polio surveillance encompasses all activities related to monitoring, detecting, and reporting polio cases, including laboratory testing, field investigations, and data management.\")##\n(\"entity\"<|>\"COVID-19 response efforts\"<|>\"event\"<|>\"COVID-19 response efforts refer to public health activities undertaken to control the spread of COVID-19, including reemployment of polio surveillance staff and logistical assets.\")##\n(\"entity\"<|>\"Batching\"<|>\"event\"<|>\"Batching refers to the grouping of specimens for shipment, which became necessary due to movement restrictions during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Specimen shipping\"<|>\"event\"<|>\"Specimen shipping is the process of transporting biological samples from collection sites to laboratories for testing, affected by movement and travel restrictions.\")##\n(\"entity\"<|>\"Laboratory networks\"<|>\"organization\"<|>\"Laboratory networks refer to interconnected groups of laboratories, such as GPLN, that collaborate on specimen testing and surveillance for polio and other diseases.\")##\n(\"entity\"<|>\"Field staff\"<|>\"person\"<|>\"Field staff are personnel involved in collecting specimens, conducting surveillance, and supporting public health response activities in the field.\")##\n(\"entity\"<|>\"Logistical support\"<|>\"event\"<|>\"Logistical support refers to the provision of resources and coordination for specimen transport, data management, and surveillance activities.\")##\n(\"entity\"<|>\"Surveillance indicators\"<|>\"event\"<|>\"Surveillance indicators are metrics used to assess the sensitivity, timeliness, and adequacy of polio surveillance systems.\")##\n(\"entity\"<|>\"Public health response\"<|>\"event\"<|>\"Public health response refers to coordinated actions taken to address polio and COVID-19 outbreaks, including surveillance, laboratory testing, and contact tracing.\")##\n(\"entity\"<|>\"Specimen analysis\"<|>\"event\"<|>\"Specimen analysis is the laboratory examination of biological samples for the presence of poliovirus or COVID-19.\")##\n(\"entity\"<|>\"Testing workload\"<|>\"event\"<|>\"Testing workload refers to the volume of specimens and analyses conducted by laboratory staff, which increased during the COVID-19 pandemic.\")##\n(\"entity\"<|>\"Annual accreditation\"<|>\"event\"<|>\"Annual accreditation is the yearly process of evaluating and certifying laboratory performance and compliance with standards.\")##\n(\"entity\"<|>\"Separate timeliness indicators\"<|>\"event\"<|>\"Separate timeliness indicators are specific metrics used for laboratories conducting environmental surveillance, distinct from those used for AFP surveillance.\")##\n(\"entity\"<|>\"Specimen receipt\"<|>\"event\"<|>\"Specimen receipt refers to the arrival of biological samples at laboratories, with timeliness indicators measuring the speed of subsequent testing.\")##\n(\"entity\"<|>\"Paralysis onset\"<|>\"event\"<|>\"Paralysis onset is the time when symptoms of AFP begin, used as a reference point for measuring timeliness of laboratory results.\")##\n(\"entity\"<|>\"Testing results\"<|>\"event\"<|>\"Testing results are the outcomes of laboratory analyses, including identification of poliovirus strains and reporting of surveillance data.\")##\n(\"entity\"<|>\"Genotype detection\"<|>\"event\"<|>\"Genotype detection refers to the identification of specific poliovirus genotypes, such as the South Asia genotype, through genomic sequencing.\")##\n(\"entity\"<|>\"Genetic mutation\"<|>\"event\"<|>\"Genetic mutation refers to changes in the poliovirus genome, which can lead to the emergence of VDPV and cVDPV strains.\")##\n(\"entity\"<|>\"Surveillance gaps\"<|>\"event\"<|>\"Surveillance gaps refer to deficiencies in the detection and reporting of polio cases, indicated by orphan isolates and other metrics.\")##\n(\"entity\"<|>\"Specimen collection\"<|>\"event\"<|>\"Specimen collection is the process of obtaining biological samples from AFP cases or environmental sources for laboratory testing.\")##\n(\"entity\"<|>\"Specimen testing\"<|>\"event\"<|>\"Specimen testing is the laboratory analysis of collected samples to detect poliovirus or COVID-19.\")##\n(\"entity\"<|>\"Report publication\"<|>\"event\"<|>\"Report publication refers to the dissemination of surveillance findings in official documents such as the Morbidity and Mortality Weekly Report.\")##\n(\"entity\"<|>\"Surveillance data\"<|>\"event\"<|>\"Surveillance data are the collected and analyzed results from polio and COVID-19 monitoring activities, used to inform public health decisions.\")##\n(\"entity\"<|>\"Public health agencies\"<|>\"organization\"<|>\"Public health agencies are organizations such as WHO, CDC, and national ministries of health involved in disease surveillance and response.\")##\n(\"entity\"<|>\"Ministries of health\"<|>\"organization\"<|>\"Ministries of health are national government agencies responsible for public health, including polio surveillance and laboratory accreditation.\")##\n(\"entity\"<|>\"Polio cases\"<|>\"event\"<|>\"Polio cases refer to individuals diagnosed with poliovirus infection, detected through AFP surveillance and laboratory testing.\")##\n(\"entity\"<|>\"COVID-19 specimens\"<|>\"event\"<|>\"COVID-19 specimens are biological samples tested for the presence of SARS-CoV-2, increasing the workload of laboratory staff during the pandemic.\")##\n(\"entity\"<|>\"Polio detection systems\"<|>\"event\"<|>\"Polio detection systems are surveillance and laboratory networks designed to identify and report polio cases.\")##\n(\"entity\"<|>\"Sensitive surveillance\"<|>\"event\"<|>\"Sensitive surveillance refers to the ability of a system to detect all or most cases of polio, measured by indicators such as NPAFP rates.\")##\n(\"entity\"<|>\"High NPAFP rates\"<|>\"event\"<|>\"High NPAFP rates are surveillance metrics that may indicate sensitive detection systems, but can also reflect reporting of non-polio AFP cases.\")##\n(\"entity\"<|>\"Reporting\"<|>\"event\"<|>\"Reporting refers to the process of submitting surveillance and laboratory data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance limitations\"<|>\"event\"<|>\"Surveillance limitations are factors that restrict the effectiveness or interpretation of polio monitoring activities.\")##\n(\"entity\"<|>\"Specimen adequacy\"<|>\"event\"<|>\"Specimen adequacy is a measure of whether collected samples meet the requirements for laboratory testing.\")##\n(\"entity\"<|>\"Specimen batching\"<|>\"event\"<|>\"Specimen batching is the grouping of samples for shipment, used during movement restrictions to facilitate transport.\")##\n(\"entity\"<|>\"Specimen impediment\"<|>\"event\"<|>\"Specimen impediment refers to obstacles in transporting samples to laboratories, such as international travel restrictions.\")##\n(\"entity\"<|>\"Polio laboratory networks\"<|>\"organization\"<|>\"Polio laboratory networks are groups of laboratories, such as GPLN, collaborating on polio surveillance and testing.\")##\n(\"entity\"<|>\"Multiple laboratory networks\"<|>\"organization\"<|>\"Multiple laboratory networks refer to the various interconnected groups of laboratories involved in specimen analysis for polio and COVID-19.\")##\n(\"entity\"<|>\"Surveillance findings\"<|>\"event\"<|>\"Surveillance findings are the results and conclusions drawn from polio and COVID-19 monitoring activities.\")##\n(\"entity\"<|>\"Surveillance interpretation\"<|>\"event\"<|>\"Surveillance interpretation is the analysis of surveillance data to inform public health decisions.\")##\n(\"entity\"<|>\"Surveillance decline\"<|>\"event\"<|>\"Surveillance decline refers to the reduction in performance of polio monitoring systems, noted in priority countries during the reporting period.\")##\n(\"entity\"<|>\"Surveillance improvement\"<|>\"event\"<|>\"Surveillance improvement refers to increased performance in polio monitoring systems, noted in WPR countries during the reporting period.\")##\n(\"entity\"<|>\"Surveillance metrics\"<|>\"event\"<|>\"Surveillance metrics are quantitative indicators used to assess the effectiveness of polio detection and reporting systems.\")##\n(\"entity\"<|>\"Surveillance adequacy\"<|>\"event\"<|>\"Surveillance adequacy is a measure of whether surveillance systems are sufficiently sensitive and comprehensive.\")##\n(\"entity\"<|>\"Surveillance reporting\"<|>\"event\"<|>\"Surveillance reporting is the submission of surveillance data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance coverage\"<|>\"event\"<|>\"Surveillance coverage refers to the extent to which surveillance systems monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance sensitivity\"<|>\"event\"<|>\"Surveillance sensitivity is the ability of a system to detect all or most cases of polio, measured by indicators such as NPAFP rates.\")##\n(\"entity\"<|>\"Surveillance adequacy decline\"<|>\"event\"<|>\"Surveillance adequacy decline refers to the reduction in the proportion of AFP cases with adequate stool specimens collected.\")##\n(\"entity\"<|>\"Surveillance performance decline\"<|>\"event\"<|>\"Surveillance performance decline refers to the reduction in effectiveness of polio monitoring systems at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance performance improvement\"<|>\"event\"<|>\"Surveillance performance improvement refers to increased effectiveness of polio monitoring systems, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance data limitations\"<|>\"event\"<|>\"Surveillance data limitations are factors that restrict the interpretation and usefulness of collected surveillance data.\")##\n(\"entity\"<|>\"Surveillance indicator limitations\"<|>\"event\"<|>\"Surveillance indicator limitations are factors that restrict the interpretation of surveillance metrics, such as security concerns and hard-to-reach subpopulations.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation is the analysis of surveillance metrics to inform public health decisions.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy\"<|>\"event\"<|>\"Surveillance indicator adequacy is a measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity\"<|>\"event\"<|>\"Surveillance indicator sensitivity is the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting\"<|>\"event\"<|>\"Surveillance indicator reporting is the submission of surveillance metrics to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage\"<|>\"event\"<|>\"Surveillance indicator coverage refers to the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline\"<|>\"event\"<|>\"Surveillance indicator decline refers to the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement\"<|>\"event\"<|>\"Surveillance indicator improvement refers to increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data\"<|>\"event\"<|>\"Surveillance indicator data are the quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings\"<|>\"event\"<|>\"Surveillance indicator findings are the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations are factors that restrict the analysis of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline\"<|>\"event\"<|>\"Surveillance indicator adequacy decline refers to the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline\"<|>\"event\"<|>\"Surveillance indicator performance decline refers to the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement\"<|>\"event\"<|>\"Surveillance indicator performance improvement refers to increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations\"<|>\"event\"<|>\"Surveillance indicator data limitations are factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations\"<|>\"event\"<|>\"Surveillance indicator reporting limitations are factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations\"<|>\"event\"<|>\"Surveillance indicator coverage limitations are factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations are factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations are factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations\"<|>\"event\"<|>\"Surveillance indicator findings limitations are factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings are the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings are the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings are the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings are the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings are the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings are the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings are the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings are the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings are the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings are the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings are the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings are the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings are the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings are the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings are the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings are the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings are the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings are the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings are the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings are the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the analysis and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of whether metrics detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of quantitative results from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator interpretation limitations findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the interpretation of surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in the proportion of AFP cases with adequate stool specimens collected, as measured by surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance decline interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of the reduction in effectiveness of surveillance metrics at national and subnational levels.\")##\n(\"entity\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator performance improvement interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of increased effectiveness of surveillance metrics, noted in WPR countries.\")##\n(\"entity\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator data limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the interpretation and usefulness of surveillance metric data.\")##\n(\"entity\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator reporting limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the submission of surveillance metric data to public health agencies and publications.\")##\n(\"entity\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator coverage limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the extent to which surveillance metrics monitor all relevant populations and regions.\")##\n(\"entity\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator sensitivity limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the ability of metrics to detect all or most cases of polio.\")##\n(\"entity\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator adequacy limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation is the analysis of factors that restrict the measure of whether surveillance metrics accurately reflect system performance.\")##\n(\"entity\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings\"<|>\"event\"<|>\"Surveillance indicator findings limitations interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings is the analysis of factors that restrict the results and conclusions drawn from surveillance metrics.\")##\n(\"entity\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation findings interpretation\"<|>\"event\"<|>\"Surveillance indicator interpretation findings interpretation findings interpretation findings interpretation findings",
    "model": "gpt41"
  },
  "60c3b172a77c48c27208cd1f85344d81": {
    "return": "The Morbidity and Mortality Weekly Report (MMWR) is a weekly publication series produced by the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services. As part of the MMWR Series and a service mark of the U.S. Department of Health and Human Services, it serves as an authoritative source for timely, reliable, accurate, objective, and useful public health information and recommendations. MMWR disseminates surveillance data, epidemiological analyses, laboratory services updates, and findings from outbreak investigations, including studies on vaccine effectiveness, vaccine safety, injury rates and trends, and disease surveillance such as polio, acute flaccid paralysis (AFP), and poliovirus transmission. The publication provides comprehensive public health statistics, analysis, and recommendations, supporting public health professionals and policymakers in monitoring and responding to health issues. MMWR is widely referenced as the source for study findings and public health updates, ensuring the dissemination of critical information to improve public health outcomes.",
    "model": "gpt41"
  },
  "30d2e8902ea7acfc15474029df7a3505": {
    "return": "The US Department of Health and Human Services (HHS) is a federal government department responsible for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. HHS oversees a range of health-related agencies, including the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). The department is involved in public health surveillance, disease prevention, health statistics reporting, medical research, welfare programs, and health policy development.\n\nHHS plays a key role in overseeing and publishing surveillance data related to diseases such as polio and COVID-19, and is actively involved in vaccine safety and monitoring systems, including VAERS and V-safe. The department supports public health initiatives such as immunization, injury prevention among older adults, and the publication of important reports like the Morbidity and Mortality Weekly Report. Through its leadership and oversight of agencies like the CDC and FDA, HHS is central to the United States efforts in public health, disease prevention, and the promotion of essential human services.",
    "model": "gpt41"
  },
  "8cd869da80a0a003dd56de6218da28f3": {
    "return": "The United States is a country located in North America and serves as the primary geographic focus for numerous studies, data collection efforts, and public health activities described in the report. It is referenced as the location for multiple COVID-19 vaccine effectiveness studies, vaccine administration, safety monitoring, and regulatory activities, including those conducted by the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS). The United States is also the jurisdiction for vaccine safety monitoring systems such as VAERS and V-safe, and is where mass vaccination sites operated and vaccine doses, including 7.98 million doses of the Janssen COVID-19 vaccine as of April 21, 2021, were administered and monitored for adverse events.\n\nAdditionally, the United States is the setting for the collection and analysis of injury-related emergency department visits and hospitalizations among adults aged 65 years and older, with population data weighted to represent the US population. The country is the site of multisite evaluations of COVID-19 vaccine effectiveness, involving 24 medical centers across 14 states, as well as a multistate network of hospitals participating in related studies. Public health surveillance, reporting activities, and recommendations are conducted nationwide, including the investigation of outbreaks such as the multistate E. coli O157:H7 outbreak in 2019, which involved 12 states. Overall, the United States is the location where vaccination events, public health recommendations, and comprehensive monitoring and evaluation activities described in the report take place.",
    "model": "gpt41"
  },
  "00b93324b277ad2c45db2f3327ea1454": {
    "return": "The Centers for Disease Control and Prevention (CDC) is a major U.S. federal public health agency and the national public health institute of the United States, operating under the Department of Health and Human Services (HHS) and headquartered in Atlanta, Georgia. The CDC is responsible for protecting public health and safety through the control and prevention of disease, injury, and disability. Its core functions include conducting public health research, disease surveillance, laboratory testing, and the reporting and analysis of data related to various health threats, such as acute flaccid paralysis (AFP), poliovirus outbreaks, and COVID-19.\n\nThe CDC leads numerous public health campaigns and initiatives, both nationally and globally, including immunization programs, vaccine safety monitoring, and collaborations with organizations such as the World Health Organization (WHO) on polio eradication and pandemic response efforts. It provides health information, guidance, and recommendations to the public and healthcare professionals, with a particular focus on preventing injuries and promoting health across all age groups, including older adults.\n\nAs part of its commitment to transparency and public health communication, the CDC publishes the Morbidity and Mortality Weekly Report (MMWR), which disseminates important findings on disease trends, vaccine effectiveness, and other public health issues. Through its comprehensive surveillance activities, research, and reporting, the CDC plays a central role in safeguarding the health of the U.S. population and contributing to global health initiatives.",
    "model": "gpt41"
  }
}